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Abstract 
 
Casein Kinase 2 (CK2) is a ubiquitous serine/threonine kinase. Due to its pleiotropic nature 
CK2 is involved in a multitude of cellular pathways including cell survival, proliferation and 
apoptosis. Therefore it has come as no surprise that a requirement for CK2 activity has been 
identified during the repair of DNA damage.  Here we have described a novel role for CK2 in 
the response to DNA double-strand breaks. We have shown the mediator of DNA damage 
checkpoint 1 (MDC1) is constitutively phosphorylated by CK2, which is required for an 
interaction with the MRE11/RAD50/NBS1 (MRN) complex, via the FHA domain of NBS1. 
Moreover, disruption of this interaction resulted in loss of MRN foci following ionizing 
radiation and a partial G2/M checkpoint defect. Furthermore, the identification of three 
siblings presenting NBS/Seckel-like phenotypes with a unique mutation in the BRCT domain 
of NBS1, that phenocopied some of our observations, provided additional evidence for the 
importance of phospho-dependent interactions within the cell. Lastly, the identification of 
putative CK2 target residues in MRE11 and our preliminary data suggest that the kinase may 
play further roles in regulating the activity of the MRN complex that lie outside its activity in 
DNA double-strand break repair.  
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CHAPTER 1 
 1 
Chapter 1 General Introduction  
1.1 Genomic instability and Cancer  
Cancer is a collective term used to describe a range of pathologies resulting from an inability 
to control cell growth and proliferation. Under normal circumstances, cell division is tightly 
regulated by a multitude of signalling pathways, that if disrupted can lead to uncontrollable 
cell growth, giving rise to precancerous lesions and potentially tumours. 
Tumourigenesis is a multistep process that requires a complex interplay between numerous 
genetic and epigenetic events that influence the oncogenic potential of a cell. Genomic 
stability, which is used to describe the loss or gain of genetic material through mutations or 
chromosomal rearrangements including translocations, deletions and inversions, can arise 
from improper repair of damaged DNA in the cell (Hanahan and Weinberg, 2011, 
Hoeijmakers, 2001). The cellular genetic material is constantly exposed to exogenous and 
endogenous factors that have the potential to generate a vast array of different DNA lesions. 
To ensure that DNA is accurately repaired, cells have evolved a plethora of pathways that 
cooperate in order to prevent the transmission of dangerous DNA lesions to the daughter cell. 
Pivotal roles in the coordination of the detection, signalling and recruitment of necessary 
factors as well as accurate and timely repair of DNA lesions is facilitated by a complex 
protein network termed the “DNA Damage Response” (DDR). The role of the DDR is to 
sense lesions in the DNA and then halt cell cycle progression in a process known as cell-cycle 
checkpoint activation. This event allows time for removal and repair of the DNA lesions. If 
the damage is irreparable, cellular senescence or cell death is triggered. Failure in any of these 
processes can result in the accumulation and transmission of DNA damage leading to 
genomic instability. 
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Previous work has shown elevated levels of unrepaired/persisting DNA damage in 
precancerous lesions, thought to arise from abortive/problematic replication forks. These 
replication errors stem from the increased proliferation of these neoplastic cells. This 
phenomenon has been termed ‘replication stress’ (Bartkova et al., 2005, Gorgoulis et al., 
2005). Consequently, replication stress was shown to trigger activation of the cellular DDR 
that functions as an ‘anti-tumourigenic barrier’ through its ability to permanently halt the cell 
cycle or if the damage is too severe then induce apoptosis/senescence. However, it is clear 
that prolonged replication stress increases the probability of mutations in critical tumour 
suppressor genes required to sustain activation of the DDR such as TP53, ATM and BRCA1. 
This can disrupt their ability to induce senescence or apoptosis, allowing genetically 
compromised cells to continue to proliferate.  This could explain why many genes encoding 
DDR proteins are mutated in many different human cancers, for instance TP53 is mutated in 
over 50% of all sporadic tumours (Gumy Pause et al., 2003, Thorstenson et al., 2003, 
Vogelstein et al., 2000). Whereas abnormalities within the cellular DDR can predispose to 
cancer development or accelerate its progression, interestingly, compromising or inactivating 
the cellular DDR can also be utilised to treat tumours. Cancer cells harbouring mutations in 
DDR genes are inherently hyper-sensitive to DNA damaging agents due to compromised 
DNA repair pathways and as such treating these cells with radiation or chemotherapeutic 
drugs that induce DNA damage, such as Temozolomide, can inflict genetic damage that 
cannot be repaired inducing cell death. In a similar manner, inhibitors of various DNA repair 
pathways are now being used in conjunction with different chemotheraputics to increase the 
efficiency of the treatment (Hastak et al., 2010). 
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1.2 The DNA damage response (DDR) 
The DDR requires a large number of different proteins that are essential for detecting and 
ensuring accurate recruitment of the repair machinery, which is composed of several classes 
of enzymes, including nucleases, helicases, kinases and ligases. Before initiation of repair can 
occur an orchestrated series of events are required to take place. This involves different 
groups of proteins such as DNA damage sensors and mediators that can amplify the signal as 
well as transducers that themselves signal primarily through phosphorylation (Figure 1.1). A 
major role in controlling the cellular DDR is played by members of the phosphatidylinositol 
3-kinase-like kinase family (PIKKs), including ATM (ataxia-telangiectasia mutated), ATR 
(ataxia-telangiectasia mutated and rad3-related kinase) and DNA-PK (DNA-dependant 
protein kinase).  
 1.2.1 ATM activation and the ATM-mediated DNA damage response 
ATM is primarily required for the detection/repair of DNA double strand breaks (DSBs) in 
heterochromatin. That is chromatin, which is tightly packed. DNA-PK is also capable of 
facilitating DNA DSB repair and this will be discussed in detail later in the text. This type of 
DNA lesion is considered to be the most cytotoxic, since a single unrepaired DSB is sufficient 
to trigger cell death. A variety of sources can induce the generation of DSBs such as exposure 
to X-rays, ionising radiation (IR), or radio-mimetic chemicals whereas others can produce 
DSBs indirectly, for example, reactive oxygen species (ROS) that are often generated as by-
products of normal cellular metabolic processes. DSBs can also be generated during 
replication fork collapse, which occurs after prolonged replication fork stalling or when the 
replication machinery encounters certain lesions such as DNA single strand breaks (SSBs) or 
an abortive topoisomerase complexes (Figure 1.2). Moreover, DSBs can also arise in a  
Figure 1.1.   The DNA damage response. The cellular response to 
DNA damage involves a tightly orchestrated series of events, termed 
the DNA damage response. This signalling cascade is dependent on a 
number of different proteins that can be grouped as sensors, those that 
sense the damage, transducers, proteins that transmit the DNA damage 
response signal and effector proteins that facilitate the appropriate 
response to the lesion.  
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Figure 1.2.  DNA double-strand breaks generated at the replication 
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encountering an endogenous DNA single-strand break (SSB) the 
replication machinery (replisome) disassociates and the replication 
fork collapses resulting in a one-ended DSB.  
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programmed manner during V(D)J (variable (diversity) and junction) recombination and class 
switch recombination (CSR) that are essential for development of the immune system 
(discussed later in the text) (Hiom, 2010, Jackson and Bartek, 2009).  
Upon the formation of a DSB, the first factor to sense the damage is the 
MRE11/RAD50/NBS1 (MRN) complex, which functions to tether as well as stabilise the free 
DNA ends (Williams et al., 2007).  Once bound to a DSB, the MRN complex triggers the 
activation of ATM via its association with the C-terminus of NBS1 (Falck et al., 2005, Lee 
and Paull, 2004). In the absence of DNA damage, ATM exists as an inactive dimer. 
Following break recognition by the MRN complex the inactive ATM dimers dissociate and 
form active monomers. This damaged-induced event occurs by autophosphorylation of ATM 
in trans on serine (S) 1981, S367, S1893 and S2996, as well as acetylation on lysine 3016 by 
the histone acetyltransferase Tip60 (Bakkenist and Kastan, 2003, Kozlov et al., 2011, Kozlov 
et al., 2006, Sun et al., 2005). These modifications then allow ATM to be activated and exert 
its kinase activity on numerous downstream targets. One of the first ATM targets is the 
histone H2A variant (γH2AX), which becomes phosphorylated on S139 (Rogakou et al., 
1998). The damage-induced phosphorylation of H2AX on S139 is coupled with a 
dephosphorylation of a nearby tyrosine, 142, which is constitutively phosphorylated in the 
absence of damage, by the EYA phosphatase (Cook et al., 2009, Xiao et al., 2009). This 
rapidly modified histone then serves to coordinate and amplify the damage signal in a highly 
structured way. The phosphorylation and dephosphorylation of H2AX allows for the 
recruitment of the mediator protein, mediator of DNA damage checkpoint 1 (MDC1), which 
interacts directly with the γH2AX, via its BRCA1 C-terminal (BRCT) domain (Lee et al., 
2005b, Lou et al., 2006, Stucki et al., 2005). The binding of γH2AX to MDC1 stimulates the 
recruitment of additional MRN complexes to the site of DNA damage, which serves to recruit 
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more activated ATM therefore spreading the γH2AX signal along the chromatin either side of 
the lesion. Using this positive ATM-dependent feedback loop, this process results in 
amplification of the intracellular signal generated by the DNA damage (Chapman and 
Jackson, 2008, Lou et al., 2006, Lukas et al., 2004a, Melander et al., 2008, Spycher et al., 
2008) (Figure 1.3).   
In conjunction with its role as a mediator protein, MDC1 also functions as a scaffold protein 
recruiting other DDR response proteins along the chromatin flanking the break. Through its 
interaction with ATM, the N-terminus of MDC1 becomes phosphorylated, creating a binding 
platform recognised by the forkhead-associated (FHA) domain of the E3 ubiquitin ligase, 
RNF8 (Huen et al., 2007, Kolas et al., 2007, Mailand et al., 2007). RNF8 catalyses the 
ubiquitylation of H2A and H2AX surrounding the break. The ubiquitylation of H2A-type 
histones signals the recruitment of another E3-ubiquitin ligase, RNF168, which interacts with 
the ubiquitylated histones via two atypical ubiquitin-interacting motifs (termed motifs 
interacting with ubiquitin or MIUs). RNF168, together with the E2 conjugating enzyme 
UBC13, catalyses the lysine 63 (K63) -linked poly-ubiquitylation of H2A/H2AX, which is 
thought to facilitate chromatin relaxation proximal to the break and also create an interaction 
platform for the recruitment of downstream DNA repair/checkpoint proteins, such as BRCA1 
and 53BP1 (Doil et al., 2009, Pinato et al., 2011, Stewart, 2009) (Figure 1.3).  
Poly-ubiquitylated H2A and γH2AX are both recognised by the tandem ubiquitin-interacting 
motifs (UIMs) of RAP80 (receptor associated protein 80) an adaptor protein that is involved 
in facilitating the recruitment of the BRCA1-A complex to sites of DNA damage via its 
association with another protein, Abraxas (Kim et al., 2007a, Sobhian et al., 2007, Wang et 
al., 2007).  
Figure 1.3 	
 The ATM-mediated DNA damage  response. Following the generation 
of a DSB the MRN complex is recruited to the lesion, which in turn recruits ATM, which 
is then activated by MRN and Tip60. ATM then phosphorylates H2AX. γH2AX directly 
interacts  with  MDC1.  MDC1  is  then  phosphorylated  by  ATM,  and  phosphorylated 
MDC1 is recognized by RNF8, that along with RNF168 and the E2 UBC13 catalyse the 
H2A-type histone ubiquitylation which results in chromatin relaxation, permitting the 
recruitment recruitment of 53BP1 and the BRCA1-A-complex. (Adapted from Ciccia and 
Elledge 2010). 	
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Despite a requirement of BRCA1 for homolgous recombination repair (HR) as well as 
activation of both the intra-S and G2/M cell cycle checkpoints following the induction of 
DNA damage, the contribution of its E3 ubiquitin ligase to these functions remains elusive. 
H2A and H2AX ubiquitylation also serves to facilitate the accumulation of 53BP1 to sites of 
damage. The ‘opening up’ of the chromatin structure by the ubiquitylation of histones is 
thought to allow recognition of an epigenetic mark on histone H4 (H4K20me2), which 
normally remains buried within nucleosomes in undamaged chromatin, by the Tudor domain  
of 53BP1 (Botuyan et al., 2006). Once recruited, one proposed function of 53BP1 is to 
promote the repair of DSBs by non-homologous end-joining (NHEJ) through its ability to 
limit DNA end resection and as a consequence, HR (Bothmer et al., 2010, Chapman et al., 
2012).  
In addition to activating and/or stimulating proteins required to repair DNA DSBs, ATM also 
serves to halt cell cycle progression through its ability to phosphorylate a number of key cell 
cycle regulatory proteins e.g. CHK1, CHK2, p53 and BRCA1 (Banin et al., 1998, Canman et 
al., 1998, Cortez et al., 1999, Khanna et al., 1998, Matsuoka et al., 2000, Saito et al., 2002). 
As a consequence cells derived from patients with ataxia-telangiectasia (A-T) display a defect 
in their ability to activate the G1/S, intra-S and G2/M phase cell cycle checkpoints following 
the induction of DNA DSBs.  
 Given the multitude of the cellular roles of ATM, it was an unexpected observation that 
approximately only fifteen percent of DSB are repaired in an ATM-dependent manner 
(Riballo et al., 2004). Furthermore, the repair of this subset of breaks was found to have 
“slow” kinetics compared to the rest of the DSB repair in the cell. It has been proposed that 
this “slow” component of repair is not only related to the biochemical complexity of some 
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DNA breaks but also to the cells ability to detect the damage in the context of the localised 
chromatin structure e.g. heterochromatin versus euchromatin (Goodarzi et al., 2010). 
In addition to the MRN-dependent activation of ATM in response to DNA damage, ATM can 
also be activated in an MRN-independent manner in the absence of DNA damage. A number 
of reports have shown that in response to hypoxia, ATM is both active and phosphorylated, 
and this activation does not require the presence of detectable DNA damage and is MRN-
independent (Bencokova et al., 2009, Hammond et al., 2003a). Hypoxia is used to describe 
low oxygen conditions in the cellular environment and is a common feature of many solid 
tumours. Hypoxic conditions do not generate DSBs, but instead are thought to cause 
replication stress in the form of stalled replication forks, due to depletion of 
deoxyribonucleotides (dNTPs) (Loffler et al., 1997).  This replication stalling leads to an 
increase in ATR activity potentially regulating cell cycle checkpoints and repair (Hammond et 
al., 2002). Since hypoxia does not generate detectable DSBs the precise mechanisms involved 
in ATM activation and signalling in this cellular environment is still unclear. Although it has 
been hypothesised that ATR activation, as a result of single-stranded DNA at the stalled 
replication fork may be a contributing factor (Bencokova et al., 2009). However, it may be 
that ATM plays a more important role in signalling a cellular response during reoxygenation, 
a process that often occurs following transient periods of hypoxia. It is likely that ROS 
produced during reoxygenation induces sufficient DNA damage to trigger an ATM-dependent 
response although the collapse of stalled forks attempting to restart may also contribute to this 
(Freiberg et al., 2006, Hammond et al., 2003b). The ability of ATM to initiate a G2 phase cell 
cycle arrest following reoxygenation may allow time for any DNA damage incurred to be 
repaired.  
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1.2.2 ATR activation and the ATR-mediated DNA damage response 
Another PIKK kinase, Ataxia telangiectasia mutated and rad3-related  (ATR), is thought to be 
activated by exposed ssDNA that can be generated by the stalling of replication fork 
progression due to the presence of lesions across which the replicative polymerases are unable 
to synthesise DNA. These can be photoproducts generated by ultraviolet (UV) light, depletion 
of the cellular pool of dNTPs induced by treatment with compounds that inhibit 
ribonucleotide reductase e.g. hydroxyurea (HU) or DNA base alkylation. For this reason, 
ATR is active during every S-phase, where it functions to regulate replication origin firing, 
stabilise stalled forks and prevent the untimely entry into mitosis (Cimprich and Cortez, 
2008). In the presence of replication stress ssDNA is thought to occur due to the uncoupling 
of the DNA helicase from the replicative polymerases (Byun et al., 2005). This leads to a 
situation where the level of DNA unwinding is greater than synthesis, producing stretches of 
unwound ssDNA, resulting in ATR activation.  ATR can also be activated by the production 
of ssDNA generated through end resection of a DSB (see homologous recombination section) 
(Jazayeri et al., 2006, Myers and Cortez, 2006).  
The ssDNA rapidly becomes coated with the ssDNA binding protein, replication protein A 
(RPA) and evidence suggests that this is one of the key events for ATR activation and its re-
localisation to sites of damage (Zou and Elledge, 2003). The RPA coated ssDNA is 
recognised by the ATR-interacting protein, ATRIP, through direct interaction, and it is this 
association that mediates the recruitment of ATR (Ball et al., 2007, Cortez et al., 2001). 
Although the ATR signalling pathway requires RPA-coated ssDNA, this alone is not adequate 
for ATR activation. Adjacent to the ssDNA is dsDNA, which is not coated by RPA and this 
structure also plays a part in ATR activation. This junction of ssDNA and dsDNA is 
recognised by the replicative sliding clamp complex, RAD9-RAD1-hus1 (9-1-1) complex, 
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and the RAD17-replication factor C (RAD17-Rfc) complex, which serve to recruit other ATR 
regulators (Bermudez et al., 2003, Parrilla-Castellar et al., 2004, Zou et al., 2002). One such 
regulator is topoisomerase-binding protein-1 (TopBP1), which binds to the 9-1-1 complex, 
via the phosphorylated C-terminal of RAD9 and hyper-activates ATR through a direct 
interaction with ATRIP (Kumagai et al., 2006, Mordes et al., 2008).  Once bound, TopBP1 
acts by stimulating ATR kinase activity (Figure 1.4).   
The assembly of an activated ATR complex on the DNA allows for the coordination of the 
necessary response to the lesion, including the stabilisation and restart of DNA replication 
forks as well as the activation of cell cycle checkpoints. The latter is the best characterised of 
these responses and involves activation of the effector serine/threonine kinase CHK1, a 
substrate of ATR. Activation of CHK1 requires its phosphorylation on Ser317 and Ser345 by 
ATR (Liu et al., 2000). The mediator/adaptor protein Claspin is also essential for this 
activation, bringing ATR and CHK1 together (Kumagai and Dunphy, 2000).  In addition to 
Claspin, phosphorylation of CHK1 by ATR is also facilitated by the Timeless-Tipin complex, 
which interacts with RPA, via Tipin. This stable complex is responsible for the recruitment of 
Claspin to promote CHK1 activation (Kemp et al., 2010). Following its phosphorylation, 
CHK1 can then phosphorylate substrates such as the phosphatases CDC25A and CDC25C, 
inhibiting their activity and as a result preventing CDK activity required for cell cycle 
progression (Chen et al., 2003, Uto et al., 2004). 
Figure 1.4   The ATR-mediated DNA damage response. ssDNA generated either 
by DNA damage or replication stress is rapidly coated with RPA. The RPA coated 
ssDNA is recognised by ATRIP/ATR. The double-stranded DNA adjacent to the break 
recruits the 9-1-1 complex and RAD17 Rfc. TopBP1 then binds to the C-terminus of 
Rad9 and stimulates ATR activation. The Timeless/TIPIN complex interacts with RPA 
and recruits Claspin which promotes the CHK1 phosphorylation by ATR (Adapted 
from Nam & Cortez 2011, Kemp et al 2010) 
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1.3 Cell cycle checkpoints in response to DNA damage  
Cell cycle checkpoints function to ensure the integrity of the genome is maintained. This is 
achieved by halting the progress of the cell cycle in response to DNA damage, allowing time  
for repair. The checkpoints are activated by the PIKKs, and associated effector kinases, 
including CHK1 and CHK2. There are four main cellular checkpoints: the G1/S checkpoint 
prevents cells with damaged DNA entering S phase. The intra-S checkpoint/replication 
checkpoint controls replication origin firing and stabilises stalled DNA replication forks. The 
G2/M checkpoint prevents cells with damaged DNA from entering mitosis and the Spindle 
Assembly Checkpoint, which delays cell division in the event of problems during 
chromosome segregation.  
Cyclin-dependent kinases (CDKs) in conjunction with regulatory subunits called Cyclins are 
central to controlling the transition between each phase of the cell cycle. Phosphorylation of 
the CDKs on threonine 14 and tyrosine 15 by the WEE1/MIK1/MYT1 kinases keeps these 
proteins in an inactive state (Chow et al., 2003). Dephosphorylation of these residues by 
members of the CDC25 protein phosphatase family activates the CDK-Cyclin complex and as 
such promotes cell cycle progression. In mammalian cells there are three related CDC25 
proteins, CDC25A, CDC25B and CDC25C, which despite having a similar function, all have 
specific roles in the regulation of cell cycle (Donzelli and Draetta, 2003, Galaktionov and 
Beach, 1991). CDC25A regulates both the G1/S phase transition with its associated Cyclins 
E/A and CDK2 complex activity, as well as the progression into mitosis involving the Cyclin 
B/Cdk1 complex (Hoffmann et al., 1994). In contrast, CDC25B and C are involved in 
activating Cyclins A/B with CDK1 and ultimately controlling the transition through G2/M 
(Lammer et al., 1998, Perdiguero and Nebreda, 2004).  
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If substantial DNA damage is present in the genome, CDC25A becomes phosphorylated by 
CHK1 (and possibly CHK2), and this phosphorylation marks the CDC25A for ubiquitin-
mediated degradation via the proteasome (Falck et al., 2001, Mailand et al., 2000). Two 
ubiquitin ligases are involved in degrading CDC25A depending on the cell cycle phase. If 
CDC25A is phosphorylated during the mitotic exit, then the anaphase promoting complex 
(APC/C) plays a role, whereas the SKIP1-CUL1-F-box ligase containing the F-box protein 
βTRCP (SCFβTRCP) is responsible for ubiquitylating CDC25A throughout the cell cycle as 
well as after DNA damage (Busino et al., 2003, Donzelli et al., 2002). In contrast, 
phosphorylation of CDC25C by CHK1 (and CHK2) creates a binding site for 14-3-3 proteins, 
that promotes the transport of CDC25C out of the nucleus, thereby preventing activation of 
the CDK1-Cyclin B complex and progression of cells from G2 into mitosis (Lopez-Girona et 
al., 1999). It has been shown that the in vivo phosphorylation of CDC25B by p38, which is 
activated in response to UV damage, similarly creates a 14-3-3 binding site on CDC25B, 
suggesting that this phosphatase may also be exported from the nucleus to prevent cell cycle 
progression in response to damage. However, whether this is the case in vivo is unclear 
(Bulavin et al., 2002).  
CHK1 and CHK2 phosphorylation by ATR/ATM following DNA damage leads to the 
activation of the CDK inhibitory kinases (WEE1/MIK1/MYT1) providing further regulation 
on cell cycle progression (Kastan and Bartek, 2004). Lastly, activation of p53 by ATR/ATM, 
results in the upregulation of p21, which has an inhibitory role on several Cyclin-CDKs 
complexes (Bunz et al., 1998, Spurgers et al., 2006). 
It is clear that the cell possesses various strategies to halt the cell cycle if genomic integrity is 
compromised, and it is the activation of these checkpoints that allow time for the controlled 
repair/re-organisation of the DNA.   
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1.4 DNA double-strand break repair 
DNA DSBs can be repaired in different ways. The two main mechanisms involved are Non-
homologous end-joining (NHEJ) and Homologous recombination (HR). Repair of DNA 
lesions by the NHEJ machinery is thought to be performed with “fast” kinetics, and can take 
place throughout the cell cycle, but predominates during G1. The NHEJ pathway involves re-
ligating the DNA ends at the lesion. This method of repair is termed ‘error-prone’, as there is 
a potential for nucleotide loss surrounding the break. In contrast, HR is considered ‘error-free’ 
as it requires the presence of a sister chromatid, which acts as a template to repair the 
damaged DNA. Although, some evidence suggests that uncontrolled/excessive HR especially 
at repetitive DNA regions can also be deleterious for the cell. For instance, increases in the 
HR protein RAD51 seen in some tumour cells may result in unwarranted recombination 
resulting in potential genetic instability (Richardson et al., 2004, Vispe et al., 1998). The 
dependency on the presence of a sister chromatid means that HR is primarily restricted to the 
S and G2 phases of the cell cycle, where it serves to repair lesions arising during or after 
DNA replication.  
Once a DSB has been detected, the early assembly of certain DDR proteins facilitates the 
choice of the appropriate repair strategy and this depends on several factors including the cell 
cycle phase, the structure of the damaged DNA ends and presence of DNA homologous to the 
damaged sequence (Bunting et al., 2010, Shibata et al., 2011, Shrivastav et al., 2008, Takata 
et al., 1998). Two proteins coupled to this selection of repair are 53BP1 and BRCA1.  
Evidence has suggested that both these proteins serve as molecular switches governing the 
competition between the two repair pathways for the repair of DSBs (Bunting et al., 2010, 
Escribano-Diaz et al., 2013). Following damage, occurring in cells in G1 phase, the 
accumulation of BRCA1 is inhibited by 53BP1 and another protein, RIF1, allowing NHEJ to 
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be the preferred repair pathway. Whereas in S/G2 cells, RIF1 is suppressed by BRCA1 and 
CtBP-interacting protein 1 (CtIP), favouring HR as the pathway for the repair of DSB 
(Chapman et al., 2013a, Chapman et al., 2013b, Di Virgilio et al., 2013, Escribano-Diaz et 
al., 2013, Feng et al., 2013, Zimmermann et al., 2013). 
1.4.1 Homologous recombination  
BRCA1 has been shown to promote repair by HR if conditions favouring this type of repair 
are present (Moynahan et al., 1999). BRCA1 acts as a mediator during HR, recruiting and 
activating a number of proteins. Prior to the repair of DSBs, HR requires resection of the 
DNA end, which exposes single stranded DNA 3’termini, allowing for strand invasion into 
the sister chromatid (Mimitou and Symington, 2011). Resection of the DNA is tightly 
controlled and in vertebrates is instigated by CDKs via the phosphorylation of CtIP (Huertas 
and Jackson, 2009, Ira et al., 2004). Keeping CtIP at low levels during G1 phase via 
proteosomal degradation provides further regulation of resection, ensuring that it only takes 
place during S and G2 phases (Buis et al., 2012, Germani et al., 2003). In addition, the 
phosphorylation of CtIP on serine 327 by CDKs, governs complex formation with other key 
HR proteins, such as the MRE11/RAD50/NBS1 (MRN) complex and BRCA1 in the S/G2 
phase of the cell cycle (Chen et al., 2008, Yu and Chen, 2004). A second CDK-dependent 
phosphorylation on theronine 847 of CtIP activates resection (Huertas and Jackson, 2009). 
Once CtIP forms a complex with MRN and BRCA1, BRCA1 can then ubiquitylate CtIP, a 
modification that serves to retain the protein at the sites of DNA damage (Yu et al., 2006). 
The phosphorylation and expression of CtIP is also thought to be governed by the MRE11 
subunit of the MRN complex, by an interaction with both MRE11 and CDK2 (Buis et al., 
2012). This interaction (between CtIP and the MRN) is necessary for resection to initiate and 
has no impact on the other characterised roles of the MRN, such as sensing of DSBs and 
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ATM re-localisation/activation. Lastly, phosphorylation of CtIP by ATR on threonine 818 
contributes to CtIP chromatin association and robust resection (Peterson et al., 2013). ATM is 
also thought to be required for CtIP localisation, all though whether this is through a 
phosphorylation event is still unclear (Peterson et al., 2013, You et al., 2009). 
Whilst the mechanism of resection was first elucidated from studies in yeast, revealing a two-
step process, a similarly conserved process has also been observed in higher eukaryotes 
(Mimitou and Symington, 2008, Zhu et al., 2008). Firstly, MRE11 cooperates with CtIP 
(sae2) to process the 5’ DSB end via the MRE11 exonuclease activity. This initial processing 
then paves the way for long range resection catalysed by the exonuclease EXO1 (exonuclease 
1) and DNA2 (DNA replication helicase 2) together with BLM (Bloom syndrome protein), a 
helicase, which acts to unwind the DNA and promote resection (Gravel et al., 2008, 
Nimonkar et al., 2011, Nimonkar et al., 2008).  The exposed single stranded DNA is then 
rapidly coated with RPA, which activates ATR and checkpoint signalling, allowing time for 
repair to occur (Figure 1.5). This is then followed by displacement of RPA by RAD51 with 
assistance from RAD52 (Sugiyama and Kowalczykowski, 2002). RAD51 is recruited directly 
by BRCA2 and its binding partner PALB2 (partner and localiser of BRCA2), which are the 
primary mediators of RAD51 nucleoprotein filament formation (Sy et al., 2009, Xia et al., 
2006, Yuan et al., 1999). The accumulation of these factors results in the formation of the 
RAD51 nucleoprotein filament, which along with the ATPase RAD54, can invade the 
homologous sister chromatid and form a displacement loop (D-loop) structure in order to 
switch from strand invasion to DNA synthesis (Kiianitsa et al., 2006, Li et al., 2007b) (Figure 
1.6).  Once the D-loop is formed, the invading strand can be extended by DNA polymerases 
using the homologous strand as a template. A number of polymerases have been proposed to 
be involved in HR-DNA synthesis including Polε (Polymerase epsilon), Polη (eta), Polδ  
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Figure 1.5   DNA end-resection. MRN is recruited to the DSB. Where in 
complex with Cdk2 phosphorylated CtIP and BRCA1, initiates resection through 
the nuclease activity of MRE11. This early processing then allows the nucleases 
EXO1 and DNA2 to perform long range resection at the break, in conjunction 
with the BLM helicase, which acts in stimulatory capacity. The single-stranded 
resected DNA is then coated with RPA. (Adapted from Ciccia & Elledge 2010, 
Polo et al 2012) 
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(delta) and more recently Polζ (zeta) (Kawamoto et al., 2005, Maloisel et al., 2008, Sebesta et 
al., 2013, Sharma et al., 2012).  
Synthesis of a new DNA strand instigates the  “removal” of the D-loop, which can occur in a 
number of ways. The predominant method is synthesis-dependent strand annealing (SDSA), 
whereby the newly synthesised strand is displaced from the D-loop and annealed to the 
resected DNA strand at the other end of the break (Paques and Haber, 1999) (Figure 1.5). 
This method does not lead to crossovers, and thus, genomic rearrangements, and is thought to 
be promoted by the helicase regulator of telomere length 1 (RTEL1) possibly by dissolution 
of the D-loop (Barber et al., 2008). Alternatively, in a process called second-end capture, the  
second resected DNA strand is annealed to the displaced strand of the D-loop (Nimonkar et 
al., 2009).  If this scenario occurs, a Holliday junction is formed which can be resolved by a 
number of structure-specific endonucleases (Chapman et al., 2012). One such structure-
specific endonuclease is the resolvase MUS81 and its partner EME1 (Boddy et al., 2001, 
Chen et al., 2001, Ciccia et al., 2003).  
MUS81-EME1 is not specific to any HR outcome and could, therefore, be considered as 
promiscuous, eliciting its activity on a variety of intermediates possibly formed during HJ 
resolution, although, it does have a preference toward nicked Holliday junctions 
(Hollingsworth and Brill, 2004, Osman et al., 2003). The branch migration of the D-loop, as a 
consequence of second strand capture, can produce double Holliday junctions (dHJs) (Figure 
1.6). A fraction of structure-specific endonucleases identified are thought to be specific to 
resolving dHJs. GEN1 and SLX1/SLX4 promote the resolution of dHJs by symmetrically 
cleaving the four-way nucleotide junction, producing either a crossover or non-crossover  
 
Figure 1.6   Homologous recombination repair of DSBs.  RAD51, recruited by 
BRCA2 and PALB2, displaces RPA from the ssDNA, generated during resection. 
The RAD51 nucleoprotein filament, aided by RAD54 can then invade the sister 
chromatid, where several scenarios can arise to repair the DSBs that result in 
crossover and non-crossover events (Adapted from San Filippo et al 2008). 
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recombination outcome (Fekairi et al., 2009, Ip et al., 2008, Munoz et al., 2009, Svendsen et 
al., 2009) (Figure 1.6). Recent evidence has shown that SLX4 acts as a scaffold recruiting 
SLX1, XPF and MUS81 to dHJ (Fekairi et al., 2009). Lastly, the BLM helicase in complex 
with TOPOIIIα can dissolve dHJs by migration of the two HJs towards each other, followed 
by decatenation of the resulting structure; a process, which yields non-crossover products 
(Wu and Hickson, 2003). As the resolution of dHJs by structure-specific endonucleases can 
produce crossover events, they must be tightly regulated as this can lead to loss of 
heterozygosity and genomic rearrangements in mitotic cells (Ciccia and Elledge, 2010).  
1.4.1.1 Single-strand annealing and break-induced replication 
Another homology related DNA repair pathway is single-strand annealing (SSA). SSA can be 
utilised in two possible situations. Firstly, if HR components such as BRCA2 or RAD51 are 
absent, the latter being required to promote strand invasion, a shift will be observed from HR 
to SSA (Stark et al., 2004). Secondly, SSA can occur if the DSB arises near regions of 
sequence homology within the same strand. The initial step of SSA requires the same group 
of proteins required for HR, as the DNA either side of the lesion requires resection. Resection 
occurs until the two regions of homology are exposed, where RAD52 facilitates the annealing 
of the two repeat regions (Singleton et al., 2002). As a product of resection, 3’ prime tails are 
created which are cleaved by the flap endonucleases, excision repair cross complementation 
(ERCC1)/Xeroderma Pigmentosum F (XPF) complex, after which the two strands can then be 
ligated (Al-Minawi et al., 2008).  Repair via SSA is potentially mutagenic, compared to 
canonical HR, as it involves loss of large regions of genetic information due to resection 
(Figure 1.6). One study revealed that >2kb of resection had to occur in order for SSA to 
happen (Stark et al., 2004).  
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Break-induced replication (BIR) occurs if a second end is lacking, which results in the single 
end invading either the sister chromatid or a homologous chromosome (Malkova et al., 1996, 
San Filippo et al., 2008). Again like SSA, the break is resected, followed by invasion of the 
free 3’tail, which then invades the donor strand. BIR is highly mutagenic, maybe due to the 
lack of a second end, resulting in the invading strand undergoing repeated rounds of 
homology searching during synthesis, possibly encountering regions of non-homologous 
sequence (Llorente et al., 2008, Smith et al., 2007) (Figure 1.6).  
1.4.2 Non-homologous end-joining 
NHEJ is the primary method for repairing DSBs. Following the generation of a DSB, the 
KU70/80 heterodimer binds to the DNA ends and serves as a dock for other NHEJ proteins at 
the break (Blier et al., 1993, Mimori and Hardin, 1986). The binding of the KU complex onto 
the DNA on either side of the break changes its conformation allowing for the interaction of 
the serine/theronine kinase, DNA-dependent protein kinase catalytic subunit (DNA-PKcs). It 
has been observed that Ku does not form a stable interaction with DNA-PKcs in the absence 
of DNA (Yaneva et al., 1997). Recent evidence has suggested the ATP-dependent chromatin-
remodelling factor (ACF1) is required for the localisation of KU to DNA via a direct 
interaction (Lan et al., 2010). A molecular bridge is then created between the DNA-PKcs 
molecules bound to each DNA end, termed a synapsis (DeFazio et al., 2002, Dobbs et al., 
2010). Interaction of DNA-PKcs with both KU and DNA activates its kinase activity, leading 
to the phosphorylation of a number of substrates including KU70/80, X-ray cross 
complimenting 4 (XRCC4) and Artemis, though it is unclear what impact these modifications 
have on the regulation of the NHEJ process (Douglas et al., 2005, Goodarzi et al., 2006, Yu et 
al., 2003). Interestingly, DNA-PKcs also phosphorylates itself, on a number of 
autophosphorylation sites, and studies have demonstrated that this is required for efficient 
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NHEJ (Chan et al., 2002, Ding et al., 2003). The DNA ends at the break must become 
ligatable for repair to continue, as the two ends are rarely compatible for re-ligation and often 
harbour 3’-5’ overhangs. In mammalian NHEJ, Artemis is the key end-processing enzyme 
and its recruitment to DSBs is likely mediated through an interaction with DNA-PKcs (Ma et 
al., 2002, Moshous et al., 2001). Artemis possesses DNA-PKcs-dependent endonuclease and 
DNA-PKcs-independent 5’-3’ exonuclease activity and where necessary, the protein can trim 
the DNA ends (Ma et al., 2005). In addition to Artemis, if the processing of the lesion is 
complex, gaps may need to be filled by polymerases. Members of the polymerase X family, 
which include polymerase µ (mu) and polymerase λ (lambda) are thought to facilitate this 
process during NHEJ (Ma et al., 2004, Mahajan et al., 2002). The last step of NHEJ requires 
the ligation of the DNA ends and is coordinated by XRCC4/DNA ligase IV/XRCC4-like 
factor (XLF)/Cernunnos complex (Grawunder et al., 1997, Wu et al., 2007) (Figure 1.7). 
XRCC4 lacks any enzymatic activity but is thought to act as a protein scaffold, bringing DNA 
Ligase IV and XLF interacting partners into proximity with Ku and the DNA (Nick 
McElhinny et al., 2000). It has also been shown that XRCC4 is phosphorylated by CK2, 
which promotes its interaction with polynucleotide kinase/phosphatase (PNKP), a 
bifunctional DNA end-processing enzyme that can repair damaged DNA termini possessing 
3’phosphate and a 5’hydroxyl groups, thereby facilitating DNA ligation (Figure 1.7) (Koch et 
al., 2004, Mani et al., 2010).  
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Figure 1.7   Non-homologous end-joining. The KU70/KU80 heterodimer 
binds to the DSB, changing its conformation, which allows the binding of DNA-
PKcs, and activates its kinase activity. Both KU70/KU80 and DNA-PKcs create 
a molecular bridge between the two DNA ends. The DNA nuclease Artemis is 
then recruited to process the DNA ends, or if gaps need to be filled then 
polymerases are recruited. Once the DNA ends have been processed the break is 
ligated by the XRCC4/DNA ligase IV/XRCC4-like factor (XLF) complex 
(Adapted from Weterings & Chen 2008). 
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1.4.2.1 Alternative end-joining 
Alternative end-joining (Alt-EJ) occurs when classical NHEJ proteins, for instance Ku, 
XRCC4 or DNA ligase IV are absent (Hartlerode and Scully, 2009).  Alt-EJ is also reliant on 
short regions of sequence homology at the sites of damage and its usage has been associated 
with the formation of chromosomal deletions and translocations (Bennardo et al., 2008, 
Della-Maria et al., 2011, Guirouilh-Barbat et al., 2007). Microhomology-mediated end-
joining (MMEJ) is just one of the possible means of repairing DNA breaks via Alt-EJ, 
however, the two are mutually exclusive (McVey and Lee, 2008). Like SSA, which also relies 
on regions of homology, repair of the break by Alt-EJ requires resection of the DNA by 
MRN/CtIP, albeit over a shorter region than during HR (Della-Maria et al., 2011, Rass et al., 
2009). However, Alt-EJ differs from SSA in that RAD52 partially inhibits and ERCC1 only 
partially promotes repair by Alt-EJ, whereas both of these proteins promote SSA (Bennardo et 
al., 2008). Resection serves to reveal the short regions of homology allowing for ligation to 
occur. Error-prone polymerases may also be involved in Alt-EJ, where they are required to 
process the resected DNA ends. MMEJ, requires Polη and Polζ in Saccharomyces cerevisiae, 
and Polymerase θ (theta) in Drosophila melanogaster (Chan et al., 2010). Which polymerases 
are required for re-synthesis across DNA gaps during this repair process in mammalian cells 
is still unclear. Ligation of the DSB during Alt-EJ occurs independently of DNA ligase IV 
and instead is thought to require DNA ligase I and DNA ligase IIIα/XRCC1, although their 
relative contributions to this process requires further investigation (Boboila et al., 2012, Liang 
et al., 2008). Most likely, the absence of NHEJ proteins allows access for other factors to be 
recruited to the DSB. For example, Poly(ADP-ribose) polymerase-1 (PARP-1), normally 
associated with DNA single-strand break repair (SSBR), is thought to promote recruitment of 
the DNA ligase IIIα/XRCC1 complex to lesions undergoing Alt-EJ (Audebert et al., 2004). 
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The MRN complex also associates with DNA ligase IIIα/XRCC1, in cells deficient in 
classical NHEJ machinery, where they function together to join DNA ends (Della-Maria et 
al., 2011).  
1.4.3 Programmed double-strand breaks 
As discussed previously, DSBs caused by endogenous or exogenous agents are highly toxic to 
the cell and need to be dealt with in a quick and coordinated manner. In spite of this, the 
development of the immune system requires the DDR cascade and interestingly, creation of 
DSBs in a controlled and highly restrictive manner.  
V(D)J recombination produces  diversity in T-cell receptors and immunoglobulins (Ig) 
through genetic recombination in developing lymphocytes (Malu et al., 2012). V(D)J 
recombination achieves this by joining combinations of variable (V), diversity (D) and 
junction (J) regions of DNA sequences and utilises  NHEJ to join the breaks (Figure 1.8). The 
target regions for this process are the Ig and T-cell receptor (TCR) genes, which have 
recombination signal sequences (RSS) embedded within them (Jung and Alt, 2004). This 
process involves cleavage of the DNA by recombination activating genes 1 and 2 (RAG1, 
RAG2), which recognise the RSSs, inducing a DSB adjacent to the V, J and D sequences and 
creating a hairpin structure at coding ends. The KU heterodimer is able to bind to the cleaved 
DNA end and begin the repair phase. DNA-PKcs can then localise and bridge the coding 
ends, where it also serves to recruit and activate the nuclease required to open the hairpin 
generated by RAGs. Whereas in vitro studies have implicated the RAG complex, MRN and 
Artemis in DNA hairpin opening, data from knockout mouse models suggests that Artemis 
plays a major role in opening the hairpin in vivo (Besmer et al., 1998, Ma et al., 2002, Malu et 
al., 2012, Paull and Gellert, 1999, Rooney et al., 2002, Shockett and Schatz, 1999). Once 
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open, the hairpin coding ends may require further processing, either from the addition of 
nucleotides by TdT, known as N-additions, or the removal of nucleotides by an as yet 
unidentified nuclease(s) (Desiderio et al., 1984, Malu et al., 2012). Both the removal and 
addition of nucleotides serves to increase the diversity within the antigen binding regions of 
these surface receptors and as a consequence, the range of putative antigens recognised. 
Finally, the coding ends can be ligated by the XRCC4/DNA ligase IV/XLF complex, 
generating a new variable region (Figure 1.8).  
Class-switch recombination (CSR) takes place both inside and out of germinal centres (GC). 
This process functions to promote antibody maturation by replacing the constant regions (CH) 
within the antibody heavy chain, resulting in the production of different antibody isotypes that 
can interact with different effector molecules (Alt et al., 2013, Chaudhuri et al., 2007, Xu et 
al., 2012).  The activation induced cytidine deaminase (AID) initiates CSR, by deaminating 
cytidine residues in S (switch) regions, converting them to uracils, creating a U/G DNA 
mismatch (Figure 1.9) (Soulas-Sprauel et al., 2007b). This mismatch is recognised by the 
base excision repair (BER) protein uracil-N-glycosylase (UNG), which removes the uracil 
from the DNA generating an abasic site (Imai et al., 2003, Rada et al., 2002). The abasic site 
is then recognised by apurinic/apyrimidic endonucleases (APE1 and APE2) that induce the 
formation of a ssDNA nick (Stavnezer et al., 2008). As AID is able to target both strands of 
DNA within the S region, two closely located ssDNA nicks can become a DSB (Soulas-
Sprauel et al., 2007b, Stavnezer, 2011, Xu et al., 2012). If the ssDNA nicks are close to each 
other, DSBs will form spontaneously. After the DSB has been correctly processed, 
recombination between the donor and acceptor regions can initiate (Figure 1.9) (Stavnezer et 
al., 2008). Members of the NHEJ machinery KU70/KU80 and XRCC4/DNA-ligase IV are 
important for the completion of CSR (Casellas et al., 1998, Manis et al., 1998, Soulas-Sprauel  
V D J 
V(D)J region in Ig or T cell 
receptor genes. 
RSSs embedded within  
V(D)J region.  
Cleavage at RSSs by 
RAG1 and RAG2, and 
formation of hairpin 
structure.  
Sensing and repair of DNA 
DSB by NHEJ factors 
including KU, DNA-PKcs, 
Artemis and XRCC4/LIGIV. 
DNA DSB is resolved, 
generating a new variable 
region.   
Figure 1.8   V(D)J Recombination. V(D)J recombination occurs in 
developing lymphocytes. It is the process by which diversity in T-cell receptors 
and immunoglobulins (Ig) is achieved. Briefly DNA DSBs are created in the 
variable region of  Ig or T-cell receptor genes, resulting in cleavage of a specific 
segment of DNA . The DNA DSBs is then processed and repaired using NHEJ 
proteins, creating a new variable region and therefore increasing antigen 
recognition (Adapted from Posey et al 2004).  
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Figure 1.9  Class-switch Recombination. CSR takes place both in and out of 
the germinal centres.  It is required for antibody maturation by rearranging the 
constant regions within the antibody heavy chain. This is achieved by creating 
DNA DSBs at specific switch regions (S) embedded in the constant region (C). 
The DSB is then processed by NHEJ proteins in addition to other repair factors 
such as the  MRN complex, resulting in rearrangement of the constant region 
and production of different antibody isotypes (Adapted from Posey et al 2004).   
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et al., 2007a, Yan et al., 2007a). Surprisingly, studies have revealed that in the absence of 
NHEJ factors, CSR is still active suggesting that alternative pathways may compensate 
(Boboila et al., 2010a, Yan et al., 2007a). Alt-EJ during CSR is thought to rely heavily on 
microhomologies, and the type of Alt-EJ required depends on which NHEJ factor is missing. 
In the absence of XRCC4/DNA ligase IV, KU is still activated and alternative ligases (either 
DNA ligase I or III) are used to join the break (Boboila et al., 2010b). In this situation, 
resection of the DNA is a prerequisite prior to ligation, to reveal regions of homology, and 
possibly involves the nucleolytic activity of MRE11 (Dinkelmann et al., 2009, Lahdesmaki et 
al., 2004). Cells deficient in either KU70 or KU80 can still undergo CSR, and this scenario 
also relies on regions of microhomology.  
The contribution of DDR proteins in the development of the immune system becomes more 
apparent when studying genetic syndromes that result from mutations in these proteins.  
1.5 Human DSB repair deficiency syndromes 
Intact DSB repair pathways and cell cycle checkpoints are integral in preventing genomic 
instability. The cellular and clinical features of syndromes caused by deficiencies in these 
pathways often overlap, including radiosensitivity, immunodeficiency and neurological 
phenotypes. Below describes a selection of diseases associated with mutations in DSB 
signalling and repair pathways. 
1.5.1 Ataxia-Telangiectasia 
Ataxia-Telangiectasia (A-T) is an autosomal-recessive disease, with the biological cause of 
the disease pinned to mutations in the ATM gene (Savitsky et al., 1995a, Savitsky et al., 
1995b). Typical clinical features are of early onset, and include progressive cerebellar cortical 
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degeneration, specifically from loss of Purkinje and granule cells, leading to ataxia (loss of 
motor control and balance) (Figure 1.10). In addition to neuropathologies patients also exhibit 
oculomotor apraxia (problems in eye coordination), dysarthria (impaired articulation-speech), 
ocular telangiectasia (dilated blood vessels), immunodeficiency and a predisposition to the 
development of cancers, including leukemia and breast (Figure 1.10) (Chun and Gatti, 2004, 
Frappart and McKinnon, 2006, Kerzendorfer and O'Driscoll, 2009, McKinnon, 2004, 
Stankovic et al., 1998, Taylor and Byrd, 2005). Cellular features of A-T include increased 
radiosensitivity, presumed to occur due to defects in ATM-dependent DSB repair involved in 
a sub-set of breaks associated with heterochromatin and defects in cell cycle checkpoint 
activation (Figure 1.10) (Goodarzi et al., 2008, Houldsworth and Lavin, 1980, Painter and 
Young, 1980). The vast majority of patient mutations in the ATM gene cause instability in the 
protein resulting in a complete absence of ATM (Becker-Catania et al., 2000, Demuth et al., 
2011, Gilad et al., 1998, Stankovic et al., 1998, Verhagen et al., 2012). The lack of expression 
of the ATM protein in these patients does not appear to be governed by the type of mutation 
or position in the gene. However, some mutations associated with a milder disease course 
have been documented to give rise to detectable levels of mutant protein expression that 
retains some kinase activity (Chun et al., 2003, Frappart and McKinnon, 2006, Lakin et al., 
1996, Stewart et al., 2001).  
1.5.2 Syndromes associated with mutations in the MRN complex 
Described formally in 1981 as an A-T variant, due to a number of overlapping features with 
A-T, Nijmegen Breakage Syndrome (NBS) is a result of mutations in the NBN gene (Shiloh, 
1997, Varon et al., 1998, Weemaes et al., 1981, Weemaes et al., 1993). Unlike the genetic 
causes of A-T, more than 90% of all NBS results from a single 5bp hypomorphic mutation,  
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Figure 1.10  Examples of clinical and cellular phenotypes associated with 
Ataxia-telangiectasia. (A) Neurodegeneration. Reduced cerebellum (left panel) 
of an A-T patient, compared to an unaffected individual (right panel). (B) 
Ocular telangiectasia. Dilated blood vessels in the eye of an A-T patient. (C) 
Radiosensitivity. Colony survival assay of A-T (A-T) patient derived and normal 
lymphoblastoid cell lines (LCL), 10 days post 1 Gy of IR, compared to 
unirradiated control. Taken from Chun & Gatti 2004.   
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termed 657del5 (Digweed and Sperling, 2004, Maser et al., 2001).  Carriers of the 657del5 
mutation produce two truncated forms of NBS1. An N-terminal fragment encompassing the 
FHA and BRCT domains, p26 and a larger 70kDa protein named p70 incorporating the C-
terminus of NBS1 (Figure 1.11) (Maser et al., 2001).   
As mentioned, NBS shares many cellular and clinical traits with A-T, including a hyper-
sensitivity to ionising radiation, cell cycle checkpoint defects, immunodeficiency, both at the 
cellular and humoral level and cancer predisposition (Digweed and Sperling, 2004). The 
cancers associated with affected individuals are lymphomas. Unlike A-T patients, NBS 
patients do no suffer from progressive neurodegeneration (loss of neural tissue) and instead 
exhibit microcephaly, defined as a head circumference 3 SD (Standard deviations) below the 
norm, intellectual deficiency and delayed growth (Digweed and Sperling, 2004). 
Even though ATM and NBS1 both function in the repair of DSBs and damage signalling, it is 
unclear why these two syndromes exhibit such different neurological pathology. A recent 
theory suggests the explanation may be linked to discrepancies in the activation of ATM-
dependent apoptosis during neurological development, resulting in microcephaly and 
progressive cerebellar degeneration, in NBS and A-T patients respectively (Shull et al., 2009). 
In A-T patients the inability of cells to undergo ATM-dependent apoptosis may cause an 
accumulation of un-repaired DSBs. Despite this, fairly normal brain development can occur. 
Eventually a threshold of unrepaired breaks is reached and the neurological cells begin 
apoptosing in an ATM-independent manner, leading to the cerebellar cortical degeneration 
associated with these patients. It is thought NBS patients however, can undergo ATM-
dependent apoptosis, therefore NBS1 deficient cells harbouring elevated levels of unrepaired 
DNA damage are eliminated. The removal of these cells during early stage development of 
the brain reduces the overall number or neuronal cell populations, resulting in microcephaly. 
Figure 1.11   NBS1 protein fragments arising from the NBS 675del5 
mutation. (A) Schematic of the full length NBS1 protein. Highlighting 
functional domains (purple) with amino acid positioning. (B) Two NBS1 protein 
fragments (p26 & p70) produced as a result of the 657del5 mutation occurring 
in 90% of NBS patients.     
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Whilst there is experimental evidence supporting this hypothesis, it is clear that other factors 
contribute to the type of neurological deficit exhibited by patients with either A-T or NBS. 
This is highlighted by the identification of two NBS patients with typical mutations in the 
NBN gene that exhibit severe microcephaly but no overt defects in DNA DSB repair 
(Seemanova et al., 2006). Similarly, two classical A-T patients expressing no ATM protein 
were found to present with progressive ataxia as well as microcephaly and mental retardation 
(Curry et al., 1989).  
Like NBS, Ataxia-Telangiectasia-Like Disorder (A-TLD) also results from mutations in a 
member of the MRN complex. In this instance the syndrome arises from hypomorphic 
mutations in the MRE11 gene (Stewart et al., 1999). Apparent from its title, A-TLD presents 
with a similar clinical and cellular phenotypes to A-T, including occulomotor apraxia, 
dysarthria, although not as severe, with a later onset of ataxia and slower neurodegeneration, 
radiosensitivity and a failure to active both the intra-S and G2/checkpoints (Taylor et al., 
2004). Surprisingly, none of the identified patients display immunodeficiency. However, 
translocations are observed in chromosomes 4 and 17 which contain genes linked to the 
immune system (Frappart and McKinnon, 2006). To date only 9 A-TLD families have been 
documented, totaling 20 patients, indicating that this syndrome is relatively rare in 
comparison to both A-T and NBS (Reynolds and Stewart, 2013). Unlike A-T and NBS 
patients, a cancer predisposition phenotype in ATLD individuals is still inconclusive, which 
may be a reflection of the low incidence of this syndrome. Although, recently two A-TLD 
patients have been identified that developed lung adenocarcinoma, but whether this is due to 
the patients disorder is still unclear and to be determined (Uchisaka et al., 2009).  
Given the MRN complexes role in ATM activation it is not surprising mutations in MRE11 
present similar clinical phenotypes to A-T patients. However, the underlying cause why there 
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are disparities between the neurological conditions exhibited by patients with ATLD and NBS 
remains unclear. It could be inferred that the microcephaly exhibited by NBS patients is 
related to the restricted set of mutations in the NBN gene causing this disorder. Furthermore, 
since a complete loss of NBS1 is lethal, it is likely that the residual NBS1 protein expressed 
in patient derived cells is clearly sufficiently functional to prevent cerebellar degeneration. 
Interestingly, most ATLD patients express extremely low levels of Nbs1 protein, due to 
destabilising effect of MRE11 mutations, and it has been reported that some patients do 
present microcephaly and mental retardation in addition to cerebellar ataxia, providing 
evidence for an overlap of symptoms (Fernet et al., 2005, Uchisaka et al., 2009). Conversely, 
NBS-like phenotypes, but with no cerebellar degeneration were reported in two unrelated 
individuals with mutations in MRE11 (Matsumoto et al., 2011). This implies that different 
mutations in ATLD patients can give rise to neurological abnormalities similar to that of A-T 
and/or NBS patients. Again, the clinical outcome of this variation maybe based on the type of 
mutation and its impact on ATM-dependent apoptosis in neurological tissue.  
Lastly a single patient has been identified with a mutation in RAD50, the third component of 
the MRN complex, and this has been termed NBS-Like Disorder (NBS-LD) (Waltes et al., 
2009). As indicated from the name the clinical features exhibited by this individual are similar 
to those of NBS, as opposed to those seen in A-T and the majority of A-TLD patients. The 
mutation in RAD50 gives rise to low levels of protein, which disrupts the interaction of 
RAD50 with NBS1 and MRE11. Interestingly, levels of MRE11 in RAD50-deficient cells are 
more stable than levels of NBS1, which may explain clinical similarity with NBS patients 
(Waltes et al., 2009). The cellular features of NBS-LD include radiosensitivity, impaired 
ATM activation and signaling, and defects in cell cycle checkpoint activation (Waltes et al., 
2009). Despite its namesake the cellular features are not as severe as those seen in NBS-
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derived patient cells. Similarly, this mirrors ATLD cells, which present milder cellular 
phenotypes compared to A-T cells. The varying traits exhibited by these three syndromes 
caused by mutations in such closely interacting proteins serves as a reminder to the many 
functions of the MRN complex in maintaining genomic instability. 
1.5.3 Syndromes associated with mutations in RNF168 
To date only two patients have been identified with pathological mutations in the E3 ubiquitin 
ligase RNF168 gene (Devgan et al., 2011, Stewart et al., 2009, Stewart et al., 2007). 
Disruption of RNF168, impacts on the ubiquitin-dependent arm of DNA DSB repair required 
for the accumulation of repair factors including 53BP1 and BRCA1. The first patient 
described (15-9BI) exhibited heterozygous mutations (c.397dupG & c.1323-1326 delACAA), 
that were predicted to encode for two truncated forms of the protein, named A133fsX and 
Q442fsX (Figure 1.12) (Stewart et al., 2009, Stewart et al., 2007). The second patient (RS66), 
haboured nonsense homozygous mutations, which ablated RNF168 protein production 
(Devgan et al., 2011). Although both patients presented with growth retardation, 
radiosensitivy and immunodeficiency, patient RS66 also displayed microcephaly, ataxia and 
telangiectasia (Devgan et al., 2011, Stewart et al., 2009, Stewart et al., 2007).   The severity 
of clinical phenotypes observed in patient RS66, compared to patient 15-9BI, could be 
attributed to absence of the RNF168 protein in the former.  In addition, whilst it is unknown 
whether deficiencies in RNF168 predispose to cancer, the father of patient 15-9BI developed 
chronic B-cell lymphocytic leukemia, that is also associated with A-T (Stewart et al., 2009). 
1.5.4 Seckel Syndrome 
Seckel Syndrome (SCKL) is an inherited autosomal-recessive disorder, and was first 
described in 1960, by the German pediatrician Helmut Paul George Seckel (Seckel, 1960).    
c.397dupG c.1323_1326delACAA 
N RING 1 MIU1 MIU2 C 571 
N RING 1 MIU1 487 
N RING 1 141 
15 58 168 191 439 462 
A133fsX 
Q442fsX 
Figure 1.12  RNF168 mutations in patient 15-9BI. (A) Schematic of the full 
length RNF168 protein. Functional domains are highlighted with corresponding 
amino acid position. Also highlighted are the heterozygous mutations identified 
in patient 15-9BI, c.397dupG and c.1323_1326delACAA. (B) Predicted proteins 
produced as a result of patient 15-9BI RNF168 mutations. (Adapted from 
Stewart et al 2009).   
A 
B 
	  
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Via genetic mapping, causation of the syndrome has been accounted to at least five genomic 
loci, termed SCKL1-5 with four genes identified (Borglum et al., 2001, Goodship et al., 2000,  
Griffith et al., 2008, Kalay et al., 2011, O'Driscoll et al., 2003, Ogi et al., 2012, Qvist et al., 
2011). Therefore, unlike the previous conditions it is a genetically heterogeneous disorder. 
Patients with SCKL syndrome clinically display severe intrauterine growth retardation, 
intellectual disabilities, microcephaly, skeletal abnormalities, including joint laxity and 
dislocation and characteristic facial dysmorphology, such as receding forehead and chin, and 
a pronounced nose (Majewski and Goecke, 1982). Some patients also have been reported to 
have lymphoma.   
A single mutation in the ATR gene (A>G 2101), named ATR-Seckel syndrome (SCKL1), was 
identified as the first causal defect in two related families (O'Driscoll et al., 2003). The 
mutation was shown to be hypomorphic and impact on ATR-dependent damage signalling 
(O’Driscoll et al., 2003). Recently, two unrelated UK Seckel patients have also been 
identified with the same heterozygous mutation in ATR (Ogi et al., 2012). In addition to 
ATR, mutations have been found in other genes within the reported SCKL loci. For instance 
mutations in the centrosomal protein CEP152 have been found in several SCKL patients 
(Kalay et al., 2011). The recent identification of mutations in the CTIP gene as the underlying 
cause for a SCKL-like disorder provides the first molecular link between this disorder and 
DSB repair (Ogi et al., 2012, Qvist et al., 2011). One common characteristic between 
individuals with SCKL syndrome is defects in ATR-dependent damage signaling, suggesting 
that the genes mutated in these patients all participate within the same cellular pathway. 
Indeed the most recent gene mutation reported in a Seckel patient was discovered in the ATR 
interacting protein ATRIP, supporting this notion (Ogi et al., 2012).  The clinical features of 
SKCL patients often overlap with other related disorders, such as Microcephalic Primordial 
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Dwarfism, primary microcephaly and radiosensitive SCID. To highlight this, mutations in 
another centrosomal protein, Pericentrin (PCNT1) have been identified in a large cohort of 
patients exhibiting clinical features consistent with SCKL syndrome (Griffith et al., 2008). 
The identification of further mutations in PCNT1 in the primordial dwarfism microcephalic 
osteodyplastic primordial dwarfism type II (MOPDii) suggests Seckel syndrome and MOPDii 
appear to be sub-classifications of a clinical spectrum with an overlapping underlying 
pathobiology (Rauch et al., 2008). 
1.5.5 Ligase IV syndrome 
 DNA Ligase IV syndrome (LIG4 syndrome) arises from mutations in the gene coding for the 
NHEJ protein Ligase IV (O'Driscoll et al., 2001). Clinically, subjects affected by this 
mutation share phenotypes with other DNA damage syndromes, such as NBS and Seckel 
syndrome. These include severe immunodeficiency, growth retardation, microcephaly, and 
developmental delay (Chistiakov et al., 2009, Murray et al., 2014, O'Driscoll et al., 2001). 
Cells from these patients are extremely radiosensitive but show normal cell cycle checkpoint 
activation (O'Driscoll et al., 2001). The radiosensitivity documented in these cells stems from 
defects in the NHEJ pathway, in which DNA ligase IV is required to ligate the DNA ends. 
Since, NHEJ represents a major pathway for repair of DSBs in mammalian cells, 
unsurprisingly loss of DNA ligase IV in knockout mouse models results in embryonic 
lethality (Frank et al., 1998). In contrast, mouse models with a hypomorphic mutations in 
LiGIV recapitulate many of the features exhibited by LIG4 patients, such as a severe DSBR 
defect, abnormal brain development and immune system abnormalities caused by 
compromised V(D)J recombination (Nijnik et al., 2007). As the NHEJ machinery functions in 
immune system development, LIG4 patients also present unusual V(D)J recombination 
phenotypes including reduced joining events (O’Driscoll  et al., 2001). It has also been 
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suggested that LigIV has a role in lymphocyte proliferation that extends beyond V(D)J 
recombination, and this may explain why a number of patients display a high number of B- 
and T- cell tumors (Buck et al., 2006a, Buck et al., 2006b, Enders et al., 2006, O'Driscoll et 
al., 2001, Riballo et al., 1999, Toita et al., 2007).  
1.5.6 RS-SCID (Associated with Artemis or XLF deficiency) 
Patients diagnosed with severe combined immune deficiency (SCID), show marked defects in 
T and B cell production. A subset of these patients display radiosensitivity and are named 
radiosensitive-SCID (RS-SCID). The condition is autosomal recessive, and can be further 
divided again into Artemis-associated RS-SCID and XLF-associated RS-SCID, where 
presentation is a result of mutations in the ARTEMIS and XLF genes respectively (Ahnesorg 
et al., 2006, Buck et al., 2006b, Moshous et al., 2001).  
Mutations in the ARTEMIS gene give rise to radiosensitive T-B-SCID (absence of both T and 
B cells) (Dvorak and Cowan, 2010, Moshous et al., 2001). Patients present with 
immunological defects due to the repair of RAG induced DSB being impaired, in support of 
the role that Artemis plays as part of the NHEJ machinery. However, it should be noted that 
unlike cells with hypomorphic LIGIV mutations, Artemis deficient cells display repair defects 
in a small percentage of IR-induced DSB comparable to those observed in A-T/NBS cells 
(Deckbar et al., 2007, Kerzendorfer and O'Driscoll, 2009, Riballo et al., 2004, Rooney et al., 
2003, Wang et al., 2005b). A variety of different mutation types have been identified in 
Artemis-associated RS-SCID patients, ranging from exon deletions to truncations of the 
protein (Kobayashi et al., 2003, Li et al., 2002c). Potential hypomorphic missense mutations 
have also been found in some patients that interestingly have been noted to have an increased 
association with the formation of B cell lymphomas (Moshous et al., 2003).  
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Unlike Artemis-associated RS-SCID, individuals with XLF-associated RS-SCID, as well as 
having NHEJ defects and thus problems with V(D)J recombination, also exhibit 
microcephaly, growth retardation, bone malformations and ‘bird-like’ facial features (Dvorak 
and Cowan, 2010). The presentation of microcephaly in these patients suggests a role for XLF 
in nervous system development, similar to other syndromes associated with the defective 
repair of DSBs e.g. LIGIV syndrome and NBS. What is clear for both Artemis/XLF-
associated RS-SCID is that these are solely DNA repair disorders as cell cycle checkpoints 
are functional in both (Deckbar et al., 2007, Kerzendorfer and O'Driscoll, 2009).  
1.6 Mediators of DNA repair   
Mediator proteins involved in the signalling of DNA damage are downstream substrates of 
the main kinases, ATM and ATR. Upon recruitment and activation, mediators serve to attract 
repair factors to the lesion. In doing this they provide scaffolding for protein complexes 
localised at the site of DNA damage which are required for chromatin remodelling, protection 
of the area surrounding the lesion, amplification of the DDR, checkpoint activation and repair. 
To date a number of mediators have been identified that participate in the DDR.  
MDC1, 53BP1, BRIT1 (BRCT-repeat inhibitor of hTERT expression 1)/MCPH1 
(Microcephalin), PTIP, BRCA1 and NBS1 operate as mediators in response to ATM 
activation. Whereas, Claspin and TopBP1 respond to ATR activation (Harper and Elledge, 
2007). All these mediators contain phospho-binding domains (either FHA domains and/or 
BRCT domains) that can interact with phosphorylated proteins. These domains act as binding 
platforms that can facilitate the assembly of phosphorylation-dependent DNA 
repair/checkpoint protein complexes (Bork et al., 1997, Callebaut and Mornon, 1997, 
Durocher et al., 1999, Mohammad and Yaffe, 2009, Polo and Jackson, 2011). FHA domains 
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tend to bind to proteins containing phospho-threonine residues, whereas in contrast BRCT 
domains target proteins with phosphorylated serine residues (Durocher et al., 1999, Li et al., 
2002b, Liao et al., 2000, Manke et al., 2003, Mohammad and Yaffe, 2009). With the 
exception of BRCA1 that displays E3 ubiquitin ligase activity, these proteins have no known 
enzymatic activity and are thus thought to function as molecular scaffolds ((FitzGerald et al., 
2009, Li and Zou, 2005, Lukas and Bartek, 2004) 
1.6.1 Claspin  
Claspin was originally identified as a CHK1 interacting protein in Xenopus egg extracts 
(Kumagai and Dunphy, 2000). This protein of 1332 amino acids is involved in the ATR-
dependent intracellular signalling in response to DNA damage or replication stress. It is 
required for the effective phosphorylation of CHK1 by ATR via an association with CHK1 
(Chini and Chen, 2003, Kumagai and Dunphy, 2000). It has been shown that casein kinase 1 
gamma 1 (CK1γ1) phosphorylates Claspin within its C-terminal CHK1-activating domain 
(CKAD) that facilitates both its binding to and the subsequent activation of CHK1 (Meng et 
al., 2011). In addition to CK1γ1 phosphorylation, Claspin is also phosphorylated in response 
to DNA damage on threonine 916 and serines 945/982 and these damage-dependent 
phosphorylations are also required for CHK1 interaction and activation (Chini and Chen, 
2006, Clarke and Clarke, 2005). The kinase responsible for this phosphorylation has not been 
identified but it has been suggested that it may be CHK1 itself, therefore producing a positive 
regulatory feedback loop (Chini and Chen, 2006). Claspin has also been found to associate 
with replication forks in undamaged cells, suggesting a potential function in monitoring both 
normal replication progression as well as checkpoint control (Lee et al., 2005a, Petermann et 
al., 2008, Scorah and McGowan, 2009). In addition to its contribution to checkpoint 
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activation in the presence of DNA damage, the participation of Claspin in DNA replication 
through interactions with the replication machinery in a DNA damage-independent manner, 
may also contribute to its role in promoting genetic integrity (Sar et al., 2004, Scorah and 
McGowan, 2009, Sercin and Kemp, 2011). It has been previously shown that the N-terminus 
of Claspin is important for its interaction with the replication MCM helicase co-factor Cdc45, 
in contrast to its CKAD domain being located at its C-terminus suggesting that its 
involvement in the regulation of perturbed and unperturbed replication are separable (Chini 
and Chen, 2006, Clarke and Clarke, 2005, Jeong et al., 2003, Kumagai and Dunphy, 2003).  
1.6.2 TopBP1 
Similar to Claspin, TopBP1 also participates in regulating CHK1 activity during the ATR-
dependent response to DNA replication stress. However, unlike Claspin, TopBP1 is required 
to promote the activation of ATR directly and as a consequence, the phosphorylation of most 
downstream targets, rather than being specific to CHK1 (Delacroix et al., 2007, Greer et al., 
2003, Lee et al., 2007, Mordes et al., 2008). TopBP1 was first identified in a two-hybrid 
screen as a binding partner of topoisomerase IIβ (Garcia et al., 2005, Kumagai et al., 2006, 
Yamane et al., 1997). This 1522 amino acid protein contains eight BRCT domains and has 
roles in both replication initiation and checkpoint signalling (Garcia et al., 2005). Upon 
replication stress, which activates ATR-dependent responses, TopBP1 is recruited by the 
phosphorylated C-terminus of RAD9, a member of the 9-1-1 complex (Delacroix et al., 2007, 
Greer et al., 2003, Lee et al., 2007, Mordes et al., 2008). It should be noted that the 
recruitment of TopBP1 by RAD9 is independent of ATR/ATRIP (Kondo et al., 2001, Melo et 
al., 2001). However, TopBP1 also interacts directly with ATRIP, and this is required for its 
ability to stimulate ATR activation, since disruption of this interaction results in an inability 
of cells to recover from replication stress or to activate cell cycle checkpoints (Mordes et al., 
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2008). Importantly, it has been shown that a region between the sixth and seventh BRCT 
domain of TopPBP1, termed the ATR Activation Domain (AAD) is absolutely essential for 
the activation of ATR, although the underlying mechanism for how this is achieved in unclear 
(Kumagai et al., 2006, Mordes et al., 2008). Therefore, the activation of ATR by TopBP1 is 
critical for proper ATR signaling in response to replication stress. TopBP1 is phosphorylated 
in response to replication fork stalling agents or ionising radiation, but the biological 
relevance of these modifications has not been ascertained yet (Yamane et al., 2003). In 
keeping with its role as a mediator protein, TopBP1 has a number of other binding partners 
including, CtIP, BRCA1-associated C-terminal helicase 1 (BACH1) and the MRN complex 
(Duursma et al., 2013, Gong et al., 2010, Leung et al., 2010, Ramirez-Lugo et al., 2011, Yoo 
et al., 2009). The significance of these multiple interactions is not well understood but it could 
influence the regulation of TopBP1-ATR signalling, depending on the type of genotoxic 
stress (Nam and Cortez, 2011). 
1.6.3 53BP1 
Originally identified as a p53 interacting protein in a yeast two-hybrid screen, 53BP1 has 
been characterised as an integral part of the DNA damage response to DSBs (Iwabuchi et al., 
1994). 53BP1 has several well-defined domains that are specific to its various functions. 
Similar to the classical mediator proteins, 53BP1 has C-terminal tandem BRCT domains. 
However, in addition it also possesses a tandem Tudor domain, which is necessary for 
interaction with methylated histones and a GAR (glycine/arginine-rich region) domain, 
possibly required for DNA binding (Alpha-Bazin et al., 2005, Boisvert et al., 2005c, Bork et 
al., 1997, Charier et al., 2004, Huyen et al., 2004). Upstream of these domains lie a number of 
PIKKs consensus motifs, which are phosphorylated in a PIKK-dependent manner in response 
to IR (Jowsey et al., 2007, Lee et al., 2009, Lee et al., 2010). The characterisation of these 
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phosphorylations is still not understood, however, work has shed light on the phosphorylation 
of serine 1219 which was found to be involved in DNA damage signaling and activation of 
the G2/M checkpoint following IR (Lee et al., 2009). In addition phosphorylation of 53BP1 
on serine 25 by ATM is required for an interaction with Pax2 transactivation domain-
interacting protein (PTIP), and disruption of this interaction resulted in hypersensitivity to IR 
(Munoz et al., 2007). Furthermore it has been shown RIF1, which promotes NHEJ, 
recruitment is also dependent on phosphorylated 53BP1 (Chapman et al., 2013a, Di Virgilio 
et al., 2013, Escribano-Diaz et al., 2013, Feng et al., 2013, Zimmermann et al., 2013). Recent 
evidence has suggested the interaction of PTIP or RIF1 to distinct phosphorylated residues on 
53BP1 occurs independently and serves as a mechanism by which either mutagenic DNA 
repair is suppressed or productive CSR is promoted (Callen et al., 2013).  
The ubiquitylation of H2A-type histones in response to DNA damage, is thought to promote 
relaxation of the chromatin structure allowing exposure of otherwise hidden epigenetic marks 
e.g. histone H3 methylated on lysine-79 or histone H4 methylated on lysine-20. Exposure of 
these methyl groups allows 53BP1 to bind to the chromatin surrounding the break. This is 
achieved through its Tudor domains, which were originally proposed to bind di-methylated 
K79 of histone H3. However, this has widely been disputed and rather it is thought that its 
Tudor domains preferentially bind to di-methylated K20 of histone H4 (Botuyan et al., 2006, 
Huyen et al., 2004). The recruitment of 53BP1 to damaged chromatin is also dependent on 
additional factors.  For instance the histone acetyltransferase (HAT) activity of Tip60, that 
facilitates acetylation of histones possibly opening the chromatin further, is necessary for 
53BP1 foci formation (Murr et al., 2006). Moreover, 53BP1 has been reported to interact 
directly with RNF168 ubiquitylated H2A on K15 via its C-terminal ubiquitination-dependent 
recruitment (UDR) motif (Fradet-Turcotte et al., 2013). The above examples suggest the 
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recruitment of 53BP1 to DNA DSBs is highly dependent on histone modifications instigated 
by damage signalling pathways. Once bound, 53BP1 serves to amplify ATM signalling and 
assist in the repair of the break. Interestingly, despite exhibiting defective repair of DSBs, 
cells lacking 53BP1 show only a mild ATM signalling deficits (Shibata et al., 2010). This 
suggests that the role of 53BP1 in signal amplification maybe dispensable compared to its 
role in the repair of DSBs. Indeed, work has shown that following exposure to high doses of 
IR, ATM activity, substrate phosphorylation and cell cycle checkpoints are effectively normal 
in 53BP1 deficient cells (Noon and Goodarzi, 2011, Shibata et al., 2010). However, 
accumulation of the MRN complex at later stages of the DDR signalling is reliant on 53BP1. 
In particular, 53BP1 contributes to this accumulation by interacting with Rad50 via its BRCT 
domains and this then allows further phosphorylated KAP1-dependent remodelling of 
heterochromatin proximal to the break (Lee et al., 2010, Noon and Goodarzi, 2011, Noon et 
al., 2010). 
In summary, 53BP1 seems to regulate a number of pathways that promote genomic integrity. 
This is achieved through multiple roles including the recruitment of protein complexes, 
protection of DNA ends from re-section and a degree of chromatin remodelling to render the 
local environment surrounding the damage favourable for repair.  
1.6.4 BRCA1 
Of all the mediators of DNA damage, BRCA1 is perhaps the best studied, which is probably 
due to the fact that germline heterozygous mutations in the BRCA1 gene account for a 
significant proportion of hereditary breast and ovarian cancers (Brody and Biesecker, 1998, 
Futreal et al., 1994). Since the mapping and cloning of the BRCA1 protein 20 years ago, 
several hundred mutations have been identified, with the most common of these heavily 
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investigated with regards to breast and ovarian cancer predisposition (Caestecker and Van de 
Walle, 2013, Hall et al., 1990, Miki et al., 1994). BRCA1 plays a role in a number of cellular 
functions involving DNA DSBs including repair of the lesion and cell cycle checkpoint 
activation.  
The varied roles of BRCA1 in the cell may be attributed to the number of interacting proteins 
that bind to its different domains. The N-terminus of BRCA1 houses a really interesting new 
gene (RING) domain and a nuclear export signal (NES), whereas the C-terminus contains two 
BRCT domains (Rodriguez and Henderson, 2000, Wu et al., 1996). Other domains found 
between the N and C-terminus includes two nuclear localisation signals (NLS) and an S/TQ 
cluster domain (Koonin et al., 1996, Thakur et al., 1997). In addition to providing an 
interaction platform for a several protein complexes, BRCA1 functions with its binding 
partner BARD1 as a heterodimeric E3 ubiquitin ligase. Despite this, the identity of the in vivo 
targets for this activity has been a matter of considerable debate. To date, histone H2A and 
CtIP have been proposed as being substrates for the E3 ubiquitin ligase activity of the 
BRCA1/BARD1 complex, although the experimental evidence supporting these claims have 
been disputed (Yu et al., 2006, Zhu et al., 2011). The interaction between BRCA1 and 
BARD1 is mediated via the BRCA1 RING domain (Meza et al., 1999). The formation of the 
BRCA1/BARD1 heterodimer acts to stabilise both proteins, so it could be suggested that the 
interaction is necessary for BRCA1, and by association BARD1, to carry out cellular 
functions (Joukov et al., 2001). BARD1 enhances BRCA1 ubiquitin ligase activity once 
bound, and clinically the importance of this association as well as that of the BRCA1 ligase 
activity can be deduced from the observation that mutations in the BRCA1 RING domain are 
found frequently in patients with a predisposition for developing breast/ovarian cancer 
(Hashizume et al., 2001, Xia et al., 2003). Interestingly, BRCA1 has been found to be a part 
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of at least three different complexes, the assembly of which depends on the cellular response 
to the type of DNA damage present in the cell (Deng and Brodie, 2000, Greenberg et al., 
2006, Huen et al., 2010, Wang et al., 2000). BARD1 is present in each of these complexes, 
with the variation coming from distinct sub-units. The BRCA1-A complex refers to BRCA1 
when in association with RAP80, Abraxas, BRCC4, BRCC5 and MERIT40 (Wang and 
Elledge, 2007, Wang et al., 2007). Abraxas phosphorylation on serine 406 facilitates a 
specific interaction with the BRCT domains of BRCA1 (Kim et al., 2007b, Liu et al., 2007, 
Wang et al., 2007). Abraxas then acts as a bridge between BRCA1 and RAP80, which acts to 
bring BRCA1 to the sites of damage (Huen et al., 2010). The localisation of the BRCA1-A 
complex also relies on RNF8 and RNF168, whose E3 ligase activity promotes the creation of 
poly-ubiquitin chains on histones proximal to the DSB. It is thought that RAP80, along with 
the other members of the BRCA1-A complex have binding affinity for ubiquitin chains and, it 
this which helps to secure BRCA1 at the lesion (Kim et al., 2007a, Sobhian et al., 2007, van 
Attikum and Gasser, 2009, Wang and Elledge, 2007, Wang et al., 2007, Yan et al., 2007b). 
Once located at the break, one function of the BRCA1-A complex is to promote activation of 
G2/M checkpoint (Huen et al., 2010). This activity of BRCA1 is known to be partly through 
its ability to regulate Chk1 phosphorylation (Yarden et al., 2002). However, it is clear that 
since cells deficient in other subunits of the BRCA1-A complex, such as RAP80 and Abraxas, 
only have partial defects in G2/M checkpoint activation, recruitment of BRCA1 to sites of 
DNA damage foci is not an absolute requirement for the checkpoint to be initiated and that 
perhaps its involvement in other damage responsive protein complexes also play a role in this 
(Huen et al., 2010).  
The second complex, BRCA1-B (Wang and Elledge, 2007), contains BRCA1-interacting 
protein C-terminal helicase 1 (BACH1, also known as FANCJ or BRIP1) and TopBP1 
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(Cantor et al., 2001, Greenberg et al., 2006). Evidence has pointed to the involvement of the 
BRCA1-B complex in activation of the intra-S-phase checkpoint following the induction of 
DNA damage (Huen et al., 2010, Xu et al., 2001, Xu et al., 2002b). In response to IR, 
BRCA1 has been demonstrated to be phosphorylated on multiple sites by ATM and this is 
indispensable for the intra-S-phase checkpoint. Although, it is likely that its phosphorylation 
on the same residues by ATR following the induction of damage by agents that perturb DNA 
synthesis is involved in its ability to activate the replication checkpoint (Cortez et al., 1999, 
Kumaraswamy and Shiekhattar, 2007, Xu et al., 2001, Xu et al., 2002b). In addition to this, 
BRCA1 and BACH1 have been reported to interact throughout S-phase and importantly the 
association of these proteins with TopBP1 upon replication stress may play a role in 
facilitating the efficient activation of ATR (Greenberg et al., 2006, Yu and Chen, 2004).  
Despite the identification of numerous key regulators of the intra-S phase and replication 
checkpoint, the mechanisms underlying how the cell is able to suppress DNA synthesis is 
relatively unclear. It is known that DNA damaging agents such as IR are capable of 
suppressing the ability of the cell to fire dormant origins of replication (Merrick et al., 2004). 
Whilst it is known that the CHK1-dependent inhibition of CDK activity plays a major role in 
activation of this checkpoint, it is thought that preventing the loading of the replication 
initiation factor CDC45 onto origins also contributes to this suppression of new origins of 
replication firing (Falck et al., 2002). TopBP1 and BACH1 have both been reported to 
regulate the loading of CDC45, the former regulating loading in the absence of damage and 
the latter preventing loading in the presence of damage (Greenberg et al., 2006, Schmidt et 
al., 2008). Given that TopBP1 interacts with BRCA1/BACH1 in a damage dependent 
manner, it could be postulated that following treatment with IR, the interaction between 
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TopBP1 and BRCA1/BACH1 not only promotes CHK1 activation but also prevents loading 
of CDC45 (Greenberg et al., 2006).  
The last of the three complexes BRCA1 is thought to form in response to DNA damage is the 
BRCA1-C complex ((Wang and Elledge, 2007)Wang et al 2007a). Here, BRCA1 associates 
with the MRN and CtIP, and this complex is central to HR-mediated repair during the S/G2 
phase of the cell cycle. The phosphorylation of CtIP, possibly by ATM and CDKs, promotes 
its interaction with BRCA1 as well as enhancing the binding of BRCA1 to the MRN complex 
(Chen et al., 2008, Yu and Chen, 2004). It is then thought that BRCA1 acts as a scaffold 
keeping MRN/CtIP at the break where 5’ DNA-end resection can take place. The 
BRCA1/CtIP interaction, although active during HR, is not essential for this process (Reczek 
et al., 2013).  One study suggested that CtIP ubiquitylation by BRCA1/BARD1 is required to 
promote its retention on the DNA. However, a recent study has revealed that it is the 
dimerisation of CtIP that is essential for proper HR repair (Wang et al., 2012, Yu et al., 
2006). The formation of the BRCA1-C complex is also necessary for activation of the 
ATR/ATRIP-dependent G2/M checkpoint in response to DSB, as insufficient resection of the 
DNA will prevent the loading of RPA and the subsequent activation of ATR/ATRIP. In 
addition to promoting resection during HR, BRCA1 is also required for the recruitment of 
RAD51 to the processed DNA ends although it is unclear as to whether there is a direct 
interaction between these two proteins (Chen et al., 1998). 
1.6.5 MDC1 
MDC1, also known as NFBD1 (Nuclear Factor with BRCT domains), was first isolated 
nearly twenty years ago during analysis of large cDNAs originating from a human myeloid 
cell cDNA library (Nagase et al., 1996). Since then, MDC1 has been the subject of many 
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studies focused on assessing its contribution to the DDR (Goldberg et al., 2003, Lou et al., 
2003a, Lou et al., 2003b, Peng and Chen, 2003, Shang et al., 2003, Stewart et al., 2003, Xu 
and Stern, 2003). The demonstration that MDC1 plays a key regulatory role in coordinating 
the DDR is highlighted by the observations showing that loss of MDC1 results in an increased 
sensitivity to a variety of different DNA damaging agents, intra-S and G2/M phase checkpoint 
defects, as well as impaired recruitment of DNA repair factors to sites of damage (Stewart et 
al., 2003, Goldberg et al., 2003).   
1.6.5.1 Structure  
MDC1 is a large protein spanning 2089 amino acids in length comprising an N-terminal FHA 
domain, a large central PST repeat domain and tandem BRCT (tBRCT) domains located at its 
C-terminus (Figure 1.13). Early studies demonstrated that MDC1 lacking the tBRCT domains 
failed to form IRIF and moreover, cells expressing this mutant protein exhibited reduced 
γH2AX foci (Shang et al., 2003). Further biochemical and cellular studies confirmed that the 
tBRCT domains interact directly with the phosphorylated C-terminus of γH2AX and it has 
become widely accepted that this is the primary function of this domain (Lee et al., 2005, 
Stucki et al., 2005, Lou et al., 2006). However, more recent evidence suggests that the tBRCT 
of MDC1 also serves as a phospho-binding platform for CDC27, a subunit of the APC/C as 
well as DNA topoisomerase IIα (Topo IIα) (Coster et al., 2007, Luo et al., 2009, Townsend 
et al., 2009). The tBRCT domains of MDC1 have also been reported to interact with the 
V(D)J recombination recombinase RAG1 in a phospho-dependent manner (Coster et al., 
2012). The N-terminus of MDC1 harbours an FHA domain. Early studies into the role of this 
domain and how it contributes to MDC1 function have proven to be inconclusive. Firstly, 
CHK2 was proposed to interact with this region, however, the two proteins do not seem to co- 
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localise in undamaged cells and more importantly, following exposure to DNA damaging 
agents, MDC1 forms IRIF but CHK2 remains dispersed in the nucleus (Lukas et al., 2003).  
The lack of co-localisation suggested that despite the fact that the two proteins have affinity 
for each other, the interaction may not be relevant within the cellular context or that if it does 
occur, it may be very transient (Jungmichel and Stucki, 2010). Another putative MDC1 FHA 
domain interacting factor has been suggested to be ATM (Lou et al., 2006). The interaction 
was noticeably weak when ATM was incubated with the FHA domain of MDC1 in vitro, 
suggesting the interaction may not be direct (Lou et al., 2006). In addition to CHK2 and 
ATM, RAD51 has also been suggested to be a MDC1 FHA binding protein, albeit in a 
phospho-independent manner, and that this interaction is required for MDC1 to stimulate HR 
(Zhang et al., 2005). Again though, due to conflicting evidence, this observation has not been 
substantiated (Bekker-Jensen et al., 2006, Goldberg et al., 2003). Recently, two studies have 
provided more convincing evidence that a major role for the FHA domain of MDC1 is to 
promote dimerisation. Both studies demonstrate the ATM-dependent phosphorylation of 
MDC1 on threonine-4 creates a binding site for the FHA domain of a different MDC1 
molecule. It has been proposed that this damage-inducible dimerization of MDC1 is required 
to promote its efficient accumulation at sites of DNA damage. However, it is unclear to what 
impact loss of MDC1 dimerisation has on its ability to promote DSB repair or activate the 
intra-S and G2/M checkpoints (Jungmichel et al., 2012, Liu et al., 2012, Luo et al., 2012).  
Downstream of the FHA domain lies a group of PIKKs consensus sequences 
(Serine/Threonine-Glutamine). Subsets of these motifs have been demonstrated to be 
phosphorylated by ATM following IR (Kolas et al., 2007, Mailand et al., 2007). 
Phosphorylation of this cluster promotes the interaction with the FHA domain of RNF8, and 
this in turn facilitates RNF8 recruitment to damaged chromatin (Huen et al., 2007, Kolas et 
 56 
al., 2007, Mailand et al., 2007). Disruption of this interaction negatively impacts on the DNA 
damage signalling cascade, which becomes evident from the loss of both BRCA1 and 53BP1 
IRIF. 
C-terminal to the PIKK motif clusters lies a proline-serine-threonine (PST)-rich repeat 
domain, the function of which has not yet been characterised. This region, consisting of 13 
consecutive repeats, occupies almost a third of MDC1, and displays no known sequence 
homology with any other proteins (Jungmichel and Stucki 2010, Coster et al., 2012). The 
recruitment of both MDC1 and all downstream factors is independent of the PST repeat 
region (Lou et al., 2004, Shang et al., 2003, Xie et al., 2007). Earlier work suggested that this 
region bound DNA-PK, and its deletion resulted in a partial NHEJ defect (Lou et al., 2004). 
However, this observation has not been reproduced by others. Moreover, it has been 
demonstrated that the recruitment of DNA-PK to sites of DNA damage occurs independently 
of MDC1 (Bekker-Jensen et al., 2006, Gottlieb and Jackson, 1993). In addition, it was more 
recently shown that this PST repeat region is required to promote HR rather than NHEJ (Xie 
et al., 2007). Interestingly, this region is also important for mitotic progression in the absence 
of DNA damage as cells expressing a mutant form of MDC1 lacking this domain, displayed 
an increased accumulation of mitotic cells (Townsend et al., 2009).   
1.6.5.2 Function 
As discussed, MDC1 contains a number of structural and functional domains, which permit 
the protein to elicit its cellular activity. The importance of its biological function is 
highlighted from research that showed firstly, that loss of MDC1 in mice is coupled with 
increased tumour frequency, and secondly, that loss or reduction of MDC1 protein levels has 
been observed in various cancers (Bartkova et al., 2007, Minter-Dykhouse et al., 2008). 
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1.6.5.2.1 DNA double-strand break repair 
The activation of γH2AX along regions of chromatin flanking the break initiates the 
signalling cascade necessary for repair. One way γH2AX achieves this is by binding directly 
to MDC1. The phosphorylated C-terminus of γH2AX contains the following binding 
sequence pS-X-X-Y/F-COOH (where X denotes any amino acid) (Stucki et al., 2005). A 
phospho-serine peptide library screen showed that the tBRCT domain of MDC1 had a strong 
selective affinity for this motif (Rodriguez et al., 2003). In light of this, further investigation 
showed that the phosphorylated C-terminal tail of γH2AX provided a direct binding platform 
for the tBRCT of MDC1 (Lee et al., 2005b, Lou et al., 2006, Stucki et al., 2005). Disruption 
of this interaction leads to abrogation of the recruitment of several DDR proteins into IRIF, 
such as phosphorylated ATM, MRN, 53BP1, BRCA1 and MDC1 itself, emphasising the 
importance of MDC1 for the re-localisation of a number of DSB repair proteins to DNA 
breaks (Lou et al., 2006, Stucki and Jackson, 2006). Once bound, MDC1 creates a positive 
feedback loop propagating the damage signal along the chromatin by recruiting more 
phosphorylated ATM possibly via its FHA domain and thus, more γH2AX and subsequently 
more MDC1 and its interacting partners. In support of the requirement of MDC1 in signal 
propagation and amplification, is the observation that loss or disruption of MDC1 leads to 
reduced phosphorylation of H2AX and in the formation of smaller γH2AX foci (Lou et al., 
2006, Stewart et al., 2003, Stucki et al., 2005). One explanation for the reduced H2AX 
phosphorylation observed in the absence of MDC1 could be attributed to the fact that MDC1 
may be protecting γH2AX from phosphatases. Previous work showed that in vitro, a 
recombinant GST-fused tBRCT domain prevented phosphatases from dephosphorylating the 
C-terminus of γH2AX, and in vivo, overexpression of the tBRCT led to hyperphosphorylation 
of γH2AX (Stucki et al., 2005). In undamaged cells, H2AX is phosphorylated on tyrosine 142 
 58 
located within a region that mediates binding to MDC1 tBRCT and this prevents the 
interaction with MDC1 (Cook et al., 2009, Xiao et al., 2009). Following exposure of cells to 
DNA damaging agents, this residue becomes dephosphorylated, allowing the association 
between H2AX and MDC1 and thus, providing another level of regulation of the DDR 
signalling cascade (Coster and Goldberg, 2010, Jungmichel and Stucki, 2010).  
Once recruited to the break, MDC1 can then mediate the recruitment of its binding partners. 
Although the activation of ATM is not MDC1 dependent, accumulation of phosphorylated 
ATM appears to be. Cells depleted of MDC1 show a reduction in phosphorylated ATM 
recruitment and retention on the chromatin in response to DNA damage (Lou et al., 2006). 
The same study demonstrated that there is a direct interaction between ATM and the FHA 
domain of MDC1, and another study showed that this interaction was also dependent on the 
phosphorylation of ATM on serine 1981 (Lou et al., 2006, So et al., 2009). This phospho-
dependent recruitment of ATM via MDC1 is one of the key components in the response to 
DSBs. The ability of MDC1 to retain phosphorylated ATM on the chromatin leads to an 
increase in phosphorylated H2AX, with further MDC1 re-localisation and therefore increased 
retention of phosphorylated-ATM.  
In addition to binding phosphorylated ATM, MDC1 is also phosphorylated by the kinase in 
response to IR, on a cluster of PIKK motifs (Kolas et al., 2007, Mailand et al., 2007, 
Matsuoka et al., 2007). It was shown that the phosphorylation of these sites on MDC1 
facilitates the binding of the E3 ubiquitin RNF8, via a direct interaction of the FHA domain of 
RNF8 with the phosphorylated MDC1 motifs (Huen et al., 2007, Kolas et al., 2007, Mainland 
et al., 2007). The discovery of this interaction also revealed a function for MDC1 in 
promoting activation of the ubiquitin-dependent arm of DSB repair. Disruption of this 
interaction led to loss of 53BP1 and BRCA1 IRIF, whose localisation relies on the formation 
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of ubiquitin conjugates at the break region (Huen et al., 2007, Kolas et al., 2007, Mainland et 
al., 2007). MDC1 has also been shown to interact directly with 53BP1 (Eliezer et al., 2009). 
Interestingly though, this interaction was seen to decrease following the generation of DSBs. 
It was suggested that a pool of MDC1 and 53BP1 interact in undamaged cells, and that 
following damage, the fraction of MDC1 bound to 53BP1 re-localises to the sites of DSBs 
where they disassociate and bind to different partners, MDC1 with γH2AX and 53BP1 with 
methylated histones (Eliezer et al., 2009).  
In addition to its role in facilitating and amplifying DNA damage signalling at DSBs, MDC1 
has also been implicated in the DSB repair process as its depletion by siRNA reduces the rates 
of both NHEJ and HR (Lou et al., 2004, Zhang et al., 2005). One possible way, by which 
MDC1 may influence NHEJ, is through interacting with DNA-PKCS. DNA-PK was 
discovered as an MDC1 PST-repeat region binding protein, and it was suggested that this 
interaction was important for DNA-PK activation (Lou et al., 2004). The same study showed 
that NHEJ was defective in MDC1 depleted cells and that this defect was dependent on the 
PST region of MDC1. However, exactly how MDC1 influences DNA-PK is still unknown. 
Another indication that MDC1 has a role in NHEJ came from work examining the recruitment 
of DDR proteins at dysfunctional telomeres. Uncapped telomeres are recognised as DSBs and 
can be fused in a NHEJ dependent manner. Loss of MDC1 itself or of its ability to localise at 
telomeric regions resulted in a decrease in telomeric fusions (Dimitrova and de Lange, 2006).  
A putative role of MDC1 in HR comes mainly from the work by Zhang, et al 2005 who 
showed direct interaction between MDC1 and RAD51, a protein essential for sister chromatid 
strand invasion during HR. Rather than regulating RAD51 localisation, MDC1 seems to 
regulate RAD51 stability based on the observation that upon MDC1 depletion, a marked 
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increase in RAD51 degradation is observed. Furthermore, under similar conditions RAD51 
foci are also reduced (Goldberg et al., 2003, Zhang et al., 2005).  
Following work that highlighted the contribution of ubiquitylation in DDR regulation, it was 
also revealed that MDC1 is targeted itself by ubiquitin and this was linked to its degradation 
(Zhang et al., 2006). However, another study looking at the ubiquitylation of the tBRCT 
domain suggested this modification does not mark the protein for degradation (Strauss et al., 
2011). It was shown that the tBRCT undergoes ubiquitylation through K63 linkages, a 
modification primarily thought to regulate protein-protein interaction and localisation. Indeed, 
the ubiquitylation of MDC1 in this context fuels an interaction between MDC1 and the UIMs 
of RAP80. In particular, the interaction requires the poly-ubiquitylation of MDC1 on K1977, 
and the E2 conjugating enzyme UBC13 (Strauss and Goldberg, 2011). This study revealed 
that this modification of MDC1 was damage independent.  
Ubiquitylation also regulates MDC1 turnover following completion of DNA repair. Earlier 
work indicated that the turnover of MDC1 foci depended on ubiquitin mediated degradation 
by the proteasome, as these foci persisted when the cells were treated with proteasomal 
inhibitors (Shi et al., 2008).  MDC1 has 103 lysines spanning its length and identifying which 
are important for its degradation remained elusive at the time of the above study. More 
recently, lysine 1840 of MDC1 has been reported to be sumoylated in response to DNA 
damage by PIAS4, and this modification was shown to target MDC1 for ubiquitylation and 
subsequent degradation by the E3 ubiquitin ligase RNF4 (Galanty et al., 2012, Luo et al., 
2012, Yin et al., 2012).  
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1.6.5.2.2 Cell cycle checkpoint control 
MDC1 was suspected to have a role in cell cycle checkpoint control based mainly on the 
observation that proteins containing BRCT and FHA domains commonly participate in the 
regulation of this process (Bork et al., 1997). Indeed, cells depleted of MDC1 exhibit 
defective intra-S-phase and G2/M checkpoint activation following IR (Goldberg et al., 2003, 
Lou et al., 2003a, Lou et al., 2003b, Stewart et al., 2003). When activated, for example after 
IR, the intra-S-phase checkpoint acts to inhibit DNA synthesis. Two mechanisms exist to 
activate the intra-S-phase checkpoint in response to IR.  The first involves CHK1/CHK2 
phosphorylation by ATM and the other, NBS1 and SMC1 phosphorylation also by ATM 
(Lim et al., 2000, Yazdi et al., 2002). Cells harbouring a defect in the activation or 
maintenance of the intra-S-phase checkpoint display radioresistant DNA synthesis (RDS) 
(Falck et al., 2001). Higher levels of RDS have been observed in cells treated with MDC1 
siRNA, following IR, compared to controls, in several studies (Goldberg et al., 2003, Lou et 
al., 2003a, Lou et al., 2003b, Stewart et al., 2003). How MDC1 influences the intra-S-phase 
checkpoint is unclear as loss of MDC1 results in only a mild reduction in the phosphorylation 
of Chk1, which is required to initiate the checkpoint (Lou et al., 2003b, Peng and Chen, 2003, 
Stewart et al., 2003). A reduction in SMC1, but not NBS1, phosphorylation was also reported 
in cells depleted of MDC1 (Goldberg et al., 2003, Stewart et al., 2003). On the other hand, 
CDC25A degradation, which is also required for checkpoint activation remained unaffected 
(Goldberg et al., 2003). Therefore, the precise mechanism with which MDC1 influences the 
intra-S-phase checkpoint requires further investigation.  
Similarly elusive is the mechanism by which MDC1 influences the G2/M checkpoint. An 
increase in the mitotic marker phospho-histone H3 was detected in MDC1 knockdown cells 
exposed to IR compared to controls (Stewart et al., 2003). This suggested that in the absence 
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of MDC1 and following IR, cells are unable to arrest the cell cycle at the G2/M transition. In 
support of this, a similar reduction upon MDC1 depletion was also observed in the levels of 
phosphorylated CHK1 on serine 345, another marker of the G2/M checkpoint activation 
(Stewart et al., 2003). Interestingly, a reduction in phospho-histone H3 was also observed in 
undamaged cells with low levels of MDC1, implying that MDC1 is also required for normal 
G2/M transition even in the absence of DNA damage (Bu et al., 2010).  
1.6.5.2.3 Mitosis 
A major factor in the regulation of mitotic progression is the multi-subunit complex APC/C. 
In the absence of APC/C, cells are unable to separate sister chromatids in anaphase, and 
cannot exit from mitosis (Peters, 2006). Through its ubiquitin ligase activity, APC/C plays a 
pivotal role in the proteasome-mediated degradation of cell cycle regulators (Castro et al., 
2005, Peters, 2006, Wasch and Engelbert, 2005). MDC1 has been reported to interact with 
APC/C in a phosphorylation-dependent manner. In particular, the tBRCT domain of MDC1 
interacts with the CDC27 subunit of the APC/C complex and this interaction is enhanced in 
response to IR (Coster et al., 2007). Interestingly, the MDC1 binding region on CDC27 
(APC3) is similar to that on γH2AX, and given that both interacting proteins associate with 
the MDC1 tBRCT domain, this could suggest that there may be some competition for 
binding. Alternatively, binding may occur in separate circumstances or there may be different 
MDC1 complexes in the cell (Coster and Goldberg, 2010, Coster et al., 2007). A second 
study, expanded these observations, and showed that MDC1 also bound to CDC20, an 
activator protein of APC/C complex that is required for APC/C to control the metaphase-
anaphase transition in mitosis (Townsend et al., 2009). The study of Townsend, et al 2009, 
showed that depletion of MDC1 by siRNA resulted in a mitotic block at metaphase, further 
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indicating that MDC1 has a role in mitosis in undamaged cells (Townsend et al., 2009). From 
these observations it is likely that MDC1 has separable roles within the cell, one which is 
involved in controlling the DDR and the other is crucial for regulating the cell cycle in the 
absence of genotoxic stress.  
1.6.5.3 Additional functions 
Clearly MDC1 has been best characterised with respect to its function in promoting DNA 
repair and cell cycle checkpoint activation. Yet, a number of studies point towards the 
contribution of MDC1 in other cellular pathways. 
Studies have suggested that MDC1 has anti-apoptotic potential, and one putative avenue 
through which this is achieved is via intervention of p53-dependent apoptosis. In one report, 
MDC1 was seen to protect cells from apoptotic death by blocking p53 activity (Nakanishi et 
al., 2007). Upon DNA damage caused by ionising radiation p53 is phosphorylated on serine 
15 by ATM, which results in p53 protein stabilisation and upregulation as well as an increase 
in its transcriptional activity that targets pro-apoptotic genes (Banin et al., 1998, Canman et 
al., 1998). Over expression of MDC1 was seen to reduce the damage-dependent 
phosphorylation of p53 on serine 15, suggesting an inhibitory role of the p53 stabilisation and 
upregulation (Nakanishi et al., 2007). This inhibition was concluded to occur through the 
binding of p53 to the MDC1 tBRCT domain. Furthermore, a second study reported that 
MDC1 interacts with the p53 mediator Mouse double minute 2 homolog (MDM2) and 
increases its stability (Inoue et al., 2008). MDM2 is an E3 ubiquitin ligase as well as a 
transcriptional target of p53, which once upregulated, targets p53 for poly-ubiquitylation and 
proteosomal degradation. Western blotting analysis revealed that the levels of both MDM2 
and MDC1 decrease at later stages of the DDR signalling and that the two proteins interact in 
vitro. The tBRCT domain of MDC1 also mediates this interaction. The fact that both p53 and 
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MDM2 bind to the tBRCT of MDC1 suggests that MDC1 could be a platform for the MDM2-
p53 interaction (Inoue et al., 2008, Nakanishi et al., 2007). 
Previous work has identified a region of MDC1 that activated transcription of a 
chloramphenicol acetyl transferase reporter (Ozaki et al., 2000). This led to the discovery of a 
number of genes that were down-regulated in MDC1 knockdown cells in the absence of DNA 
damage, and surprisingly, these were not DDR proteins (Wilson et al., 2011). In addition, and 
due to MDC1 potentially regulating p53 activity, the same experiment was carried out in 
p53/MDC1 double knockdown cells, and similar results were achieved suggesting that the 
regulation was also p53 independent (Wilson et al., 2011). How MDC1 regulates the 
expression of these genes remains elusive.  
Over the last decade MDC1 has been classified as a typical mediator of DNA damage 
signaling in the cell. The numerous domains spanning the length of the protein serve as 
protein interaction platforms, which are normally phosphorylation-dependent. The majority of 
studies assessing MDC1 function have focused on its role in the mammalian DNA damage 
response, where it serves as a molecular bridge recruiting repair proteins to the sites of 
damage, ensuring an intact cellular damage response. The importance of the role of MDC1 in 
the DDR is underlined by the defects in cell cycle checkpoint activation and lack of proper 
damage signalling observed upon reduction of its protein levels. While the mechanisms with 
which MDC1 recruits various repair factors to DNA breaks has been thoroughly studied, the 
role of MDC1 in undamaged cells remains unclear. To further complicate matters, a fraction 
of protein-protein interacting domains on MDC1 have multiple binding partners and these 
events can be either damage-dependent or independent. The ability of these domains to bind 
several different partners suggest that MDC1 exists in a number of diverse complexes present 
in damaged or undamaged cells that are capable of carrying out distinct tasks.  
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1.6.6 The MRN complex 
Described as a sensor of DNA damage, the MRN complex can also be grouped with the 
mediator proteins, as one of its subunits, Nbs1, has protein-protein interaction domains that 
recruit repair factors to the sites of breaks. The diseases resulting from mutations in members 
of the complex highlight the significance of the MRN complex functions within the DDR. 
Mutations in MRE11, NBS1 or RAD50 cause the genetic syndromes ATLD, NBS and NBS-
LD respectively, and have been discussed earlier in the text.  
The MRN complex functions at the core of the cellular response to DSBs, and plays pivotal 
roles in sensing the lesion, initiating cell-cycle checkpoint activation and DNA damage 
signalling, as well as promoting or in the case of HR initiating DNA repair. In addition, the 
MRN complex is also required during telomere maintenance, DNA replication and meiosis. 
The complex was identified from genetic screens in S. cerevisiae looking for mutations in 
genes that resulted in sensitivity to DNA damaging agents or resulted in meiotic deficiencies, 
and as such were named:  mre11 (meiotic recombination 1), rad50 (radiation sensitive 50) 
and xrs2 (X-ray sensitive 2) (MRX) complex (Ajimura et al., 1993, Game and Mortimer, 
1974, Ivanov et al., 1992). MRE11 and RAD50 are highly conserved and have homologues in 
a number of organisms, whereas NBS1 is the orthologue of xrs2 and seems to be unique to 
higher eukaryotes.  The products of these genes were shown to form a complex in both yeast 
and mammals and displayed epistatic properties (Dolganov et al., 1996, Ogawa et al., 1995, 
Trujillo et al., 1998, Usui et al., 1998). It is the individual properties of each subunit that 
provide the opportunity for the complex to carry out numerous functions within the DDR and 
beyond. The association of the MRN components and formation of the complex is extremely 
important for its stabilisation and function. For instance, mutations in MRE11 or siRNA 
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mediated MRE11 knockdowns result in a reduction in the levels of both RAD50 and NBS1 
(Stewart et al., 1999, Zhong et al., 2005). 
1.6.6.1 MRE11 
The structure of MRE11 is composed of an N-terminal phosphoesterase domain, within which 
lies the NBS1 interaction domain, and two C-terminal DNA-binding domains. MRE11 also 
interacts with RAD50, and this binding domain resides in between the two DNA-binding 
domains (Figure 1.14). MRE11 stably dimerises, and this dimerisation is required for MRN 
complex function. MRE11 specific functions include DNA binding, DNA-end synapsing and 
endo/exonuclease activity on various DNA substrates (de Jager et al., 2001, Paull and Gellert, 
1998, Williams et al., 2008). Observations in vitro have shown MRE11 to possess ssDNA 
endonuclease activity, 3’-5’ ssDNA exonuclease, dsDNA exonuclease and hairpin opening 
activity (Furuse et al., 1998, Paull and Gellert, 1998, Trujillo and Sung, 2001, Trujillo et al., 
1998, Usui et al., 1998). The nuclease activity of MRE11 is required to process DNA ends, 
leading the way for repair in a variety of pathways. In total, five motifs located in the N-
terminal region of MRE11 are required for the nuclease activity (Moreau et al., 1999, 
Williams et al., 2008). From work in S. pombe, two specific residues were identified that 
could separate the exonuclease and endonuclease activity of MRE11 (Williams et al., 2008). 
Mutating histidine-68 resulted in a loss of its 3’-5’ exonuclease activity whereas mutation of 
histidine-134 abrogated both its 3’-5’ exonuclease activity and endonuclease activities 
(Williams et al., 2008). Disruption of the MRE11 nuclease activity had no effect on MRN 
checkpoint signaling, suggesting they act independently of each other. Despite this, the 
nuclease activity of MRE11 is essential for viability and DNA repair functions (Buis et al., 
2008). The nuclease activity of MRE11 and its DNA binding capabilities are, however, reliant  
Figure 1.14   Schematics of the members of the human MRN complex. (A) 
MRE11. MRE11 is 708 amino acids in length. Located at the N-terminus are five 
residues, named the phosphesterase domain which are required for MRE11 nuclease 
activity. Situated within this region is the NBS1 binding domain. At the C-terminus of 
MRE11 is the GAR motif and RAD50 binding domain, flanked by two DNA binding 
regions. (B) RAD50. 1312 amino acids in length, RAD50 contains a Walker A domain 
and a Walker B domain at the N and C terminus respectively. Proximal to the Walker 
motifs are the MRE11 interacting domains. Located centrally is the “hinge” region 
which in the presence of ATP can fold back in on itself bringing the coiled-coiled 
regions together. (C) NBS1. NBS1 is 754 amino acids in length, and possess an FHA 
domain and two BRCT domains at the N-terminus. Upstream of these binding 
domains is the nuclear localisation signal (NLS). The region responsible for binding 
to MRE11 is located at the C-terminus, as is the region required for ATM activation 
(Adapted from Rupnik et al 2010).  
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on the interaction with both RAD50 and NBS1. The MRE11 dimer forms the “core” complex 
of MRN, with each molecule of MRE11 binding one molecule of RAD50. A single molecule 
of NBS1 then binds to the complex via MRE11 (van der Linden et al., 2009).  
1.6.6.2 RAD50 
Related to members of the structural maintenance of chromosome (SMC) family, with which 
it shares sequence and structural similarities, RAD50, like SMC proteins, can influence 
chromatid cohesion. In addition to this, RAD50 possesses other attributes necessary for the 
function of the MRN complex as a whole. The N and C termini of RAD50 contain a Walker 
A and B motif respectively, and in the presence of ATP they are required for binding and 
partial unwinding of the DNA (Chen et al., 2005, de Jager et al., 2002, Hopfner et al., 2000, 
Raymond and Kleckner, 1993). Structural studies have shown that between the Walker A and 
B motifs is a coiled-coil domain separated by a central “hinge” region containing a zinc-hook, 
which has the ability to fold back on itself, bringing the two Walker motifs in close proximity 
to form a globular ATP-binding cassette (ABC)-type ATPase domain (Hopfner et al., 2001, 
Hopfner et al., 2000) (Figure 1.14). MRE11 has been shown to bind to RAD50 at the base of 
the globular domain (Hopfner et al., 2001, Moreno-Herrero et al., 2005).  
Like MRE11, two molecules of RAD50 exist within the MRN complex bringing both ABC-
ATPase domains from each molecule in close proximity with each other (Williams et al., 
2010). The binding of ATP to the RAD50 globular head, switches the conformation of the 
MRN complex from an ‘open’ to a ‘closed’ state. In the ‘open’ form the coiled-coil arms are 
not touching and the two Walker motifs of the same RAD50 molecule are distal from each 
other. The ‘closed’ state results in the coiled-coil arms coming together, bringing the Walker 
A and B motifs together, thus allowing the zinc-hooks from each molecule to interlock. In  
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addition to a requirement for ATP, this conformational change to the ‘closed’ form is also 
dependent on DNA binding, and once RAD50 and MRE11 are bound to NBS1, the 
conformation remains unchanged (Moreno-Herrero et al., 2005). RAD50 switches back to the 
‘open’ conformation following hydrolysis and release of ATP (Hopfner et al., 2001, Williams 
et al., 2007). When present in the closed state, the coiled-coil arms protrude away from the 
globular ABC-ATPase domains (de Jager et al., 2001). Here, they can either link with the 
coiled coil arms of the second molecule of RAD50, bound to the same strand of DNA, as 
described above, or act as a bridge, tethering two separate DNA strands via dimerisation with 
a different MRN complex bound to a distal DNA molecule (Hopfner et al., 2002, Moreno-
Herrero et al., 2005). This long-range tethering is thought to benefit homology-mediated 
repair, by creating a bridge between the sister chromatids. Evidently, the ATP-dependent 
conformational states of RAD50 are essential for the MRN complex function and 
furthermore, it was shown that ATP binding and hydrolysis by RAD50 also influences 
MRE11 nuclease activity in an NBS1-dependent manner, by regulating the switch between 
exo and endonuclease activities (Paull and Gellert, 1999, Trujillo and Sung, 2001, Williams et 
al., 2010) (Figure 1.15).  
1.6.6.3 NBS1 
The NBS1 subunit is essential for the recruitment of both RAD50 and MRE11 to the nucleus. 
This recruitment is dependent both on the nuclear localisation signal of NBS1 as well as its C-
terminus that interacts with MRE11 (Carney et al., 1998, Cerosaletti et al., 2000, Desai-
Mehta et al., 2001). The interaction of NBS1 with MRE11 and RAD50 stimulates the 
nuclease activity of MRE11 and the ATP-dependent unwinding of the DNA by RAD50 (Paull 
and Gellert 1999). Despite this stimulatory role, NBS1 lacks intrinsic enzymatic properties. 
However it is thought to act as a mediator/adaptor subunit within the MRN complex through 
Figure 1.15   RAD50 and MRN configurations. (A) Schematic of RAD50 in the ‘open 
conformation. (B) The MRN complex bound to chromatin. A cartoon showing MRN bound 
to a DSB. Two RAD50 molecules are in the ‘closed’ conformation,  where the coiled- coil 
domains have folded back on themselves, bringing the Walker A and B domains of each 
molecule into close proximity, forming a globular domain.  The zinc hooks of the two 
molecules can then interlock. The MRE11 dimer resides at the globular domain bound to 
RAD50, where it can then interact with NBS1. (C) The MRN bridging sister chromatids. 
The coiled-coils protruding out from one MRN complex can link with zinc hooks of another, 
bound to a distal molecule of DNA. This conformation can be utilised when homology-
mediated repair is required. (Adapted from Stracker & Petrini, 2011).  
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its ability to promote the recruitment of other key DDR proteins to the site of a aDSB. This is 
mediated via its N-terminal FHA and tBRCT domains and the presence of these domains 
within NBS1 gives the MRN complex a role in DNA damage signaling (Lloyd et al., 2009). 
Known damage response proteins that interact with these regions on NBS1 include ATR, 
TopBP1 and CtIP. The FHA/tBRCT domain is known to regulate the accumulation of γH2AX 
possibly through interacting with MDC1, although the mechanism by which this occurs 
remains elusive (Lloyd et al., 2009, Williams et al., 2009). NBS1 also contains an ATM 
interaction motif at the C-terminus, and this regulates accumulation of ATM at DSB (Falck et 
al., 2005, You et al., 2005).  It should be noted that the interaction between NBS1 and ATM 
is not essential for the re-localisation and activation of the kinase, as disruption of this 
interaction can be compensated for by other mediator proteins (Difilippantonio et al., 2007, 
Stracker et al., 2007) (Figure 1.8).  
 1.6.6.4 Sensing DSBs and repair 
It is widely accepted that the MRN complex is one of the earliest factors to arrive at the sites 
of DSBs and functions upstream of the ATM kinase. Once at the lesion, the MRN complex 
may help to prevent premature degradation of the free DNA ends and/or reduce the chance of 
the free ends migrating away from each other (Lamarche et al., 2010). The MRN complex 
then initiates ATM-dependent signaling in part by assisting in the recruitment and activation 
of ATM via the C-terminus of NBS1, and therefore, propagating ATM autophosphorylation 
and in turn amplification of the cellular damage response to facilitate the recruitment of 
downstream DDR proteins. 
In parallel to the sensing and signaling role of MRN, the complex also begins the processing 
of the DNA ends at the break, which can include unwinding, resection, removal of inhibitory 
complexes and the resolution of DNA structures such as hairpins (Rupnik et al., 2010). 
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Strikingly, this arm of MRN function, which is facilitated through the MRE11 nuclease 
activity, is dispensable for ATM and checkpoint activation, but essential for the repair of 
DNA breaks (Buis et al., 2008). MRN, and more specifically MRE11, has been shown to 
function in both HR and NHEJ repair pathways. Of the two, the role of MRE11 in HR has 
been better studied, where the nuclease activity is required to process the DNA ends to allow 
invasion of the sister chromatid. As described previously, HR is restricted to the S and G2 
phases of cell cycle as in G1 there is a lack of a sister chromatid. It is thought that MRE11, in 
conjunction with CtIP, can promote resection of the DNA ends, which are then further 
processed by a second set of nucleases, namely EXO1 and DNA2. The precise mechanism of 
resection by MRE11 during HR is still under discussion, due to the fact that MRE11 possess 
3’-5’ but not 5’-3’ exonuclease activity that is normally required for resection.  One possible 
strategy proposed by Garcia et al (2011), involves MRE11/CtIP creating multiple nicks near 
the break. MRE11 then resects the DNA toward the break, with EXO1 performing long-range 
resection away from the break (Garcia et al., 2011). In support of this hypothesis, MRX in 
yeast is only capable of resecting several hundred nucleotides, insufficient for complete HR 
and therefore requiring further processing by nucleases such as EXO1 (Mimitou and 
Symington, 2008, Zhu et al., 2008). Although not possessing nuclease activity itself, CtIP has 
been shown to enhance the nuclease activity of MRE11 (Sartori et al., 2007, You et al., 
2009). Resection of the DNA relies also on BRCA1, which forms a complex with the MRN 
complex as well as CtIP and potentially functions to anchor MRN and CtIP at the lesion 
(Chen et al., 2008, Sartori et al., 2007, Yun and Hiom, 2009). The formation of this complex 
is also dependent on CDK activity, with work showing that both CtIP and NBS1 are 
phosphorylated by CDK kinases and that these modifications are essential for resection and 
therefore, HR (Falck et al., 2012, Huertas and Jackson, 2009).  
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Evidence has implicated a role for MRN in both NHEJ and Alt-EJ as siRNA knockdown of 
MRE11 in both Xrcc4-/- and Xrcc4+/+ backgrounds resulted in end joining defects (Rass et 
al., 2009, Xie et al., 2009). The role of MRN during NHEJ may be a structural one, as a 
nuclease deficient Mre11 mutant expressed in S.cerevisiae exhibited no defects in end-joining 
(Zhang and Paull, 2005). Another possibility is that MRN along with CtIP may serve to 
remove unwanted DNA structures and inhibitory proteins, “preparing” the ends for other 
processing enzymes (Rass et al., 2009). The potential role of MRN during Alt-EJ is a little 
clearer, and would appear that the MRE11 nuclease activity is required in the absence of 
classical NHEJ nucleases to resect the DNA needed for homology searching (Xie et al., 
2009). More recently, MRN has been shown to interact with DNA ligase IIIα/XRCC1, a 
participant of Alt-EJ, where it functions in a stimulatory capacity aiding the joining of the 
DNA molecules, possibly via end-bridging followed by resection (Della-Maria et al., 2011).  
NHEJ seems to be the major pathway for DSB repair throughout the cell cycle (Fattah et al., 
2010). Furthermore, factors such as the absence of a sister chromatid as well as the low levels 
of CtIP during G1 reduces the likelihood of HR repair happening. NHEJ repair is initiated by 
the KU70/KU80 heterodimer, which like the members of the MRN complex is in high 
abundance throughout cell cycle. Even in S/G2 phases where repair can occur via HR, a 
number of reports have demonstrated NHEJ still repairs the vast majority of the DSBs in the 
later phases of cell cycle (Beucher et al., 2009, Karanam et al., 2012). The question, 
therefore, arises as to what determines which repair pathway is utilised to repair DSB in 
S/G2? Very little is understood about how this is regulated but it could be that the MRN and 
the KU complexes compete at the site of breaks to determine the repair process or that the cell 
defaults to using NHEJ but if this fails then MRN-dependent repair processes take over 
(Lamarche et al., 2010).  
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1.6.6.5 MRN and cell cycle checkpoint control 
Indications that the MRN complex contributes to cell cycle checkpoints arose from the 
observation that genetic syndromes caused by hypomorphic mutations in any gene of the 
complex displayed defects in the G1, intra-S and G2/M cellular checkpoints. Following 
exposure to IR or treatment with radiomimetic drugs, cells from NBS patients display defects 
in cell cycle checkpoint activation (Jongmans et al., 1997, Yamazaki et al., 1998). Elevated 
levels of RDS in these cells point to an inability to activate the intra-S-phase checkpoint, 
resulting in the continuation of DNA synthesis following damage. Exactly how NBS1 
influences intra-S-phase checkpoint control is still unclear. A number of mechanisms exist to 
regulate the intra-S-phase checkpoint and all rely on ATM following IR (Falck et al., 2002). 
Two of these mechanisms are dependent on NBS1 and may shed light on the proteins 
function in regulating the checkpoint. The first involves SMC1, whose phosphorylation on 
serine 957 and 966 is required for checkpoint activation and suppression of RDS, and this is 
dependent on the phosphorylation of NBS1 on serine 287 and 343 by ATM (Kim et al., 2002, 
Yazdi et al., 2002). The second may involve the ATM-dependent phosphorylation of 
FANCD2 on serine 222 that is also dependent on ATM mediated phosphorylation of NBS1 at 
serine 343 (Nakanishi et al., 2002, Taniguchi et al., 2002). In addition to these findings, a role 
for MRN in regulating the intra-S-phase checkpoint downstream of the Nbs1 dependent 
phosphorylation of SMC1 has also been reported. MRN was shown to associate with RPA 
through MRE11 in a cell cycle-dependent manner more preferably at the G1-S phase 
transition and to relocalise to replication origins during S-phase in both undamaged and 
irradiated cells (Olson et al., 2007b). Interestingly, in response to IR, ATM phosphorylates 
MRN bound to RPA and this prevents DNA replication initiation, suggesting that 
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phosphorylated MRN somehow interferes with RPA function at replication origins (Olson et 
al., 2007). 
The role of MRN in the G1/S checkpoint regulation has presented some controversy. Again 
based on work using patient NBS deficient cells, checkpoint abnormalities were observed at 
low doses of IR but not at high doses, suggesting that MRN may in some way contribute to 
the activation of this checkpoint (Zhao et al., 2000). However, other studies have failed to 
report such defects (Antoccia et al., 1999, Jongmans et al., 1997). What is consistent in NBS 
deficient cells is a reduction in p53 stabilisation following IR and transcriptional upregulation 
of its effector protein p21waf1, which are required for G1 cell cycle arrest (Antoccia et al., 
1999, Girard et al., 2002, Jongmans et al., 1997, Matsuura et al., 1998, Yamazaki et al., 
1998). More recently, problems in G1 checkpoint activation were also reported in a patient 
harbouring mutations in RAD50 (Waltes et al., 2009).  
The MRN complex has also been found to be required for ATM-dependent CHK2 
phosphorylation following IR. Cells derived from NBS patients display reduced CHK2 
activation and as consequence, an inability to prevent transit into mitosis. The ATM 
phosphorylation of NBS1 on serine 343 has been found to be required for G2/M checkpoint 
activation, as NBS deficient cells expressing NBS1 mutated at this site failed to activate the 
checkpoint in response to IR (Buscemi et al., 2001). Although more recently from 
experiments in Nbs1 knockout mice observations showed that the phosphorylation on serine 
343 and serine 278, both targeted by ATM in the response to DNA damage, were not required 
for the G2/M checkpoint or indeed the S-phase checkpoint (Difilippantonio et al., 2007). 
However the same study did show that activation of both these checkpoints was dependent on 
the FHA domain of NBS1. In conclusion, it appears that the MRN complex, possibly but not 
exclusively through NBS1, can regulate cellular checkpoint activation. 
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1.6.6.6 Additional functions 
The MRN complex is involved in telomere homeostasis. Dysfunctional telomeres that arise in 
the absence of components of the Shelterin complex become recognised as DNA DSB, in an 
ATM-dependent manner (Takai et al., 2003). MRN is localised to these regions 
independently of its nuclease activity, suggesting that the complex may be required for 
sensing and signalling of DNA breaks rather than DNA end-processing (Denchi and de 
Lange, 2007). Studies in yeast described a second role for MRN at telomeres, based on the 
observation that disruption of members of the MRX complex resulted in shortened telomeres 
in S.cerevisiae (Chamankhah and Xiao, 1999, Kironmai and Muniyappa, 1997). In yeast 
telomeres are synthesised during S-phase by telomerase, which prevents telomeric erosion. 
Further work led to the speculation that MRX may resect telomeres, which are then bound by 
Cdc13, a telomeric DNA binding protein in yeast, that then recruits telomerase (Tsukamoto et 
al., 2001). An indication that this may also be the case in higher eukaryotes arose from the 
observation that NBS1 deficient cells displayed shortened telomeres, and that expression of 
both NBS1 and telomerase in these cells resulted in longer telomeres than expression of 
telomerase alone (Ranganathan et al., 2001). Again how MRN functions within the telomere 
micro-environment in vertebrates requires further investigation.  
The MRE11 nuclease activity is utilised during meiotic recombination. Meiotic 
recombination occurs prior to the first meiotic division and ensures that the correct 
chromosomes are physically paired through connection of homologous chromosome arms and 
cohesion between sister chromatids (Kleckner, 2006, Neale and Keeney, 2006, Petronczki et 
al., 2003). Essentially, the cell creates DNA DSB breaks and then uses repair to lock 
chromosomes together. These scheduled DSB breaks are created by the topoisomerase II-like 
enzyme SPO11, which functions as a dimer and once the break has been created one molecule 
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remains covalently linked on each side of the break. In order for repair to take place, the 
SPO11 molecules must be removed from either side of the break. Work in yeast has provided 
evidence that the nuclease activity of Mre11, along with Sae2 (CtIP in humans), is needed for 
the removal of SPO11 (Lengsfeld et al., 2007, Neale et al., 2005). Upon removal of SPO11, 
repair via HR, the repair mechanism in meiosis due to NHEJ being suppressed, can initiate 
(Goedecke et al., 1999). In mammalian cells MRE11 is likely to cooperate with CtIP, the 
orthologue of Sae2, during meiotic recombination to carry out similar functions (Sartori et al., 
2007).  
MRN also has roles during immune system development. Based on studies from mice models, 
the MRN complex, although not essential, may play a regulatory role in V(D)J recombination. 
In a Nbs1 hypomorphic mutants, the joining but not the ligation step of coding ends via Alt-
EJ during V(D)J was impaired (Deriano et al., 2009). This finding suggested the MRN 
complex deals with V(D)J recombination intermediates by stabilising break ends and 
preventing unwanted joining reactions. Moreover, MRN involvement in V(D)J recombination 
seems to require NBS1 but not the MRE11 nuclease activity (Deriano et al., 2009).  
The role of MRN in CSR appears to be more involved. One role is the processing of DNA 
ends. However, only a subset of programmed DNA breaks generated during CSR, those that 
are repaired using NHEJ, require the nuclease activity of MRE11 (Dinkelmann et al., 2009). 
The same study also reported that a nuclease-deficient MRE11 mutant displayed only a mild 
defect in CSR compared to complete MRN loss, adding support to the notion that the 
nucleolytic function of MRN in CSR is not essential for repair. A second possible role of 
MRN that may support the severe CSR defect noted with complete MRN loss may be the 
requirement for RAD50 to bridge distal DNA ends for ligation following resection essential 
for microhomology searching (Dinklemann et al., 2009). In contrast to the first proposed role 
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of MRN in CSR, resection over longer regions of DNA is active when the generated DSB are 
repaired through the Alt-EJ machinery, and therefore, MRN may function in two separate 
pathways that can be utilised by the cell to repair breaks of this type.  
The individual properties of each subunit allow the MRN complex to participate within 
different cellular processes. Reduced levels of any of the members results in the 
destabilisation of the complex, reiterating the epistatic nature of MRN, and explaining the 
similar phenotypes seen in patients harbouring mutations in MRE11, NBS1 or RAD50. A role 
of MRN during DNA replication is beginning to surface, with many of the functions of the 
complex required in DNA repair overlapping. For instance, evidence has shown the MRN 
complex, and specifically the nuclease activity of MRE11, is required for replication fork 
restart following collapse or stalling of the fork (Bryant et al., 2009). Just exactly how the 
MRN complex is regulated to carry out its functions over a wide subset of cellular pathways 
is still to be revealed.  
1.7 Post-translational modifications and the DNA DSB damage 
response 
As previously discussed, the cellular response to DNA DSB is a tightly regulated orchestrated 
series of events, involving a large number of different proteins. The recruitment of these 
proteins to damage sites or their activation relies on various post-translational modifications 
(PTM). These modifications can act either to promote the activity of DDR proteins or 
suppress activity once the lesions are repaired. From work dissecting repair pathways a 
multitude of PTMs have been uncovered that are required to control the sensing of damaged 
DNA, signalling of the damage response and ultimately initiate cell cycle checkpoints.  
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1.7.1 Ubiquitylation in response to DNA DSBs 
Studies have revealed ubiquitin to be highly important in the response to DSBs. In support of 
this, disruption of these ubiquitin-dependent mechanisms required for an intact DDR, 
increases cancer risk (Scully and Livingston, 2000, Wang and Elledge, 2007). The ubiquitin 
machinery involves three enzymatic steps (Hershko et al., 2000). Firstly, in an ATP-
dependent manner the E1 enzyme activates ubiquitin, which is then transferred to an E2 
conjugating enzyme that along with an E3 ligase attaches the ubiquitin to the substrate.  Two 
families of E3 ligases exist. The larger of the two are the really interesting new gene (RING) 
E3 ligases, which number more than 600 in mammalian cells (Li et al., 2008). The second 
family, and the smaller of the two is the homolgous to E6-AP carboxy terminus (HECT) E3 
ligases. The RING E3 ligases facilitate the transfer of the ubiquitin molecule from the E2 
conjugating enzyme to the substrate (Zheng et al., 2000). Whereas the HECT domain E3 
ligases are thought to possess catalytic activity and this is required for attachment of ubiquitin 
to the substrate (Scheffner and Kumar, 1995).  
Ubiquitin can either be bound to the substrate as a single molecule, or form chains. Ubiquitin 
itself contains several lysines and in theory any one of them could be a targeted for chain 
formation. The generation of ubiquitin chains and how each ubiquitin molecule is linked 
dictates the outcome of the substrate. For example it is accepted that ubiquitin chains formed 
through K48 ubiquitin linkage usually direct the substrate for degradation by the proteosome, 
whereas those chains linked via K63 are associated with signalling mechanisms (Glickman 
and Ciechanover, 2002, Hicke, 2001, Messick and Greenberg, 2009, Thrower et al., 2000). 
Current understanding denotes, in addition to K48 and K63 linkage, ubiquitin chains can also 
form through linkages at K6, K11, K27, K29 and K33, although the functional consequences 
of attaching these atypical ubiquitin chains to a substrate is unclear (Kim et al., 2007c). It has 
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been recently demonstrated that the ubiquitin chains catalysed by the APC/C linked through 
K11 may be involved in tagged proteins for proteasome-dependent degradation (Dimova et 
al., 2012). 
Within the DDR, a role for ubiquitin was first identified in yeast with the discovery that 
RAD6, a protein involved in postreplication repair, was an E2 ubiquitin-conjugating enzyme 
(Jentsch et al., 1987). Subsequent investigations revealed a major role for ubiquitin in 
mammalian DNA repair (Bekker-Jensen et al., 2010, Doil et al., 2009, Galanty et al., 2012, 
Hashizume et al., 2001, Huen et al., 2007, Kolas et al., 2007, Mailand et al., 2007, Stewart, 
2009, Wang and Elledge, 2007). While certainly ubiquitin-mediated degradation of DDR 
proteins occurs, surprisingly, most of the ubiquitin conjugates identified during repair seem to 
be associated with protein-protein interactions.  Several E3 ubiquitin ligases that modulate the 
cellular response to DNA DSBs have been identified, including BRCA1, RNF8, RNF168, 
HERC2 and RNF4. BRCA1, along with its binding partner BARD1, was the first to be 
identified (Table 1.1) (Hashizume et al., 2001, Morris and Solomon, 2004). The importance 
of the BRCA1 ubiquitin ligase activity is highlighted by the number of clinical mutations 
reported in the BRCA1 RING domain necessary for the catalysis of ubiquitin conjugation to 
the substrate (Yu et al., 2006). The ubiquitylation of histones H2A and H2AX has been 
attributed to RNF8, an E3 ligase that is recruited to DNA breaks by interacting with MDC1. 
The ubiquitylation of histones by RNF8 causes chromatin relaxation around the break that 
allows the recruitment of further DDR proteins such as 53BP1 and BRCA1 to DNA breaks. 
The E3 ubiquitin ligase HERC2 is also required in this process, by recruiting the E2-
conjugating enzyme UBC13 (Bekker-Jensen et al., 2010). The RNF8-dependent 
ubiquitylation of histones is further amplified by a third E3 ubiquitin ligase, RNF168 in  
DUB Substrate or Interaction partner 
USP3 H2A 
USP10 p53 
USP11 H2A, BRCA2 
USP16 H2A 
USP28 53BP1, TopBP1, MDC1. 
USP44 H2A 
BRCC36 BRCA1, BRCA2, RAD51, RAP80 
POH1/PSMD14 K63 ubiquitin chains 
OTUB1 UBC13 
 
E3 ligase  Target 
BMI1 !H2AX 
BRCA1 Unknown 
HERC2 Promotes chromatin ubiqutitylation 
RNF8 H2A/H2AX 
RNF168 H2A/H2AX 
TRIP12 RNF168? 
UBR5 RNF168? Additional DDR E3s 
 
Table 1.2  DUBs and target proteins involved in the cellular response to DNA 
double-strand breaks.    
Table 1.1  E3 ligases and substrates involved in the cellular response to DNA 
double-strand breaks. 
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collaboration with other  ubiquitin ligases such as TRIP12 and UBR5 (Table 1.1) 
(Gudjonsson et al., 2012). How TRIP12 and UBR5 achieve this is unclear. An additional 
study showed B lymphoma Mo-MLV insertion region 1 homolog (BMI1) and RING2, both 
members of the polycomb group proteins involved in maintaining gene repression patterns, 
are also required for mono-ubiquitylating γH2AX (Ismail et al., 2010). The recruitment of 
these proteins and ubiquitylation is independent of RNF8, however depletion of BMI1 does 
have an impact on the formation of both 53BP1 and BRCA1 foci (Ismail et al., 2010). It is 
commonly thought that the ubiquitylation of histones after DNA damage results in relaxation 
of the local chromatin structure, allowing visualisation of di-methylated H4K20 by the Tudor 
domain of 53BP1 to promote its recruitment (Botuyan et al., 2006). However, recent evidence 
suggests that the Tudor domains of JMJD2A/B preferentially bind this methylated residue on 
histone 4 in the absence of damage. Following exposure to IR, RNF8 and RNF168, as well as 
ubiquitylating H2A, are thought to catalyse the ubiquitin-dependent degradation of 
JMJD2A/B, allowing 53BP1 access to the methylated histone (Mallette et al., 2012). Lastly, 
the ubiquitin chains formed on damaged chromatin can be recognised by proteins containing 
ubiquitin interacting motifs (UIM) and motif interacting with ubiquitin (MIU) domains. For 
example, the recruitment of RAP80, a BRCA1 associated protein, to the sites of DNA breaks 
is thought to be mediated through its tandem UIMs that recognise poly-ubiquitylated histones 
(Kim et al., 2007a, Sobhian et al., 2007, Wang et al., 2007).  
Deubiquitylation at sites of DSB repair plays an equally important role in the regulation of 
these events (Table 1.2). Many of the deubiquitylation enzymes (DUBs) identified so far 
active in various DNA DSB repair pathways, function to down-regulate the RNF8/RNF168-
dependent DDR. BRCC36, a member of the BRCA1-RAP80 complex, has affinity for K63-
linked ubiquitin chains, and is thought to remove such chains generated by RNF8 and UBC13 
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(Cooper et al., 2009b, Shao et al., 2009a). Similarly, a proteasome-associated DUB, 
POH1/PSMD1, which also exhibits a strong selectivity for K63-linked ubiquitin, was shown 
to have a negative impact on the RNF8 pathway (Butler et al., 2012, Cooper et al., 2009a). 
This is an example of the tight interplay involved in the ubiquitin regulated DDR. Several 
other DUBs are involved in this regulation, for example USP3, USP16 and OTUB1, which 
counteract the products of RNF8/RNF168 ubiquitin ligase activities. Both USP3 and USP16 
have also been shown to act on ubiquitylated H2A (Joo et al., 2007, Nicassio et al., 2007). 
Interestingly, OTUB1 negatively regulates the activity of the E2 enzyme, UBC13, by 
disrupting its ability to transfer ubiquitin to an RNF168 bound substrate (Juang et al., 2012, 
Wiener et al., 2012). More recently, in a DUB overexpression screen USP44 was shown to 
antagonise the RNF8/RNF168 pathway through de-ubiquitylation of H2A (Mosbech et al., 
2013). Whereas the majority of DUBs identified so far in this pathway act on the ubiquitin 
chains formed on the histone H2A, the DUB, USP28 was shown to be involved in stabilising 
the mediators TopBP1, 53BP1 and MDC1 (Zhang et al., 2006).  
1.7.2 SUMOylation in response to DNA DSBs 
SUMOylation involves the conjugating of a ubiquitin-like molecule, SUMO (small ubiquitin-
related modifier) to target substrates, which can target substrates for degradation, alter their 
cellular localisation or promote protein-protein interactions. Mammalian cells possess 4 
SUMO isoforms, SUMO-1, and the highly related SUMO-2 and SUMO-3. A fourth gene 
encoding SUMO-4 occurs in the human genome but it is unclear whether its product can be 
conjugated to proteins (Zlatanou and Stewart, 2010). Differing by only three amino acids, 
SUMO-2 and -3 are able to form poly-SUMO chains whereas only a single molecule of 
SUMO-1 can be attached to a substrate (Morris, 2010). Targeting of SUMO to substrates is 
mediated by a single E1 SUMO activating enzyme, Uba2/Sae2, a single SUMO conjugating 
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enzyme E2, UBC9 and a handful of E3s and like ubiquitin this is usually coordinated onto a 
lysine residue on the substrate (Desterro et al., 1999, Hochstrasser, 2001, Jackson, 2001, 
Kagey et al., 2003, Okuma et al., 1999, Pichler et al., 2002). SUMOylation is reversible and 
SUMO molecules are removed by the peptidases SENP1-SENP3 and SENP5-SENP7 (Yeh et 
al., 2000). 
SUMOylation was recently identified as an additional modification in the cellular response to 
DSBs with the observation that SUMO1-3, UBC9 and the E3 ligases PIAS1/4 and MMS21 
localised to sites of laser-induced DSB (Galanty et al., 2009, Morris et al., 2009). More 
specifically inactivation of PIAS4 abrogated RNF168 accumulation, while depletion of 
PIAS1 affected RAP80 and BRCA1 recruitment. Unsurprisingly, depletion of PIAS1 and 4 
also showed a negative affect on the HR and NHEJ repair pathways (Galanty et al., 2009, 
Morris et al., 2009). RNF168 and HERC2 were found to be SUMOylated in a PIAS4-
dependent manner, as ablation of PIAS4 led to reduced levels of RNF168, impacting on 
HERC2 binding to RNF8 (Danielsen et al., 2012). 
It has been demonstrated that the E3 ubiquitin ligase activity of BRCA1 is enhanced by 
SUMOylation following the induction of DSBs, possibly by regulating its interaction with its 
E2 or recruiting proteins containing SUMO interacting motifs (SIMS) that are BRCA1 
ubiquitin-targeted proteins (Morris et al., 2009). For this reason, BRCA1 is termed a SUMO-
regulated ubiquitin ligase (SRUbL). Therefore, the role of SUMO maybe to enhance the 
ubiquitin ligase activity of E3s during the DNA DSB repair pathway. This may also be true of 
the role SUMO plays in regulating RNF168 and HERC2 activities. Further cross talk between 
ubiquitylation and SUMOylation is evident in a group of proteins termed SUMO-targeted 
ubiquitin E3 ligases (STUbLs). In particular, SUMOylation of a protein is recognised by the 
SIM of the STUbL, resulting in the ubiquitylation of the target protein and its subsequent 
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degradation. The mammalian E3 ubiquitin ligase RNF4 is one such ligase that is recruited to 
DNA DSBs and facilitates DSB repair (Galanty et al., 2012, Lallemand-Breitenbach et al., 
2008, Tatham et al., 2008, Weisshaar et al., 2008). RNF4 is shown to be recruited to a 
number of SUMOylated repair proteins via its tandem SIM domains, including RPA1 and 
MDC1, regulating their turnover during the repair process (Galanty et al., 2012). It has also 
been reported that MDC1 was SUMOylated on lysine 1840 by PIAS4 in a damage-dependent 
manner and was then targeted by RNF4, leading to its ubiquitylation and proteasome-
mediated degradation (Luo et al., 2012). 
In summary, SUMOlyation appears to aid both the recruitment and retention of repair proteins 
within the topography of the DDR landscape. Beyond this, recent evidence has revealed a role 
for SUMOylation in regulating E3 ubiquitin ligase activity, as well as providing a means of 
interaction between E3s and SUMOlyated substrates, resulting in degradation of the substrate.  
1.7.3 Methylation and acetylation in response to DNA DSBs 
Unlike the previously described PTMs, methylation, especially that of histones seems to occur 
constitutively (Huyen et al., 2004, Sanders et al., 2004). It is thought that in the absence of 
damage methylated histones are hidden due to the chromatin conformation, and upon the 
formation of DSBs the chromatin conformation changes in order to expose the methylated 
histones (Huyen et al., 2004, Sanders et al., 2004). For example, the ubiquitylation of histones 
in response to DSBs results in the relaxation of the chromatin surrounding the break, 
revealing their methylated residues that are recognised by the Tudor domains of 53BP1 
(Botuyan et al., 2006). 
More recently, studies have shown that arginine methylation of individual DDR proteins is 
required for their recruitment. In mammalian cells, there are 9 protein arginine N-
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methyltransferases (PRMTs) that catalyse this PMT (Bedford and Clarke, 2009). In the 
context of the damage response, PRMT1 seems to be the main PRMT and has an affinity for 
glycine-arginine-rich (GAR) motifs present in some DDR proteins (Boisvert et al., 2005b, 
Boisvert et al., 2005c, Dery et al., 2008, Tang et al., 2000).  
53BP1 contains a GAR domain that was shown to be methylated via PRMT1 irrespective of 
damage (Boisvert et al., 2005c). The same study also showed that the methylation of 53BP1 
on this domain promoted its association with both single and double-stranded DNA. Although 
mutation of the GAR domain did not disrupt 53BP1 localisation to sites of DNA damage, the 
authors hypothesised that methylation of its GAR domain served to strengthen the interaction 
between the Tudor domains of 53BP1 and the exposed methylated histones following DNA 
damage (Boisvert et al., 2005c). MRE11 also possesses a GAR domain that is methylated by 
PRMT1 (Boisvert et al., 2005a). More importantly, disruption of the MRE11 GAR domain 
impairs its exonuclease activity and its ability to activate the intra-S-phase checkpoint 
(Boisvert et al., 2005a). Another study showed that in the absence of damage, MRE11 co-
localises with PRMT1 in PML bodies and that its methylation is required for its re-
localisation to sites of DNA damage (Boisvert et al., 2005b). Finally, a more recent study 
supported these findings by demonstrating that methylation of MRE11 was required both for 
nuclease activity and chromatin retention (Dery et al., 2008). Like 53BP1, the methylation of 
MRE11 is thought to be constitutive, as no increase in methylation was observed in response 
to DNA damage (Dery et al., 2008).  
Acetylation and deacetylation, often associated with transcription, have also been shown to be 
involved in regulating the DDR. The acetyltransferase Tip60 is recruited to sites of DNA 
damage where it functions in two ways. Firstly, Tip60 acetylates ATM on lysine 3016, a 
modification required for its autophosphorylation and subsequent activation following the 
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induction of DSBs (Sun et al., 2005, Sun et al., 2007). This observation implies that the 
acetylation of ATM is possibly the earliest PTM to occur during the DSB signaling cascade. 
Tip60, which is ubiquitously expressed also targets histones H2A and H4, and it is thought 
that the acetylation of these proteins promotes chromatin relaxation proximal to the break 
increasing its accessibility for the recruitment of repair factors such as 53BP1 and BRCA1 
(Murr et al., 2006). Furthermore, the acetylation of H4 on lysine 16 (H4K16) by the MOF 
(males absent on the first) acetyltransferase, has been shown to promote MDC1 foci, possibly 
by stimulating an interaction between H4 and H2AX which in turn might regulate the binding 
between MDC1 and γH2AX (Li et al., 2010, Sharma et al., 2010). Interestingly it has recently 
been shown that acetylation and deacetylation by Tip60 and HDACs respectively determines 
53BP1 and BRCA1 association at the chromatin (Tang et al., 2013).  
Deacetylation observed at DSBs is carried out by members of the histone deacetylase 
(HDAC) family, SIRT1 and SIRT6 (Kao et al., 2003, Murr et al., 2006, Oberdoerffer et al., 
2008). For instance, SIRT1 was shown to directly interact with Nbs1 and that deacetylation of 
Nbs1 was necessary for its re-localisation to DSBs as well as for its ability to promote 
checkpoint activation (Oberdoerffer et al., 2008, Yuan and Seto, 2007). HDACs also play a 
role in the repair of the breaks during HR and NHEJ. CtIP is deacetylated by SIRT6, an event 
required for resection, which is essential for HR mediated repair (Kaidi et al., 2010). In 
addition, DSB repair by NHEJ requires the deacetylation of histone H3K56 mediated by 
HDAC1 and 2, which is thought to promote chromatin compaction (Miller et al., 2010). The 
same study suggested that during HR, acetylation functions to relax the chromatin in order to 
promote this type of repair. In contrast, during NHEJ a more compact and therefore, 
deacetylated chromatin seems to be beneficial (Miller et al., 2010).  
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1.7.4 Phosphorylation in response to DNA DSBs 
Of all the protein modifications that occur during DNA DSBs repair and checkpoint signaling 
phosphorylation has been the most studied. This comes as no surprise considering the vast 
number of phosphorylated targets within the DDR that have been identified by stable isotope 
labeling by amino acids in cell culture (SILAC)-based mass spectrometry screens (Bennetzen 
et al., 2010, Matsuoka et al., 2007, Stokes et al., 2007). In light of the requirement for 
phosphorylation during the DDR this type of modification has been extensively described in 
previous sections. For this reason only the salient phosphorylation events will be covered 
here. 
The serine/theronine PIKKs kinases, ATM, ATR and DNA-PK are extremely important in the 
repair of damaged DNA. Activation of these kinases is responsible for the phosphorylation of 
numerous downstream targets, either by the kinases themselves or as a result of their 
activation. This group of kinases display levels of redundancy, in particularly ATM and ATR, 
and are able to phosphorylate the same downstream targets. ATM, primarily required for the 
repair of DNA DSBs is activated by autophosphorylation on a number of residues following 
IR, and once this occurs it can phosphorylate downstream substrates such as H2AX, MDC1 
and Nbs1. Phosphorylation of these targets facilitates the recruitment and protein-protein 
interactions essential for a proper damage signaling. Exactly how activation of ATM occurs in 
response to DNA DSBs is still under discussion. However, it is clear from studies, where 
these sites have been modified and the subsequent defects seen in the ATM-dependent DDR 
that these autophosphorylation targets are essential (Kozlov et al., 2006, Kracker and 
Durandy, 2011). Activated ATM has also been shown to facilitate chromatin decondensation, 
which is vital for the repair of these lesions. The KRAB-associated protein (KAP1) is 
phosphorylated in an ATM-dependent manner on serine 824, which leads to the spreading of 
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KAP1 along the chromatin (Li et al., 2007a, White et al., 2012). Loss of this phosphorylation 
was shown to reduce the amount of damage induced chromatin relaxation near the lesion and 
caused sensitisation to DNA damaging agents (Ziv et al., 2006).  
Once these early phosphorylation events have occurred, further phosphorylation-mediated 
mechanisms can then control the next steps of the signalling cascade. The phosphorylation of 
proteins by the PIKKs creates docking sites for repair proteins harbouring phospho-peptide 
binding domains. This ensures that only when proteins become phosphorylated can 
downstream regulatory proteins be recruited ensuring the temporal and spatial coordination of 
signalling events are tightly regulated. This is exemplified by MDC1, which only following 
the interaction with γH2AX can it then be phosphorylated by ATM, and this then allows the 
recruitment RNF8 through its FHA domain. Repair of the breaks themselves is also 
dependent on phosphorylation. For instance phosphorylation of BRCA2 by CDKs causes its 
disassociation with Rad51, allowing for the formation of the nucleoprotein filament and 
therefore repair via HR (Esashi et al., 2005).  
Whilst repair of the DNA DSBs is occurring, cell cycle checkpoints are activated to allow 
time for this to happen. The control of cell cycle progression during damage signalling and 
repair involves phosphorylation and dephosphorylation of substrates. These PMTs are 
coordinated by ATM and ATR and aided by the Chk1 and Chk2 kinases, which upon 
activation, phosphorylate downstream substrates such as members of the Cdc25 family and 
p53, thereby instigating cell cycle arrest (Falck et al., 2001, Hirao et al., 2000, Sanchez et al., 
1997). In one example upon ATR recruitment, following exposure of ssDNA possibly 
through resection, Chk1 is phosphorylated on serine 345. Chk1 is thought to be recruited to 
the chromatin in response to damage, then following its phosphorylation it disassociates from 
 90 
the break into the nucleus, where it can then phosphorylate the Ccdc25 phosphatases and 
inhibit CDK cell cycle progression (Smits, 2006). 
Like all the PMTs occurring in the response to DNA DSBs, phosphorylation of substrates is 
balanced by the removal of the modification. Equally important as the phosphorylation of 
substrates, dephosphorylation of substrates has been observed in response to damage 
(Bennetzen et al., 2010, Bensimon et al., 2010). The activation of ATM kinase activity by 
autophosphorylation is prevented in undamaged cells by the Repo-Man (Recruits PP1 onto 
mitotic chromatin at anaphase)-PP1γ complex, which contains the PP1 phosphatase. 
Following DNA DSB induction, PP1 no longer associates with ATM, leading to the kinases 
activation and initiation of the DDR (Peng et al., 2010). ATM autophosphorylation is also 
regulated by the PP2A phosphatase, as is the ATR, DNA-PKs and furthermore Chk1 and 
Chk2 kinases (Douglas et al., 2001, Dozier et al., 2004, Freeman et al., 2010, Goodarzi et al., 
2006, Leung-Pineda et al., 2006). The wild-type p53-inducible phosphatase 1 (Wip1), also 
involved in dephosphorylating ATM, has been shown to dephosphorylate γH2AX (Cha et al., 
2010, Shreeram et al., 2006). The dephosphorylation of γH2AX is thought to revert the 
modified histone back to H2AX once repair has been completed. The dephosphorylation of 
these kinases acts to downregulate the signalling pathway once repair has been carried out, 
returning cell cycle progression back to normal. The ability for the cell to “turn off” these 
pathways is equally important as “turning them on”, as in the case of the DDR pathway 
persistence of signalling can be just as harmful as unrepaired DNA DSBs. 
1.8 Casein Kinase 2 (CK2) 
As previously highlighted, phosphorylation is an extensively studied modification in the 
cellular DDR cascade. In addition to the kinases described so far, several reports have also 
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indicated a significant contribution in the phosphorylation events of this pathway by another 
kinase, namely, Casein Kinase (CK2) (Iles et al., 2007, Loizou et al., 2004, Yata et al., 2012). 
Discovered nearly 60 years ago from studies using casein as a substrate, the actual 
physiological roles of CK2 were not been investigated until sometime later (Burnett and 
Kennedy, 1954). Since, CK2 has proven to be a promiscuous kinase with the number of its 
identified substrates reaching over 300 (Meggio and Pinna, 2003). This figure is likely to be a 
conservative estimate as a recent analysis of 10,899 phosphorylation sites present in the 
cellular proteome indicated that 2275 conformed to a typical CK2 phosphorylation consensus 
motif (Salvi et al., 2009). CK2 preferentially targets serine/threonine residues surrounded by 
acidic amino acids: S/T-X-X-D/E, where X denotes any amino acid (Pinna, 1990). 
Ubiquitously expressed in numerous tissues and cell types, CK2, unlike many other kinases, 
is constitutively active. For this reason it has been observed to play a role in a wide range of 
cellular pathways including cell survival, apoptosis, gene expression to name but a few 
(Izeradjene et al., 2004, Lin et al., 1992, Lorenz et al., 1994, Pepperkok et al., 1994, Yamane 
and Kinsella, 2005a). Interestingly, fluctuations in CK2 levels have been noted in several 
human diseases, and more specifically an elevation in the levels of CK2 has been reported in 
a number of cancers (Landesman-Bollag et al., 2001, Wang et al., 2006). Unsurprisingly, this 
observation has encouraged the development of CK2 inhibitors as potential anti-cancer 
treatments. 
1.8.1 Structure and activity  
CK2 often exists as a tetrameric complex, comprising of two catalytic subunits and two 
regulatory subunits. The catalytic subunits in human cells have two isoforms, named CK2α 
and CK2α´ (Litchfield et al., 2001). A third isoform has also been identified termed CK2α´´ 
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although this only makes up a small fraction of the cellular pools of CK2 catalytic subunits 
(Shi et al., 2001). In contrast, a single regulatory subunit, CK2β, exists in humans, and forms 
dimers in the CK2 tetrameric complex (Boldyreff et al., 1996, Chantalat et al., 1999, Gietz et 
al., 1995, Graham and Litchfield, 2000). CK2 complexes can contain combinations of the two 
catalytic subunits: CK2α/CK2α, CK2α´/CK2α´ or CK2α/CK2α´(Gietz et al., 1995). CK2α 
and CK2α´ both exhibit approximately 90% homology in their catalytic domains, and 
subsequently, display similar traits regarding their enzymatic activity, at least in vitro 
(Bodenbach et al., 1994, Litchfield et al., 1990). The third catalytic subunit, CK2α´´ is 
closely related to CK2α however, little is known about this subunit (Shi et al., 2001). The C-
terminal domains of CK2α and CK2α´ differ in amino acid sequence, suggesting existence of 
some non-redundant functions. For instance, CK2α is phosphorylated at sites located in its C-
terminal domain, and this phosphorylation was shown to be cell cycle-dependent (Bosc et al., 
1995, Litchfield et al., 1992). Thus, it could be that CK2α and CK2α´ are regulated 
differentially during cell cycle (Litchfield, 2003). Interestingly, knockout mouse models have 
demonstrated that the loss of either CK2α or CK2α´ does not result in lethality, supporting 
the notion that these subunits can compensate for the loss of each other. However, male 
CK2α knockout mice did display fertility defects indicating that is not the case for all CK2-
dependent functions (Xu et al., 1999). 
The regulatory subunit, CK2β, is highly conserved between species (Heller-Harrison et al., 
1989, Jakobi et al., 1989). From structural studies a dimer of CK2β was shown to sit at the 
centre of the tetrameric CK2 complex, with the two catalytic subunits attaching separately to 
the dimer (Boldyreff et al., 1996, Chantalat et al., 1999, Gietz et al., 1995, Graham and 
Litchfield, 2000, Niefind et al., 2009). A number of studies have shown that CK2β, within the 
CK2 tetrameric enzyme, serves to promote the catalytic activity, the stability of the complex 
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and the regulation of substrate specificity (Marin et al., 1999, Meggio et al., 1992). The CK2β 
subunit has also been reported to have higher expression levels than the catalytic subunits 
(Luscher and Litchfield, 1994). In light of this observation CK2β, via immunofluorescence 
experiments, has been reported to localise in areas where the α catalytic units are not present 
(Krek et al., 1992). Indeed, it is accepted that a population of CK2β exists independently of 
the CK2 complex and has separate functions. To highlight this, the kinase Chk1 has been to 
shown to interact with CK2β independently of the catalytic subunits (Guerra et al., 2003). 
Moreover, the same study noted that CK2β in complex with CK2α/α´ was unable to bind to 
Chk1, and conversely CK2β in complex with Chk1 could not form a complex with the 
catalytic subunits. The interaction between CK2β and Chk1 was seen to enhance the kinase 
activity of Chk1 (Guerra et al., 2003).  
Clearly, a kinase containing subunits that function independently of each other in addition to 
functioning within a complex, broadens the number of potential functional interactions as 
well as substrates of CK2. For this reason, and in the context of this study, only substrates 
targeted by the holoenzyme will be focused on, and more specifically, a subset of those 
involved in regulation of the cell cycle, apoptosis and the DNA damage response.  
1.8.2 CK2 and cell cycle 
The involvement of CK2 in cell cycle regulation has been known for some time. Several 
studies have demonstrated that siRNA depletion or inhibition of CK2 halts cell cycle 
progression at the G0/G1, G1/S and G2/M borders in mammalian cells (Lorenz et al., 1994, 
Pepperkok et al., 1994). Furthermore, CK2 is itself also phosphorylated in a cell cycle-
dependent manner. Cdk1, the primary mitotic cyclin-dependent kinase, has been shown to 
phosphorylate both CK2β and CK2α (Bosc et al., 1995, Litchfield et al., 1991, Litchfield et 
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al., 1992). However, the CDK-dependent phosphorylation of either of the subunits did not 
affect the overall activity of the holoenzyme, and therefore, the physiological reasoning 
behind these events is unknown. One possibility is that the CDK-dependent phosphorylation 
of CK2 may aid in the recruitment or the selection of substrates. Equally, it could function to 
direct CK2 away from substrates not required for cell cycle progression. Below are two 
examples of how CK2 influences cell cycle progression. 
At the onset of mitosis, the Wee1 family, which prevents entry into mitosis by suppressing the 
CDKs, is degraded (Watanabe et al., 2004). Phosphorylation of Wee1 by CDKs, CK2 and 
Plk1 on serines 123, 121 and 53 respectively, mark it for proteasomal degradation via 
ubiquitylation by the E3 ligase SCFβ-TrCP (van Vugt et al., 2004, Watanabe et al., 2005, 
Watanabe et al., 2004). The phosphorylation of all three residues is essential for its interaction 
with SCFβ-TrCP, and thus for the subsequent degradation of Wee1, which stimulates 
progression of the cell into mitosis (Watanabe et al., 2005).  
In addition to a requirement of CK2 for cell cycle progression, the kinase can also function to 
suppress cell cycle in the presence of DNA damage. It has been shown that the tumour 
suppressor p53 is phosphorylated by CK2 on serine 392 in response to UV irradiation and this 
enhanced both its DNA binding as well as its transcriptional activity (Kapoor and Lozano, 
1998, Keller and Lu, 2002). Elevating the transcriptional activity of p53 results in the up-
regulation of p53 target genes which function to stall the cell cycle, the best example of this 
being the CDK inhibitor p21WAF1/CIP1 (Sherr and McCormick, 2002). Moreover, the CK2 
kinase activity towards p53 is increased by a UV-dependent interaction between CK2 and the 
facilitating chromatin-mediated transcription (FACT) complex, containing hSPT16/CDC68 
and structure specific recognition protein 1 (SSRP1) (Keller and Lu, 2002, Keller et al., 
2001).  
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1.8.3 CK2 and apoptosis  
Many studies have pointed towards a role for CK2 in apoptosis. This can either be through 
receptor-mediated apoptosis or apoptosis that is a result of excessive DNA damage 
(Izeradjene et al., 2004, Yamane and Kinsella, 2005a). Similarly treating cells with CK2 
inhibitors is sufficient to induce cell death (Ruzzene et al., 2002, Wang et al., 2005a). From 
the literature it becomes apparent that CK2 is a pro-survival enzyme, preventing apoptosis by 
phosphorylating a number of proteins involved in anti-apoptotic pathways. In many examples, 
phosphorylation by CK2 of proteins involved in apoptosis prevents caspase-mediated 
degradation (Desagher et al., 2001, Krippner-Heidenreich et al., 2001). The caspases are a 
group of proteases that in response to pro-apoptotic signals function to cleave a group of 
proteins culminating in the breakdown of the cell. Caspase-inhibiting proteins that prevent 
caspase activity contain a caspase recruitment domain (CARD) (Hofmann et al., 1997, Koseki 
et al., 1998, Roy et al., 1997). One such protein is “Apoptosis Repressor with a CARD” 
(ARC) (Koseki et al., 1998). ARC requires phosphorylation on theronine 149 to carry out its 
caspase inhibiting function, and this phosphorylation is facilitated by CK2 (Li et al., 2002d). 
Specifically, the phosphorylation allows ARC to localize to the mitochondria, where it can 
then prevent caspase 8 activation, thereby inhibiting apoptosis (Li et al., 2002c). On the other 
hand CK2-dependent phosphorylation can also regulate caspase activation. Pro-caspase 2 is 
phosphorylated by CK2 on serine 157, and this modification acts by repressing its pro-
apoptotic activity (Shin et al., 2005).  
1.8.4 CK2 and the DNA damage response  
In light of the ubiquitous nature of CK2, it comes as no surprise that the kinase is involved in 
DNA damage signaling and repair. Often, CK2-dependent phosphorylation of DNA repair 
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proteins creates a phospho-motif capable of mediating an interaction with FHA and BRCT 
binding domain containing proteins.  
The first study to reveal a role for CK2 during DNA repair, reported the phosphorylation of 
XRCC1 by CK2 (Loizou et al., 2004). XRCC1 is required for single-strand DNA break repair 
(SSBR) as well as DSB during Alt-EJ, where it acts as a scaffold recruiting a number of repair 
factors. Phosphorylation by CK2 on a cluster of consensus motifs on XRCC1 promotes its 
interaction with the FHA domain of PNKP. As a consequence, either mutation of the CK2 
phosphorylation sites on XRCC1 or treatment of cells with a CK2 inhibitor impairs SSBR 
(Loizou et al., 2004). A similar CK2-dependent phosphorylation motif was also identified in 
the NHEJ protein XRCC4. This modification promotes an interaction between XRCC4 and 
the FHA domain of PNKP (Koch et al., 2004). Again, disruption of this interaction impaired 
DNA repair, although more specifically DNA end joining by DNA ligase-IV. It could be 
speculated that the two interactions represent a method by which constitutive CK2-dependent 
phosphorylation ensures a pool of XRCC1/PNKP and XRCC4/PNKP exists in the absence of 
damage, already primed and ready to respond immediately following the induction of 
genotoxic stress. 
Interestingly, the CK2-mediated phosphorylation of XRCC1 and XRCC4 was also found to 
be important for the binding of Aprataxin, the product of the gene mutated in the autosomal 
recessive disorder Ataxia-oculomotor 1 (AOA1). This interaction was required for Aprataxin 
to repair abortive DNA ligation intermediates following exposure to IR (Ahel et al., 2006, 
Date et al., 2004). Lastly, to complicate matters, a third FHA domain containing protein 
termed Apprataxin –and PNKP-like factor (APLF) was also reported to bind to the same CK2 
phosphorylated motifs on XRCC1 and XRCC4 (Iles et al., 2007). Like the previous studies 
this interaction appears to promote NHEJ and stimulate the ligation of IR induced DNA DSBs 
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(Grundy et al., 2013). Taken together the above studies demonstrate that CK2-dependent 
phosphorylation of XRCC1 or XRCC4 is essential for establishing separate DNA end-
processing repair complexes. 
Another example of CK2 mediated recruitment of proteins in response to DNA damage 
involves TopBP1 and the 9-1-1 complex. Briefly, the BRCT1 domain of TopBP1 was shown 
to be the binding site for RAD9 phosphorylated on serine 387 by CK2, and that this 
interaction is necessary for the association of TopBP1 with the 9-1-1 complex at 
dsDNA/ssDNA junctions (Rappas et al., 2010). The biological importance of this interaction 
is emphasized by the observation that mutation of this phosphorylation site in RAD9 results 
in an increased cellular sensitivity to UV radiation and to methyl methane sulphonate (MMS) 
(Takeishi et al., 2010).  
Modification of a substrate by CK2 can also be dependent on the phosphorylation of adjacent 
residues by other kinases. Examples of these CK2 “phosphorylation cascades” can be found 
within the cellular response to DNA damage. Plk1 phosphorylates the HR protein RAD51 on 
serine 14 in a cell cycle- and DNA damage-dependent manner. However, this phosphorylation 
primes RAD51 for phosphorylation by CK2 on threonine 13 (Yata et al., 2012). The 
phosphorylation of RAD51 on threonine 13 facilitates an association with NBS1, via its FHA 
domain. This study also showed that mutation of theronine 13 to an alanine prevented IR-
induced RAD51 foci, suggesting that this series of events promotes the chromatin retention of 
RAD51 through its interaction with NBS1 and thus, HR (Yata et al., 2012). Moreover, an 
interplay between CK2 and another kinase was reported for structure of maintenance of 
chromosome 3 (SMC3), a member of the cohesin complex. The cohesin complex is essential 
for the cohesion of sister chromatids during S and G2 phase and for DNA repair (Strom et al., 
2004, Uhlmann and Nasmyth, 1998). SMC3 is also constitutively phosphorylated by CK2 on 
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serine 1067, and this modification is required to promote its phosphorylation by ATM on a 
neighbouring serine residue (Ser-1083) and the subsequent activation of the intra-S phase 
checkpoint. As such, a Radio-resistant DNA Synthesis (RDS) phenotype was observed in 
cells expressing SMC3 harbouring a mutation on either serine 1067 or 1083 (Luo et al., 
2008). Furthermore, a similar S-phase checkpoint defect was also seen in cells lacking CK2. 
Therefore, it appears that can CK2 participate in DNA damage checkpoint activation through 
its ability to prime key effector proteins for phosphorylation by ATM and ATR. In support of 
this, it has also been documented for the transcription factor cyclic AMP response element-
binding protein (CREB), whose target genes include a number of DNA damage repair 
enzymes and cell cycle regulators (Impey et al., 2004, Mayr and Montminy, 2001). Work by 
Shanware, et al, (2007) showed that basal phosphorylation of CREB by CK2 on serine 111, 
which occurs in the absence of DNA damage, is necessary for several other sites (serine 108, 
serine 114, serine 117 and serine 121) to be phosphorylated, the latter of which is targeted by 
ATM following the induction of DNA damage (Shanware et al., 2007). Therefore, it would 
appear that constitutive phosphorylation of proteins by CK2 provides the cell with a 
mechanism with which to control both the order and timing of subsequent stimulus-induced 
PTMs.  
Lastly, as previously mentioned, chromatin relaxation at DNA breaks is necessary for the 
recruitment of DDR proteins as well as for amplification of the damage response signal. The 
heterochromatin protein 1 (HP1-β) is essential for chromatin compaction and is recruited to 
DNA breaks through an interaction with H3K9me (Ayoub et al., 2008). Following IR, HP1-β 
is phosphorylated by CK2 on theronine 51 increasing its mobilisation (Ayoub et al., 2008). In 
the presence of a CK2 inhibitor, HP1-β mobilisation was suppressed and a reduction in 
γH2AX foci was also observed (Ayoub et al., 2008). This suggests that the increased 
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mobilisation of HP1-β following CK2 phosphorylation after IR may relax the chromatin, 
which could then allow for the correct recruitment of DDR proteins.  
1.9 Aims and objectives 
The past decade has revealed an emerging role of CK2 in the DDR. In a number of examples 
the phosphorylation of substrates by CK2 permits interactions with proteins via specifc 
phosphopeptide binding domains namely FHA and BRCT domains. The publication of a 
number of largescale phosphoproteomic screens has aided in the identification of as yet 
uncharacterised putative phospho-residues on a wealth of proteins, including many involved 
in the repair of DNA breaks. Studying this data we noted a cluster of putative CK2 repeat 
motifs located on the N-terminus of MDC1. MDC1 is classed as a mediator protein, where 
upon recruitment to sites of DNA DSBs it functions as a scaffold to recruit other repair 
proteins to the lesions, promoting checkpoint activation and repair of the lesion. Both XRCC1 
and XRCC4, required for the repair of DNA breaks by Alt-EJ and NHEJ respectively, are also 
classed as scaffold proteins, and both are phosphorylated by CK2 on several residues. 
Phosphorylation of these residues permits the binding to a number of interacting partners with 
FHA domains (Iles et al., 2007, Koch et al., 2004, Loizou et al., 2004). The discovery of the 
CK2 motif cluster on MDC1, and comparisons to XRCC1 and XRCC4 function led to the 
hypothesis that these residues may be phosphorylated by CK2 and permit binding, and 
therefore the recruitment of other DNA DSB repair factors, in a mechanism that echoes that 
seen with XRCC1/XRCC4. Therefore the aims and objectives of this study were: 
i) Verify the putative CK2 sites of MDC1, using in vitro and in vivo 
techniques; 
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ii) Identify potential binding partners of MDC1, whose interaction may be 
mediated by these motifs; 
iii) Investigate other CK2 substrates involved in the DDR.  
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Chapter 2 Materials and Methods 
2.1 Molecular biology techniques 
2.1.1 Bacterial strains 
 
Strain Genotype 
DH5α 
(Invitrogen) 
 
F- φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, 
mk+) phoA  
supE44 λ- thi-1 gyrA96 relA1  
 
Stbl2 
(Invitrogen) 
 
F- mcrA ∆(mcrBC-hsdRMS-mrr) recA1 endA1lon gyrA96 thi 
supE44 relA1  
λ- ∆(lac-proAB)  
  
 
BL21 
(Stratagene) 
E. coli B F– dcm ompT hsdS(rB– mB–) gal  
 
XL1-Blue 
supercompetent cells 
(Agilent) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́ proAB 
lacIZΔM15 Tn10 (Tet)]  
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2.1.2 Media 
Luria Broth (LB): LB was purchased from Sigma and was made up to a concentration of 25 
g per litre, pH 7.3-7.5, and sterilised prior to use via autoclaving. 
LB-agar plates: Prior to sterilisation LB was supplemented with 1.2% agar (Sigma) per 100 
mls. Once sterilised, the LB-agar was melted, allowed to cool, and the relevant antibiotic 
added. 
2.1.3 Antibiotics 
Ampicillin (Sigma) was added to LB and LB-agar at a concentration of 50 µg/ml. 
Kanamycin (Roche) was added to LB and LB-agar at a concentration between 25-50 µg/ml. 
2.1.4 Primer design 
All primers were purchased from Sigma at a concentration of 0.5 µmol and pre-purified via 
desalting. Primer lengths varied according to the method used, but were generally 25-30 base 
pairs (bp) in length, with an A/T and C/G content of 50%. On arrival primers were kept at a 
stock concentration of 1 µg/µl at -20 °C. 
2.1.5 Enzymes 
Taq polymerases were either obtained from Stratagene or Roche. ABI PRISM® BigDye 
Terminator v 3.0 Cycle Sequencing Ready Reaction kit with ampli-Taq DNA Polymerase was 
purchased from Applied Biosystems (ABI), Perkin Elmer. 
All restriction enzymes were either purchased from New England Biolabs (NEB) or Roche. 
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2.1.6 Transformation of bacteria 
Transformation of plasmids into DH5α was carried out as follows: cells were thawed on ice, 
then between 20-50 ng of DNA were added and gently mixed. Next, cells were incubated on 
ice for 30 minutes, heat shocked at 42 °C for 30 seconds followed by further incubation on ice 
for 2 minutes. After addition of 400 µl of SOC media, (Invitrogen) cells were incubated at 37 
°C for 1 hour at 200-220 rpm in a shaking incubator. Between 20-50 µl of the reaction was 
then spread on to pre-prepared LB-agar plates containing the relevant antibiotic and incubated 
over night at 37 °C. 
For Stbl2 competent cells, 50 µl of cells were aliquoted into a pre-chilled 14 ml falcon tube 
and between 20-50 ng of DNA added, which was then gently mixed by swirling the tube. The 
cells were incubated on ice for 30 minutes, heat shocked for 25 seconds at 42 °C then placed 
on ice for a further 2 minutes. Next, 450 µl of SOC media (Invitrogen) was added to the cells 
which were then incubated for 1.5 hours at 30 °C shaking at 200-220 rpm. Following this, 20-
50 µl of the reaction was spread on LB-agar plates and then incubated at 37 °C overnight. 
When using BL21 competent cells, 100 µl of thawed cells were added to a pre-chilled 14 ml 
falcon tube followed by addition of 50 ng of DNA. Cells were then gently mixed by pipetting, 
incubated on ice for 30 minutes, heat shocked for 20 seconds at 42 °C and incubated on ice 
for 2 minutes. SOC media was pre-heated to 37 °C, then 900 µl was added to the cells which 
were then incubated at 37 °C for 1 hour shaking at 200-220 rpm. After this last step 20-50 µl 
of the reaction was plated out on LB-agar plates supplemented with the relevant antibiotic, 
and incubated overnight at 37 °C. 
 Gene Vector Source 
MDC1 (aa1-381) WT pGEX4T-1 PCR from cDNA 
MDC1 (aa341-752) WT pGEX4T-1 PCR from cDNA 
MDC1 (aa141-621) WT pGEX5X-3 Digested from pEGFP-C2 MDC1 
MDC1 (aa141-621) CK2 S>A 1 pGEX5X-3  
MDC1 (aa141-621) CK2 S>A 2 pGEX5X-3  
MDC1 (aa141-621) CK2 S/T>A 3 pGEX5X-3  
MDC1 (aa141-621) CK2 S/T>A 4 pGEX5X-3  
MDC1 (aa141-621) CK2 S/T>A 5 pGEX5X-3  
MDC1 (aa141-621) CK2 S/T>A 6 pGEX5X-3  
MDC1 (aa141-621) CK2 S/T>A 7 pGEX5X-3  
MDC1 (aa141-621) CK2 S/T>A 8 pGEX5X-3  
MDC1 (aa141-621) CK2 S>A 9 pGEX5X-3  
MDC1 (aa141-621) CK2 S>A 10 pGEX5X-3  
MDC1 WT FL pEGFP-C2  
MDC1 !CK2 pEGFP-C2 Dr G Stewart 
MDC1 CK2 S>A 3-8 pEGFP-C2  
MDC1 CK2  S>A 1+3-8 pEGFP-C2  
hMRE11 (aa360-708) WT pGEX4T-1 Xiaohua Wu (TRSI, California, USA) 
hMRE11 (aa360-708) 1A pGEX4T-1  
hMRE11 (aa360-708) 2A pGEX4T-1  
hMRE11 (aa360-708) 3A pGEX4T-1  
hMRE11 (aa360-708) 4A pGEX4T-1  
hMRE11 WT pCLNC Dr M Weitzman 
hMRE11 1A pCLNC  
hMRE11 2A pCLNC  
hMRE11 3A pCLNC  
hMRE11 4A pCLNC  
MRE11 WT pCDNA5 FRT Digested from pCLNC MRE11 using AscI and NotI 
hMRE11 1A pCDNA5 FRT  
hMRE11 2A pCDNA5 FRT  
hMRE11 3A pCDNA5 FRT  
hMRE11 4A pCDNA5 FRT  
Table 2.1   DNA constructs used in the study 
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2.1.7 DNA constructs 
A list of all DNA constructs used in this study can be found in Table 2.1. 
2.1.8 Small-scale preparation of DNA constructs 
Individual colonies were picked from positive LB-agar plates and cultured in 150 µl of LB 
media containing antibiotics in a 96 well plate, for approximately 3 hours or until turbid. Next 
10 µl of this culture was used to inoculate 5 mls of LB media which was then shaken at 200-
220 rpm at 37 °C overnight. Following this, 3 ml of the culture was pelleted by centrifugation 
at 12000 g for 1 minute. All small-scale preparation of plasmid DNA was performed using the 
Sigma GenElute™ Plasmid Miniprep Kit as per instructions supplied by the manufacturer. 
The DNA was then stored at -20 °C. 
2.1.9 Large-scale preparation of DNA constructs 
Briefly, 10 µl of culture from the previously described 96 well plate was used to inoculate 10 
ml of LB media supplemented with antibiotic, and incubated at 37 °C overnight shaking at 
200-220 rpm. The following day 250 µl of the overnight culture was used to inoculate 200 ml 
of LB media plus antibiotic, which was further incubated overnight at 37 °C shaking at 200-
220 rpm. The bacteria were then pelleted at 4000 g for 10 minutes. All maxipreps were 
carried out using the Invitrogen PureLink™ HiPure Plasmid Filter Purification Kit. Next, the 
eluted DNA was split into two falcon tubes and 5.25 ml of isopropanol added, and mixed. The 
DNA was precipitated by centrifugation at 5000 g for 1 hour. The isopropanol was carefully 
removed and the pellet resuspended in 5 ml of 70% ethanol and combined with the second 
pellet from the same sample. The DNA was then spun for a further hour at 5000 g, the ethanol 
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removed and the pellet air-dried. The pellets were then rehydrated using between 300-500 µl 
of DNase-free water and stored at -20 °C. 
2.1.10 Measuring DNA concentrations 
All DNA concentrations were measured using the Nanodrop 1000 (Thermo Scientific) 
spectrophotometer. Briefly, 1 µl of DNA was loaded on to the pedestal, after blanking and 
calibrating the apparatus with distilled water according to the manufacturers instructions, and 
the concentration in ng/µl and 260/280 ratio noted. 
2.1.11 Cloning 
2.1.11.1 PCR of a gene sequence from plasmid DNA constructs 
Primers were designed to the 5’ and 3’ regions of the gene of interest. For sub-cloning 
purposes the primers were engineered to also have unique 5’ restriction sites that were present 
in the target vectors multiple cloning site but did not appear within the gene of interest. 
Primers for cloning were generally 25-30 bp long. A list of primers used for sub-cloning can 
be found in Table 2.2. 10-20 ng of plasmid DNA was mixed with 250 ng of forward and 
reverse cloning primers, 5 µl of 10x buffer, 1.5 µl of dNTPS (10 mM), 1 µl of pfuUltra DNA 
polymerase (Stratagene) and injection water, to a final volume of 50 µl. The PCR reaction 
was then mixed by pipetting, placed in a thermal cycler (Applied Biosystem Veriti 96 Well 
Thermal Cycler) and subjected to the following conditions: 94 °C for 3 minutes, proceeded by 
37 cycles of 94 °C for 30 seconds, 60 °C for 30 seconds, 68 °C for 1 minute/Kb followed by 
68 °C for 10 minutes. 
 Gene Sequence Restriction Site 
MDC1 Fragment 
1 Forward 
(aa1-381) 
5'CATGCAGTCGACTGATGGAGGACACCCA
GGCTATTGAC 3' 
Sal1 
GTCGAC 
MDC1 Fragment 
1 Reverse 
(aa1-381) 
5’ATCAGCGCGGCCGCCACATCTGTATCACT
ACCAGCCTG 3' 
Not1 
GCGGCCGC 
MDC1 Fragment 
2 Forward 
(aa341-725) 
5’GCATCGGTCGACTGACCCCAGTTGTCATT
CCTATGAAG 3' 
Sal1 
GTCGAC 
MDC1 Fragment 
2 Reverse 
(aa341-725) 
5’CGTATCGCGGCCGCCAACATGAAGGCCT
GGGTAGGTTC 3’ 
Not1 
GCGGCCGC 
MRE11 FRT 
Forward 
5’5’TCATGAGGCGCGCCAATGAGTACTGCA
GATGCACTTGAT 3’ 
Asc1 
GGCGCGCC 
MRE11 FRT 
Reverse 
5’CAAACCGCGGCCGCTTATCTTCTATTTTT
CTTCTTAAGA 3’ 
Not1 
GCGGCCGC 
Table 2.2  Primers used for subcloning genes 
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2.1.11.2 Visualising PCR products via agarose gel electrophoresis 
Purified PCR products were visualised on 0.8% agarose gel. Firstly, 100 ml of 1X TBE (880 
mM tris, 890 mM orthoboric acid, 20 mM Na2EDTA) buffer containing 0.8 g of agarose 
(Sigma) was heated, and 1 µl of ethidium bromide added to a final concentration of 1 µg/ml. 
The solution was poured into a gel caster and allowed to cool. Next 1 µl of sample was mixed 
with 2 µl of loading buffer (30% v/v of glycerol, 0.25% w/v of bromophenol blue in injection 
quality water) and 7 µl of 0.25x TBE buffer and loaded along with a DNA marker (Roche). 
The agarose gel was placed in 1X TBE buffer and ran at 120 V for 45 minutes depending on 
the product size. DNA was visualised using the G:BOX gel doc system (Syngene). 
2.1.11.3 Gel extraction 
DNA generated from PCR reactions was exercised and purified from agarose gels using the 
QIAquick Gel Extraction kit (Qiagen) as per the manufactures instructions. 
2.1.11.4 Restriction digest and ligation 
Restriction digests were either carried out on PCR products harbouring engineered restriction 
sites or plasmid DNA. Reactions were usually performed at 37 °C for approximately 1 hour 
and contained 100 ng to 3 µg of PCR or plasmid DNA, 5 µl of enzyme-specific 10x buffer 
and 10 units of the restriction enzyme. If two enzymes were required for the reaction and the 
buffers for a double digest were not compatible, a sequential digest was performed, which 
involved passing the first reaction through a PCR clean up column (Roche) before adding the 
second buffer and enzyme. Plasmid DNA was treated with alkaline phosphatase (1 unit/µl) to 
prevent religation, which was added to the final ligation reaction. 
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Pre-digested PCR product and vector DNA were ligated overnight at 11-14 °C. The total 
reaction volume was 20 µl comprising of 2 µl 10x buffer, 50 ng of vector, the relevant 
amount of PCR insert, 1 µl of T4 ligase (Invitrogen) and injection water. The following day, 3 
µl of the ligation was transformed into competent cell lines as described above. 
2.1.11.5 Screening of colonies via bacterial PCR 
Colonies were picked and cultured in a 96 well plate as mentioned. After 3 hours, 1 µl of the 
culture was taken and added to 2.5 µl of 5x buffer+Mg2+, 0.75 µl of dNTPS (10 mM), 1 µl of 
forward and reverse primers (250 ng) and 0.5 µl of Taq polymerase (Roche). Injection water 
was added to a final volume of 25 µl. The PCR conditions were as follows: 1 cycle of 94 °C 
for 4 minutes, 37 cycles of 94 °C for 15 seconds, 60 °C for 30 seconds, 68 °C for 3 minutes, 
then 1 cycle of 68 °C for 10 minutes. Positive colonies were screened using agarose gel 
electrophoresis. 
2.1.11.6 Sequencing 
Sequencing was required to verify the ligated PCR product was in the correct reading frame 
and that no mutations had occurred during the PCR reaction. A kit from ABI was used for all 
reactions. Firstly 200-500 ng of purified PCR product was added to 3.5 µl of 2.5x sequencing 
buffer, 125 ng of primer (Table 2.3), 1 µl of terminator ready reaction mix (Big Dye™ 
terminator V3.0) and made up to a final volume of 20 µl with injection grade water. Samples 
were then placed in a thermal cycler and subjected to the following parameters: 95 °C for 10 
seconds, 50 °C for 5 seconds and 60 °C for 4 minutes, the conditions were repeated over 30 
cycles. Following this step the PCR products were precipitated. This was achieved by adding 
2 µl of 3 M sodium acetate, pH5.2, and 50 µl of 100% ethanol to the reaction and incubating 
at room temperature for 15 minutes. Samples were then spun at 15000 g for 20 minutes, the  
 Primer Sequence 
pGEX4T1/pGEX5X-3 Forward 5' GGGCTGGCAAGCCACGTTTGGTG 3' 
pGEX4T1/pGEX5X-3 Reverse 5' CCGGGAGCTGCATGTGTCAGAGG 3' 
pEGFP-C3 Forward 5' CCTGAGCAAAGACCCCAACGAGAAG 3' 
pEGFP-C3 Reverse 5' CCCCCTGAACCTGAAACATAAAATG 3' 
pCLNC Forward 5' CTCCATAGAAGACACCGGGACCGA 3' 
pCLNC Reverse 5' TTGATCTGAACTTCTCTATTCTCA 3' 
pCDNA3 Forward 5' GGCAAATGGGCGGTAGGCGTG 3' 
pCDNA3 Reverse 5' TAGAAGGCACAGTCGAGG 3' 
MDC1 1B Forward 5' ACAACATGCAGAGATTGAA 3' 
MDC1 2 Forward 5' TTCATCGACAGCGACACTGATGCG 3' 
MDC1 2B Forward 5' AACAGCGATACAGATGACGAGG 3' 
MDC1 1 Reverse 5' AGGGCCCCGGGAGACAAAGGGCAGGAGG 3' 
MDC1 1C Reverse 5' TACCATACGCCTTTCAGAAAG 3' 
MDC1 2A Reverse 5' CACATCTGTATCACTACCAGCCTG 3' 
MDC1 2B Reverse 5' CTGCAGAAGGACCACACGTTG 3' 
MDC1 2D Reverse 5' TGTGTTGATGTCCACTGTGGTG 3' 
MRE11 19235 Forward 5' AGTATTCATGGCAATCATGACG 3' 
MRE11 19237 Forward 5' TCCTCTTCACACAGTGCGGCAG 3' 
MRE11 21464 Forward 5' CCAGAGAAGCCTCTTGTACGACTG 3' 
MRE11 19239 Forward 5' GAACGTCATATTGATGCCCTCG 3' 
MRE11 21584 Forward 5' AGGAGGGTCTCAAAGAGGAAG 3' 
MRE11 22219 Forward 5' CTACCCGTAGCAGGAACTCAAAGAC 3' 
MRE11 19236 Reverse 5' TCTATCTTCTCCACAGACATTG 3' 
MRE11 19238 Reverse 5' AAACAGAAGCTTTGTATGGCTTG 3' 
MRE11 19240 Reverse 5' GCCCTGGTCATAGCCTCACGGAC 3' 
MRE11 19242 Reverse 5' TCTTCCACATCTGATTCATCTAC 3' 
Table 2.3   Sequencing primers used in the study 
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supernatant was removed and 250 µl of 70% ethanol added, briefly vortexed and then spun 
again at 15000 g for 5 minutes. Following removal of the supernatant, samples were either 
dried in an air cabinet or using a vacuum centrifuge. Before loading, 10 µl of formamide was 
added to the sample, which was then vortexed, heated for 5 minutes at 95 °C and then 
quenched on ice. The reaction was then loaded onto the ABI Prism 337 Automated DNA 
sequencer (Perkin Elmer, Applied Biosystems). Sequences were analysed using a 
combination of FinchTV (http://www.geospiza.com/Products/finchtv.shtml) and the NCBI 
nucleotide–nucleotide BLAST analysis (http://www.ncbi.nlm/nih.org). 
2.1.12 Mutagenesis 
All mutagenesis reactions were carried out using a Stratagene QuickChange® Site-Directed 
Mutagenesis Kit (Stratagene). This contained the DNA polymerase, dNTPs and the competent 
cells required. 
2.1.12.1 Primer design 
Table 2.4 lists all primers used for mutagenesis in these studies. Primers were designed to 
contain either a single point mutation, a number of mutations or deletion of an entire region of 
the gene of interest. The primers were constructed in such a way that both the forward and 
reverse contained the mutation and annealed to the same region on the opposite strands of the 
sequence of interest. Primers were between 25-45 bp in length, the mutation(s) being located 
in the middle of the primer with approximately 10-15 bases of sequence either side, had a 
minimum G/C content of 40% and a melting temperature of >78 °C. The following 
calculation was used to determine the melting temperature: 
Tm=81.5+0.41(%GC)-675/N-% mismatch 
Where N is primer length in bases, and values for %G/C and % mismatch are whole numbers. 
Primer Sequence 
MDC1 S/T>A 1 Forward 5' CCGCCTTTTGCCTTCAAT TTGAACGCTGACGCAGATGTGGAAG 3' 
MDC1 S/T>A 1 Reverse 5' CTTCCACATCTGCGTCAGCG TTTCAAATTGAAGGCAAAAGGCGG 3' 
MDC1 S/T>A 2 Forward 5' CCTCCTGGAGAGGACGC TGACGCAGATGTGGATGATGAC 3' 
MDC1 S/T>A 2 Reverse 5' GTCATCATCCACATCTG CGTCAGCGTCCTCTCCAGGAGG 3' 
MDC1 S/T>A 3 Forward 5' GGCTTCATCGACGCCGA CGCTGATGCGGAAGAAGAG 3' 
MDC1 S/T>A 3 Reverse 5' CTCTTCTTCCGCATCAG CGTCGGCGTCGATGAAGCC 3' 
MDC1 S/T>A 4 Forward 5' AGCCAGGCTGGTGCTGA TGCAGATGTGGAAGAAGGC 3' 
MDC1 S/T>A 4 Reverse 5' GCCTTCTTCCACATCTGC ATCAGCACCAGCCTGGCT 3' 
MDC1 S/T>A 5 Forward 5' GCTTCCATGGTTATCAAC GCCGATGCAGATGACGAGGAAGAAG 3' 
MDC1 S/T>A 5 Reverse 5' CTTCTTCCTCGTCATCTG CATCGGCGTTGATAACCATGGAAGC 3' 
MDC1 S/T>A 6 Forward 5' ACCACTGAGAGAGACGC TGACGCAGACGTGGAGGAG 3' 
MDC1 S/T>A 6 Reverse 5' CTCCTCCACGTCTGCGTCA GCGTCTCTCTCAGTGGT 3' 
MDC1 S/T>A 7 Forward 5' TTGGCTGAGGACGCGGAG GAGGAAGTAGATTTTC 3' 
MDC1 S/T>A 7 Reverse 5' GAAAATCTACTTCCTC CTCCGCGTCCTCAGCCAA 3' 
MDC1 S/T>A 8 Forward 5' TCTGTGATAGTTCCAG AGGCTGATGAAGAGGGGCATTCC 3' 
MDC1 S/T>A 8 Reverse 5' GGAATGCCCCTCTTC ATCAGCCTCTGGAACTATCACAGA 3' 
MDC1 S/T>A 9 Forward 5' AGAAGCCAAGCCTCCGCC ACAGTGGACATCAAC 3' 
MDC1 S/T>A 9 Reverse 5' GTTGATGTCCACTGTG GCGGAGGCTTGGCTTCT 3' 
MDC1 S/T>A 10 Forward 5' GGGGACTGTGAAGCA GATGCAGAGGAGGGCACC 3' 
MDC1 S/T>A 10 Reverse 5' GGTGCCCTCCTCTGC ATCTGCTTCACAGTCCCC 3' 
MRE11 S649A Forward 5' GTGATTGAGGTAGA TGAAGCAGATGTGGAAGAAGACA 3' 
MRE11 S649A Reverse 5' TGTCTTCTTCCACATC TGCTTCATCTACCTCAATCAC 3' 
MRE11 S688/689A 
Forward 
5’TCGAAAGGGGGTTGATTTTGAAGCA
GCTGAGGATGATGATGATGATCCT 3' 
MRE11  S688/689A 
Reverse 
5'AGGATCATCATCATCATCCTCAGCTG
CTTCAAAATCAACCCCTTTCGA 3' 
MRE11 S541A Forward 
5' 
GAGTCTGCTTCTGCCTTTGCTGCTGATG
ACCTTATGAGT 3' 
Table 2.4  Mutagenesis primers used in the study  
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2.1.12.2 PCR 
Briefly, 5-50 ng of template DNA was mixed with 5 µl of 10x reaction buffer, 1 µl of dNTP 
mix, 125 ng of forward and reverse primer, 1 µl of PfuUltra HF DNA polymerase (2.5 U/µl) 
and made up to 50 µl with injection water. Reactions were then placed in a thermal cycler and 
subjected to the following conditions, 95 °C for 30 seconds, 95 °C for 30 seconds, 55 °C for 1 
minute then 68 °C for 1 minute/per Kb of plasmid length. The last three cycling parameters 
were dependent on the type of mutation required. 
2.1.12.3 Digestion and transformation 
Following PCR, 1 µl of Dpn1 was added to the reaction and mixed by pipetting followed by 
incubation at 37 °C for approximately 3 hours. For transformation, XL1 Blue Supercompetent 
Cells were thawed on ice and 50 µl aliquotted into a 14 ml falcon tube, 1 µl of the digested 
mutagenesis reaction was added to the cells, mixed by gentle swirling and then allowed to 
incubate on ice for 30 minutes. Reactions were then heat-shocked at 42 °C for 45 seconds and 
left on ice for a further 2 minutes. After the addition of 500 µl of SOC media the cells were 
incubated at 37 °C for 1 hour shaking at 200-220 rpm. The entire transformation reaction was 
then plated on two LB-agar plates and left overnight at 37 °C. Clones were then picked and 
screened as described above. 
2.1.13 GST purification 
GST plasmids containing sequences of interest were transformed into BL21 competent cells 
as described above. Colonies were picked and cultured in 150 µl of LB media for 3 hours. 
Next 10 µl of the culture was used to inoculate 10 ml of LB media which was grown 
overnight at 37 °C shaking at 200-220 rpm. This was used to inoculate 1L of LB media which 
was then grown for 3 hours at 37 °C shaking at 200-220 rpm or until an OD of between 0.3-
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0.4 was reached. The culture was then induced with 1 mM of IPTG overnight at room 
temperature shaking at 200-220 rpm. Cultures were then pelleted at 8,000 g for 15 minutes, 
and then lysed by sonication (5x for 30 seconds on ice) in PBS containing 1% Triton X-100 
supplemented with Complete Protease Inhibitor Cocktail (Roche). If the protein induced was 
insoluble then pellets where lysed in SSTE buffer (1.5% Sarcosyl, 50 mM Tris, 120 mM 
NaCl, 1 mM EDTA). The bacterial lysate was then spun at 48,000 g for 10 minutes, the 
supernatant transferred to a fresh tube and spun again for a further 20 minutes at 48,000 g . 
The supernatant was then filtered through a 0.45 µM syringe filter. For samples that were 
insoluble 1/5th the supernantant volume of 20% trition was added to re-anneal proteins. 4 ml 
of glutathione sepharose beads were pre-washed three times in PBS containing 1% Triton X-
100 and twice in PBS containing 1 mM EDTA. The washed beads were resuspended in PBS 
containing 1 mM EDTA to give 8 mls of 50% beads slurry of which 4 mls was then added to 
the lysate. The lysate was then rotated at 4 °C for 2 hours. The lysate was removed and the 
beads washed three times in PBS containing 1 mM EDTA and 1% Triton X-100 and twice in 
PBS containing 1 mM EDTA. Following this, 4 ml of elution buffer (25 mM glutathione 
pH8.0, 50 mM Tris, pH8.0) was added to the beads, which were then rotated at 4 °C for 1 
hour. The beads were pelleted, the eluent removed and a further 4 ml of elution buffer added 
to the beads, which were again rotated at 4 °C for 1 hour. The beads were again pelleted and 
the eluent removed and combined with the first elution. This was then added to dialysis tubing 
(MWCO 12-14 Daltons) which had been boiled in 2 mM EDTA, 3% Sodium Bicarbonate for 
1 minute, and dialysed in 5 litres of dialysis buffer (50 mM Tris pH7.5, 10%v/v glycerol and 
1 mM DTT) overnight at 4 °C. The following day the protein concentration was determined 
using Bradford reagent (Biorad) as described. 
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2.1.14 Generation of cDNA for sequencing  
2.1.14.1 RNA extraction and purification  
Cells were harvested and pelleted at 4 °C for 5 minutes at 600 g.  RNA extraction was carried 
out using the Qiagen RNeasy® Mini Kit. Firstly pelletes were disrupted by flicking, and then 
lysed in RLT buffer by passing the lysate a minimum of five times through a 20-gauge 
needle. One volume of 70% ethanol was then added to the lysed and pellet, which was then 
transferred to a RNeasy spin column and centrifuged for 15 seconds at 8, 000 g. The through 
flow was discarded and 700 µl of buffer RW1 was added to the column, which was again 
spun at the above conditions. Next 500 µl of buffer RPE, which previous to use had been 
diluted with 4 volumes of ethanol, was added to the column following the discard of the 
through flow, followed by further centrifugation. Again the through flow was discarded and a 
further 500 µl of buffer RPE added to the column which was then spun for 2 minutes at 8, 000 
g. The column was then placed in a fresh RNase free collection tube and 30 µl of RNase free 
water added and the tube span at maximum speed for 1 minute. This step was repeated to 
ensure maximum yield of RNA from the prep. The concentration of RNA extracted, in ng/µl, 
was then determined using a Nanodrop 1000 (Thermo Scientific) spectrophotometer as 
described. RNA samples were then stored at -80 ºC for further use. 
2.1.14.2 Production of cDNA  
cDNA was generated using the Invitrogen SuperScript® VILO™ cDNA Synthesis Kit. Briefly 
up to 2.5 µg of RNA was added to 4 µl of 5X VILO™ Reaction Mix, 2 µl 10X SuperScript® 
Enzyme Mix and made up to a volume of 20 µl of DEPC-treated water in an RNase-free tube. 
The contents were mixed and then incubated at 25 ºC for 10 minutes, 42 ºC for 60 minutes 
and followed by termination of the reaction at 85 ºC for 5 minutes. The cDNA was either 
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stored at -20 ºC or used in a PCR with primers specific to the gene or interest, followed by 
sequencing of the PCR product.  
2.2 Tissue culture techniques  
2.2.1 Cell lines 
Cells used in this study are listed in Table 2.5. The HCT116 Flp-In/T-Rex cell line was 
received as a kind gift from Dr Daniel Durocher, Toronto, Canada. The U2OS Flip-In/T-Rex 
were a gift from Jakob Nilsson’s laboratory at the Novo Nordisk Foundation Centre for 
Protein Research, University Copenhagen. 
2.2.2 Tissue culture media and solutions 
Cells were either cultured in Dulbecco modified eagle medium (DMEM) or McCoy’s 5A 
medium supplemented with 10% foetal calf serum (FCS), 30,000 units penicillin and 3,000 
mg streptomycin (pen/strep). When necessary cells were cultured in the presence of 
combinations of selective antibiotics (Geneticin (Invitrogen), Puromycin (Clontech), 
Blasticidin (Invitrogen), Hygromycin (Roche)). All media and reagents were obtained from 
Invitrogen. Media was stored at 4 °C for up to 3 months. 
2.2.3 Maintenance of cells 
Cells were incubated at 37 °C in humidified incubators supplied with 5% CO2. Cells were 
allowed to reach confluency before passage, at which stage all media was removed, and the  
 Name Type ATCC number 
HeLa Human cervical carcinoma cell line.  
ATLD2 Human skin fibroblasts hypomorphic mutation in 
MRE11. 
 
HCT116 Human colon carcinoma missense mutation in 
MRE11. 
CCL-247™ 
HT29 Human colon adenocarcinoma. HTB-38™ 
HCT116 Flp-In™ T-rex Human colon carcinoma missense mutation in 
MRE11. Containing an integrated FRT site. 
 
U2OS Flp-In™ T-rex Human osteosarcoma cell line. Containing an 
integrated FRT site. 
 
 
Target Protein Name Sense Sequence 
Non-silencing Control  siRNA CGUACGCGGAAUACUUCGAdTdT 
CK2! CK2!  siRNA GAUGACUACCAGCUGGUUCdTdT 
CK2!' CK2!' siRNA CAGUCUGAGGAGCCGCGAGdTdT 
MRE11 MRE11 5'UTR GAACCUGGUCCCAGAGGAGdTdT 
 
  6% 10% 
H2O 27.4 ml 22 ml 
1 M Tris/1 M Bicine 4 ml 4 ml 
Acrylamide 30% 8 ml 13.4 ml 
SDS 10% 400 !l 400 !l 
TEMED 80 !l 80 !l 
Table 2.5   Human cells lines used in the study 
Table 2.6   siRNAs used in the study 
Table 2.7  SDS gel components 
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cells were washed with warmed, sterile PBS. To detach the cells the PBS was removed, 1.5 
ml of 1x trypsin (Invitrogen) added and the cells incubated at 37 °C for a maximum of 5 
minutes. Tapping the flask dislodged any cells still adhering to the flask. Fresh warmed media 
was added to halt the trypsinisation and the appropriate amount of cells transferred to a new 
flask containing fresh media. Cells were routinely checked for infection by Mycoplasma 
using the MycoAlert™ detection kit (Lonza) as per manufacturers instructions.  
2.2.4 Cryopreservation of cell lines 
Cells were washed and trypsinised as above. Upon the addition of media, the cells were 
transferred to a sterile 15 ml falcon tube and centrifuged at 596 g for 5 minutes. The media 
was removed and the cell pellet resuspended in 1 ml of 50% FCS, 40% media, containing no 
FCS or antibiotics, and 10% DMSO (Sigma). The cells were transferred to a 1.5 ml cryovial 
and cooled slowly at -80 °C in isopropanol for at least 24 hours. The frozen aliquots were 
then placed in liquid nitrogen for long-term storage at -180 °C. When required, cells were 
thawed rapidly at 37 °C, added to fresh media supplemented with FCS and antibiotics, 
pelleted by centrifugation, resuspended in fresh media and plated out. 
2.2.5 Transient transfection of DNA constructs into cell lines 
Firstly, 3x105 cells were plated per well of a 6-well plate in media lacking antibiotics a day 
prior to the transfection. The following day 0.8 µg plasmid DNA and 6 µl of Lipofectamine 
(Invitrogen) was added to 50 µl of Opti-MEM I Reduced Serum Medium (Invitrogen) 
separately, and allowed to incubate at RT for 5 minutes. The DNA/Opti-MEM mixture was 
then added to the Lipofectamine/Opti-MEM, mixed gently and incubated for 20 minutes at 
RT. The DNA/Lipofectamine mixture was then added to the cells which were slowly shaken 
to evenly disperse the transfection cocktail and left for 4 hours at 37 °C. The media was then 
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removed from the cells and replaced with fresh media lacking antibiotics. Western blotting or 
immunofluorescence between 24-72 hours later monitored exogenous expression of the gene 
of interest. 
2.2.6 Generation of stable cell lines via retroviral transfection 
On the first day, 293T cells were seeded at a density of approximately 1x107 on a 10 cm dish 
in the relevant media lacking antibiotics but supplemented with 10% FCS. Cells were then 
left overnight at 37 °C. The following day the cells were transfected with Lipofectamine 2000 
(Invitrogen) using a ratio of 3 µl of reagent per 1 µg of DNA. The DNA ratio added was, 4 µg 
retroviral backbone, 6 µg GAG/Pol (psPax2) plasmid and 2 µg VSV-G (pMD2.G) plasmid. 
Briefly 36 µl of the Lipofectamine reagent was added to 1.5 ml Opti-MEM and mixed by 
gentle pipetting, followed by incubation at RT for 5minutes. The DNA was added to 1.5 ml of 
OPTI-MEM, mixed by gentle pipetting and then combined with the Lipofectamine/OPTI-
MEM mix. The transfection mixture was then incubated at RT for 20 minutes. This was then 
added drop wise onto the cells in 5 ml of complete media lacking antibiotics. The cells were 
then rocked gently to ensure even distribution of the transfection mixture and left overnight at 
37 °C.   
The next day the media was removed from the cells and replaced with 5 ml of fresh media 
lacking antibiotics. On day three the viral supernatant was harvested, filtered through a 0.45 
µM syringe filter to remove any contaminating cells and was stored at 4 °C overnight. Fresh 
media was added to the cells. Additionally on the third day, the target cells were plated out to 
50% confluency on 6 cm dishes. The following day, the second lot of viral supernatant was 
harvested and combined with the previous days supernatant, which was then aliquoted and 
stored at -80 °C. On the same day polybrene was added to final concentration of 4 µg/ml to 2 
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ml of viral supernatant per 6 cm dish and mixed gently by pipetting. The media from the 
target cells was removed and replaced with the retroviral supernatant/polybrene mixture. The 
cells were then left overnight at 37 °C. The virus was removed on day 5 and the previous days 
steps repeated with fresh virus. On day 6 the virus was removed again and the dishes washed 
once with complete media, followed by the addition of fresh media. Finally on day seven the 
media was removed and replaced with media containing the selective antibiotic. These were 
then left to allow outgrowth of antibiotic resistant cells. Expression of the virally-encoded 
protein was determined by Western blotting. Cells were cloned to allow for isolation of a 
single population of cells containing equal levels of expressed protein. 
2.2.7 Generation of stable Flp-In/T-Rex cell lines 
Host Flp-In/T-Rex cells containing an integrated FRT recognition site were plated out at a 
density of 3x105 in DMEN media, supplemented with zeocin (15.5 µg/ml), blasticidin (5 
µg/ml) and 10% FCS. The cells were left overnight at 37 °C. The following day the host Flp-
In cell lines were transfected with a modified pcDNA5 FRT TO vector containing a pcDNA3 
flag-tagged polylinker, (received from the Durocher Laboratory, University of Toronto, 
Canada) in addition to the gene of interest, and a pOG44 vector. Again a ratio of 3:1, 36 µl of 
Lipofectamine 2000 to 12 µg of DNA, was used for each transfection. However the 12 µg of 
DNA comprised of both the pcDNA5 FRT TO vector, containing the gene of interest and the 
pOG44 vector. For the purpose of this transfection protocol, 2 µg of pcDNA5 FRT vector was 
mixed with 10 µg of pOG44 vector. The DNA and Lipofectamine were added to 1.5 ml of 
Opti-MEM and the separate reactions incubated for 5 minutes. Following this the DNA/Opti-
MEM mix was mixed with the Lipofectamine/ Opti-MEM mix and incubated for a further 20 
minutes. During this incubation the media was removed from the cell lines and 5 ml of 
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DMEN added, supplemented with 10% FCS, but no antibiotic. The Lipofectamine/DNA 
reaction was then spotted on to the cells and the cells then left for 48 hours. After 48 hours the 
media was removed and replaced with DMEN containing hygromycin (250 µg/ml), 
blasticidin (5 µg/ml) and 10% FCS. The cells were then left in the selection media to allow 
outgrowth of those non-resistant cells. Once the cells had reached confluency they were split, 
allowed to grow again, then a proportion taken to test induction of the gene of interest by 
addition of doyxcycline (1 µg/ml), and the remainder frozen down for future experiments.  
2.2.8 Cell irradiation 
Cell lines were mock-treated or treated with ionising γ-rays from a 137Cs source at a dose rate 
of approximately 1 Gy per 20 seconds and then incubated at 37 °C.  
2.2.9 Treatment of cells with DNA damaging agents 
For cell lines treated with camptothecin (CPT), growth media was completely removed and 
replaced with media supplemented with 100 nM camptothecin. Cells were then incubated at 
37 °C and harvested at relevant timepoints.  
2.2.10 Transfection of cell lines with siRNA 
The required number cells, dependent on type, were plated per 60 mm dish, in media lacking 
antibiotics the day before the transfection. The following day media was removed, the cells 
washed once in 2 mls Opti-MEM warmed to 37 °C and then 1.6 ml of Opti-MEM was added 
to each dish. Next two mixtures were made, one containing 10 µl siRNA (stock 20 µM) and 
360 µl of Opti-MEM per dish, and the other containing 8 µl oligofectamine (Invitrogen) and 
22 µl of Opti-MEM per dish. These two volumes were left at room temperature for 5 minutes, 
and then mixed, adding the oligofectamine/Opti-MEM mixture to the siRNA/Opti-MEM 
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mixture, and left for a further 20 minutes at room temperature. Next, 400 µl of the 
siRNA/oligfectamine mixture was then drop-pipetted on to the cells. The dish was then 
rocked gently and incubated for 4-6 hours. Then 2 ml of media containing 20% FCS without 
antibiotics was added to each dish. Cells treated with siRNA were generally left for 72 hours 
to achieve sufficient depletion of target genes. Depletion of the target gene was assayed by 
Western blotting.  All siRNA used in the study is listed in Table 2.6. 
2.2.11 Cell extraction and protein purification 
Cells were trypsinised as above, transferred to a 30 ml universal and spun at 596 g for 5 
minutes to pellet. The media was then removed, the pellet washed in 10 ml of sterile PBS and 
spun for a further 5 minutes at 596 g. All the PBS was removed and the pellet re-suspended in 
approximately 50-200 µl of lysis buffer (8 M urea, 50 mM Tris, 150 mM β-mercaptoethanol, 
pH7.5). Cells were sonicated twice for 10 seconds and then spun at 25 000 g for 20 minutes at 
4 °C. The supernatant was then transferred to a pre-chilled 1.5 ml tube, flash frozen in liquid 
nitrogen and stored at -80 °C. 
2.2.12 G2/M checkpoint assay and cell cycle analysis  
Cells were irradiated at indicated doses and harvested after 1 hr. During harvesting the media 
and wash PBS were kept until the cells were pelleted. Once trypsinised, washed and pelleted, 
the cells were resuspended in 3 ml of PBS. Cells were then fixed in 7 ml of ice-cold ethanol, 
which was added while vortexing, as this prevented the cells from clumping. The fixed cells 
could then be stored at -20 °C overnight or longer. 
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When required, the cells were pelleted at 596 g for 5 minutes and washed twice in PBS. The 
cells where then permeabilised in ice-cold PBS containing 0.25% Triton X-100 for 15 
minutes. Following this, cells were washed in 10 mls of PBS with 1% BSA, then incubated 
with an anti-phospho-histone H3 (Ser 10) antibody (NEB) in 100 µl PBS/BSA for 1.5 hours 
at room temperature. The samples were then washed twice with 1ml PBS containing 1% w/v 
BSA, then resuspended in 100 µl of PBS/BSA containing fluorescein isothiocyante (FITC) 
conjugated anti-rabbit antibody (Invitrogen), and left in the dark at RT for 30 minutes. Cells 
were again washed in 1 ml PBS/BSA then 1 ml of PBS only, followed by re-suspension in 1 
ml PBS containing propidium iodide (PI) (25 µg/ml) and 0.1 mg/ml of RNAse A, and 
incubated in the dark at RT. Fluoresence was then measured using a Coulter XL-MCL flow 
cytometer (Beckman-Coulter). For measuring cell cycle only, cells were harvested as 
described above, permeablised, washed in PBS and then PI and RNAse added to the sample.  
2.3 Protein biochemistry techniques  
2.3.1 Protein determination 
The BioRad Bradford Reagent was used to measure the protein concentration of cell lysates. 
Briefly, a stock of BSA 1 mg/ml was diluted to give standards ranging from 0-500 µg/ml and 
10 µl aliquotted into a well of a 96 well plate in triplicate. Cell lysates were usually diluted 
1:10 in sterile water and 10 µl aliquotted into a well of a 96 well plate in triplicate. The 
protein determination reagent was diluted 1:5 with sterile water and 200 µl of this was added 
to both the standards and samples. Samples were then read in a plate reader using a 
wavelength of 595 nm (BioRad). Protein concentration was then calculated using Microsoft 
Excel. 
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2.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE gels were prepared with the percentage of acrylamide varying depending on the 
size of the protein being studied (Table 2.7). Generally, proteins over 50 kDa were run on a 
6% Acrylamide gel. Proteins less than 50 kDa were run on a 10% Acrylamide gel. The Gel 
apparatus was purchased from GE Healthcare and assembled according to manufacturers 
instructions, with gels run in buffer containing 100 mM Tris/bicine (1 M Tris/1 M Bicine) and 
1% SDS. Typically, 50 µg of cell lystate or purified protein was loaded on each gel. These 
were prepared by the addition of equal volumes of 2x Laemmli buffer and boiling for 5 
minutes followed by centrifugation at 15,000 g for 1 minute. Molecular weight markers (GE 
Healthcare) were also loaded on gels for identification of protein size. Gels were run at 0.02 
mA for approximately 5 hours. However, this varied depending on protein size. 
2.3.3 Visualisation of proteins 
Following separation of proteins, gels were placed in coomassie blue solution (0.1% 
Coomassie Brilliant Blue R-250 (Sigma), 40% methanol, 10% glacial acetic acid and water) 
to stain for 10 minutes at room temperature with agitation. Gels were then placed in a 
destaining solution (10% glacial acetic acid, 20% methanol and water) overnight at room 
temperature again with agitation. Destained gels were then dried in a vacuum gel dryer at 80 
°C for 2 hours. 
2.3.4 In-gel digestion of protein for analysis by mass spectrometry 
Proteins were separated on pre-cast Tris/Glycine gels using the NuPAGE Novex system 
(Invitrogen) and stained with colloidal coomassie (0.08% Coomassie Brilliant Blue, 1.6%
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 orthophosphoric acid, 8% ammonium sulphate, 20% methanol) for 6 hours, then destained in 
1% acetic acid in distilled water until the background was clear. Using a sterile scalpel blade, 
bands were excised form the gel and placed in a sterile 1.5 ml tube and washed twice with 
100 µl of 50% acetonitrile/50 mM ammonium bicarbonate for 45 minutes at 37 °C with 
agitation. The gel slices were then dried in a DNA-Mini vacuum centrifuge for 30 minutes. 
Next, 50 µl of 50 mM DTT, diluted in 10% acetonitrile/50 mM ammonium bicarbonate, was 
added and the gel fragment incubated at 56 °C for 1 hour. The supernatant was removed and 
50 µl of 10% acetonitrile/50mM ammonium bicarbonate containing 100 mM iodoacetamide 
added. The gel pieces were allowed to incubate at room temperature in the dark for 30 
minutes. The samples were then washed 3 times with 10% acetonitrile in 40 mM ammonium 
bicarbonate for 15 minutes at room temperature with agitation. The gel slice was then dried in 
a DNA-Mini vacuum centrifuge for 30 minutes. To digest any fixed proteins the gel slice was 
re-hydrated in 20 µl of 12.5 µg/ml Promega seq. grade modified trypsin in 10% 
acetonitrile/40 mM ammonium bicarbonate for 1 hour at room temperature. To cover the gel 
slice, 20 µl of 10% acetonitrile/40 mM ammonium bicarbonate was added to the tube and 
then left to incubate overnight at 37 °C. The following day the supernatant was collected and 
transferred to a new 1.5 ml tube. 30 µl of 3% formic acid in water was then added to each gel 
slice and incubated at 37 °C for 1 hour. The supernatant was then removed and added to the 
previous supernatant. A further 30 µl of 3% formic acid was added to the gel slice with 
incubation at 37 °C for 30 minutes and then the supernatant collected again. The collected 
supernatant could then be stored at -20 °C until mass spectrometric analysis. 
2.3.5 In vitro kinase assay 
Purified GST fusion proteins were incubated with 5 µl of 5x kinase buffer (100 mM Tris, 250 
mM KCl, 50 mM MgCl2, 1 mM ATP pH7.5), 1 µl recombinant CK2 (500,000 U/ml) (NEB), 
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10 µCi ATP (α-32P) (Perkin Elmer), 1 µg GST fusion protein, made up to a final volume of 25 
µl with nuclease free water and incubated for 10 minutes at 30 °C. For mass spectrometry the 
radio-labelled ATP was omitted from the reaction. The reaction was then stopped with 8.3µl 
of 4x Laemmli buffer, boiled for 5 minutes then span at 16,000 g for 1 minute. The reaction 
was then run on an SDS-PAGE gel as described above. Gels were then stained, destained and 
dried as previously stated. The gels were then exposed to autoradiography film (GE 
Healthcare) for detection of radio-labelled proteins. 
2.3.6 GST pull-down 
Firstly, purified GST fusion proteins were incubated with 100 Units of recombinant CK2 
(NEB). Following this, 5 µg of the purified protein was mixed with 200 µg of cell extract and 
incubated at 4 °C for 30 minutes to allow binding. Next 20 µl of Glutathione-Sepherase beads 
were added and the reaction incubated for a further 60 minutes at 4 °C. The beads were then 
washed three times with wash buffer (50 mM Tris, pH 7.5, 120 mM NaCl, 1 mM DTT, and 
0.2% NP-40). Laemmli buffer was then added, and the samples boiled for 5 minutes and then 
run on an SDS-PAGE gel.  
2.4 Immunochemistry techniques 
2.4.1 Antibodies 
All antibodies, dilutions and origins are listed in Table 2.8. 
2.4.2 Western blotting 
Following separation on SDS-PAGE, proteins were transferred onto nitrocellulose membrane 
(Thermo) using a Hoeffer Scientific Transfer system. In brief, gels along with the 
 127 
nitrocellulose membrane were soaked in transfer buffer (20% Methanol, 50 mM Tris, 190 
mM glycine), sandwiched between two pre-soaked pieces of Whatman 3 mm blotting paper 
and two pre-soaked sponges and then placed in a cassette. The cassette was then placed into a 
transfer tank and electro-transfer carried out at 200 mA for up to 18 hours at RT depending on 
protein size. The nitrocellulose was then stained with Ponceau S solution (Sigma) for 1-2 
minutes and then washed in distilled water until the excess Ponceau was removed and protein 
bands became visible. The residual Ponceau was completely removed by washing in either 
PBS-T (1x PBS, 0.1% Tween) or TBS-T (200 mM Tris and NaCl, 0.1% Tween pH7.6) 
depending on the primary antibody. The membrane was then placed in 5% milk powder 
(Marvel) in PBS-T/ TBS-T for 2 hours, with agitation to block non-specific binding. 
Following a brief wash, in either PBS-T or TBS-T, the blots were then incubated with 
primary antibodies diluted in 5% milk at the indicated dilution, amount of time and 
temperature, with agitation (Table 2.7). Next the blots were washed three times for 10 
minutes in either PBS-T or TBS-T before incubation with the relevant horseradish 
peroxidase-conjugated secondary antibody (Dako) diluted in 5% milk/PBS-T/TBS-T for 1 
hour at room temperature with agitation. After another three 10 minute washes in PBS-
T/TBS-T, the blots were incubated for 1 minute with enhanced chemiluminescence (ECL) 
reagents (GE Healthcare) and proteins detected using GE Healthcare Hyperfilm. 
 2.4.3 Immunoprecipitation 
Following trypsinisation, cells were washed in PBS, resuspended in 0.5 ml NETN buffer (50 
mM Tris/HCl pH 7.5, 150 mM NaCl, 1% NP40, 90 U/ml Benzonase (Novagen), 2 mM 
MgCl2, supplemented with protease inhibitors (Roche)), transferred to a thick walled 1.5 ml 
centrifuge tube and rotated for 30 minutes at 4 °C. The Lysed cells were then spun at 84,000 g 
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for 30 minutes at 4 °C. Next, 25 µl pre–washed protein G or A beads (dependant on antibody 
subclass) and 10 µg of non-specific species-matched antibody were added to the supernatant 
to aid removal of any non-specific immunoglobulin/protein A/G-binding proteins, and rotated 
at 4 ºC for 1 hour. Samples were then spun at full speed in a microcentrifuge at 4 ºC for 5 
minutes, and the supernatant transferred to a new tube. Next, 5-10 µg of immunoprecipitating 
antibody was then added followed by a 2-3 hour incubation at 4 °C with rotation. Lystates 
were then spun for 15 minutes at 84,000 g, the supernatant removed, 30 µl of pre-washed 
protein A/G beads added and rotated for 1-2 hours at 4 °C. Lastly, samples were spun at 833 g 
for 20 seconds and the supernatant removed. The immunoprecipitated proteins bound to the 
beads were washed in NETN (0.5% NP-40, without Benzonase) by inversion 4 times. 
Following the last wash, all the supernatant was removed with a syringe needle and 25 µl of 
Laemmli Sample Buffer added to elute the protein complexes. Samples were then boiled and 
either loaded onto a SDS-PAGE gel for separation and Western blotting or stored at -80ºC. 
2.4.4 Immunofluoresence 
Cells were trypsinised washed and seeded onto poly-L-lysine coated coverslips or 12-well 
glass slides and left overnight at 37 °C in the appropriate growth media.  The following day, 
media was removed and cells fixed in either ice-cold methanol for 10 minutes, or 
permeablised, first in extraction buffer (10 mM pipes pH 6.8, 300 mM sucrose, 20 mM NaCl, 
3 mM MgCl2, 0.5% TX-100) and then fixed in 3.6% paraformaldahyde in PBS. Coverslips 
and slides were washed once in PBS at RT and then blocked in 10% filtered FCS/PBS for 1 
hour at room temperature or overnight at 4  °C. Coverslips and slides were then washed twice 
with PBS. Primary antibodies were made up in 2% FCS/PBS to the relevant dilution, spotted 
onto the coverslips or wells on the glass slide and then incubated for 1 hour at room 
temperature (for antibody dilutions see Table 2.7). This was followed by three washes in PBS 
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and an hour incubation at RT in the dark with the secondary antibodies (Alexa-Fluor, 
Invitrogen) diluted to the appropriate concentration in 2% FCS/PBS (Table 2.7). The slides or 
coverslips were then washed a further three times in PBS. Slides and coverslips were then 
mounted in Vectashield Mounting Medium (Vector Laboratories) containing 4’, 6-diamidino-
2-phenylindole (DAPI) and the edges sealed with nail polish. Slides and coverslips were 
stored at 4 °C in the dark. Cells were viewed using a Nikon Eclipse E600 microscope using 
the Velocity imaging software. 
 
 
 
 
 
 
 
 
 
 Antibody Antigen Species Application Dilution Source 
KIAA0170 MDC1 Rabbit IF 1:500 G.Stewart 
BRAC1 BRAC1 Mouse IF 1:500 Santa Cruz 
NBS1 NBS1 Rabbit IF 1:100 Merck 
Phospho-H2AX 
Ser 139 
Phospho-H2AX 
Ser 139 Mouse 
IF 
WB 
1:1000 
1:1000 Millipore 
H2A H2A Rabbit WB 1:5000 Upstate 
MRE11 MRE11 Rabbit WB 1:1000 Abcam 
NBS1 NBS1 Rabbit WB 1:10000 Genetex 
Phospho-NBS1 
Ser 343 
Phospho-NBS1 
Ser 343 Rabbit WB 1:500 Signalway 
RAD50 RAD50 Mouse WB 1:3000 Abcam 
53BP1 53BP1 Rabbit WB IF 
1:1000 
1:300 
Novus 
Biologicals 
Phospho-53BP1 
Ser1778 
Phospho-53BP1 
Ser 1778 Rabbit WB 1:1000 Cell Signalling 
11G12 ATM Mouse WB 1:500 M.Taylor 
Phospho-ATM 
Ser 1981 
Phospho-ATM 
Ser 1981 Mouse 
WB 
IF 1:1000 Upstate 
SMC1 SMC1 Rabbit WB 1:1000 Bethyl 
Phospho-SMC1 
Ser 966 
Phospho-SMC1 
Ser 966 Rabbit WB 1:1000 Bethyl 
CHK1 CHK1 Mouse WB 1:1000 Santa Cruz 
Phospho-CHK1 
Ser 345 
Phospho-CHK1 
Ser 345 Rabbit WB 1:1000 Cell Signaling 
CHK2 CHK2 Rabbit WB 1:10000 S.Elledge 
Phospho-Chk2 
Thr 68 
Phospho-Chk2 
Thr 68 Rabbit WB 1:500 
R and D 
Systems 
RPA2 RPA2 Mouse WB 1:1000 Merck 
Table 2.8   Antibodies used in the study 
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 Phospho-histone   
H3 
Ser 10 
Phospho-histone   
H3 
Ser 10 
Rabbit FACS 1:100 Cell Signaling 
Anti-Mouse 
HRP 
Mouse 
IgG 
Goat WB 1:1000 DAKO 
Anti-Rabbit 
HRP 
Rabbit 
IgG 
Swine WB 1:3000 DAKO 
Alexa fluor! 488 
anti-Rabbit 
Rabbit 
IgG Donkey FACS 1:50 Invitrogen 
Alexa fluor! 546 
anti-Rabbit 
Rabbit 
IgG Goat IF 1:1000 Invitrogen 
Alexa fluor! 488 
anti-Mouse 
Mouse 
IgG Goat IF 1:1000 Invitrogen 
Table 2.8   Antibodies used in the study 
 
Antibody Antigen Species Application Dilution Source 
Phospho-RPA2 
Ser 4/8 
Phospho-RPA2 
Ser 4/8 Rabbit WB 1:100 Cell Signaling 
CK2! CK2! Rabbit WB 1:3000 Bethyl 
CK2!' CK2!' Rabbit WB 1:5000 Bethyl 
"Actin "Actin Mouse WB 1:25000 Sigma-Aldrich 
Phospho-MRE11 
Ser 676 
 Phospho-Mre11 
Ser 676 
Rabbit WB 1:500 Cell Signaling 
Phospho-MRE11 
Ser 688 
Phospho-Mre11 
Ser 688 
Rabbit WB 1:250 Invitrogen 
Methylated-
MRE11 Arg587 
Methylated-
Mre11 Arg587 Rabbit WB 1:1000 
Stephane 
Richard 
Quebec, Canada 
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Chapter 3 Constitutive phosphorylation of MDC1 by CK2 is 
required for retention of the MRN complex at the sites of 
DNA double-strand breaks. 
3.1 Introduction 
MDC1 was first shown to have involvement early in the DNA damage response after it was 
seen to colocalise with γH2AX following IR (Shang et al., 2003). Following this, further 
insight into the role that MDC1 undertakes in the DDR has come to light. MDC1 is now 
classed as a member of the mediator/adapter protein family, which also includes 53BP1, 
BRCA1 and TopBP1 (Schultz et al., 2000, Venkitaraman, 2001, Wang et al., 2002, Yamane 
et al., 2002). This particular group of proteins is characterised by the presence of BRCT 
domains and/or FHA domains, which act as phospho-peptide binding platforms that mediate 
the interaction with other DDR proteins. 
MDC1 localises at the sites of damaged chromatin via its ability to bind to γH2AX through its 
C-terminal BRCT domains. Once localised to the sites of DNA breaks, MDC1 functions as a 
scaffold allowing further recruitment of several DNA damage response proteins, including the 
MRN complex, RNF8 and 53BP1 (Eliezer et al., 2009, Goldberg et al., 2003, Kolas et al., 
2007, Mailand et al., 2007, Stewart et al., 2003). Therefore, MDC1 functions to amplify the 
intracellular signal generated following the induction of DNA damage and potentiate its repair 
by facilitating the recruitment of various DNA repair proteins.  Due to the early involvement 
of MDC1 in the DDR, loss of the protein is likely to have a detrimental affect on the cells 
ability to maintain the integrity of its genome. For instance, loss or lack of MDC1 results in a 
failure to efficiently recruit the MRN complex, BRCA1 and 53BP1 to the sites of DNA 
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damage which, as a consequence, disrupts the cells ability to activate both the intra-S phase 
and G2/M checkpoints as well as promote DNA repair (Goldberg et al., 2003, Stewart et al., 
2003). Consequently loss of MDC1 is associated with genomic instability and cancer 
predisposition (Minter-Dykhouse et al., 2008). 
In addition to binding proteins via its phospho-protein binding domains, MDC1 itself is also 
phosphorylated in response to DNA damage. A TQXF domain is targeted by ATM following 
treatment with IR leading to the recruitment of RNF8 (Jungmichel and Stucki 2010, Kolas et 
al., 2007, Mailand et al., 2007). Moreover, following the publication of various large-scale 
phosphoproteomic screens, it became apparent that MDC1 is a highly phosphorylated protein 
even in the absence of DNA damage (Beausoleil et al., 2004, Dephoure et al., 2008, 
Matsuoka et al., 2007, Olsen et al., 2006). Interestingly, a number of the MDC1 
phosphorylation sites identified in these screens clustered in a conserved N-terminal region 
consisting of 6 repeated motifs bearing the consensus sequence for the serine/threonine 
kinase, Casein Kinase 2 (or CK2) (Beausoleil et al., 2004, Dephoure et al., 2008, Olsen et al., 
2006).  
Recently evidence has started to emerge for CK2 playing a critical part in regulating the DNA 
damage response. For instance, phosphorylation of the SSB repair protein XRCC1 by CK2 
facilitates an interaction with the FHA domain containing DNA repair proteins PNK and 
APTX (Loizou et al., 2004). Of note, not unlike MDC1, XRCC1 is also classified as a 
mediator/adaptor protein and is thought to provide a scaffold function for the binding of 
SSBR factors to the sites of DNA damage. In this respect, its phosphorylation by CK2 
provides the specificity with which it can interact both PNKP and APTX. Based on this, it is 
therefore conceivable that the CK2 sites identified on MDC1 also mediate the interaction with 
one or more binding proteins that contain phospho-peptide binding domains that are critical 
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for its role in DNA repair of cell cycle checkpoint activation. Therefore the aims of this study 
were to: 
 
i) Validate the phosphorylation of MDC1 by CK2 
ii) Investigate the potential role of CK2-dependent phosphorylation in regulating 
the function of MDC1 during the cellular DNA damage response 
3.2 Results 
3.2.1 Identification of potential phosphorylation motifs on MDC1 
Large-scale screens using mass spectrometry on protein sequences has aided the identification 
of novel target motifs for protein modification. Results from a number of published phospho-
proteomic screens identified a number of phosphorylated residues on MDC1 that lie within 
motifs consistent with those targeted by the protein kinase CK2 (Table 3.1). Typically CK2 
target motifs consist of either a serine (S) or threonine (T) residue followed by either an 
aspartic acid or a glutamic acid (E) residue located at the n+3 position relative to the 
phosphorylated Ser or Thr (S/T-X-X-D/E). Interestingly, 12 of the 16 potential CK2 
phosphorylation sites clustered within an N-terminal domain of MDC1 that consisted of a 
repetitive amino acid motif, S-D-T-D-X-E-E termed SDTD motifs (Figure 3.1.A).  
An indication of whether regions of proteins have significant biological function can be 
obtained by comparing the sequences of various species to see whether there is any evidence  
Table 3.1   Summary of potential CK2 phosphorylation sites in MDC1: Φ peptide 
detected/used for in silico analysis. δ number designated in present study.  
 
Phosphorylation 
Site 
Peptide ! Reference Designation
" 
S168 LLLAEDS*EEEVDF Olsen, et al. 2006. 
Dephoure, et al. 2008. 
Beausoleil, et al. 2004. 
 
7 
S196 SVIVPES*DEEGHS http://phospho.elm.eu.org/ 8 
S218 FAFNLNS*DTDVEE http://phospho.elm.eu.org/ 1 
T220 FNLNSDT*DVEEGQ   
S299 QPPGEDS*DTDVDD Dephoure, et al. 2008. 2 
T301 GEDSDT*DVDDDS Dephoure, et al. 2008.  
S329 PFGFIDS*DTDAEE Beausoleil, et al. 2004, 
Olsen, et al. 2006. 
Dephoure, et al. 2008, 
 
 
3 
T331 GFIDSDT*DAEEER Olsen, et al, 2006. 
Dephoure, et al. 2008. 
 
S376 QESQAGS*DTDVEE Matsuko, et al. 2007 4 
T378 SQAGSDT*DVEEGK Matsuko, et al. 2007  
S402 ASMVINS*DTDDEE Olsen, et al, 2006. 
Dephoure, et al. 2008. 
 
5 
T404 MVINSDT*DDEEEV Olsen, et al, 2006. 
Dephoure, et al. 2008. 
 
S453 TTTERDS*DTDVEE Dephoure, et al. 2008.  
T455 TERDSDT*DVEEEE Beausoleil, et al. 2004, 
Dephoure, et al. 2008. 
6 
T516 RSQAST*TVDINT Matsuoka, et al. 2007 9 
T579 LHGDCET*DAEEGT http://phospho.elm.eu.org/ 10 
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Figure 3.1   Location and amino acid sequence of the CK2 phosphorylation 
domain of MDC1. (A) Schematic of human the MDC1 protein showing known 
domains including the putative N-terminal CK2 phosphorylation domain. (B) 
Amino acid sequence of the MDC1 putative CK2 phosphorylation domain. 
Potential CK2 phosphorylation sites are highlighted and numbered 1-10, as in Table 
3.1.  
 CK2 phosphorylation motif: S/T-X-X-D/E 
A 
B 
BRCT C 
1970 1896 
1661 1985 2082 1129 
PST Domain 2089 
PIK
K
s 
768 699 
N FHA 
124 55 
1 CK2 Domain 
141 621 
 	  
 137 
of evolutionary conservation. Using an internet based multiple sequence alignment 
programme, Clustal omega (http://www.ebi.ac.uk/Tools/msa/clustalo/), the region of human 
MDC1 (H.sapiens) containing the cluster of CK2 SDTD motifs was aligned with MDC1 of 
mouse (M.musculus), rat (R.norvegicus), Dog (C.lupus), Swine (S.scrofa) and chimpanzee 
(P.troglodytes). Strikingly, it was apparent that the majority of the 16 potential CK2 target 
sites identified either showed complete or partial homology in all vertebrate orthologues 
studied (Figure 3.2). Of particular interest was the complete conservation of the 6 SDTD 
repeat sequences between many of the species, suggesting that these motifs may have some 
functional importance.  
3.2.2 A N-terminal region of MDC1 is phosphorylated by CK2 in vitro 
and in vivo  
In order to investigate whether the identified potential sites on MDC1 were phosphorylated by 
CK2, two overlapping GST-fusion proteins were generated spanning this N-terminal region. 
Initially the fragments were amplified from full length MDC1 by PCR. Fragment 1 
encompassed amino acids 1-381 and fragment 2 contained amino acids 341-725 (Figure 
3.3.A). The PCR products were then cloned into the pGEX 4T-1 vector, sequenced and 
transformed into BL21 competent bacteria. Recombinant protein was purified from bacterial 
extract using GST-coupled agarose beads. These two purified proteins where then used as 
substrates in a CK2 in vitro kinase assay. Each fragment, or GST alone (used as a negative 
control), was incubated with recombinant CK2, in the presence of γ(32P)-ATP. The kinase 
reaction was then separated by SDS-PAGE and the gel stained with Coomassie blue to 
visualise the proteins. Radio-labelled fragments were visualised by exposing the dried gels to 
autoradiography film. 
Figure 3.2   Amino acid alignment of MDC1 N-terminal CK2 motifs across 
species. The region of human (H.sapiens) MDC1 containing a putative CK2 
phosphorylation motifs was aligned with several other vertebrate species, Mouse 
(M.musculus), Rat (R.norvegicus), Dog (C.lupus), Swine (S.scrofa) and Chimpanzee 
(P.troglodytes), to identify any evolutionary conservation, using the internet based 
multiple sequence alignment programme, Clustal omega (http://www.ebi.ac.uk/
Tools/msa/clustalo/). Shaded areas represent conserved potential target sites for 
CK2 phosphorylation, and the number designation for this study in red.  
M.musculus     NSRVLLAADSEEEGDFPSGRCVANGQRNTASPSATVVPESDEEVSSPAPSVPGPSSPFGL  218 
R.norvegicus   NSRVLLAEDSEEEGDFPSGRSVANGSRNTASPSATVVPESDEEGSSPGPSVPGPSSPFGL  218 
C.lupus        PQGLLLAEDSEEEVDSPSERCVVKEPRTS--PLAAVVPESDEEGPSPAPDGPGPPFAFNL  238 
S.scrofa       PHRLLLAEDSEEEVDSLSERCVVKGPKT---SLTTVIPESDEEGPSPAPDGPGPPFAFNL  215 
P.troglodytes  PQRLLLAEDSEEEVDFLSERRMVKKSRTT--SSSVIVPESDEEGHSPVLGGLGPPFAFNL  216 
H.sapiens      PQRLLLAEDSEEEVDFLSERRMVKKSRTT--SSSVIVPESDEEGHSPVLGGLGPPFAFNL  216 
M.musculus     GSDTDEEQGQQPGVEESSLADSSGAAGEAEQPEANGTT---AGIQAQPTEHKLKDTKVKK  275 
R.norvegicus   GSDTDESQGQQPGVEESSLADNSGAAGEPEQPEVNGVT---TGTLAQPTKDKFKDTKMKE  275 
C.lupus        DSDTDEEESQHSAAGEASLSARRGSTAETEQ-LKAMTPATQLGKDQCSVKERNNNTKVER  297 
S.scrofa       NSDTDEEESQQPGAGEAPSAAET-------EQPKPVTTEIQLIKDQCPVKEKHKDARVKR  268 
P.troglodytes  NSDTDVEEGQQPATEEASSAARRGATVEAKQSEAEVVTEIQLEKDQPLVKERDNDTKVKR  276 
H.sapiens      NSDTDVEEGQQPATEEASSAARRGATVEAKQSEAEVVTEIQLEKDQPLVKERDDDTKVKR  276 
M.musculus     EAGRAGVSDGSVLERSPTLGEDSDTEVDED--------------HKP-GFADSETDVEEE  320 
R.Norvegicus   EAGSAGVPVGSVVEGSPTLGEDSDTEADEE--------------RQPSGSGDSDTDVEEE  321 
C.lupus        DARNGVVSLGGILERNQSAGEDSDTDVDE-SRPPVRPAEVHLERAQPSDFIDSDTDVEEE  356 
S.scrofa       AASNGVVPVGAILERSQPAGEDSDTDVDEGSGLPRRPAGAHSERAQPCGFIDSDTDAEEE  328 
P.troglodytes  GAGNGVVPAGVILERSQPPGEDSDTDVDDDSRPPGRPAEVHLERAQPFGFIDSDTDAEEE  336 
H.Sapiens      GAENGVVPAGVILERSQPPGEDSDTDVDDDSRPPGRPAEVHLERAQPFGFINSDTDAEEE  336 
M.musculus     RIPVTPPVAPVKKNQVLLAVGIGDPEAPGVAHLQDCLAGSGTDVE-DKTALDVPLERNHT  379 
R.norvegicus   RV-------PVKKNQVLLGVGIGGPGARGVAHLQDSPTGSDTDVEEDKTALAAPPERSHT  374 
C.lupus        RIPATPAVVPMKKRQIFHRVSTKSLQEPALVHLQEIPAGNDTDVEESEIQLAVPLERNQI  416 
S.scrofa       GIPATPAVVPVKKRQIFHEVGTESPQAPGVAHAQESPAGSDTDIEEGEAPRTVPLDSSRA  388 
P.troglodytes  RIPATPVVIPMKKRKIFHGVGTRGPGAPGLAHLQESQAGSDTDVEEGKAPQAVPLEKSQA  396 
H.sapiens      RIPATPVVIPMKKRKIFHGVGTRGPGAPGLAHLQESQAGSDTDVEEGKAPQAVPLEKSQA  396 
M.musculus     PMVINSDTDEEEEEEEEEVSAALTLAHLKERGIGLWSRDPGAEEVKSQPQVLVEQSQSAS  439 
R.norvegicus   AMVINSDTDEEERGEEEEVSAALTLARLKERGIALWSGEPGTEEVKSQPQVLVERSQSAS  434 
C.lupus        SMVIDSNTDDE-----EEVLAALTLARLKESGSDTWNRGTDVEEDRAQPVALLEPSQTSA  471 
S.scrofa       SMMIDSNMDDE-----EEVSAALTLARLRESQAVPWNRDAGAGDHRAQPVALLDQSQASA  443 
P.troglodytes  SMVINSDTDDE-----EEVSAALTLAHLKESQPAIWNRDAEE--DMPQRVVLLQRSQTTT  449 
H.sapiens      SMVINSDTDDE-----EEVSAALTLAHLKESQPAIWNRDAEE--DMPQRVVLLQRSQTTT  449 
M.musculus     GRDSDTDVEEESS-GRKREIIPDSPMDVDEALTVTQPESQPPRRPNDADEYMDMSSPGSH  498 
R.norvegicus   GRDSDTDVEEGSS-GGKREIVPDSPMDVDETLTVTQPESQPPCRPNDVDEDVDMSSPGSH  493 
C.lupus        GRDSKTDMEEEGLPMENRRTVPKCH-----TDKACSEKRQFPLQDSDLEVDEDKSLLEVH  526 
S.scrofa       GRDSDTDMEEEGLPLEKRGSLPKGP-----ADKAHPEKSQPPLRGSDVKVEEDERSPGVH  498 
P.troglodytes  ERDSDTDVEEEELPVENREAVLKDHTKIRALVRAHSEKDQPPFGDSDDSVEADKSSPGIH  509 
H.sapiens      ERDSDTDVEEEELPVENREAVLKDHTKIRALVRAHSEKDQPPFGDSDDSVEADKSSPGIH  509 
M.musculus     LVVNQASFAVVGKTRAQVEEEVPGPSVILGEKHQVPLEGAQPP----------------E  542 
R.norvegicus   LEGKKASSALVDKNRAQVEEEVPGPSVTLGEKHQVPLEGAQPP----------------E  537 
C.lupus        LERNQASATID-I-TQVEEKVLPGPAIILVEKHQVPVVWTDQTYVEVEGGQAKLPVMHLG  584 
S.scrofa       PGRSQASATVD-AITQVEEKAPPRPAVTLSEQHQVPVAWTPQTDVEAEGDPAKLPVVHPA  557 
P.troglodytes  LERSQASTTVD-INTQVEKEVPPGSAIIHIKKHQVSVEGTNQTDVKAVGGPAKLLVVSLE  568 
H.sapiens      LERSQASTTVD-INTQVEKEVPPGSAIIHIKKHQVSVEGTNQTDVKAVGGPAKLLVVSLE  568 
M.musculus     EAW-------ETAVQE-GSSSPEAAASVRPSQQPVAEDAGTECATAVSEQESTLEVRSQS  594 
R.norvegicus   EAR-------ETAVQE-GSSSPVA--DIRMSQQPVAEDAGTECAAAVSEQKSALEVGAQS  587 
C.lupus        EPQPPLSEDCGTDVEEDTSLAASLVADTGKHQLLAEGDAGTESAAPVLEQERVLEARAQG  644 
S.scrofa       EARPPPAGGHEPDVEKNTSLAASAGADVRKSQLLAEGDAGTEWAVAILAQDRALGAGAQS  617 
P.troglodytes  EAW-PLHGDCETDAEEGTSLTASVVADVRKSQLPAEGDAGAEWAAAVLKQERAHEVGAQG  627 
H.sapiens      EAW-PLHGDCETDAEEDTSLAASAVADVRKSQLPAEGDAGAEWAAAVLKQERAHEVGAQG  627 
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Figure 3.3C clearly shows that CK2 phosphorylated both of the MDC1 fragments in vitro. In 
order to investigate which of the motifs were potentially phosphorylated by CK2, a plasmid 
expressing a GST-MDC1 fusion protein encompassing just the CK2 motifs was constructed, 
(aa141-621), and subjected to numerous rounds of site-directed mutagenesis to sequentially 
mutate each of the potential target CK2 motifs (Figure 3.4.A). In each case the serine and/or 
threonine of each motif was mutated to an alanine. In total 10 different constructs were 
created, transformed into BL21 competent bacterial cells and the GST-tagged fusion protein 
purified with GST-coupled agarose beads. The first six GST proteins comprised of the six 
SDTD motifs found in MDC1 mutated sequentially. The additional four GST proteins 
contained each of the single potential CK2 phosphorylation sites mutated in sequence on a 
background of the 6 mutant SDTD motifs. The purified GST-MDC1 fusion proteins were 
then used in an in vitro kinase assay again using recombinant CK2 and radiolabelled ATP.  
Sequentially mutating each of the potential CK2 sites resulted in a progressive loss of the 
phosphorylation, cumulating in a complete loss of phosphorylation when all 10 of the sites 
were mutated (Figure 3.4.B). The most significant loss in phosphorylation was observed after 
mutating sites 1-6 (The SDTD motifs). This suggests that the vast majority of the 
phosphorylation sites targeted by CK2 reside within the cluster of SDTD motifs. 
 
Figure 3.3       The N-terminal region of MDC1 is phosphorylated by CK2 in vitro. 
(A) A schematic of MDC1 depicting the location of the GST fragments 1 (aa1-381) 
and 2 (aa341-725). (B) Peptide sequence of the MDC1 putative CK2 phosphorylation 
domain. The potential CK2 phosphorylation sites in fragment 1 are ringed in blue 
whereas the potential CK2 phosphorylation sites present in fragment 2 are ringed in 
red. (C) N-terminal fragments of MDC1 were expressed as GST fusion proteins and 
purified using GST-coupled agrose beads. 1 µg of GST-MDC1 fragment 1 and 2 was 
incubated with recombinant CK2 and  radio-labelled ATP (γ-32P) for 10 minutes at 
30°C.  Proteins were separated by SDS-PAGE, stained with Coomassie blue and dried. 
Radio-labelled proteins were detected via autoradiography.  
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Figure 3.4   Mapping of the CK2 phosphorylation sites on MDC1 by in vitro kinase 
assay. (A) Amino acid sequence of the MDC1 CK2 phosphorylation region. Potential CK2 
phosphorylation sites are highlighted and numbered 1-10. (B) GST-fusion proteins were 
generated, where all of the possible targeted serine or threonine residues were mutated to 
alanine. 1 µg of each of the GST proteins was incubated with recombinant CK2 and radio-
labelled ATP (γ-32P) for 10 minutes at 30 °C.  Proteins were fractionated by SDS-PAGE, the 
gels were then stained with Coomassie blue and dried. Radio-labelled proteins were detected 
by autoradiography.  
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3.2.3 Identification of MDC1 CK2 target sites by mass spectrometry 
analysis  
Since analysis of the phospho-proteomic data indicated that both the serine and the threonine 
residues of the SDTD motifs were phosphorylated in vivo either singly or in combination, it 
was necessary to determine whether CK2 preferentially targeted either one of the residues in 
the SDTD motifs for phosphorylation, or could phosphorylate both. Therefore, to determine 
which of the identified CK2 phosphorylation sites on MDC1 were phosphorylated, the WT 
MDC1 GST-fragment encompassing all the CK2 phosphorylation motifs (aa141-621) was 
subjected to an in vitro kinase assay with recombinant CK2, separated on a pre-cast 
Tris/Glycine gel and then stained with colloidal blue. The phosphorylated GST-MDC1 band 
was excised from the gel and then treated with trypsin to digest the GST-fusion protein into 
peptides. The resulting peptides were subjected to mass spectrometry analysis to determine 
which of the serine/threonine residues were phosphorylated by CK2 in vitro.  
Table 3.2 lists the identified peptides that were phosphorylated by CK2. Of the 16 potential 
phosphorylation sites originally identified at the beginning of the study, the mass 
spectrometry analysis identified 11 phosphorylated residues, of which 10 were located within 
the SDTD motifs (Figure 3.4.B). Furthermore, the mass spectrometric analysis demonstrated 
that both the serine and threonine residues of the SDTD motifs could be phosphorylated in 
combination. Taken together, this analysis highlighted the 6 clustered SDTD motifs of MDC1 
as a target for CK2-mediated phosphorylation. 
 
Table 3.2   Recombinant MDC1 phospho-peptides identified by mass spectrometry 
following phosphorylation by recombinant CK2 in vitro. Target consensus motifs are 
highlighted in red, with ‘*’ denoting putative phosphorylation site. This data was 
provided by Dr. Nicholas Morrice (University of Dundee). 
MDC1 Peptide CK2 
Phosphorylation 
Site 
Corresponding 
Designation 
DSD*TDVEEEELPVENR T455 6 
AQPFGFIDSD*TDAEEER T331 3 
LLLAED*SEEEVDFLSE S168 7 
SQASMVIN*SDTDDEEEVSAALTLAHLK S402 5 
SQASMVINSD*TDDEEEVSAALTLAHLK T404 5 
SQTTTERD*SDTDVEEEELPVENR S453 6 
SQTTTERD*SD*TDVEEEELPVENR S453 T455 6 
SQPPGED*SDTDVDDDSRPPGRPAEVHLER S299 2 
SQPPGED*SD*TDVDDDSRPPGRPAEVHLER S299 T301 2 
AQPFGFID*SD*TDAEEERIPATPVVIPMK S329 T331 3 
GPGAPGLAHLQESQAG*SD*TDVEEGKAPQAVPLEK S376 T378 4 
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3.2.4 MDC1 associates with CK2 in vivo in the presence and 
absence of damage 
To strengthen the evidence for a potential link between MDC1 and CK2, it was deemed 
important to establish whether or not MDC1 and CK2 associate in vivo. Extracts from HeLa 
cells, either mock-irradiated or irradiated with 10 Gy of IR, were separately incubated with 3 
different antibodies raised against regions of the MDC1 protein. Co-immunoprecipitated 
proteins were then separated by SDS-PAGE and Western blots probed with antibodies against 
CK2α and CK2α’, the catalytic subunits of the kinase.  
Interestingly, MDC1 seems to preferentially bind to a CK2 complex containing the α’ rather 
than α catalytic subunit (Figure 3.5).  Moreover, this association was unaffected by DNA 
damage, suggesting that the interaction may be constitutive. 
3.2.5 Loss of CK2 results in a persistent DNA damage response 
following IR 
MDC1 plays a number of critical roles during the cellular response to DNA double strand 
breaks that include recruiting repair proteins to sites of DNA damage, potentiating the 
phosphorylation of histone H2AX and facilitating the activation of Chk1 (Stewart et al, 2003, 
Lou et al 2006, Stucki 2005). To investigate whether the CK2 potentially played a role in 
activating/regulating MDC1-dependent DDR induced by exposure to IR, the individual 
catalytic subunits of CK2 were depleted in cells using siRNA and 72 h later the cells were 
irradiated with 5 Gy of IR. The IR-induced DDR was monitored over a time course post-
irradiation, using Western blotting with phospho-specific antibodies to known proteins 
involved in the ATM-mediated response.  
CK2α 
CK2α  
10 Gy IR               
2% Input IgG Ab-1 Ab-2 BL578 
α-MDC1 
Figure 3.5   MDC1 interacts with CK2 in vivo. Extracts from untreated or 
irradiated (10 Gy and harvested at 8 hr) HeLa cells were separately 
incubated with 3 different MDC1 antibodies raised against different regions 
of the protein (Ab-1 aa 326-649, Ab-2 aa 643-1015, BL578 Bethyl) or a non-
specific isotype and species-matched control IgG. Immunoprecipitates were 
then separated by SDS-PAGE, electroblotted and MDC1-associated proteins 
were detected by incubation of the filters with the indicated antibodies.  
 
  
Figure 3.6   Loss of CK2 results in a prolonged DNA damage response following 
IR. HeLa cells were transfected with control, CK2α or CK2α’ siRNA. Seventy two hours 
later the cells were irradiated with 5 Gy of IR and harvested at the indicated time points. 
Cell extracts were separated by SDS-PAGE followed by Western blotting with the 
indicated antibodies.  
1 4 0 24 8 
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Loss of the catalytic activity of CK2, in particular the α’ subunit, resulted in mild prolonged  
phosphorylation of many known ATM kinase substrates, including SMC1 and NBS1 (Figure 
3.6). This suggests that CK2 activity is may be required for the proper activation/maintenance 
of the DDR phospho-activity presumably through its ability to phosphorylate a number of 
molecules required for DNA repair. Strikingly, depletion of the α’ subunit of CK2 
destabilised endogenous CHK1. Whilst the physiological relevance of this is unknown, it has 
been demonstrated that CHK1 can bind to the regulatory β subunit of CK2, however the 
catalytic subunits are not required for this interaction (Guerra et al., 2003). Further 
investigation would be required to study the loss of native CHK1 following siRNA depletion 
of CK2α’.  
3.2.6 Loss of CK2 via siRNA or mutation of the CK2 target motifs 
does not affect MDC1 localisation  
In response to IR, DDR proteins are recruited to sites of damaged chromatin in a precise and 
tightly regulated manner. This relocalisation of repair proteins to sites of DNA damage can be 
visualised by immunofluorescence and are termed Ionising Radiation-Induced Foci (IRIF). 
MDC1 rapidly forms radiation-induced foci and colocalises with a number of other DDR 
proteins (Xu and Stern, 2003). To determine whether loss of CK2 influenced the ability of 
MDC1 to be recruited to sites of DNA DSBs, immunofluorescence was used to study MDC1 
foci formation in irradiated U2OS cells transfected with either CK2α and CK2α’ siRNA. One 
hour post-irradiation, cells where fixed and then stained with antibodies to MDC1 and 
γH2AX, the latter of which was to mark sites of damage. As shown in Figure 3.7 the loss of 
CK2 catalytic activity did not result in a loss of MDC1 radiation induced foci or indeed its 
ability to colocalise with γH2AX.  
Figure 3.7   Loss of CK2 does not affect the relocalisation of MDC1 to 
radiation-induced foci. HeLa cells were transfected with control, CK2α or CK2α’ 
siRNA and then seeded onto poly-L-lysine coated coverslips. Seventy two hours 
later cells were irradiated with 5 Gy of IR, pre- extracted and fixed after 1 h, 
followed by staining with the indicated antibodies. Images are of one cell and are 
representative of approximately ~1000 cells scored by eye from 3 separate 
experiments.  
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Moreover, to definitively verify that loss of CK2 phosphorylation on MDC1 did not affect 
MDC1 relocalisation after DNA damage, a number of GFP-MDC1 constructs were made in 
which either the entire CK2 region was deleted (ΔCK2-MDC1-GFP (aa141-621)) or where 
the both the serine and threonine residues in each of the SDTD motifs had been mutated to an 
alanine (1-6 S/T⇒A MDC1-GFP). A further GFP-MDC1 expression construct was made in 
which Serine-168, which had also been identified as a CK2 phosphorylation site that did not 
reside in an SDTD motif, had been also been mutated to an alanine (1-6+7 S/T⇒A-MDC1-
GFP). These were then transfected into HeLa cells and irradiated with 5 Gy of ionising 
radiation. Comparable to CK2 knockdown via siRNA, MDC1 lacking the putative CK2 
phosphorylation sites was still able to form radiation-induced foci and colocalise with γH2AX 
(Figure 3.8). This data suggests that phosphorylation of MDC1 by CK2 is not required for 
either its relocalisation to sites of damage or colocalisation with γH2AX in response to IR.  
3.2.7 Loss of CK2 does not impair recruitment of other DNA damage 
factors following IR 
Given that loss of phosphorylation of MDC1 by CK2 did not affect its relocalisation to DNA 
damage, it is possible that the phosphorylation maybe required for the binding/recruitment of 
other repair/checkpoint factors known to be downstream of MDC1. In keeping with this, the 
phosphorylation of XRCC1 by CK2 is not required for its ability to be recruited to SSB but is 
essential for mediating its binding to either PNKP or APTX (Loizou et al., 2004, Luo et al., 
2004). Therefore, to investigate whether the loss of CK2-dependent phosphorylation of 
MDC1 affected the recruitment of other DNA repair factors to sites of DNA DSBs, HeLa 
cells seeded onto slides were transfected with either control, CK2α or CK2α’ siRNA for 72 h,  
Figure 3.8   Loss of the CK2 phosphorylation sites on MDC1 does not affect  
its relocalisation to radiation-induced foci. HeLa cells were transfected with GFP 
Full-length MDC1 (FL-MDC1 GFP), GFP MDC1 lacking the CK2 domain 
(ΔCK2-MDC1-GFP), GFP MDC1 where 1-6 SDTD motifs had been mutated (1-6 
S/T⇒A MDC1-GFP) and GFP MDC1, where, in addition to 1-6 SDTD motifs 
mutated, residue 7 had also been mutated (1-6+7 S/T⇒A-MDC1-GFP).  Cells 
were then seeded onto poly-L-lysine coated coverslips cells, irradiated and fixed 1 
h later. The cells were then stained with the indicated antibodies. Images are of 
one cell and  are representative of approximately  ~1000 cells scored by eye from 3 
separate experiments.  
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irradiated with 3 Gy of ionising radiation, fixed 8 hour post-irradiation and stained with 
antibodies to phosphorylated ATM, 53BP1 or BRCA1. The recruitment of each repair protein 
was determined by immunofluorescence.  MDC1 interacts with activated ATM (ATM S1981-
P) via its FHA domain, which resides N-terminal to the CK2 domain and thus it is plausible 
that the phosphorylation of the SDTD motifs aids in the binding of ATM (Lou et al., 2006). 
However, loss of CK2 did not abolish the ability of ATM to be recruited to sites of DNA 
damage, as indicated by the presence of phosphorylated ATM (pATM) IRIF in cells depleted 
of either CK2α or CK2α’ (Figure 3.9). The recruitment of 53BP1 and BRCA1 was also 
investigated following CK2 knockdown. Both of these proteins rely on MDC1 for their 
localisation to DNA breaks functioning to regulate NHEJ and HRR respectively downstream 
of MDC1 (Huen et al., 2007, Kolas et al., 2007, Mailand et al., 2007). Similar to pATM, both 
53BP1 and BRCA1 formed radiation-induced foci after CK2 knockdown. This implies that 
phosphorylation of MDC1 by CK2 has no impact on recruitment of a number of major DNA 
damage proteins.  
3.2.8 siRNA-mediated reduction of CK2 results in loss of NBS1 foci 
following IR 
Like ATM, the MRN complex functions early in the DNA damage response, and rapidly 
forms foci following IR. It has been observed that MDC1 exists in a complex with MRN 
(Goldberg et al., 2003) (Figure 3.11), and that depletion of MDC1 by siRNA leads to a 
reduction of MRN nuclear foci (Goldberg et al., 2003, Lou et al., 2006, Lukas et al., 2004, 
Stewart et al., 2003). To ascertain whether loss of CK2 activity affected the MDC1-dependent 
relocalisation of the MRN complex to sites of DNA damage, HeLa cells were seeded onto 
slides and transfected with either control, CK2α or CK2α’ siRNA. The cells were then  
Figure 3.9   CK2 depletion by siRNA does not affect the recruitment of other DNA 
damage factors to radiation-induced foci. HeLa cells were transfected with CK2α,  
CK2α’ or control siRNA. Seventy two hours later the cells were then irradiated with 3 
Gy, harvested after 8 h and then fixed. Cells were then stained with the indicated 
antibodies. Images are of one cell and  are representative of approximately ~1000 cells 
scored by eye from 3 separate experiments.  
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irradiated and fixed 8 hours post-irradiation. The cells were subsequently stained with NBS1 
and γ-H2AX as a marker of DSBs. Consistent with this hypothesis, when either CK2α or 
CK2α’ was knocked down in HeLa cells using siRNA, NBS1 failed to form foci following 5 
Gy of IR compared to cells treated with control siRNA (Figure 3.10). These results suggest 
that CK2 is required for NBS1, to localise to radiation-induced foci, and that this localisation 
is possibly mediated through a phospho-dependent interaction on MDC1 involving CK2.  
It should be noted that all foci images are representative of approximately 1000 cells scored 
by eye from 3 experimental repeats. However, this method of documenting foci formation 
sways towards qualitative anaylsis and therefore, has a number of associated caveats. For 
instance modest impacts may not be detected. Scoring cell number and number of foci per cell 
would provide quantative analysis of the results, providing a statistical approach to the data. 
3.2.9 The SDTD motif of MDC1 mediates its interaction with the 
MRN complex  
Despite having demonstrated that CK2 activity is required for the relocalisation of the NBS1 
to sites of DNA damage and that MDC1 and the MRN exist constitutively bound as a 
complex in the cell, it is unclear whether the CK2-dependent phosphorylation of MDC1 plays 
a key role in this process. To investigate this, MDC1 was immuno-purified from cells 
previously treated with either control or CK2 siRNA and Western blots probed with 
antibodies to NBS1. Strikingly, NBS1 failed to co-precipitate with MDC1 in cells lacking 
CK2 activity, yet a small amount did in cells treated with control siRNA (Figure 3.11). This 
finding is consistent with the idea that CK2 phosphorylation is mediating the constitutive 
interaction of MDC1 with the MRN complex. 
 
Figure 3.10    Loss of CK2 abolishes the recruitment of NBS1 to DNA double- 
strand breaks. HeLa cells were mock-transfected or transfected with CK2α or 
CK2α’ siRNA for 72 h. Cells were seeded onto coverslips, irradiated with 5 Gy IR of 
ionising irradiation, fixed after 8 h and stained with the indicated antibodies. 
Images are of one cell and  are representative of approximately  ~1000 cells scored 
by eye from 3 separate experiments. 
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To demonstrate that CK2-dependent phosphorylation of MDC1 was critical in mediating the 
interaction with the MRN complex, a series of GST-MDC1 fragments were generated, 
containing mutations in which the threonine residue of each SDTD motif had been 
sequentially mutated to an alanine. The threonine residue was chosen since FHA domains 
have a tendancy to preferentially bind phospho-threonine rather than phospho-serine residues 
(Durocher et al., 1999). A GST-pulldown assay was performed, using the recombinant 
purified MDC1 proteins, to elucidate whether the phosphorylation of MDC1 by CK2 
mediates the interaction with the MRN complex. The GST fragments were pre-incubated with 
CK2 in the presence of ATP and then used to pull down proteins from HeLa nuclear extract. 
Samples were then separated by SDS-PAGE and Western blots probed with antibodies 
against members of the MRN complex. In the presence of CK2, the phosphorylated MDC1 
WT fragment is capable of pulling down all three members of the MRN complex. However, 
loss of 3 out of the 6 phospho-SDTD motifs was sufficient to disrupt this interaction (Figure 
3.12). Therefore the interaction is phospho-dependent and most probably mediated via NBS1 
and the CK2 phosphorylated N-terminus of MDC1. 
3.2.10 The CK2 phosphorylated N-terminus of MDC1 interacts with 
NBS1 via its FHA domain 
It has been previously demonstrated that the FHA domain of Nbs1 is required for the MRN to 
be recruited to DSBs. Interestingly, it has been shown that it is the FHA domains of PNKP 
and APTX that mediate the binding to CK2 phosphorylated XRCC1 (Loizou et al., 2004, Luo 
et al., 2004). It is conceivable that the FHA domain of NBS1 is required for binding to 
phosphorylated MDC1 and therefore its recruitment to sites of DNA damage. Previous studies 
Figure 3.11    Knockdown of CK2 using siRNA abrogates the interaction between 
MDC1 and NBS1 in vivo.  HeLa cells were depleted of CK2α or mock-depleted. 
Seventy two hours later the cells were harvested and extracts were incubated with the 
indicated antibodies. Immunoprecipitates were then separated by SDS-PAGE followed 
by Western blotting with the indicated antibodies. 
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Figure 3.12   Mutation of the MDC1 CK2 phosphorylated region prevents 
binding to the MRN complex in vitro. A MDC1 fragment (aa221-456) derived 
from mouse where a number of the SDTD motifs had been mutated to SDAD  
(3T>A: T362A, T387A and T444A: 4T>A: T315A, T362A, T387A and T444A; 
5T>A T300A, T315A, T362A, T387A and T444A; 6T>A T222A, T300A, T315A, 
T362A, T387A and T444A) was generated and expressed as GST fusion proteins in 
E. coli. The purified fragments were then incubated with recombinant CK2 in the 
presence of ATP.  Fragments were then used to pull down proteins from HeLa 
nuclear extracts. Proteins were separated by SDS-PAGE and the membranes 
blotted with antibodies against members of the MRN complex. Figure kindly 
provided by M.Stucki, Institute of Molecular Cancer Research, University Zürich. 
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have shown that a single point mutation (R28A) in the FHA domain of NBS1 abolishes the 
interaction between MDC1 and the MRN complex and results in loss of MRN accumulation 
at sites of damage in vivo (Horejsi et al., 2004, Lukas et al., 2004a). Therefore, to determine 
whether MDC1 interacted with NBS1 via its FHA domain, WT MRN and a MRN complex 
containing the R28A mutant NBS1 were expressed and purified from Sf9 cells. The mutant 
and WT complexes were then incubated with a purified GST-MDC1 fragment containing the 
SDTD motifs pre-phosphorylated by CK2. GST-coupled beads were used to isolate MDC1-
MRN protein complexes that were subsequently subjected to SDS-PAGE and Western 
blotting. Interestingly, an interaction between wild-type NBS1 and the MDC1 fragment was 
observed and this association was significantly increased when MDC1 was phosphorylated by 
CK2 (Figure 3.13). Strikingly however, this interaction was completely abrogated when the 
fragments were incubated with the MRN complex harbouring the R28A mutation in NBS1 
(Figure 3.13). It can be concluded that phosphorylation of MDC1 by CK2 facilitates the 
interaction between MDC1 and the MRN complex and that this is mediated via the FHA 
domain of NBS1.  
3.2.11 Abolishing the interaction between MDC1 and NBS1 results 
in a partial G2/M checkpoint defect  
So far, the experimental data has shown that loss of CK2 results in ablation of NBS1 foci 
following damage, and that CK2 facilitates the interaction between MDC1 and NBS1 through 
the NBS1 FHA domain. It is also apparent that disruption of this phospho-dependent  
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Figure 3.13   The CK2 phosphorylated N-terminus of MDC1 interacts with 
NBS1 via its FHA domain.  (A) A Schematic of full length NBS1, showing 
domains and location of the R28A mutation. (B) A purified GST-MDC1 
fragment  (aa301-560) was pre-incubated with CK2 and ATP. The fragment was 
then incubated with purified MRN complex containing either wild type NBS1 or 
NBS1 in which the FHA domain had been mutated (R28A). GST-purified protein 
complexes were separated via SDS-PAGE and the Western blots were probed with 
an antibody against NBS1. Figure B kindly provided by M.Stucki, Institute of 
Molecular Cancer Research, University Zürich. 
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 interaction does not impede the recruitment of early damage response proteins (Figure 3.9). 
This raises the question as to whether loss of MDC1-dependent NBS1 recruitment to sites of  
damage translates to a defect in the cellular DDR induced by exposure to IR. To ascertain 
whether the interaction between MDC1 and Nbs1 is required to mediate this response to DNA 
double strand breaks, fibroblasts lacking full length NBS1 (NBS-iLB1) were transfected with 
either WT NBS1 (NBS+WT), or the NBS1 R28A (NBS+R28A) mutant, irradiated with 
varying doses of IR and then the percentage of mitotic cells determined using phospho-
histone H3 serine-10 (p-H3) staining coupled with FACS. As expected the cells transfected 
with WT NBS1 following damage exhibited a dose-dependent drop in the percentage of 
mitotic (p-H3 positive) cells, which is indicative of G2 arrest (Figure 3.14.B). As expected 
cells completely lacking NBS1 exhibited a significantly higher percentage of p-H3 positive 
cells post-irradiation which suggests a defect in checkpoint activation allowing damaged cells 
to pass into mitosis (Figure 3.14.B). Interestingly, the cells transfected with NBS1 FHA 
mutant attenuated activation of the G2/M checkpoint, albeit not as severe as NBS cells 
lacking NBS1 expression (Figure 3.14.B). Moreover, the observed defect was not due to 
lower expression of the transduced mutant NBS1 compared to the WT (Figure 3.14.A). This 
suggests that disruption of the CK2 dependent MRN/MDC1 interaction results in G2/M 
checkpoint defect, following ionising radiation.  
Figure 3.14 Abolishing the interaction between MDC1 and NBS1 results in a partial 
G2/M checkpoint defect.  (A) Cell extracts from NBS-iLB1 fibribroblasts and NBS-iL1 
fibroblasts transduced with either WT NBS1 or R28A mutant NBS1. Proteins were 
separated by SDS-Page followed by Western Blotting with indicated antibodies. (B)   
NBS fibroblasts (NBS-iLB1) and NBS fibroblasts stably transfected with WT NBS1 
(NBS+WT) or the FHA domain mutant of Nbs1 (NBS+R28A) were mock-treated or 
irradiated with 1 Gy or 3 Gy of IR and harvested 1 hour post-irradiation.  Cells were 
fixed with ethanol and stained with an antibody against phospho-histone H3 serine 10 
which is as a marker of mitotic cells. The DNA was stained with propidium iodide and 
the cells were then analysed using FACS. Error bars represent SD. Figure kindly 
provided by M.Stucki, Institute of Molecular Cancer Research, University Zürich. 
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3.2.12 Identification of a Seckel-like family with a unique mutation in 
NBS1 
Recently, our laboratory has identified a unique family (Family 106) from the United Arab 
Emirates in which the three affected individuals currently alive, primarily present with 
moderate microcephaly and growth retardation. Initially this led to a clinical diagnosis of 
Seckel Syndrome (Figure 3.15 & 3.16). However, following DNA linkage analysis performed 
by members of Andrew Jackson’s laboratory (Institute of Genetics and Molecular Medicine, 
Edinburgh) a single homozygous mutation was discovered in exon 4 of the NBS1 gene, which 
is predicted to result in the inframe deletion of serine 118 (ΔSer118) located within the first 
BRCT domain (Figure 3.17 & 3.18). Briefly, SNP (Single-nucleotide polymorphism) arrays 
on the 3 affected individuals and their parents were undertaken using approximately 120,000 
of the most informative SNPs. The analysis using Alohomora for data manipulation, graphical 
relationship representation and Merlin for error checking and removal, and Allegro for 
linkage analysis, revealed four regions with a positive-linkage signal. Upon receipt of a 
sample from an unaffected sibling, microsatellites covering these four regions were 
genotyped, leading to removal of one region due to homozygosity in the unaffected sibling. 
The remaining three regions were then considered for candidate gene prioritisation based on 
previous disease associations, cellular function and animal models, resulting in the 
identification of the mutation in NBS1.  
Since it has been reported that in addition to its FHA domain, the BRCT1 domain of NBS1 is 
also required to mediate its interaction with phospho-MDC1, it could be suggested that the 
clinical disease exhibited by the affected individuals in this family may specifically result 
from a failure of MDC1 and NBS1 to interact (Chapman and Jackson, 2008, Hari et al., 2010, 
Wu et al., 2008). In support of this, structural modeling of this BRCT1 domain mutation, 
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performed by Scott Williams, highlighted S118 as a critical residue within this domain for 
mediating its interaction with a phospho-peptide (Figure 3.19). This data was produced via 
small angle-X-ray scattering based on published work investigating the FHA and BRCT 
domains of human NBS1 (Williams et al., 2009). Furthermore, this residue had also been 
previously identified along with another, K160, which is also thought to be important for 
phospho-peptide interactions within this domain (Lloyd et al., 2009) (Figure 3.19). 
Interestingly, when compared to classical NBS patients (that typically are homozygous for the 
657del5 NBS1 mutation and do not express full length protein), the NBS BRCT mutant 
patients (NBSBRCT) lack several of the major clinical/cellular features characteristic of this 
disorder, such as immunodeficiency, spontaneous chromosome 7;14 translocations and 
defects in DNA DSB repair (Table 3.3 & 3.4). This observation could indicate that loss of 
NBS1 binding to MDC1 only contributes to the development of a subset of the clinical 
features exhibited by classical NBS patients.  
3.2.13 ΔSer118 does not result in reduction of NBS1 protein levels 
or disrupt binding to MRE11 or RAD50  
The mutation present in 90% of classical NBS patients (657del5) is hypomorphic, which 
results in reduced levels of the NBS1 protein and subsequent destabilisation of the other 
members of the MRN complex. Therefore, it is important to establish whether the clinical 
features of the NBSBRCT patients is specifically due to the mutation, or also in part caused by a 
reduction in expression of the NBS1 protein. To assess this, extracts from lymphoblastoid cell 
lines (LCLs) derived from the 3 affected individuals from family 106 were subjected to 
Western blotting using antibodies directed against components of the MRN complex and 
ATM. Extracts from two normal individuals (Normal-1/Normal-2) and a classical 657del5 
Figure 3.15   Family 106. (A) Presentation of microcephaly in three related 
individuals, patient A, B and C from family 106 (B) Genetic pedigree of family 
106 (IV:1 patient A, IV:3 patient B, IV:5 patient C).  
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Figure 3.16   The NBSBRCT patients from family 106 exhibit microcephaly 
and growth retardation. (A) MRI scan of NBSBRCT patient A. One of the 
affected individuals (patient A) at 7 months (left panel) showing reduced 
cerebral cortex size compared to that of a normal individual of similar age 
(right panel). (B) Growth Parameters of the four affected NBSBRCT patients 
from family 106. Birth weight (BWgt), occipitofrontal circumference (OFC) 
and height (Hgt) of the four affected NBSBRCT  patients, presented as standard 
deviations (S.D.) from the norm.  
NBS-BRCT (HR) Normal 
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B 
Patient A Normal 
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 
Control NBS1 Exon 4 
NBSBRCT NBS1 Exon 4 
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Figure 3.17   Identification of a mutation in NBS1, in the affected patients 
from family 106. A homozygous deletion in exon 4 (ΔCTT) of the patients 
NBS1 gene, resulting in the loss of a single amino acid was identified through 
whole genome sequencing (lower panel).  
   
Figure 3.18   Serine-118 is located in the BRCT1 domain of NBS1 and is 
conserved across species. (A) Schematic of hNBS1 depicting the location of the 
ΔS118 on the protein. (B) Amino acid sequence alignment of NBS1 
demonstrating S118 is conserved across several species.  
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Figure 3.19   S118 of NBS1 is essential for binding to phospho-
residues.  A small angle-X-ray scattering model of the human NBS1 FHA 
and BRCT1/BRCT2 domains. It is predicted that along with Lys160 and 
Thr158, S118 interacts with phospho-peptide domains (pSer). This data 
was provided by Dr. Scott Williams (unpublished).  
   
Table 3.3   Comparison of clinical and cellular phenotypes exhibited by 
657del5 NBS vs NBSBRCT patients. This data was provided by Dr Grant Stewart. 
Immunophenotyping was carried out by the University of Birmingham's  Clinical 
Immunology Service. Sensitivity to the mentioned DNA damaging agents was assed 
by via chromosomal breakage.  
Clinical Features 657del5 NBS NBSBRCT
Microcephaly Yes Yes (4 sbilings)
Ataxia No No
Oculocutaneous telangiectasia No Yes (1 sibling)
Growth retardation Yes Yes (4 sbilings)
Intellectual disability Mild-moderate Moderate
Dvelopmental delay Yes Yes 
Dysmorphic facial features Yes Yes
Skin abnormalities Yes 1 sibling Café-au-lait spots
Genito-urinary tract abnormalities Yes Yes
Immunoglobulin deficiency Yes No
T cell abnormalities Yes No
B cell abnormalities Yes No
NK cell abnormalities Yes No
Chromosomal translocations Yes No
Radiation chromosome hypersensitivity Yes No 
MMC chromosome hypersensitivity Yes No 
CPT chromosome hypersensitivity Unknown No 
169	  
Table 3.4   Cells from the NBSBRCT patients do not exhibit chromosomal 
radiosensitivity. The cells of the NBSBRCT patients, A, B and C were treated 
with 1 Gy of IR and the number of induced chromosome aberrations in G2 
were counted in 50 metaphase spreads. These numbers were compared with a 
normal control and a 657del5 NBS patient. The range of chromosome 
damage given for the normal individual was derived from the analysis of 
over 100 individuals. This data was provided by Dr Grant Stewart.  
Chromatid 
gaps 
Chromatid 
breaks 
Tri-radial 
chromosomes 
Quadra-radial 
chromosomes 
Other 
Normal 2-10 0 0 0 0 
A 1 1 0 0 0 
B 7 2 1 0 1 
C 6 0 0 0 1 
NBS 
657del 
73 27 4 7 6 
   
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NBS patient (NBS-Classical) were used for comparison. A complete absence of full length  
NBS1 protein was observed in the classical NBS patient, compared to the normal (Figure 
3.20.A). Strikingly, the levels of NBS1 expression were unaffected in the three affected 
NBSBRCT patients (NBS-BRCT (A), NBS-BRCT (B), NBS-BRCT (C) (Figure 3.20.A). 
Moreover, the BRCT1 mutation also did not appear to affect the ability of NBS1 to bind other 
components of the MRN complex (Figure 3.20.B).  
3.2.14 The ΔSer118 mutation disrupts NBS1 binding to MDC1 and 
ablates NBS1 foci following IR 
Given that previous work has highlighted a role for the BRCT1 domain of NBS1 in mediating 
its association with phosphorylated MDC1, and that predictions from structural modelling 
highlight the importance of S118 for phospho-peptide binding (Chapman and Jackson 2008, 
Hari et al., 2010). Taken together these observations suggest that loss of this serine residue 
would specifically compromise the biochemical link between MDC1 and the MRN complex.  
Therefore, to investigate this possibility MDC1 was immunoprecipitated from cell extracts 
derived from two normal individuals, a classical NBS patient or one of the affected NBSBRCT 
patients, and the levels of associated NBS1/RAD50 determined by Western blotting. 
Strikingly, in keeping with the structural prediction, loss of S118 severely compromised the 
ability of MDC1 and the MRN complex to bind in vivo (Figure 3.21). More importantly, cells 
expressing this mutant protein failed to form NBS1 foci following the induction of DSBs
Figure 3.20   ΔSer118 does not destabilise the NBS1 protein or disrupt its binding to 
MRE11 or RAD50. (A) NBSBRCT patients express normal levels of NBS1 protein and 
members of the MRN complex. Extracts were prepared from cell lines from two normal 
individuals (1 & 2), a 657del5l NBS patient and the three affected NBSBRCT patients. 
Lysates were separated by SDS-PAGE, and Western blotting used to assess the 
expression of the MRN complex using the antibodies indicated. (B) ΔS118 does not 
affect MRN complex formation. Extracts from the indicated cell lines were incubated 
with an antibody against NBS1. Immunoprecipitates were then fractionated by SDS-
PAGE and then Western blotting was used to detect co-precipitating proteins. 
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despite forming normal γ-H2AX and MDC1 IRIF (Figure 3.22 & 3.23). These data are 
consistent with deletion of S118 in NBS1 being a pathogenic change that leads to the  
failure of this mutant protein to bind MDC1, and therefore disrupts its ability to be recruited 
to chromatin proximal to the sites of DNA damage in an MDC1-dependent manner. 
3.2.15 ΔSer118 NBS1 mutation does not result in a G2/M checkpoint 
activation defect 
Since we had previously demonstrated that the R28A FHA domain mutation in NBS1 
phenocopies the loss of S118 in the BRCT1 domain in terms of its ability to bind to phospho-
MDC1 and be recruited to sites of DSBs, it could be hypothesised that this patient derived 
NBS1 mutation would also give rise to a defect in the ability of cells to activate the G2/M cell 
cycle checkpoint. To investigate this, fibroblasts from a normal individual, a classical 657del5 
NBS patient and one of the affected patients (NBSBRCT (C) were treated with different doses 
of IR and harvested 1 hour post-irradiation. The cells were fixed, stained with an antibody for 
phospho-histone H3 ser-10 to detect mitotic cells and then subjected to FACS analysis (NB 
Fibroblasts from the classical NBS patient were only irradiated with a single dose of IR). 
Strikingly, in contrast to the expected G2/M checkpoint failure typically observed in cells 
derived from classical NBS patients, the fibroblasts from NBSBRCT patient exhibited a dose-
dependent decrease in p-H3 staining indistinguishable from that observed in the normal cell 
line (Figure 3.24). This suggests that although both the FHA and the BRCT domains of NBS1 
are essential for the phospho-dependent interaction with MDC1, it would appear that only the 
FHA domain is required for G2/M checkpoint activation. In keeping with this apparent 
disparity between the cells requirement for the FHA domain but not the BRCT domain of 
NBS1 to activate the IR-induced G2 checkpoint, it has been reported that another NBS1  
Figure 3.21   Loss of NBS1 S118 disrupts its binding to MDC1. Cellular 
extracts were incubated with an antibody against MDC1 and  
immunopreciptates were subjected to SDS-Page and Western blotting with the 
antibodies indicated. 
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Figure 3.23   The IR-induced G2/M checkpoint is intact in cells derived from 
one of the NBSBRCT patients. (A) Fibroblasts from one of the affected NBSBRCT 
individuals (NBSBRCTAR), a classical NBS patient (657del5) and a normal 
(Normal-KB) were irradiated with 1, 2 and 3 Gy of IR and harvested 1 hour later. 
The cells were then fixed in 70% ethanol and incubated with a phospho-histone H3 
serine-10 antibody. Cells were then stained with propidium iodide and analysed 
using FACs. The data is an average of 3 experiments, error bars represent standard 
error and data has been normalised to 100%. (B)  Representative FACS profiles at 
0 Gy and 3 Gy for each cell line tested.  
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BRCT1 mutation (K160M), that also disrupts MDC1 binding, does not result in an inability to 
regulate this checkpoint (Hari et al., 2010).  
3.3 Discussion 
MDC1 acts as a molecular scaffold that coordinates both the temporal and spatial regulation 
of the cellular DDR. This function of MDC1 is mediated through its ability to bind 
simultaneously to a multitude of different damage response proteins. For instance, the MDC1 
FHA domain alone has several documented binding partners, including CHK2, 
phosphorylated ATM and RAD51 (Lou et al., 2006, Lou et al., 2003b, Stewart et al., 2003, 
Zhang et al., 2005).  Here, we have identified and characterised a novel region of MDC1, 
termed the SDTD domain, which is constitutively phosphorylated by CK2. This modification 
facilitates an interaction with the FHA domain of NBS1 , and as a consequence is necessary 
for the recruitment of the NBS1 to DNA damage foci and activation of the G2/M checkpoint 
following IR.  
The requirement for CK2 phosphorylation to mediate protein-protein interactions within the 
DDR is not specific to MDC1 and NBS1. As described previous, a similar cluster of CK2 
phosphorylation sites on XRCC1 and XRCC4 mediates their ability to bind the FHA domains 
of either APTX or PNK (Clements et al., 2004, Koch et al., 2004, Luo et al., 2004). This 
repeated requirement for CK2-dependent phosphorylation to mediate many protein-protein 
binding highlights this as an essential cellular process. In keeping with this, the budding yeast, 
S. cerevisiae, homolog of NBS1, Xrs2, binds in a phospho-dependant manner to the XRCC4 
homolog Lif1, via its FHA domain of Xrs2 (Matsuzaki et al 2008, Palmbos et al 2008). Taken 
together, this conservation of phosphorylated SDTD motifs mediating binding to FHS/BRCT 
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domain containing proteins suggest that this may represent a fundamental mechanism for 
controlling protein function/localization (Lloyd et al 2009).  
The observations from this study show MDC1 and NBS1 exist in a complex, which is 
dependent on CK2. However, based on data presented here and from work by others there is 
evidence to suggest that not all NBS1 is bound to MDC1. Upon CK2 knockdown, therefore 
disrupting its association with MDC1, NBS1 foci are abolished (Figure 3.10). Yet, the NBS1-
dependent accumulation of phosphorylated-ATM is not affected, suggesting that NBS1 is still 
present at the site of a DNA double-strand break (Figure 3.9). Furthermore, cells lacking 
MDC1 or CK2 can still efficiently activate the ATM-dependent DDR (Figure 3.6) (Lou et al., 
2006, Stewart et al., 2003). This is further supported by the observation that NBS1 is still able 
to accumulate within striped laser damage, in the presence of MDC1 lacking the SDTD 
region (Chapman & Jackson 2008).  Moreover, early research showed that cells transfected 
with an NBS1 R28 FHA mutant still displayed ATM activation following IR, yet failed to 
form NBS1 IRIF (Horejsi et al 2004). Therefore, it would seem a fraction of NBS1 not bound 
to MDC1 is able to localise to the sites of DNA damage, and that this pool of NBS1, along 
with the other members of the MRN complex, is responsible for the activation of ATM and 
the ATM-dependent DDR. It could be speculated that once the ATM-dependent signalling 
cascade has been activated, the second pool of NBS1/MRN, that which is bound to MDC1, is 
recruited to chromatin via the interaction between MDC1 and γH2AX. The localisation of this 
second pool of NBS1/MRN could serve to amplify the intra-cellular DNA damage signal by 
further activation of ATM and γH2AX accumulation. This amplification step may be 
necessary to reach a signalling threshold for cell cycle checkpoints to become activated, 
which is supported by the partial G2/M checkpoint defect observed in cells expressing an 
NBS1 FHA domain mutant, and an intra-S pahse checkoint defect in MDC1 deficient cells 
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complemented with a mutant lacking the SDTD repeat domain (Figure 3.14) (Wu et al., 
2008). It could be inferred that although there is partial activation of the G2/M checkpoint at 
low doses of IR in NBS cells expressing an FHA point mutation, the CK2-dependent 
MDC1/MRN interaction is required to fully activate the checkpoint. Overall, these 
observations imply that following ATM activation at a DNA DSB, the focal recruitment of 
NBS1 to the chromatin is required to amplify the intra-cellular signal induced by low but not 
high levels DNA damage. In keeping with this, previous work has shown that a different 
NBS1 FHA domain mutant, H45A, also displays a partial G2/M checkpoint at low but not 
high does of IR (Difilippantonio et al 2007).  
If only a proportion of NBS1 is constitutively bound to MDC1, what are the mechanisms that 
regulate the interaction? Mirroring XRCC1, it could be that multiple different proteins 
interact in a phospho-dependent manner with the same site on MDC1 and that the regulatory 
control occurs at the level of the binding partner rather than whether the scaffold protein is 
phosphorylated or not. In this respect Aprataxin and TopBP1 have been shown to interact 
with SDTD domain of MDC1 via their FHA or BRCT domains respectively (Becherel et al 
2009, Wang et al 2011). Therefore, it is possible that this cluster of phosphorylation sites on 
MDC1 may also provide a binding platform for other as of yet unidentified phospho-peptide 
binding domain-containing proteins that prevents its interaction with NBS1. Despite the vast 
majority of CK2-dependent phosphorylation being constitutive, some degree of cellular 
regulation could be achieved by a stimulus-mediated increase or decrease in the association of 
CK2 with its substrate. In this respect it has been shown that the localisation of CK2 can 
change after the exposure to cells to specific types of genotoxic agent and that this may be 
involved in promoting DNA damage-inducible phosphorylation of a subset of CK2 substrates 
e.g. HP1-β, histone H4 or p53 (Ayoub et al., 2008, Cheung et al., 2005, Keller and Lu, 2002, 
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Keller et al., 2001, Olsen et al., 2012, Yamane and Kinsella, 2005b). Furthermore, it is 
tempting to speculate that the level of regulating CK2-mediated phospho-interactions occurs 
at the level of dephosphorylation. Following completion of repair, the cell needs to 
disassemble the DNA repair machinery and inactivate the checkpoint machinery in order to 
re-enter into the cell cycle. It has been reported that this can, in part be achieved through the 
dephosphorylation of H2AX mediated by PP2A, PP4 and PPM1D (Cha et al., 2010, 
Chowdhury et al., 2005, Chowdhury et al., 2008, Moon et al., 2010, Nakada et al., 2008). 
Based on this it could be postulated that the SDTD motifs of MDC1 may also be a target for 
these phosphatases and that this could be one mechanism with which the MDC1/MRN-
dependent DDR is terminated of how different pools of MDC1 and NBS1 are maintained. 
However, this would require further investigation.  
The importance of the interaction between MDC1 and NBS1 (MRN complex), described 
here, is highlighted by the identification of a novel NBS family from the United Arab 
Emirates, in which the affected individuals carry a homozygous Nbs1 gene mutation that 
disrupts this association. This mutation is a single amino acid deletion, ΔS118, in the BRCT1 
domain of NBS1, that not only not only abolishes the interaction between MDC1 and NBS1, 
but also completely blocks the ability of NBS1 to form IRIF (Figure 3.21, 3.22 & 3.23). 
These observations are supported by work from other groups, demonstrating that the BRCT 
domains of NBS1 are also required to mediate binding to the SDTD domain of MDC1 
(Chapman and Jackson, 2008, Melander et al., 2008, Spycher et al., 2008, Wu et al., 2008, 
Hari et al., 2010). However, unlike mutating the FHA domain of NBS1, the BRCT1 S118 
mutation does not result in a G2/M checkpoint defect (Figure 3.24). This preliminary analysis 
recapitulates much of what is known about this domain obtained from studies using the 
K160M mutation (Hari et al., 2010, Lloyd et al., 2009). Moreover, evidence from one of these 
Figure 3.24  Residues necessary for BRCA1 BRCT/BACH1 phospho-dependent 
interactions are partially conserved in human NBS1 (hNbs1).  Stick model taken 
from Lloyd et al., 2009, showing conservation of NBS1 K160/K1702 and S118/
S1655 in BRCA1, respectively.     
   
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studies showed, via structural analysis, that residues analogous to K160 and S118 of NBS1 
are positionally conserved in the BRCT domains of other proteins, supporting the evidence 
presented here that both these residues are critical for phospho-dependent interactions (Figure 
3.19 & 3.25) (Lloyd et al., 2009). Despite both these domains being required for focal 
recruitment of NBS1 and its interaction with MDC1, why is a G2/M checkpoint defect only 
observed following mutation of the FHA domain? It could be speculated that the FHA domain 
of NBS1 may have an as yet unidentified binding partners, and it is this association with these 
proteins that is required for checkpoint activation in the presence of DNA DSBs. In this 
respect, the S.pombe end-processing factor Ctp1 contains a domain similar to the SDTD 
region of MDC1. Several studies have demonstrated that this region is potentially 
phosphorylated by CK2 and interacts also with the FHA domain of NBS1 (Dodson et al., 
2010, Hari et al., 2010, Lloyd et al., 2009, Williams et al., 2009). Therefore, it is possible that 
the human orthologue, CtIP, may be another potential binding partner for the phospho-
dependent binding activities of NBS1 that is regulated by CK2.  Indeed a direct interaction 
has been seen with CtIP and NBS1 in human cells (Chen et al., 2008). Moreover, CtIP has 
previously been implicated in activation of the G2/M checkpoint (Yu and Chen, 2004). 
Theses observations suggest that the MDC1/NBS1 interaction and foci accumulation, 
although perhaps still necessary for signal amplification, may not be required for G2/M 
checkpoint activation. 
 Intriguingly, the affected patients from this family only exhibit some of the clinical 
abnormalities commonly associated with NBS patients carrying the hypomorphic 657del5 
mutation. Moreover cells from these patients lack many of the major cellular phenotypic 
defects associated with mutations in this gene, the major one being genome instability. Initial 
characterisation of cells derived from the affected patients has shown that the ΔS118 mutant 
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NBS1 protein is expressed at normal levels and binds efficiently to MRE11 and RAD50  
(Figure 3.20, 3.21). Strikingly cells from these patients do not appear to have a defect in the 
repair of DNA DSBs, as judged by chromosomal breakage studies and the lack of 
immunodefciency (Table 3.4). This suggests that although the ΔS118 mutation disrupts the 
ability to bind to MDC1 and foci formation, it does not appear to impact on the DDR to 
DSBs. Therefore, it could be speculated that the ΔS118 mutation in the patients described 
here may disrupt other functions of NBS1. 
 The microcephaly and developmental defects presented in the affected individuals from this 
unique NBS family have phenotypic similarities that overlap with other human disorders 
associated with developmental defects, such as Seckel Syndrome (SCKL). Based on 
neurodevelopmental characterisation of the ATRsckl/sckl mouse model, it has been proposed 
that the underlying cause of these phenotypes is caused by a failure to overcome replication 
stress that occurs during embryonic development (Murga et al., 2009). It is therefore tempting 
to speculate that the clinical symptoms presented in the NBSBRCT patients may be as a result 
of problems in dealing with replication stress, rather than due to an overt DSB repair defect. 
There are several lines of evidence that support this hypothesis: Firstly, NBS1 has been 
shown to be required for efficient activation of ATR in response to replication damage and 
secondly, cells from NBS patients exhibit similar problems restarting stalled replication forks 
as those found in cells with a compromised ATR pathway, signalling is defective in NBS 
cells, which also display problems in recovery following replication stalling, suggesting 
NBS1 and ATR function in the same pathway (Stiff et al., 2005, Stiff et al., 2008). Given that 
the 657del5 NBS patients and the NBSBRCT patients both present comparable severity of 
microcephaly and growth defects, it could be postulated that the BRCT of NBS1 is critical for 
protecting neuroprogenitor cells from replication stress. Since replication stress is prevalent in 
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these cells due to their highly proliferative nature, it seems likely that if not dealt with 
appropriately the accumulation of abnormal replication intermediates represents the most 
likely cause of neuronal cell death. If theses lesions are not deal with, the accumulation of 
replication-born DSBs could result in cell death. Indeed, published data has shown that the 
deletion of NBS1 in mouse neuronal tissue triggers excessive apoptosis in proliferating 
neuroprogentitor cells (Zhou et al., 2012).  Furthermore, it was suggested that this was caused 
by the accumulation of endogenous replication intermediates, resulting from improper fork 
resolution, being converted to DSBs, and activating a p53-dependent cell death pathway 
(Bruhn et al., 2014). Thus, NBS1 clearly has a function during replication. However, whether 
it is loss of this function of the protein that gives rise to the neurodevelopmental phenotype 
exhibited by the NBSBRCT patient’s remains to be elucidated. Despite this, it is clear that the 
study of these extremely rare patients could provide an opportunity to study the role of the 
NBS1 protein during the cellular response to replication stress, independently of its role in 
DSB repair. From this, the overall goal will be to attribute some aspects of the clinical 
phenotype exhibited by patients with mutations in this gene to a specific function of the 
protein.  
 
 
 
 
 
 
 
 
 
CHAPTER 4 
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Chapter 4 Identification of putative CK2 motifs on Mre11 
4.1 Introduction 
Like many DDR proteins, MRE11 is post-translationally modified before and after the 
induction of DNA damage, but how these regulate its specific functions remains unclear. It 
has been demonstrated that MRE11 is constitutively methylated on arginine residues within 
its GAR domain by PRMT1 and this modification is essential for its exonuclease activity, 
checkpoint activation and end-resection-dependent HR (Boisvert et al., 2005a, Yu et al., 
2011). However, in contrast, little is known about what role, if any, phosphorylation plays in 
controlling the MRE11-dependent DDR. Several large phospho-proteomic screens have 
identified both constitutive and DNA damage-inducible phosphorylation sites on MRE11 but 
their functional relevance has not been thoroughly addressed (Beausoleil et al., 2004, 
Dephoure et al., 2008). A single study using an in vitro Xenopus egg extract system has 
shown that the DNA damage-inducible phosphorylation of MRE11 mediated by ATM and 
other PIKKs is required to reduce its ability to tether DNA ends and maintain ATM-
dependent signaling (Di Virgilio et al., 2009). The authors suggest that the phosphorylation of 
MRE11 in response to DNA damage is modulated by phosphatases, which ensure that the 
MRN complex does not disassociate from the chromatin prematurely, but at the same time 
prevents MRN from spreading uncontrollably along the chromatin surrounding the break. 
They propose that lack of regulation in this scenario could be harmful to the cell by 
potentially prolonging DDR signalling, cell-cycle arrest and/or inducing apoptosis (Di 
Virgilio et al., 2009). Thus, the phosphorylation-dependent removal of the MRN complex 
from the chromatin could constitute a means through which the cell can ‘switch off’ the DDR 
and trigger re-entry into the cell cycle. 
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In addition to PIKK-dependent phosphorylation of MRE11, a report published by Kim in 
2005, identified another phosphorylation site within MRE11 (serine-649) and suggested that 
this residue is constitutively modified in vivo (Kim, 2005). Interestingly, the author suggested 
that this site might be targeted by CK2 indicating that this kinase may not only regulate the 
ability of the MRN complex to bind to MDC1 as previously described in the previous chapter, 
but may also modulate directly one or more activities of the complex itself. In support of this 
potential biochemical link between MRE11 and CK2, additional in vivo phosphorylated sites 
on MRE11 have been identified by mass spectrometry that lie within amino acid sequences 
that conform to the consensus CK2 phosphorylation motif (Beausoleil et al., 2004, Dephoure, 
et al., 2008). 
Given the growing body of experimental evidence documenting a major role for CK2 in 
regulating a variety of different cellular DDR signalling pathways, and our own observations 
demonstrating that CK2-dependent phosphorylation is essential for the interaction between 
the MRN complex and MDC1, the aims of this study were: 
 
i)  Identify the sites of CK2-dependent phosphorylation of MRE11. 
ii) Investigate the contribution of CK2-dependent MRE11 phosphorylation of 
MRE11 to regulation of cellular DDR. 
 
 
 
 
 187 
4.2 Results 
4.2.1 A C-terminal region of MRE11 is phosphorylated by CK2 in 
vitro 
MRE11 has previously been shown to be phosphorylated by CK2 on serine 649 (S649) in 
vivo (Kim 2005).  The results from this study, and the large number of proteins that contain 
putative CK2 phosphorylation motifs prompted the search for other potential CK2 target sites 
within MRE11. Referring to published, large-scale phospho-protein screens and several 
commercial websites (http://scansite.mit.edu/, http://phospho.elm.eu.org/, 
http://www.phosphosite.org/, (http://www.dabi.temple.edu/disphos) designed to identify 
putative phosphoryaltion sites, two additional MRE11 CK2 sites were identified up-stream of 
S649 at serine 688 (S688) and 689 (S689) (Beausoleil et al., 2004, Dephoure et al., 2008) 
(Table 4.1.). Using an online protein alignment tool, Clustal omega 
((http://www.ebi.ac.uk/Tools/msa/clustalo/), all three sites were shown to be conserved across 
Human (H.sapiens), Chimpanzee (P. troglodytes), Mouse (M.musculus), Rat (R.norvegicus) 
and Frog (X.laevis), which suggests that these residues may have a functional significance 
(Figure 4.1). 
To investigate whether the identified residues were CK2 targets, a GST-tagged expression 
construct encompassing a C-terminal fragment of MRE11 containing the 3 putative CK2 
phosphorylation sites (GST-MRE11 (aa360-708)) recived from Dr Xiahua Wu, TRSI, 
California, was expressed in bacteria and the induced protein purified using glutathione beads.  
The purified Mre11 protein was then incubated with recombinant CK2 and radio-labelled 
γ(32P)-ATP, for 10 minutes at 30°C. The kinase reactions were run on an SDS-PAGE gel, 
which was then stained with Coomassie Brilliant Blue and phosphorylated proteins were 
!Phosphorylation 
Site 
Peptide Reference 
S649 EVIEVDES*DVEEDIF 
Kim, 2005. 
Dephoure, et al, 2008 
http://scansite.mit.edu/ 
http://phospho.elm.eu.org/ 
http://www.phosphosite.org/ 
http://www.dabi.temple.edu/disphos/ 
S688 SKGVDFES*SEDDDDD 
Beausoleil, et al, 2004. 
Dephoure, et al, 2008. 
http://scansite.mit.edu/ 
http://phospho.elm.eu.org/ 
http://www.phosphosite.org/ 
http://www.dabi.temple.edu/disphos/ 
S689 KGVDFESS*EDDDDDP 
Beausoleil, et al, 2004. 
Dephoure, et al, 2008. 
http://scansite.mit.edu/ 
http://phospho.elm.eu.org/ 
http://www.phosphosite.org/ 
http://www.dabi.temple.edu/disphos/ 
Table 4.1   Summary of potential CK2 phosphorylation sites (*) in MRE11 
identified in vivo. 
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Figure 4.1   MRE11 putative CK2 phosphorylation residues are conserved 
between species. The C-terminal region of human MRE11 (H.sapiens) containing the 
putative CK2 phosphorylation motifs was aligned with several other vertebrate 
species, Pan troglodytes (P.trolodytes), Mus musculus (M.musculus), Rattus 
norvegicus (R.norvegicus)and Xenopus laevis (X.laevis) to identify any evolutionary 
conservation, using an internet based multiple sequence alignment programme, 
Clustal omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). The potential CK2 sites are 
shaded in grey.  
H.sapiens     LEKTQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRSQSEESA 537 
P.troglodytes LEKTQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRFQSEESA 537 
M.musculus    LEKTQRFLKERHIDALEDKIDEEVRRFRESRQRNTNEEDDEVREAMSRARALRSQSETST 538 
R.norvegicus  LEKTQRFLKERHIDALEDKIDEEVRRFRESRQRNTNEEDDEVREAMSRARALRSQSENAA 538 
X.laevis      LEKTQRFLKERHIDAEEEKIDEEVRKFRETRKTNTNEEDEEVREAIQRARTHRSQAPDVE 540 
H.sapiens     SAFSADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGRADT 597 
P.troglodytes SAFSADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGRAHT 597 
M.musculus    SAFSAEDL-SFDTSEQTANDSDDSLSAVPSRGRGRGRGRRGARGQSSAPRGGSQRGR-DT 596 
R.norvegicus  SAFSADDL-SFDITEQTADDSDDSQSAVPSRGRGRGRGRRGGRGQSTAPRGGSQRGR-DT 596 
X.laevis      MSDEDDDALLR---KVSLSDDEDVRASMPARGRGRGRA-RGGRGQSTTTRGTSRRGRGSA 596 
H.sapiens     GLETSTRSRNSKTAVSASRNMSIIDAFKSTRQQP-SRNVTTKNYSEVIEVDESDVEEDIF 656 
P.troglodytes GLETSTRSRNSKTAVSASRNMSIIDAFKSTRQQP-SRNVTTKNYSEVIEVDESDVEEDIF 656 
M.musculus    GLEITTRGRSSKATSSTSRNMSIIDAFRSTRQQP-SRNVAPKNYSETIEVDDSD-EDDIF 654 
R.norvegicus  GLGISTRGRSSKATASTSRNMSIIDAFRSTRQQP-SRNVATKNYSETIEVDESD-DDDSF 654 
X.laevis      SADQPSSGR---ATKATGKNMSILDAFKPSSRQPTARNVAKKTYSEDIEDDDSDLEEVSF 653 
H.sapiens     PTTSKTDQRWSSTSSSKI-----MSQSQVSKGVDFESSE-DDDDDPFMNTSSLRRNRR  708 
P.troglodytes PTTSKTDQRWSSTSSSKI-----MSQSQVSKGVDFESSE-DDDDDPFMNTSSLRRNRR  708 
M.musculus    PTNSRADQRWSGTTSSKR-----MSQSQTAKGVDFESDE-DDDDDPFMSSSCPRRNRR  706 
R.norvegicus  PTSSRADQRWSGTAPSKR-----MSQSQTAKGVDFESDE-DDDDDPFMSGSCPRRNRR  706 
X.laevis      TPSSVIESRRTSSTSTSYSRKSTQPQSQATKAHFFDDDDDEEDFDPFKKSGPSRRGRR  711                                        
   
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visualised by audioradiography.  Consistent with the data published by Kim (2005), the GST-
MRE11 fragment containing the CK2 phosphorylation motifs was robustly phosphorylated by 
CK2 in vitro compared to the GST control (Figure 4.2). This data indicated that CK2 can 
target MRE11 directly for phosphorylation, albeit in vitro. 
To assess which of the 3 phosphorylated serine residues were targeted within the MRE11 C-
terminus identified as putative CK2 targets, three new recombinant GST-MRE11 (aa360-708) 
fragments were produced. In each of these fragments the serine of each potential CK2 motif 
had been mutated to alanine. The fragments were named 1A (S649A), 2A (S688A/S689A) 
and 3A (S649A/S688A/S689A). Following sequential rounds of mutagenesis, the constructs 
were sequenced to ensure that no additional mutations had occurred during the amplification 
steps. The mutant recombinant proteins were again expressed in bacteria, purified as 
previously described and then used as substrates in an in vitro CK2 kinase assay. A specific 
CK2 inhibitor, 4,5,6,7-Tetrabromobenzotriazole (TBB), was added to half the kinase 
reactions to verify that any observed phosphorylation of the mutant MRE11 proteins was not 
due to a contaminating kinase (Battistutta et al., 2001, Sarno et al., 2001). Interestingly, in 
disagreement with the observations by Kim (2005) mutation of serine 649 to alanine did not 
reduce the in vitro phosphorylation of MRE11 by CK2 (Figure 4.3). However in contrast, 
mutation of serines 688/689 appeared to compromise the CK2-dependent phosphorylation of 
MRE11. Moreover, a similar reduction in vitro phosphorylation was also seen following 
sequential mutation of all 3 putative CK2 sites, suggesting that at least in vitro serine 649 is 
not a major target for CK2-dependent phosphorylation, and that serines 688/689 may be the 
preferred sites for modification, although this would require further investigation (Figure 4.3).  
Despite this, a significant amount of MRE11 phosphorylation was still observed even when 
all three serine residues were mutated in combination. This observation suggested the 
Figure 4.2   The C-terminal region of MRE11 is phosphorylated by CK2 in 
vitro. (A) A schematic of MRE11 showing known domains and the location of 
the amino acid 360-708 MRE11 GST fragment. (B) A C-terminal region of 
MRE11 is phosphorylated by CK2 in vitro. A GST-tagged MRE11 C-terminal 
fragment spanning amino acids 360-708 was expressed in E.coli  and purified. 1 
µg of the GST MRE11 or GST alone was then incubated with recombinant CK2 
and radio-labelled ATP (γ-32P) at 30°C for 10 minutes. Proteins were separated 
by SDS-PAGE, stained with Coomassie blue and dried. Radio-labelled proteins 
were detected via autoradiography.  
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Figure 4.3   In vitro phosphorylation of mutant MRE11 lacking putative CK2 
phosphorylation sites. WT or mutant recombinant MRE11 was used as a substrate 
in a CK2 in vitro kinase assay as described before in Figure 4.2. WT denotes a wild 
type MRE11 protein fragment encompassing amino acids 360-708. Mutant MRE11 
protein fragments 1A, 2A and 3A refer to the S649A, S688A/S689A and S649A/
S688A/S689A mutations respectively. The CK2 inhibitor 4,5,6,7-
Tetrabromobenzotriazole (TBB) was added to some kinase reactions to rule out any 
non-specific phosphorylation catalysed by a contaminating kinase(s). Kinase 
reactions were fractionated by SDS-PAGE, stained with Coomassie blue and dried. 
Radio-labelled proteins were detected by autoradiography.  
   
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existence of an additional site(s) of CK2-dependent phosphorylation within the C-terminal 
half of the MRE11 protein.  
4.2.2 Generation of ATLD2 stable cell lines 
Whilst it was evident from the in vitro kinase assays that additional potential CK2 
phosphorylation exist in the C-terminal half of MRE11, only serines 649, 688 and 689 had 
been identified as being phosphorylated in vivo. Therefore, it was decided that this project 
would be split into two halves: 
 
1) Determine the physiological relevance of the in vivo phosphorylation of Mre11 on 
S649, S688 and S689 
2) Identify additional sites on Mre11 phosphorylated by CK2 using in vitro kinase assays 
(This aspect of the project will be discussed in section 4.2.6)  
 
In order to investigate the physiological relevance of these putative CK2 phosphorylation sites 
on MRE11, it was necessary to model a mutant MRE11 lacking these residues in vivo. Cells 
derived from the ATLD1/2 patients have a homozygous nonsense mutation in MRE11 
(1897C→T, R633 stop) that gives rise to the expression of a highly unstable truncated protein 
(Stewart et al., 1999). As a consequence of this MRE11 mutation, the overall stability of the 
MRN complex is significantly reduced, and as such the expression of both NBS1 and RAD50 
are also affected. These cells therefore provide an ideal system with which either exogenous 
WT or mutant MRE11 can be re-expressed without interference from the endogenous protein. 
Using site-directed mutagenesis, a retroviral expression vector (received from Dr Matthew 
Weitzman), containing full-length, FLAG-tagged MRE11 was used to produce a panel of 
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MRE11 expression constructs ablating the putative CK2 phosphorylation sites: 1A (S649A), 
2A (S688/689A) and 3A (S649/688/689A). These constructs were transfected into the 293FT 
packaging cell line and the media containing the infectious viral particles was used to 
transduce hTERT immortalized ATLD2 fibroblasts. Individual clones were cultured and 
selected on whether they exhibited physiological levels of MRE11 protein determined by 
Western blotting (Figure 4.4). Those clones that expressed levels of exogenous Mre11, 
comparable to the level of endogenous MRE11 expressed in a normal fibroblast, were used 
for future experiments. The presence of the mutated MRE11 was also confirmed by 
sequencing across the mutated region using cDNA from the complemented cell lines (data not 
shown). 
4.2.3 Mutation of MRE11 putative CK2 sites does not lead to instability of the 
MRN complex or loss of MRE11 arginine methylation. 
It has previously been shown that loss of members of the MRN complex, either through 
mutation or siRNA-mediated depletion leads to a reduction in expression of the other 
members and instability of the complex (Stewart et al., 1999, Zhong et al., 2005). To 
determine whether mutation of the identified CK2 motifs in MRE11 affected expression of the 
members of the MRN complex, stably transfected ATLD2 cell lines were lysed and the cell 
extracts were separated by SDS-PAGE. The proteins were transferred to nitrocellulose 
membranes and the blots were probed with antibodies against components of the MRN 
complex. The ATLD2 cell line containing an empty vector (V) and, therefore, lacking full-
length WT MRE11, showed a significant reduction in the levels of RAD50 and NBS1 (Figure 
4.5.A). In contrast, the WT and, more importantly, the three mutant stable ATLD2 cell lines, 
1A, 2A and 3A all exhibited normal expression of RAD50, NBS1 and MRE11 itself 
Figure 4.4   Colony screening of ATLD2 stable cell lines expressing 
Flag-tagged MRE11. ATLD2 fibroblasts were infected with retroviruses 
expressing either WT, 1A, 2A, 3A MRE11 or an empty vector. Infected 
cells were selected using neomycin. Individual clones were isolated and 
then screened by Western blotting for expression of the exogenous 
MRE11 protein. 1A, 2A and 3A refer to the S649A, S688A/S689A and 
S649A/S688A/S689A MRE11 mutations respectively, V refers to the 
ATLD2 fibroblasts infected with an empty vector and N refers to a 
fibroblast cell line expressing endogenous levels of MRE11.  
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indicating that mutation of the CK2 sites on MRE11 does not affect the stability of the other 
subunits of the MRN complex (Figure 4.5.A).  
Since the three potential CK2 phosphorylation sites reside in close proximity to the RAD50 
binding site, it is possible that mutation of these sites may compromise the ability of Mre11 to 
bind RAD50. Therefore, to investigate this, NBS1 was immunoprecipitated from cell extracts 
made from each of the complemented ATLD2 cell lines, separated the purified proteins by 
SDS-PAGE and then probed Western blots with antibodies to all three components of the 
MRN complex. In keeping with the ability of the MRE11 phospho-mutants to rescue the 
stability of RAD50 and NBS1 in the ATLD2 cells, similar amounts of RAD50 and MRE11 
co-precipitated with NBS1 from both WT and mutant MRE11 ATLD2 cell extracts. This 
observation indicated that mutations in the putative CK2 phosphorylation sites in MRE11 do 
not affect the ability of the MRN complex to assemble in vivo. As expected there was a 
significant reduction in the levels of all members of the MRN complex in ATLD2-Vector 
only cell extracts that lack full-length MRE11 (Figure 4.5.B). 
As the putative CK2 phosphorylation sites are located near to the GAR domain of MRE11, a 
second immunoprecipitation experiment coupled with Western blotting was performed to 
ascertain whether mutation of these phospho-sites affected the ability of PRMT1 to target this 
domain for modification. MRE11 immunoprecipitates from the ATLD2 cell lines were 
separated by SDS-PAGE, and Western blots probed with an arginine-methylated MRE11 
specific antibody. The level of arginine methylation of the mutant Mre11 proteins was found 
to be comparable to those observed for the WT protein, demonstrating that compromising the 
phosphorylation on serine 649, 688 and 689 of MRE11 does not have any influence on 
methylation of the MRE11 GAR domain (Figure 4.6)  
Figure 4.5   Mutation of the putative CK2 phosphorylation sites on 
MRE11 does not compromise its binding to NBS1 and RAD50. (A) Western 
blot showing the expression of MRE11, RAD50 and NBS1 in selected stable 
ATLD2 fibroblast clones expressing either WT or mutant MRE11, 1A, 2A and 
3A refer to the S649A, S688A/S689A and S649A/S688A/S689A MRE11 
mutations respectively or an empty vector (V). β-Actin was used as a loading 
control. (B) NBS1 immunoprecipitates from ATLD2 cell extracts were 
subjected to SDS-PAGE and Western blotting using the antibodies indicated.  
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Figure 4.6   Mutation of the putative CK2 phosphorylation sites on 
MRE11 does result in loss of arginine methylation. MRE11 
immunoprecipitates from ATLD2 cells transduced with retroviral constructs 
1A, 2A or 3A were subjected to SDS-PAGE and Western blotting using an 
antibody specific to arginine-methylated MRE11. 1A, 2A and 3A refer to the 
S649A, S688A/S689A and S649A/S688A/S689A MRE11 mutations 
respectively. 
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4.2.4 Mutation of MRE11 CK2 phosphorylation sites does not 
prevent the MRE11 protein from forming ionising radiation-induced 
foci (IRIF) 
Given that the putative CK2 phosphorylation sites are located near to the C-terminal DNA 
binding domain of MRE11, and that it has been previously shown that MRE11 
phosphorylation regulates its retention on damaged chromatin (Di Virgilio et al., 2009). It is 
possible that the constitutive phosphorylation of MRE11 on these sites may influence its 
ability to be recruited to sites of DNA damage in a manner comparable to the binding of 
NBS1 to CK2 phosphorylated MDC1. To examine this, ATLD2 fibroblasts complemented 
with either WT MRE11, empty vector or the individual serine-to-alanine mutants (1A, 2A and 
3A) were mock-irradiated or irradiated with 10 Gy of IR and harvested at 0 h and 8 h post-
irradiation.  The cells were then fixed and stained with antibodies against MRE11 and 
γH2AX, the latter of which was used as a marker of DSBs.   
As shown in Figure 4.7, WT MRE11 and all 3 phospho-site mutants formed radiation-induced 
foci following exposure to IR that colocalised with γH2AX. In contrast, the ATLD2 cells 
containing an empty vector failed to form any MRE11 IRIF (Figure 4.7). Therefore, it can be 
concluded that the putative CK2 phosphorylation sites on MRE11 are not required for its re-
localisation to sites of DNA damage induced by IR.  
Figure 4.7   Mutant MRE11 lacking the putative CK2 phosphorylation sites 
accumulates normally at sites of DNA double-strand breaks. ATLD2 cell lines 
stably expressing either WT MRE11, mutant MRE11 (1A (S649A), 2A (S688A/
S689A) and 3A (S649A/S688A/S689A)) or an empty vector, were mock treated or 
irradiated with 8 Gy of IR and harvested at 0 and 8 h post-irradiation. The cells 
were then fixed and stained with antibodies against MRE11 and γH2AX. Images 
are of one cell and  are representative of approximately  ~1000 cells scored by eye 
from 3 separate experiments.  
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4.2.5 Mutant CK2-putative phosphosite (MRE11) transduced ATLD2 
cell lines are proficient in repair of DNA DSBs  
Whilst loss of the putative CK2 phosphorylation sites on MRE11 did not prevent its 
recruitment to damaged chromatin, it is still possible that these residues may be important for 
other aspects of MRE11 function, such as DNA repair. To test this, the stable ATLD2 cell 
lines were exposed to 2 Gy of IR and fixed at 0, 1, and 24 h post irradiation. Fixed cells were 
stained with antibodies against 53BP1 and γH2AX, and the IR-induced foci in a minimum 
number of 300 cells per experiment were quantified using fluorescent microscopy. 53BP1 
foci were used as markers of DNA double strand breaks in conjunction with γH2AX in the 
event that mutations in MRE11 compromised the ability of ATM to phosphorylate H2AX.  
In keeping with the documented defect in DSB repair in ATLD cells, the ATLD2 cell line 
complemented with the empty vector (V) showed a significant number of residual 
53BP1/γH2AX foci at 24 h post-irradiation compared to the WT cell line (Figure 4.8). In 
contrast, the mutant MRE11-expressing cell lines exhibited resolution of 53BP1 and γH2AX 
foci comparable to those observed in the WT MRE11 complemented ATLD2 cells, indicating 
that mutation of the putative CK2 phosphorylation motifs in MRE11 does not compromise 
repair of DNA DSBs induced by IR (Figure 4.8). It should be noted, as cell cycle progression 
was not controlled for with these cell lines, foci determination can be problematic as the lines 
used may cycle at different rates. If this experiment were to be repeated, evidence of how 
these four cell lines cycle could benefit the result, in addition to providing a positive control, 
for instance using a cell treated with an ATM inhibitor.  The major role of the MRN complex 
is activating the ATM-dependent DDR following the induction of DSBs, and therefore it is 
conceivable that the phosphorylation of MRE11 by CK2 could affect this process. In support 
of this, it has been previously observed that the phosphorylation of SMC3 
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Figure 4.8   ATLD2 cell lines stably expressing phospho-site mutants of 
MRE11 repair DSBs normally.  Each of the stable ATLD2 cell lines were 
mock treated or irradiated with 2 Gy of IR. The cells were then harvested at 
0hrs, 1 h and 24 h post-irradiation, fixed and stained with antibodies against 
53BP1 and γH2AX. 53BP1 foci were then counted in each of the five cell lines 
for each time point, 0hrs (A), 1 h (B) and 24 h (C) and the percentage of cells 
with foci was calculated (n=300). Values represent the mean of three 
experiments ± standard error.  * = <p=0.05 (t-test) compared to wildtype. 
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by ATM requires its prior phosphorylation by CK2 on a neighbouring residue (Luo et al., 
2008). To assess this, the panel of stable ATLD2 cell lines were irradiated with 2 Gy, 
harvested at 0, 1, and 24 h post-irradiation and then extracts from these cells subjected to 
SDS-Page and Western blotting using phospho-specific antibodies that recognize a range of 
known ATM substrates. After performing this assay numerous times it became apparent that a 
substantial variation in the expression of the non-phosphorylated form of many of these ATM 
targets, such as SMC1, H2AX and RPA, occurred between the different isogenic cell lines as 
well as between different clones of the same cell line (data not shown). As a result, this 
variation made drawing any conclusions as to whether mutation of the putative CK2 
phosphorylation motifs in MRE11 affected activation of the ATM-dependent DDR extremely 
challenging. In addition to this, despite being hTert immortalised, the growth of the cloned 
ATLD2 complemented cell lines started to slow down significantly over time, and eventually 
reached a point where they stopped growing at all. Similar growth defects were observed in 
multiple different isolated clones of each cell line, as well as following revival of earlier 
passages of the same cell line from stocks stored in liquid nitrogen. The expression of hTERT 
was verified again by PCR in each of the cloned cell lines to rule out the possibility that these 
growth defects arose from loss of its expression, and as a consequence the induction of 
senescence. However, this did not seem to be the case. 
Since the quality of the foetal calf serum (FCS) added to culture media can have a 
considerable affect on the ability of patient-derived cell lines to grow in vitro, especially 
fibroblasts, alternative sources of the foetal calf serum were used in different concentrations 
to determine whether this maybe the underlying cause for the growth failure of these cells. 
Unfortunately this failed to rectify the problem. 
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Taken together, it was decided that a different cell system was required to determine whether 
loss of putative CK2-dependent phosphorylation of MRE11 affected the cellular response to 
DNA damage. 
4.2.6 Identification of an additional putative MRE11 CK2 
phosphorylation motif  
Previous in vitro kinase assays demonstrated that mutating all three in vivo putative CK2 
phosphorylation sites within the C-terminus of MRE11 did not completely abolish its 
phosphorylation. This observation indicated the existence of additional residues targeted by 
CK2 at least in vitro (Figure 4.3). In light of this, reducing the stringency with which two 
web-based phospho-protein search tools identify putative kinase phosphorylation motifs 
within an amino acid sequence resulted in serine 541 (S541) of MRE11 being suggested as 
another putative CK2 phosphorylation target (Table 4.2). Furthermore, aligning the amino 
acid sequence of human MRE11 with those of other vertebrate species revealed S541 to be 
conserved (Figure 4.9).  
A new GST-MRE11 (aa360-708) fragment was generated in which S541 was mutated to 
alanine on a 3A background, termed 4A (S541A/S649A/S688A/S689A). This new MRE11 
mutant protein was expressed in bacteria, purified and then used in an in vitro CK2 kinase 
assay, alongside the WT MRE11 C-terminal fragment, the 1A, 2A and the 3A mutant 
fragments. Strikingly, a complete loss of CK2-dependent phosphorylation was seen in the 4A 
fragment, implying that at least in vitro, S541 is major site for the phosphorylation of MRE11 
by CK2 (Figure 4.10). This supports the residual phosphorylation of the 3A construct seen in 
this and previous experiments (Figure 4.3 & 4.10).  
 
Phosphorylation 
Site 
Peptide Reference 
S541 EESASAFS*ADDLSI http://scansite.mit.edu/ 
http://www.dabi.temple.edu/disphos/ 
S649 EVIEVDES*DVEEDIF 
Kim, 2005. 
Dephoure, et al, 2008 
http://scansite.mit.edu/ 
http://phospho.elm.eu.org/ 
http://www.phosphosite.org/ 
http://www.dabi.temple.edu/disphos/ 
S688 SKGVDFES*SEDDDDD 
Beausoleil, et al, 2004. 
Dephoure, et al, 2008. 
http://scansite.mit.edu/ 
http://phospho.elm.eu.org/ 
http://www.phosphosite.org/ 
http://www.dabi.temple.edu/disphos/ 
S689 KGVDFESS*EDDDDDP 
Beausoleil, et al, 2004. 
Dephoure, et al, 2008. 
http://scansite.mit.edu/ 
http://phospho.elm.eu.org/ 
http://www.phosphosite.org/ 
http://www.dabi.temple.edu/disphos/ !
Table 4.2   Identification of an additional putative CK2 phosphorylation site on 
MRE11.  
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Figure 4.9   Conservation of S541 of MRE11 across species. The region of 
human MRE11 (H.sapiens) containing the newly identified putative CK2 
phosphorylation motif was aligned with several other vertebrate species, Pan 
troglodytes, Mus musculus (M.musculus), Rattus norvegicus (R.norvegicus) and 
Xenopus laevis (X.laevis) to identify any evolutionary conservation, using an 
internet based multiple sequence alignment programme, Clustal omega (http://
www.ebi.ac.uk/Tools/msa/clustalo/). The putative CK2 site is highlighted in grey.  
H.sapiens     LEKTQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRSQSEESA 537 
P.troglodytes LEKTQRFLKERHIDALEDKIDEEVRRFRETRQKNTNEEDDEVREAMTRARALRFQSEESA 537 
M.musculus    LEKTQRFLKERHIDALEDKIDEEVRRFRESRQRNTNEEDDEVREAMSRARALRSQSETST 538 
R.norvegicus  LEKTQRFLKERHIDALEDKIDEEVRRFRESRQRNTNEEDDEVREAMSRARALRSQSENAA 538 
X.laevis      LEKTQRFLKERHIDAEEEKIDEEVRKFRETRKTNTNEEDEEVREAIQRARTHRSQAPDVE 540 
H.sapiens     SAFSADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGRADT 597 
P.troglodytes SAFSADDLMSIDLAEQMANDSDDSISAATNKGRGRGRGRRGGRGQNSASRGGSQRGRAHT 597 
M.musculus    SAFSAEDL-SFDTSEQTANDSDDSLSAVPSRGRGRGRGRRGARGQSSAPRGGSQRGR-DT 596 
R.norvegicus  SAFSADDL-SFDITEQTADDSDDSQSAVPSRGRGRGRGRRGGRGQSTAPRGGSQRGR-DT 596 
X.laevis      MSDEDDDALLR---KVSLSDDEDVRASMPARGRGRGRA-RGGRGQSTTTRGTSRRGRGSA 596 
H.sapiens     GLETSTRSRNSKTAVSASRNMSIIDAFKSTRQQP-SRNVTTKNYSEVIEVDESDVEEDIF 656 
P.troglodytes GLETSTRSRNSKTAVSASRNMSIIDAFKSTRQQP-SRNVTTKNYSEVIEVDESDVEEDIF 656 
M.musculus    GLEITTRGRSSKATSSTSRNMSIIDAFRSTRQQP-SRNVAPKNYSETIEVDDSD-EDDIF 654 
R.norvegicus  GLGISTRGRSSKATASTSRNMSIIDAFRSTRQQP-SRNVATKNYSETIEVDESD-DDDSF 654 
X.laevis      SADQPSSGR---ATKATGKNMSILDAFKPSSRQPTARNVAKKTYSEDIEDDDSDLEEVSF 653 
H.sapiens     PTTSKTDQRWSSTSSSKI-----MSQSQVSKGVDFESSE-DDDDDPFMNTSSLRRNRR  708 
P.troglodytes PTTSKTDQRWSSTSSSKI-----MSQSQVSKGVDFESSE-DDDDDPFMNTSSLRRNRR  708 
M.musculus    PTNSRADQRWSGTTSSKR-----MSQSQTAKGVDFESDE-DDDDDPFMSSSCPRRNRR  706 
R.norvegicus  PTSSRADQRWSGTAPSKR-----MSQSQTAKGVDFESDE-DDDDDPFMSGSCPRRNRR  706 
X.laevis      TPSSVIESRRTSSTSTSYSRKSTQPQSQATKAHFFDDDDDEEDFDPFKKSGPSRRGRR  711                                        
   
Figure 4.10   Mutation of S541 of MRE11 abrogates its CK2-dependent 
phosphorylation in vitro. (A) A schematic of MRE11, showing the location of the 
additional CK2 site (circled in red). (B) A GST fragment (aa360-708) was 
generated where all four putative CK2 target sites had been mutated, 4A (S541A/
S649A/S688A/S689A). The fragment was expressed in E. coli and purified. The new 
fragment, along with the 3 other GST-MRE11 mutants, were incubated with 
recombinant CK2 and radio-labelled ATP (γ-32P) for 10 minutes at 30°C. Proteins 
were separated by SDS-PAGE, stained with coomassie blue and dried. Radio-
labelled proteins were detected by autoradiography.  
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4.2.7 HCT116 Flp-In/T-Rex in vivo system 
Due to the problems with the growth of stable ATLD2 cells expressing WT or mutant 
MRE11, an alternative in vivo system was utilised. The HCT116 colorectal tumour cell line  
has a compound heterozygous mutation in a poly-T track residing in intron 4 of the MRE11 
gene that results in aberrant splicing and loss of exons 5-7, caused by a Mis-match repair 
(MMR) defect, that results in Micro-satellite instability (MSI) (Furuta et al., 2003, Giannini et 
al., 2004, Giannini et al., 2002, Takemura et al., 2006, Wen et al., 2008).  As a consequence, 
these cells express low levels of endogenous full-length MRE11 protein and an unstable 
truncated mutant protein. Despite this, HCT116 cells have a relatively high level of 
homologous recombination, due to the repair of divergent DNA sequences incurred due to 
defective MMR. As such this phenotype has been repeatedly exploited to generate somatic 
gene knockout or knockin cell models to study protein function, including a multitude of 
DNA repair/cell cycle regulatory proteins, for example ATRIP, CHK1 and KU80 (Cortez et 
al., 2001, Jardim et al., 2009, Li et al., 2002a). Taken together, this indicated that the HCT116 
cell line would be a suitable system for modeling MRE11 mutations in an isogenic genetic 
background that would overcome the problematic growth encountered when using patient-
derived cell lines. An additional benefit is that a derivative of this cell line (HCT116 Flp-In/T-
Rex) had been created to stably express the Tet-repressor, and also contain a single copy of an 
integrated FRT (Flp recombination target) site. This allows for the rapid generation of a cell 
line stably expressing an integrated copy of a gene of interest under the control of a 
tetracycline/doxycycline-inducible promoter, without the use of retro- or lenti-viruses. An 
overview of the details of this cell system can be found on the Invitrogen website 
(http://www.lifetechnologies.com). 
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To check that the HCT116 Flp-In/T-Rex derivative exhibited a similar reduction in MRE11 
protein to those previously reported for this cell line, the expression of MRE11, RAD50 and 
NBS1 were assessed by Western blotting, and compared to a parental HCT116 cell line, 
obtained from the American Type Culture Collection (ATCC). In addition, another colorectal 
tumour cell line (HT29) was also included as it displays WT levels of MRE11 expression. As 
expected, both the parental HCT116 cell line and the Flp-In/T-Rex derivative exhibited 
reduced levels of MRE11, RAD50 and NBS1 expression when compared to the HT29 cell 
line (Figure 4.11). 
4.2.8 Doxycycline-induced expression of MRE11 in HCT116 Flp-In/T-
Rex cells 
To create a stable doxycycline-inducible cell line expressing full-length MRE11, WT or 
mutant MRE11 was sub-cloned into a modified pcDNA5 FRT vector containing an N-
terminal Flag tag. The pcDNA5-Flag FRT MRE11 constructs were then transfected into the 
HCT116 Flp-In/T-Rex cell line along with a pOG44 plasmid, which expresses the Flp 
recombinase. Cells containing the gene of interest integrated into the FRT site, rather than 
randomly elsewhere within the genome, lose their resistance to zeocin, (encoded for within 
the FRT integration site) and become resistant to hygromycin. Therefore, following selection 
with hygromycin, resistant cells were pooled and checked for their sensitivity to zeocin. 
Those cell populations that met these criteria were taken forward for assessment of the level 
of inducible MRE11 expression. Since the expression of MRE11 could be induced following 
treatment of the cells with either doxycycline or tetracycline, 1 µg/ml of each antibiotic was 
added to the cells for 24 h to determine which of these would give the best inducible 
expression of MRE11. Extracts from these cells were separated by SDS-PAGE and the 
membranes probed with antibodies against MRE11 as well as the other members of the MRN 
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Figure 4.11   MRN protein expression levels in the HCT116 Flp-In/T-Rex cell 
line. Western blotting was used to compare the expression of components of the 
MRN complex in the HCT116 Flp-In/T-Rex cell line to those expressed in an 
unmodified HCT116 cell line (obtained from the ATCC) and another colorectal 
tumor cell line HT29 (obtained from the ATCC), previously reported to have WT 
MRE11. 
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complex (Figure. 4.12.A). A robust induction of Flag-tagged exogenous MRE11 was 
observed following the addition of both doxycycline and tetracycline (Figure. 4.12.A). 
Notably, induction of Flag-tagged MRE11 expression in the HCT116 Flp-In/T-Rex cell line 
resulted in an increase in the levels of both endogenous RAD50 and NBS1. For the remainder 
of the study doxycycline was chosen as the antibiotic used to induce MRE11, as it known to 
be more stable than tetracycline in solution.  
The requirements for the study involved treating the cell lines with DNA damaging agents 
and harvesting at different time points. For this reason it was necessary to examine whether 
the expression of MRE11 following induction could be maintained for longer than 24 h. For 
this, the cells were treated with 1 µg/ml of doxycycline and then harvested at 24, 48 and 72 h. 
The expression of induced MRE11 was sustained after 24 h, and up to 72 h (Figure 4.12.B). 
However, at 72 h the levels of exogenous MRE11 began to decrease, suggesting that 72 h is 
the limit at which expression of MRE11 in this system could be maintained at an 
experimental level. Lastly, to monitor the levels of expression of the different mutant MRE11 
proteins and to compare them to the levels of the WT protein, 1 µg/ml of doxycycline was 
added to HCT116 Flp-In/T-Rex cells expressing either WT MRE11, mutant MRE11 
containing the phospho-site mutations (1A, 2A, 3A and 4A) or an empty vector for 24 h, after 
which the cells were harvested. The lysates were then separated on SDS-PAGE gels and the 
expression determined by Western blotting using the indicated antibodies. As shown in Figure 
4.13, each of the phospho-mutant MRE11 proteins were expressed at levels comparable to 
that of the WT protein.  
 
 
Figure 4.12   A doxycycline inducible system for the expression of 
exogenous MRE11 in HCT116 Flp-In/T-Rex cells. (A) Either 1 µg/ml of 
doxycycline or tetracycline was added HCT116 Flp-In/T-Rex cells containing a 
Flag-tagged WT MRE11 expression construct for 24 h, the cells harvested and 
extracts were separated by SDS-PAGE. Expression of MRE11, RAD50 and 
NBS1 was assessed by Western Blotting. (B) 1 µg/ml of doxycycline was added 
to HCT116 Flp-In/T-Rex cells containing a Flag-tagged WT MRE11 expression 
construct for times indicated. The cells were then harvested, extracts separated 
by SDS-PAGE and MRE11, RAD50 and NBS1 expression was determined by 
Western blotting.  
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Figure 4.13   Expression of a doxycycline-induced mutant MRE11 in 
HCT116 Flp-In/T-Rex cells. 1 µg/ml of doxycycline was added to HCT116 
Flp-In/T-Rex cells expressing either inducible WT MRE11, an empty vector 
(V), or phospho-mutant MRE11 (1A, 2A, 3A, 4A). The cells were harvested 
24 hrs after induction of expression with doxycycline and the extracts were 
separated by SDS-PAGE. Expression of exogenous Flag-tagged MRE11 was 
determined by Western blotting using the indicated antibodies. 
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Figure 4.14   HCT116 Flp-In/T-Rex cells display constitutive 53BP1 foci. 
MRE11 expressing HCT116 Flp-In/T-Rex cell lines were incubated in 1 µg/ml of 
doxycycline for 24 h, either mock-irradiated or exposed to 2 Gy of IR and then 
fixed at 0 h, 1h and 24 h post-irradiation. Cells were then stained with 
antibodies agaisnt 53BP1 and γH2AX. 53BP1 foci were then counted in each of 
the five cell lines at each time point, 0 h (A), 1 h (B) and 24 h (C) and the 
percentage of cells with foci calculated (n=300). Values represent the mean of 
three experiments ± standard error.  
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4.2.9 HCT116 Flp-In/T-Rex cells show aberrant DNA double-strand 
breaks 
To determine whether expression of either the WT or phospho-defective MRE11 was capable 
of correcting the DSB repair defect resulting from the endogenous MRE11 mutation in the 
inducible HCT116 Flp-In/T-Rex cell system, each cell line was treated with doxycycline 24 h 
prior to irradiation with 2 Gy of IR. The cells were then fixed and stained with antibodies to 
53BP1 and γ-H2AX 1 hr or 24 h post-irradiation. Again, the percentage of 53BP1 and γ-
H2AX foci remaining at late times post-irradiation were determined by immunofluorescence 
microscopy, and used as a measure of DSB repair as in Figure 4.8. Unfortunately, it was clear 
that HCT116 cells exhibit relatively high levels of 53BP1 foci even before treatment, and that 
expression of WT MRE11 was not sufficient to correct this (Figure 4.14). Indicating that this 
cell line is not a suitable model system to study defects in the MRE11-dependent DDR. 
Moreover, preliminary analysis of the IR-dependent activation of ATM signaling cascade by 
Western blotting in HCT116 cell lines revealed that they express very low levels of ATM 
(Figure 4.15). Using the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) to look for mutations identified in 
this cell line, a heterozygous mutation (p.A1127V) in ATM has previously been reported. 
However, whether this would result in the low levels of ATM protein observed by western 
blot analysis would require further investigation. Taken together, it appears that the inducible 
HCT116 cell system is not conducive for investigating the IR-induced DDR.  
4.2.10 MRE11 expression in a U2OS Flp-In/T-Rex system 
Due to the unexpected problems encountered using the HCT116 Flp-In/T-Rex system, a 
different inducible Flp-In/T-Rex cell was used. U2OS cells were chosen based on their 
Figure 4.15   ATM signalling in HCT116 Flp-In/T-Rex cells following IR. 
Cell lines were irradiated with 5 Gy of IR and harvested at the indicated time 
points. Lysates were fractionated by SDS-PAGE, and ATM-dependent DNA 
damage signaling assayed by Western blotting using the indicated antibodies.  
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extensive use to study the cellular DNA damage response including those assessing regulation 
of ATM/MRN-mediated intracellular signaling induced by different DNA damaging agents 
(Gately et al., 1998, Yuan and Chen, 2010). However, in contrast to the HCT116 cell line, a 
disadvantage of using of U2OS cells is that they express WT levels of MRE11, which 
consequently means that before any analysis of mutant MRE11 is carried out endogenous 
MRE11 would have to be depleted with siRNA. 
As previously described, U2OS Flp-In/T-Rex cells were transfected with the Flp-In MRE11 
plasmids containing either WT MRE11, and empty vector, the 3A MRE11 mutant lacking all 
the putative CK2 phosphorylation sites identified in vivo, the 4A MRE11 mutant that also 
included loss of the major in vitro CK2 phosphorylation site (S541A) or a single mutant 
MRE11, in which only serine-541 had been mutated to alanine. Again the cells were selected 
with hygromycin and a polyclonal population of cells generated to counteract any artifacts  
caused by cloning. To assess the expression of the exogenous MRE11, each of the polyclonal 
U2OS MRE11 Flp-In/T-Rex cell lines were treated with 1 µg/ml doxycycline for 24 h and 
Western blotting on whole cell extracts was carried out using antibodies to MRE11, RAD50 
and NBS1. As shown in Figures 4.16A and B, WT and the different mutant MRE11 proteins 
were expressed at comparable levels, which was observed to be approximately 2 fold higher 
than the endogenous MRE11.  
4.2.11 Depletion of endogenous MRE11 in U2OS Flp-In/T-Rex cells 
using a 5´ UTR-directed siRNA 
Unlike the HCT116 Flp-In/T-Rex cell lines, the U2OS Flp-In/T-Rex cells do not have a 
pathogenic mutation in MRE11 that results in reduced expression of the protein. Since the 
MRE11 Flp-In expression constructs generated were not siRNA resistant, a previously 
Figure 4.16  A doxycycline inducible system for expression of MRE11 
in U2OS Flp-In/T-Rex cells. (A) 1 µg/ml of doxycycline was added to 
U2OS Flp-In/T-Rex cells stably expressing either WT MRE11 or an empty 
vector. After 24 h, the cells were harvested, extracts separated by SDS-
PAGE and the expression of MRE11, RAD50 and NBS1 was assessed by 
Western blotting. An antibody against β-Actin was used as a loading 
control. (B) 1 µg/ml of doxycycline was added to U2OS Flp-In/T-Rex cells 
stably expressing either WT MRE11, an empty vector, the 3A (S649A/
S688A/S689A) or 4A (S541A/S649A/S688A/S689A) MRE11 mutants for 24 
h. Lysates were then separated via SDS-PAGE and MRE11 expression 
determined by Western blotting. NB The autoradiograph has been altered 
to omit unnecessary data.  
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Figure 4.17   Depletion of endogenous MRE11 using a 5’ UTR-directed 
siRNA and inducible expression of exogenous MRE11 protein (A) U2OS 
Flp-In/T-Rex cells expressing WT tagged exogenous MRE11 were 
transfected with MRE11 5’UTR siRNA in the absence of doxycycline and 
harvested 48, 72, or 96 h post-transfection. Lysates were separated by SDS-
PAGE and the efficiency of MRE11 depletion was assessed by Western 
blotting. (B) Cells were treated as in part (A) except doxycycline was added 
48 h post-tranfection and cells harvested 24 h later. 
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Figure 4.18   Mutation of a fourth MRE11 putative CK2 motif does not affect 
the stability or expression of the MRN complex. U2OS Flp-In/T-Rex cells 
expressing either WT, an empty vector, a 4A (S541A/S649A/S688A/S689A) mutant 
or a single S541A mutant MRE11 were transfected with MRE11 siRNA for 72 h. 
Twenty four hours prior to harvesting,  the cells were treated with 1 µg/ml of 
doxycycline. The cells were then harvested and lysates separated by SDS-PAGE. 
Western blotting was then used to assess MRN complex stability and expression 
using indicated antibodies.  
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published siRNA to MRE11, directed towards a sequence in its 5’ untranslated region (UTR) 
was used to deplete the endogenous, but not exogenous MRE11 (Zhuang et al., 2009). 
Initially, it was necessary to determine whether this siRNA could efficiently deplete 
endogenous MRE11 protein in this cell line, and also how long this depletion lasted. Cells 
were transfected with 100 nM of the 5’UTR MRE11 siRNA, and were then harvested at 0, 48, 
72 and 96 h after transfection. Depletion of MRE11 was assessed by Western blotting. A 
significant reduction in endogenous MRE11 levels was observed 48 h post-siRNA 
transfection that lasted up to 96 h (Figure 4.17.A). To confirm the specificity of the 5’ UTR 
siRNA for the endogenous but not exogenous MRE11 (which lacks any UTR sequence), cells 
were transfected with siRNA and then treated with doxycycline for 24 h, 48 h post-
transfection. Expression of MRE11 and other components of the MRN complex were then 
determined by Western blotting on extracts made from these cells. As shown in Figure 4.17B, 
exogenous WT MRE11 protein was efficiently expressed in cells transfected with the 5’UTR 
MRE11 siRNA and this was capable of restabilising the cellular pools of both RAD50 and 
NBS1. In addition, U2OS Flp-In/T-Rex expressing MRE11 protein containing the single 
S541 mutated to an alanine did not disrupt expression or stability of the MRN complex 
(Figure 4.18). Following depletion of endogenous MRE11 and re-expression of inducible 
mutant protein.  
Before any characterisation of the cellular DNA damage response was carried out using these 
cells, FACS analysis was used to assess whether the siRNA transfection or the doxycycline-
inducible expression of the WT/mutant protein had any detrimental affects on the cell cycle 
that could potential bias any results using these cells. As shown in Figure 4.19, siRNA-
mediated depletion of endogenous MRE11 and re-expression of exogenous WT or mutant 
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Figure 4.19   Stable U2OS Flp-In/T-Rex cell lines have similar cell cycle 
profiles following siRNA-mediated depletion of endogenous MRE11 and re-
expression of exogenous MRE11. (A)  Western blot confirming depletion of 
MRE11 by siRNA and induction of exogenous MRE11 in U2OS Flp-In/T-Rex  
cell lines. (B) Cell lines were harvested and fixed in 70% ethanol. Following 
permeablisation, the cells were stained with propidium iodide and analysed by 
FACS analysis. The four figures represent cell cycle profiles for: i) WT MRE11, 
ii) V, empty vector iii) S541A MRE11 and iv) 4A (S541/649/688/689A) MRE11. 
The panels represent one among three experiments.  
   
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Figure 4.20   S688 is phosphorylated in vivo. Cell lysates were 
prepared from WT, V, 3A and 4A U2OS Flp-in/T-REX MRE11 cell lines 
that had been transfected with MRE11 5’UTR siRNA for 72 h, followed 
by treatment with doxycycline for 24 h to induce exogenous MRE11. 
The lysates were separated by SDS PAGE,  and phosphorylation of 
MRE11 was assessed using an antibody against phospho-serine 688. 
NB. The autoradiograph is part of a larger figure, but has been 
adjusted to display relevant result.  
  	 
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MRE11 had very little impact on cell cycle distribution. Although that it should be noted that 
induction of the 4A MRE11 phospho-mutant did result in an increase of cells in G2 phase. 
4.2.12 Phosphorylation of S688 is constitutive 
Phosphorylation of proteins by CK2 often occurs in the absence of any stimuli, which is a 
reflection of the constitutive activity of CK2. The availability of an antibody against 
phosphorylated S688 of MRE11 (Abcam) allowed the investigation as to whether this was the 
case for this residue in vivo. Following transfection with 5’UTR MRE11 siRNA and 
doxycycline induction of exogenous protein. Whole cell extracts were prepared from the 
MRE11 WT, the vector only and the 3A and 4A mutant U2OS Flp-In/T-Rex cell lines, which 
were then separated by SDS-PAGE. The Western blots were probed with an antibody against 
phosphorylated S688 of MRE11. Cells expressing WT MRE11 were phosphorylated on this 
residue, whereas the vector-only, and more importantly the 3A and 4A cell lines were not 
(Figure 4.20). This observation implies that S688 is phosphorylated in vivo and that the 
phosphorylation is constitutive.  
4.2.13 Mutation of the four putative CK2 phosphorylation sites in 
MRE11 does not affect its ability to relocalise to sites of DNA 
damage or to promote repair of DSBs. 
To confirm that loss of the putative CK2 phosphorylation sites on MRE11, including the 
newly identified in vitro phosphorylation site on serine-541, did not affect the ability of the 
MRE11 protein to relocalise to sites of DNA damage in U2OS cells, endogenous MRE11 was 
depleted using siRNA in U2OS Flp-In/T-Rex cell. The cell lines expressed either WT 
MRE11, an empty vector or a mutant MRE11, in which serine-541 had been mutated to  
 
Figure 4.21   Loss of putative CK2 phosphorylation of MRE11 does not 
affect its ability to relocalise to sites of DNA damage in U2OS cells. U2OS 
Flp-In/T-Rex cells expressing either WT, an empty vector, a 4A (S541A/
S649A/S688A/S689A) mutant or a single S541A mutant MRE11 were 
transfected with MRE11 siRNA for 72 h. Twenty four hours prior to 
harvesting,  the cells were treated with 1 µg/ml of doxycycline. The cells were 
then irradiated with 8 Gy of IR and fixed at 8 h, followed by staining with the 
indicated antibodies. Images are of one cell and are representative of 
approximately ~1000 cells scored by eye from 3 separate experiments.  
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Figure 4.22   Assessment of DSB repair kinetics in U2OS Flp-In/T-
Rex cells expressing WT MRE11, empty vector or mutant MRE11. The 
cells were then irradiated with 2 Gy and fixed at 0 (A), 1 (B), and 24 h 
(C) post-irradiation. The Cells were stained with the above antibodies 
and the percentage of cells with 53BP1/γ-H2AX      foci counted 
(n=300) using immunofluorescence microscopy. Values represent the 
mean of three experiments ± standard error.  
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alanine alone, or in conjunction with serines 649, 688 and 689. Exogenous MRE11 was then 
overexpressed following incubation with doxycycline for 24 h. The cells were then either 
mock treated or irradiated with 8 Gy of IR, fixed 8 h post-irradiation and stained with 
antibodies to MRE11 and γ-H2AX. In keeping with previous observations, mutation of all the 
putative CK2 target phosphorylation sites, including S541, did not affect the ability of 
MRE11 to form IRIF (Figure 4.21). 
Next to investigate that a defect in DSB repair caused by depletion of MRE11 could be 
detected in the U2OS Flp-In/T-Rex system, and to assess whether loss of the putative CK2 
phosphorylation sites on MRE11, including serine-541, had any impact on repair, the 
resolution of 53BP1 and γ-H2AX foci following exposure to low dose IR was monitored by 
immunofluorescence, as previously described in section (4.2.5). Unfortunately, similar to the 
HCT116 cells, the U2OS cells also exhibited high levels of residual 53BP1 and γ-H2AX foci 
remaining at 24 h post-irradiation that could not be complemented with the re-expression of 
WT MRE11 (Figure 4.22). This observation in conjunction with those obtained using 
HCT116 cells indicated that tumour-derived cell lines are not good in vitro cellular models 
with which to assess the contribution of MRE11 in promoting the repair of DSBs, due to the 
high levels of endogenous damage. 
4.2.14 Mutation of putative CK2 phosphorylation sites on MRE11 
affects its phosphorylation of S676 after exposure to IR. 
Despite an absence of a detectable DSB repair deficiency caused by depletion of MRE11 in 
the U2OS Flp-In/T-Rex system, it is possible that these cells would still display defects in 
ATM-dependent intra-cellular signalling. To address this, endogenous MRE11 was depleted 
in all cell lines using siRNA and the exogenous MRE11 was induced 24 h prior to IR 
exposure. Each cell line was irradiated with 5 Gy and cells harvested at 1 h and 6 h post- 
Figure 4.23   DNA damage signaling in U2OS Flp-In/T-Rex cell 
lines expressing mutant MRE11 induced by IR. Following 
transfection with MRE11 siRNA for 72 h and treatment of cells for 
24 h with doxycycline to induce either WT or mutant MRE11, cells 
were irradiated with 5 Gy of IR and harvested at the above time 
points. Proteins were then fractionated by SDS-PAGE and Western 
blots incubated with the indicated antibodies. 
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treatment. Cell extracts were then subjected to SDS-PAGE and Western blotting using 
phospho-specific antibodies to known ATM substrates. Despite getting robust knockdown of 
endogenous MRE11, only an extremely mild defect in the ATM-dependent phosphorylation 
of H2AX was observed in the U2OS Flp-In/T-Rex cells complemented with an empty vector 
(Figure 4.23). Unexpectedly, the IR-induced phosphorylation of SMC1 on serine-966 that has 
been reported to be MRN-dependent, did not show any significant decrease in the vector 
complemented cells (Kim et al., 2002, Yazdi et al., 2002). Furthermore, it has also been 
demonstrated that the phosphorylation of CHK1 following the induction of DSBs is also 
MRN-dependent (Myers and Cortez, 2006). However, in contrast to this, loss of endogenous 
MRE11 appeared to result in an increase in CHK1 phosphorylation (Figure 4.23). No 
consistent defects in the phosphorylation of any ATM target proteins were observed in cells in 
which either the 3A or 4A MRE11 mutant had been re-expressed, with the exception of 
MRE11 itself, which seemed to be reduced in cells expressing either mutant.  
4.2.15 Camptothecin-induced activation of the cellular DDR in the 
U2OS Flp-In/T-Rex cell lines expressing mutant MRE11 is 
unaffected.  
The MRN complex plays a major role in repairing DNA damage and activating ATM/ATR-
dependent intracellular checkpoint signalling particularly during S-phase (Olson et al., 2007a, 
Olson et al., 2007b).  Camptothecin (CPT) is a topoisomerase I (Top1) poison that gives rise 
to DSBs in S-phase when a replication fork collides with an abortive Top1 cleavage complex. 
This complex consists of Top1 covalently bound to the DNA, proximal to an unligated DNA 
single strand break. It is known that CPT is a potent inducer of MRN-dependent signalling, 
DNA end-resection and cell cycle checkpoint activation (Kousholt et al., 2012, Robison et al., 
2005, Takemura et al., 2006). In this respect loss of components of the MRN complex  
Figure 4.24   DNA damage signaling in U2OS Flp-In/T-Rex cell 
lines expressing mutant MRE11 induced by CPT. Following 
transfection with MRE11 siRNA for 72 h and treatment of cells for 
24 h with doxycycline to induce either WT or mutant MRE11, cells 
were incubated with 100 nM CPT and harvested at the above time 
points. Proteins were then fractionated by SDS-PAGE and Western 
blots incubated with the indicated antibodies.  
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strongly compromises DNA end-resection and consequently HR-mediated repair of the 
damage that can be visualised by a reduction in RPA2 and CHK1 phosphorylation. To 
determine whether loss of the putative CK2 phosphorylation sites on MRE11 affected DNA 
damage signaling induced by CPT-mediated replication damage, cells expressing either WT 
MRE11, an empty vector or mutant MRE11 were transfected with MRE11 siRNA, treated 
with doxycycline and then exposed to low dose CPT for either 1 or 6 hours. Western blots of 
cell extracts were then probed with phospho-antibodies to known ATM/ATR target proteins, 
including RPA2 S4/8-P and CHK1 S345-P to monitor integrity of the MRN-dependent 
signaling cascade (Figure 4.24). Again, loss of endogenous MRE11 alone did not give rise to 
an observable defect in the CPT-induced phosphorylation of any of the ATM/ATR substrates 
tested indicating that either the siRNA-dependent depletion of MRE11 is not sufficient to 
compromise the DDR or that in a manner similar to the HCT116 cells, U2OS cells are not a 
good system to model MRE11-dependent signalling. However, despite this, loss of the 
putative CK2 phosphorylation sites on MRE11 again reduced its ability to be phosphorylated  
on S676 (Figure 4.24). 
4.3 Discussion 
An increasing number of reports being published identify CK2 as a critical regulator of the 
cellular DNA damage response (Iles et al., 2007, Loizou et al., 2004, Olsen et al., 2010, 
Spycher et al., 2008). Previous observations demonstrated that CK2 associates with MDC1 
and the MRN complex, and directly phosphorylates MDC1 in vitro and in vivo. The 
identification, using large scale mass spectrometry, of three in vivo sites on MRE11 that 
conform to a CK2 consensus phosphorylation site (S649, S688 and S689), in addition to a 
report demonstrating that at least S649 of MRE11 can be directly modified by this enzyme in  
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vitro (Kim, 2005), suggested that the biochemical link between CK2 and the MRN complex is 
not just limited to NBS1. Consistent with this premise, in vitro CK2 kinase assays 
demonstrated that CK2 can directly phosphorylate MRE11 (Figure 4.2, 4.3 & 4.10). 
Although, in contrast to the study by Kim (2005), S649 was not the only target site. The 
reason for this apparent disparity remains unclear, but it is possible that since the CK2 used 
by Kim to phosphorylate MRE11 was purified by immunoprecipitation from 293 cells a 
contaminating kinase maybe responsible for the phosphorylation of MRE11 on this residue. 
Whilst mutation of the two other serine residues of MRE11 identified as potential CK2 
phosphorylation sites (S688/689) did result in a moderate reduction in its phosphorylation, it 
appeared that a more N-terminal residue (S541), that was only identified by prediction, 
represented the major site of phosphorylation in vitro (Figure 4.10). However, an antibody 
specific to phosphorylated S688 of MRE11 used on whole cell extracts from cells expressing 
WT and mutant MRE11, in an MRE11 depleted background, suggested phosphorylation of 
S688 was constitutive in vivo (Figure 4.20).  
 Despite the identified sites of in vivo MRE11 phosphorylation (S649/S688/S689) not 
representing major targets for CK2 phosphorylation, at least in vitro, it is clear that these sites 
are modified and have not been assigned to regulating any aspect of MRE11 biology. To 
investigate how loss of phosphorylation on these sites may influence the MRE11-dependent 
DDR, several cell systems were utilised to model mutant MRE11.  
Firstly, isogenic hTERT-immortalised ATLD2 patient derived fibroblasts were used, which 
express extremely low levels of endogenous MRE11. The reduced level meant that any effect 
on the DDR caused by expression of the MRE11 mutants would not be influenced by the 
endogenous protein.  Preliminary characterisation carried out on isolated ATLD2 clones 
expressing the different MRE11 mutants suggested phosphorylation of MRE11 on 
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S649/688/689 did not affect the capacity of MRE11 to bind to RAD50 and NBS1, its 
recruitment to IRIF or its ability to mediate repair of IR-induced DNA lesions (Figure 4.5, 4.7 
& 4.8).  The progressive reduction in the growth in theses cells severely hampered any further 
analysis. Verification that the cells still expressed hTERT, analysis of different clones at early 
passage in addition to changing the growth media, failed to identify the cause of the slowed 
growth. A similar report from another researcher using patient derived fibroblasts from NBS 
patients suggests that this may be an inherent problem with patient cells with defects in the 
MRN complex (Dr. Manuel Stucki, personal communication). Further to this problem, 
significant differences in the expression of DDR proteins in different ATLD2 clones, 
irrespective of the exogenous MRE11 stably expressed in these cell lines, was observed. Due 
to these problems, it became apparent an alternative approach was required to address 
whether modification on these three residues plays any role in modulating MRE11 function. 
The second cell system used to model MRE11 mutations took advantage of the HCT116 
tumour cell line. This particular cell line has been shown to have a mutation in the MRE11 
gene, which results in the expression of an unstable truncated form of the protein. Moreover, 
the availability of a derivative, HCT116 Flp-In/T-Rex, would facilitate the production of a 
relatively homogenous population of cells stably expressing a protein of interest under the 
control of an inducible promoter. This isogenic cell system would therefore minimise any 
problems associated with isolating individual clones. Despite generating HCT116 Flp-In/T-
Rex cell lines stably expressing either WT MRE11 or various phospho-mutants and getting 
robust expression of exogenous MRE11, it became apparent that HCT116 cells exhibit very 
high levels of 53BP1 foci in the absence of any treatment (Figure 4.14). Furthermore, it 
became apparent that this was not due to underlying mutation in its MRE11 gene, since re-
expression of WT MRE11 could not complement this defect. 
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One obvious caveat is that HCT116 cells have mutations in the MMR gene, MLH1, and as a 
consequence they are genomically unstable, and therefore more likely to acquire somatic 
mutations in other genes over long periods of in vitro culture (Villemure et al., 2003).  It is 
possible that this cell line has accrued mutations in other genes involved in maintaining 
genome stability. Indeed ATM levels were reduced in this cell line, and from searching the 
COSMIC database a single heterozygous mutation was identified. Furthermore, interrogating 
the same database also revealed mutations in additional DDR proteins CHK2, RAD54 and 
ATRX.  The latter has recently been reported to bind to the MRN complex and functions to 
promote replication fork and restart (Leung et al., 2013). Therefore it is highly likely that the 
elevated levels of 53BP1 foci could be a consequence of either spontaneous DNA damage due 
to a defective MMR system or as a result of acquired mutations in DDR proteins.  
In an attempt to avoid the problems associated with the HCT116 cells, but to continue using a 
tumour cell line model to avoid any growth related issues connected with using patient-
derived fibroblasts, the Flp-In/T-Rex approach was utilised in U2OS cells. In contrast to the 
HCT116 cell line, U2OS cells have a WT MRE11 gene. Therefore prior to carrying out any 
analysis of the function of mutant MRE11 the endogenous protein was depleted using siRNA. 
As feasible as this method is, it does present caveats. Firstly, siRNA-mediated depletion of 
proteins never depletes 100% of the targeted mRNA; secondly, siRNAs can target other 
mRNAs non-specifically; and thirdly, some siRNA duplexes carry high levels of inherent 
cytotoxicity. Moreover, using this approach requires the exogenous gene to be made resistant 
to the siRNA that is used to knockdown the endogenous protein. This can be achieved either 
by site-directed mutagenesis or by using siRNAs that target UTR sequences. With these 
limitations in mind, a panel of polyclonal U2OS Flp-In/T-Rex cell lines overexpressing either 
WT MRE11, an empty vector or various MRE11 mutants were made. A previously published 
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MRE11 siRNA targeting its 5’ UTR was used to knockdown the endogenous MRE11 protein 
in these cells. Unfortunately, despite achieving greater than good knockdown of the 
endogenous MRE11 in these cell lines, and robust expression of the exogenous MRE11, 
which was clearly capable of reinstating the stability of RAD50 and NBS1 caused by the 
transfection with the siRNA, a complementable defect in DSB repair could not be detected 
(Figure 4.16 & 4.22). Again using 53BP1 foci as a marker of DNA repair, 24 h post IR, foci 
persisted in both the vector-only cell line and the WT, suggesting that expression of the 
exogenous WT MRE11 is not sufficient to complement the defect. This observation is similar 
to figure 4.8. Here the ATLD vector-only cell line have reduced levels of MRE11, resulting in 
persistant 53BP1 foci 24 h post low dose IR, compared to the WT ATLD cell lines which are 
comparable to the 0 h counts. In addition a robust defect in the phosphorylation of known 
ATM substrates was not detected in cells depleted of MRE11 compared to those in which WT 
MRE11 had been re-expressed after either low dose IR or CPT treatment (Figure 4.23 & 
4.24). Again this would have been expected as ATLD cells show reduced ATM activation 
(Uziel et al., 2003)  It is likely that since the MRN complex is extremely abundant in the cell, 
despite achieving very high efficiency of endogenous siRNA MRE11 knockdown, the 
remaining small pool of protein is sufficient to carry out its function with normal 
effectiveness. In support of this, the low/barely detectable levels of mutant MRE11 protein 
expressed in ATLD2 cells are sufficient to maintain viability of the cells. In addition, other 
researchers have screened 8-10 different MRE11 siRNA sequences, and to achieve a cellular 
phenotype that is consistent with MRN dysfunction cells must be transfected with a pool of 2-
3 different siRNAs, even though many of the siRNAs tested resulted in a >85% knockdown 
of the protein as judged by Western blotting (Dr. Claus Sorensen, personal communication). 
Taken together, none of the three cell systems used to address the potential role of MRE11 
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phosphorylation on putative CK2 target motifs were able to generate a reproducible defect in 
known MRN-dependent DNA damage responses. Due to this the effect of losing 
phosphorylation on serines 541,649,688 and 689 and the effect this may have on activation of 
these pathways could not be effectively studied. Even so, a limited amount of information 
could be extracted from some of the preliminary observations: the phosphorylation on serines 
541,649,688 and 689 is required neither for MRN complex stability, nor for its recruitment to 
sites of DSBs, or its ability to promote repair of these lesions. Despite these findings it is clear 
that a different approach is required to carry out a more in depth analysis of MRE11 function 
that includes its role in activation of the intra-S and G2/M DNA damage checkpoints, 
replication fork restart, apoptosis, DNA end-resection and ATR activation.  
In spite of the problems associated with using siRNA and the U2OS Flp-In/T-Rex cells, it 
was noted that the DNA damage-induced phosphorylation of MRE11 on serine-676 was 
reduced when the putative CK2 phosphorylation sites were mutated. S676 is situated between 
S649 and the double residues S688/S689, and is a SQ motif, which is a putative PIKKs target 
residue. Based on the observed reduction in damage dependent-phosphorylation of these sites 
on induction of the MRE11 CK2 mutants, it could be speculated that phosphorylation of S676 
is dependent on CK2. Previous studies have demonstrated a mechanism by which constitutive 
phosphorylation of a CK2 substrate is a prerequisite for the phosphorylation of nearby 
residues. In one example, phosphorylation by CK2 is required for the damaged induced 
phosphorylation of a proximal serine on SMC3 by ATM, and this is required for the intra-S-
phase checkpoint (Luo et al., 2008). It has been shown that MRE11 is phosphorylated in 
response to DNA damaging agents, on a number of residues possibly including S676 (Di 
Virgilio et al., 2009, Mu et al., 2007, Stokes et al., 2007). One report suggested that the 
phosphorylation of SQ/TQ motifs on MRE11 regulates the disassociation of the MRN 
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complex from the chromatin in order to facilitate down regulation of the DDR in response to 
DSBs (Di Virgilio et al., 2009). This implies that phosphorylation on this residue may 
regulate MRE11 association with chromatin. Yet whether the phosphorylation of this residue 
is dependent on the modification of proximal motifs by CK2 would require further 
investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
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Chapter 5 Final discussion and future perspectives 
5.1 Introduction 
CK2 is a highly ubiquitous serine/theronine kinase, known to phosphorylate over 300 
substrate proteins. The large number of CK2 substrates is reflective of its constitutive activity 
and its requirement in many cellular processes, including cell survival, proliferation and 
apoptosis. Unsurprisingly, phosphorylation of proteins by CK2 has been observed during the 
DDR, both in response to ssDNA breaks and DSBs.  In this thesis we have identified a CK2-
dependent interaction between the DDR proteins MDC1 and NBS1, in addition to identifying 
a potential CK2 substrate (MRE11) also involved in the cellular response to DNA damage.  
5.2 CK2 is required for retention of NBS1 at damaged chromatin 
Based on the work presented in Chapter 3, in collaboration with work from the laboratory of 
Dr M. Stucki, (Zürich, Switzerland), we have identified a conserved N-terminal cluster of 
CK2 phosphorylation motifs on the DNA damage mediator protein MDC1. This cluster, 
which we termed the SDTD domain, was shown to facilitate an interaction between MDC1 
and the FHA domain of NBS1, a member of the MRN complex. Furthermore, we have shown 
that this phosphorylation is constitutive and that the interaction occurs even in the absence of 
DNA DSBs. These data provide a mechanistic explanation for the previously described 
interaction between MDC1 and NBS1, even in the absence of DSBs, and also for the 
requirement of MDC1 to promote MRN IRIF (Goldberg et al., 2003, Lou et al., 2006, Lukas 
et al., 2004a, Stewart et al., 2003). Disruption of this interaction, by depleting CK2, or by 
mutation of either the SDTD domain of MDC1 or the FHA domain of NBS1, resulted in the 
loss of NBS1 foci following IR and resulted in a partial G2/M checkpoint defect. Similar 
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observations have been reported by several other groups, re-enforcing the biochemical link 
between MDC1, CK2 and the MRN complex (Chapman & Jackson, 2008, Melander et al., 
2008, Spycher, et al., 2008, Wu et al., 2008). Interestingly, Wu et al,  (2008) demonstrated 
that the interaction between MDC1 and NBS1 is also required to activate the intra-S phase 
checkpoint.  In addition, these studies revealed that disruption of this interaction did not affect 
ATM activation, and therefore the CK2-dependent interaction was not required for this aspect 
of MRN function. In support of this, previous work has shown MDC1 does not seem to be 
required for the activation of ATM or the DNA end processing activities of MRN (Jazayeri et 
al., 2006, Lee and Paull, 2005). Therefore, it would seem that the purpose of the interaction 
between MDC1 and NBS1 is to ensure focal recruitment and retention of the MRN complex 
at the break, which serves to amplify the DNA damage response and trigger intra-S and G2/M 
checkpoint activation.  
A similar mechanism to that reported for XRCC1 and XRCC4, whose phosphorylation by 
CK2 permits interaction with several binding partners, may also exist with MDC1. Indeed, 
two separate studies have shown Aprataxin and TopBP1 interact with the SDTD region of 
MDC1 (Becherel et al., 2010, Wang et al., 2011). It is also plausible that the NBS1 FHA and 
BRCT domains, in addition to interacting with MDC1, may associate with other 
phosphorylated interacting partners. Although, it is currently unclear how disruption of the 
ability of NBS1 to MDC1 and/or these other potential binding partners contributes to the 
clinical symptoms exhibited by the NBSBRCT patients identified in this study. Of note, CtIP, a 
potential CK2-dependent binding partner of NBS1, is mutated in one consanguineous Seckel 
family (SKL2), which share some of the clinical phenotypes exhibited by the NBSBRCT 
patients (Borglum et al., 2001, Qvist et al., 2011). Although the microcephaly and growth 
defects seen in the SKL2 family are mild compared to the NBSBRCT patients, the overlapping 
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phenotypes could be due to defects in similar pathways. Interestingly the C-terminally 
truncated form of CtIP expressed in the affected individuals lacks an MRN interaction 
domain, which is required for DNA end-resection and thus disrupts ATR activation (Qvist et 
al., 2011, Sartori et al., 2007). To verify these speculations, mass spectrometry techniques 
could be employed to examine the identification of novel proteins that interact with either the 
SDTD domain of MDC1 or the FHA/BRCT domains of NBS1. Performing these experiments 
in the presence or absence of DNA damaging agents could potentially reveal how binding to 
these regions is regulated, as different proteins may interact depending on the type of DNA 
lesion induced.  
The identification of a homozygous mutation in the BRCT domain of NBS1 in three affected 
siblings exhibiting a clinical phenotype that overlaps with those of NBS and Seckel Syndrome 
highlights the importance of phospho-peptide binding mediated by the FHA/BRCT domain 
during neuronal development. Strikingly, we did not observe any defects in ATM or G2/M 
activation following the exposure to IR or DSB repair in cells from these patients indicating 
that phospho-dependent interactions with the BRCT domain of NBS1 are likely to be critical 
for the cellular response to different DNA lesions. Consistent with this, twins have been 
identified, compound heterozygous for the common NBS 657del5 mutation and a missense 
point mutation in the BRCT domain (643C>T (R215W), that exhibit severe microcephaly and 
growth retardation, but no chromosomal instability or radiosensitivity (Seemanova et al., 
2006). Taking this evidence together with the observations from this study, it would seem that 
the clinical/cellular phenotypes of the NBSBRCT patients may not be attributed to defects in the 
repair of DNA DSBs. One possible hypothesis is that the patients’ symptoms may result from 
problems during DNA replication or mitosis during neural development, as is thought to be 
the underlying mechanism for other syndromes that present microcephaly (Kerzendorfer et 
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al., 2013, Mokrani-Benhelli et al., 2012, Stiff et al., 2013). For instance, cells from patients 
with Seckel syndrome caused by mutations in ATR exhibit replication problems and defective 
cell cycle checkpoint activation (Alderton et al., 2004, Stiff et al., 2005, Stiff et al., 2006). 
Interestingly, ATR signalling is impaired in NBS cells, which also display problems in 
recovery following replication stalling (Stiff et al 2005). Therefore, to address this hypothesis, 
the impact of the ΔS118 mutation on ATR activation and signalling should be assessed using 
a panel of different DNA damaging agents known to cause replication stress and activate 
ATR, such as HU and UVC. To further examine whether the ΔS118 mutation impacts upon 
nervous system development in vivo, one approach would be to create a knockin transgenic 
mouse model encoding this mutation, and to use this model to further study neuronal 
development. Previous studies using mice models have been beneficial in the study of 
neuropathology. Work by Lee et al, 2012, demonstrated by studying Atr loss in the murine 
nervous system, that its depletion impacts on specific populations of cells, which suggests that 
it is required to survey genomic integrity selectively during neurogenesis. For instance Atr 
loss resulted in proliferation arrest, due to replication associated damage in the cerebella, yet 
the same stress results in apoptosis in ganglionic eminence (responsible for generating 
diversity of cortical cell types) (Lee et al., 2012). Moreover, a second group showed that by 
depleting either Nbs, Atr or both in the mouse central nervous system, loss of Nbs1 impacted 
only on proliferating neuroprogenitor cells, whereas Atr loss impacted on both proliferating 
and non-proliferating neural cells (Zhou et al., 2012). In light of this evidence, modeling the 
ΔS118 in a mouse system may reveal that this BRCT domain mutation may disrupt a function 
of NBS1 required to monitor genetic integrity in proliferating neural cells, that most likely 
impacts on ATR activity.   
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5.3 Mre11 and CK2  
During the course of this work, it was also investigated whether MRE11 was regulated by 
CK2-dependent phosphorylation. One residue within MRE11 (S649) had been previously 
shown to be phosphorylated in vivo, although the physiological relevance of this modification 
was not determined (Kim 2005). Using in vitro techniques, it was shown that the residues 
S541, S688 and S689 were phosphorylated by recombinant CK2, with residue S541 being the 
major target for CK2 in vitro. Furthermore, expressing MRE11 proteins bearing mutations in 
these sites in vivo, revealed that phosphorylation of these sites by CK2 was not required for 
the focal localisation of MRE11/MRN to IRIF following IR, nor for the repair of these lesions 
as measured by 53BP1 IRIF persistence. Similarly, the phosphorylation of several ATM 
substrates in response to DNA DSBs remained unaffected. The study of the cellular 
consequence(s) of these mutations was attempted in three independent experimental in vivo 
systems, but was hampered by technical issues, preventing significant insight into this aspect 
of MRE11 function. To definitively study whether these putative CK2 residues have a 
function in vivo, a suitable system would first need to be established in which mutated 
MRE11 could be expressed. It is possible that the spontaneous immortalized MEFs (Murine 
Embryonic Fibroblasts) generated from the ATLD2 mouse model may be a more robust cell 
system with which to study the function of MRE11 phosphorylation, especially since the 4 
serine residues that were identified as CK2 targets are conserved in rodents (Figure 4.9). As 
with using the ATLD2 patient-derived cells, these MEFs would provide an isogenic system 
with which to express low levels of endogenous mutant protein. However, the only ATLD2 
MEFs available to date are immortalised with SV40 Large T antigen, which has been 
previously shown to interact with, and compromise the function of, the MRN complex 
(Lanson et al 2000, Wu et al 2004). Furthermore, antibodies recognising mouse DDR 
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proteins, particularly phospho-specific antibodies, are not readily available. As an alternative 
to this approach, Dr. Manuel Stucki has recently identified an endometrial tumour cell line 
(AN3Ca) that expresses extremely low levels of endogenous MRE11, which would render it 
appropriate for studies requiring the expression of my MRE11 CK2 mutants. However, this 
cell line has not yet been fully characterised, and thus, in a manner similar to the HCT116 cell 
line, it is possible that AN3Ca cells may have accumulated other gene mutations rendering it 
non-permissive for studying the MRE11-dependent DDR. 
Despite these caveats, once a suitable robust experimental system is in place, then the role of 
CK2 phosphorylation on MRE11/MRN function can be thoroughly investigated. Of particular 
interest, and an avenue of further study, is the impact of CK2 phosphorylation of MRE11 on 
the phosphorylation of S676, a putative SQ/TQ motif within Mre11, which was induced by 
DNA damage. Following mutation of the four putative CK2 residues, a reduction of S676 
phosphorylation was seen. This observation suggests that the phosphorylation of S676 
requires phosphorylation of the CK2 sites to occur, prior to its own damage-dependent 
activation by ATM/ATR. A study investigating the phosphorylation of several MRE11 
SQ/TQ motifs, including S676, showed that mutating these motifs to alanines did not affect 
MRN complex expression or stability, DNA tethering or ATM activation (Di Virgilio et al., 
2009). The authors of this study concluded that phosphorylation on these SQ/TQ sites was 
damage-dependent and was required for the disassociation of MRE11 from the DNA, 
potentially providing one mechanism to down-regulate the damage signal. More recently 
ribosomal S6 kinase (Rsk), elevated in a number of cancers has been shown to phosphorylate 
S676 both in vitro and in vivo upstream of ATM. In support of earlier observations this is 
thought to preventing binding of the MRE11 to DSBs (Chen et al., 2013). Moreover the 
authors go on to suggest that phosphorylation of this residue could function to inhibit 
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activation of cell cycle checkpoints upstream of ATM, promoting tumor progression.  If 
phosphorylation of S676 requires the phosphorylation of the proximal CK2 sites for its 
activation, it could be that the association of MRE11 with chromatin is prolonged when these 
sites are mutated, which may result in excessive MRE11-dependent resection and 
excessive/uncontrolled homologous recombination. To address this question, it would be 
interesting to examine the association of MRE11 with chromatin following mutation of the 
CK2 sites in response to a variety of DNA DSB causing agents, in addition to studying 
various markers of resection such as RPA IRIF.  
Preliminary data from analysis of DNA replication using DNA fibre analysis suggested that 
U2OS Flp-In/T-Rex cells expressing mutated MRE11, where all four of the putative CK2 
sites had been mutated (4A), had DNA replication defects. This was evident by an increase in 
the proportion of stalled replication forks and defective fork restart following exposure to HU. 
This data was not included in this thesis due to the inherent caveats identified using this cell 
system. However, based on these preliminary data it is tempting to speculate that the putative 
CK2 sites on MRE11 may play some part in regulating the cellular response to replication 
stress. Investigating whether cells expressing MRE11 harbouring mutations in the CK2 sites 
have a RDS (Radioresistant DNA synthesis) would be a simple and elegant way to assess 
whether phosphorylation of MRE11 by CK2 is required during DNA replication.  
5.4 CK2 and the DNA damage response: Implications 
The work presented in this thesis provides further examples of the involvement of CK2 in the 
DDR. Based on the large number of DDR proteins that contain potential CK2 
phosphorylation residues, including those involved in the sensing, signalling and repair of 
DNA breaks, it is highly likely that other in vivo substrates of CK2 will be identified (Table 
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5.1). In support of this supposition, cells transfected with CK2 siRNA exhibit a modest 
prolonged ATM response (Figure 3.6.). Similarly, a separate study demonstrated a reduction 
in DNA-PKcs autophosphorylation and delayed DSB repair following depletion of the CK2 
catalytic subunits by siRNA (Olsen et al., 2010). Moreover, work from the same research 
group also showed CK2 co-localises with γH2AX after DNA damage, and that loss of CK2 
destabilises the interaction between KU80 and DNA-PKcs (Olsen et al., 2012). The 
phosphorylation of DDR proteins by CK2 likely results in a variety of outcomes including 
facilitating interactions with phospho-peptide binding domains, priming substrates for 
damaged-induced phosphorylation by other kinases, stability of complexes and in some cases 
altering the localisation of proteins (Iles et al., 2007, Kubota et al., 2009, Luo et al., 2008, 
Parsons et al., 2010, Yang et al., 2009). Many of the substrates of CK2 appear to be 
constitutively phosphorylated, contrasting to the function of other cellular kinases whose 
activity is often regulated in the response to a particular stimulus. This poses the question: 
why have a modification, that to all intents and purposes is permanently active? One simple 
explanation could be that phosphorylation by CK2 allows the substrate to carry out its 
function rapidly when required, omitting any need for intermediate regulatory steps. Equally, 
phosphorylation by CK2 could be extremely transient, with the phosphate being removed by 
phosphatases as quickly as it is added. Therefore substrates appear to be constitutively 
phosphorylated when this may not be the case.  
The role CK2 plays in the DDR response, in addition to its role in cellular survival and 
proliferation, has attracted attention in the field of cancer research, since defects in the cellular 
response to DNA damage may be a precursor to tumourgenesis. Equally, kinases are often 
tempting therapeutic targets in the treatment of human diseases, since the catalytic activity of 
these enzymes can be targeted using specific inhibitors, which can impact upon downstream 
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pathways in which the kinase is required. A number of p38 mitogen-activated protein kinases 
(p38 MAPK), activated during cellular stress, inhibitors have been developed to treat 
inflammatory diseases such as rheumatoid arthritis (Kumar et al., 2003, Thalhamer et al., 
2008). Moreover, targeting the kinome is also used in the treatment of cancers. For instance 
the first to do so, Herceptin (trastuzumab), targets the receptor tyrosine kinase ErbB2, which 
is overexpressed in a large number of breasts cancers (Hudis, 2007, Valabrega et al., 2007). It 
has been known for some time that CK2 expression and activity is elevated in a number of 
human cancers, and for this reason has highlighted its potential as a target for 
pharmacological inhibition (Gapany et al., 1995, Hamacher et al., 2007, Landesman-Bollag et 
al., 2001). The major benefit of CK2 as a potential target in cancer therapy is that, unlike 
canonical kinases, CK2, due to its constitutive activity, functions laterally in many pathways, 
as opposed to residing at the top of these cascades. Therefore inhibition is likely to impact on 
signalling networks at a variety of levels, although this could be at the detriment to selectivity.  
A number of kinases are frequently mutated in carcinogenesis, producing oncogenic kinases 
that become permanently activated, and driving the transformation of the cell, such as 
fibroblast growth factor receptor 2 (FGFR2) mutated in some breast cancers (Reintjes et al., 
2013).  Interestingly, CK2 does not seem to be a significant target for such somatic mutations, 
in that no mutations have as yet been identified that account for the gain of CK2 activity 
observed in tumours (Ruzzene et al., 2010). Instead, evidence suggests that CK2 does not act 
as driver of tumourgenesis per se, but that once a cell has become transformed, elevated CK2 
levels potentiate its survival by suppressing anti-apoptotic signals.  For instance, the caspase 
inhibitor, activity-regulated cytoskeleton-associated protein (ARC) is activated following 
phosphorylation by CK2 (Li et al., 2002d).  The first CK2 inhibitor to be described was DRB 
(5, 6-di-chloro-1-(β-D-ribofuranosyl)-benzimida-zole) (Zandomeni et al., 1986). However, 
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since its discovery, other inhibitors have been discovered that exhibit greater specificity, 
namely TBB and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole) (Pagano 
et al., 2004, Sarno et al., 2001). Both these inhibitors have been reported to be effective at 
inducing cell death in cancer cell lines. For example, DMAT has been shown to kill human 
breast cancer cells resistant to anti-oestrogens (Yde et al., 2007). Inhibiting such a prolific 
kinase though would presumably have caveats due to the number of putative CK2 substrates 
within the cell. Despite the inhibitors disrupting the targeted pathway, other cellular processes 
dependent on CK2 would also be affected, potentially resulting in unwanted toxicity. Though 
this may be the case, encouragingly in vivo work in mice studying an involvement of CK2 in 
retinal angiogenesis, using several CK2 inhibitors showed no additional toxicity (Kramerov et 
al., 2006, Ljubimov et al., 2004). In terms of treating cancer with CK2 inhibitors, it could be 
postulated that as CK2 levels are elevated in tumours, disrupting activity to a minimal extent 
would have an impact on the malignancy without significantly impacting on normal tissues or 
cells.   In context of the role of CK2 in the DDR, recently, a potent CK2 inhibitor (CX-4945) 
was used in combination with either the chemotherapy treatments cisplatin or gemacitabine, 
which are both DNA damaging agents, to investigate their combined therapeutic potential 
(Siddiqui-Jain et al., 2012). This study was based on the growing role of CK2 in the repair of 
DNA damage, and aimed to investigate whether CK2 inhibition could enhance the activity of 
DNA-damaging chemotherapeutics. Indeed, the study showed that treatment with the CK2 
inhibitor increased the anti-proliferative effect of these agents on ovarian cancer cells 
(Siddiqui-Jain et al., 2012). This observation opens the potential for the use of CK2 inhibitors 
in combination with DNA-targeting chemotherapy drugs to improve treatment of those 
cancers with partial resistance to these particular drugs.  
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In conclusion, the continued study of how CK2-dependent phosphorylation regulates the 
cellular DDR will be essential for understanding if CK2 inhibitors could be used clinically to 
hyper-sensitise tumours cells to chemotherapeutic agents. 
 
 
 
 
 
 
 
Table 5.1  A selection of proteins associated with the DNA damage 
response and putative CK2 sites, as predicted by a web-based search tool  
(http://scansite.mit.edu/). 
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 Introduction 
 Eukaryotic cells are equipped with sophisticated mechanisms to de-
tect, signal the presence of, and repair DNA damage. Of particular 
importance are the pathways that deal with DNA double-strand 
breaks (DSBs): highly toxic lesions that, if unrepaired or repaired 
incorrectly, can cause cell death, mutations, and chromosomal trans-
locations and can lead to diseases such as cancer. Cells react to 
DSBs by rapidly deploying a host of proteins to the damaged chro-
matin regions. Some of these factors engage in DNA repair, whereas 
others trigger a signaling pathway (called the DNA damage check-
point) that provokes delays in cell cycle progression and coordinates 
the repair process; together, these events comprise the so-called 
DNA damage response (DDR;  Zhou and Elledge, 2000 ). 
 Among the ! rst proteins that accumulate at sites of DSBs 
in eukaryotic cells is the MRE11 – RAD50 – Nijmegen breakage 
syndrome 1 (NBS1 [MRN]) complex, a conserved and essential 
DDR factor that functions in a multitude of cellular processes in-
volving DSBs, including DSB repair, checkpoint signaling, DNA 
replication, meiotic recombination, and induction of apopto-
sis ( Stracker et al., 2004, 2007 ;  Di! lippantonio et al., 2007 ). 
The MRN complex consists of three subunits. The ! rst is the 
structure-speci! c nuclease MRE11, which is most likely involved 
in nucleolytic processing of DNA ends to allow homologous re-
combination repair ( Jazayeri et al., 2006 ), and the second is the 
ATPase and adenylate kinase subunit RAD50, which, together 
with MRE11, appears to facilitate tethering of DNA molecules 
to promote DSB repair ( Costanzo et al., 2004 ;  Bhaskara et al., 
2007 ). The third subunit of the MRN complex, NBS1, does not 
exhibit any catalytic activities. Instead, its domain composition 
suggests that it belongs to the family of adaptor/mediator pro-
teins of the DDR, a group of recently emerging factors that inte-
grate, coordinate, and enhance the various cellular responses 
to DNA damage by promoting protein – protein interactions 
( D ’ Amours and Jackson, 2002 ). Consistent with this notion, 
NBS1 features both forkhead-associated (FHA) and BRCA1 
C-terminal (BRCT) domains at its N terminus, which are protein 
interaction modules that speci! cally mediate the interaction with 
The MRE11 – RAD50 – Nijmegen breakage syndrome 1 (NBS1 [MRN]) complex accumulates at sites of DNA double-strand breaks (DSBs) in microscopically dis-
cernible nuclear foci. Focus formation by the MRN com-
plex is dependent on MDC1, a large nuclear protein that 
directly interacts with phosphorylated H2AX. In this study, 
we identifi ed a region in MDC1 that is essential for the focal 
accumulation of the MRN complex at sites of DNA damage. 
This region contains multiple conserved acidic sequence 
motifs that are constitutively phosphorylated in vivo. 
We show that these motifs are effi ciently phosphorylated 
by caseine kinase 2 (CK2) in vitro and directly interact 
with the N-terminal forkhead-associated domain of NBS1 
in a phosphorylation-dependent manner. Mutation of these 
conserved motifs in MDC1 or depletion of CK2 by small 
interfering RNA disrupts the interaction between MDC1 
and NBS1 and abrogates accumulation of the MRN com-
plex at sites of DNA DSBs in vivo. Thus, our data reveal 
the mechanism by which MDC1 physically couples the 
MRN complex to damaged chromatin.
 Constitutive phosphorylation of MDC1 physically 
links the MRE11 – RAD50 – NBS1 complex to 
damaged chromatin 
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acting BRCT tandem domain at the C terminus, MDC1 also fea-
tures a unique repeat region in the middle of the protein (Pro-Ser-Thr 
[PST] repeat) and contains several highly conserved putative PIKK 
target sites, some of which are phosphorylated in response to DNA 
damage in vivo ( Matsuoka et al., 2007 ). In addition, MDC1 is also 
phosphorylated in the absence of DNA damage: several recent 
large-scale phosphorylation site screens of the human and mouse 
proteome revealed that MDC1 is constitutively phosphorylated on 
a signi! cant number of Ser and Thr residues in vivo ( Beausoleil 
et al., 2004 ;  Olsen et al., 2006 ;  Villen et al., 2007 ). 
 Although it is well established that MDC1 mediates the ac-
cumulation of many DDR factors in damaged chromatin regions 
(including the MRN complex, 53BP1, BRCA1, and ATM;  Stucki 
and Jackson, 2006 ), it is still unclear how MDC1 mediates MRN 
recruitment. The observation that MDC1 exists in a complex with 
MRN in extracts from undamaged cells suggests that MDC1 may 
recruit MRN to  ! -H2AX – containing chromatin in a simple  “ pig-
gyback ride ” mechanism whereby the physical interface between 
the two factors is made up by the NBS1 N-terminal FHA/BRCT 
region and by one or several phosphoepitopes on MDC1. 
 To put such a mechanism to the test, we set up an in vivo 
complementation system for MDC1 to search for a region in 
MDC1 that is responsible to mediate MRN foci formation. 
Through this approach, we identi! ed a new region in MDC1 
that is composed of several acidic repeats featuring a unique se-
quence motif, the Ser-Asp-Thr (SDT) motif. Furthermore, we 
provide evidence that these SDT repeats are constitutively phos-
phorylated by caseine kinase 2 (CK2) and that the phosphory-
lated form of these motifs constitute the phosphoepitope that 
the NBS1 FHA domain is binding to. These ! ndings allow us to 
draw a model of the mechanism by which MDC1 physically 
links the MRN complex to damaged chromatin. 
 Results 
 An acidic region near the N terminus of 
MDC1 is essential for NBS1 foci formation 
 Ef! cient accumulation of the MRN complex in foci at sites of 
DSBs is critically dependent on MDC1 ( Goldberg et al., 2003 ; 
 Lukas et al., 2004 ). To determine the region of MDC1 that medi-
ates MRN foci formation, we transfected MDC1  – / –  mouse em-
bryonic ! broblasts (MEFs;  Lou et al., 2006 ) with a series of 
N-terminal deletion mutants of mouse MDC1 and assessed MRN 
accumulation by indirect immuno" uorescence using an antibody 
speci! c for mouse NBS1 ( Celeste et al., 2003 ). Consistent with 
published data ( Lou et al., 2006 ), MDC1  – / –  MEFs were com-
pletely defective for NBS1 accumulation (unpublished data), but 
transient transfection of these cells with HA-tagged full-length 
mouse MDC1 readily restored NBS1 foci formation in response 
to 5 Gy of ionizing radiation (IR;  Fig. 1 B , WT). Deletion of 153 
and 295 N-terminal amino acids of MDC1 did not result in any 
detectable reduction of NBS1 foci ( Fig. 1 B ,  " N1 and  " N2), but 
deletion of 452 and 645 amino acids led to a complete loss of 
NBS1 accumulation ( Fig. 1 B ,  " N3 and  " N4). This indicated that 
the region in MDC1 essential for mediating NBS1 accumulation is 
located somewhere between amino acids 295 and 452. Indeed, inter-
nal deletion of this 157 – amino acid region completely abolished 
phosphorylated proteins ( Durocher and Jackson, 2002 ;  Glover 
et al., 2004 ). Moreover, several NBS1 interaction partners have 
been described; most prominent among these is the ataxia telan-
giectasia mutated (ATM) kinase, the key upstream component of 
DSB signaling ( Falck et al., 2005 ). Mutations in the  NBS1 gene 
leads to NBS in humans, and cells derived from NBS patients 
display a DSB repair and signaling de! ciency, including radio-
sensitivity, chromosomal instability, and checkpoint defects 
( D ’ Amours and Jackson, 2002 ). Mouse models in which the 
native mouse  NBS1 allele was exchanged with hypomorphic 
mutant alleles recapitulate many features of NBS in the mouse, 
including developmental defects, chromosomal instability, and 
checkpoint de! ciency ( Di! lippantonio et al., 2005 , 2007 ). 
 Accumulation of the MRN complex at sites of DSBs is mani-
fested by the formation of microscopically discernible subnuclear 
structures, so-called nuclear foci that represent large chromatin re-
gions containing one or several unrepaired DSBs ( Maser et al., 
1997 ). The key regulator of nuclear foci formation in higher eu-
karyotes is the histone variant H2AX, an integral component of the 
nucleosome core structure that comprises 10 – 15% of total cellular 
H2A in higher organisms ( Fernandez-Capetillo et al., 2004 ). H2AX 
is phosphorylated extensively on a conserved Ser residue at its 
C terminus in chromatin regions bearing DSBs, and this is mediated 
mainly by the ATM kinase, a member of the phosphoinositide-3-
kinase – related protein kinase (PIKK) family ( Burma et al., 2001 ). 
 Although it has been previously suggested that MRN accu-
mulation at sites of DSBs occurs through interaction between 
the FHA/BRCT region of NBS1 and phosphorylated H2AX 
( ! -H2AX;  Kobayashi et al., 2002 ), recent evidence suggests that 
the interaction between NBS1 and  ! -H2AX is not direct but is me-
diated by MDC1, a large nuclear factor that interacts with the MRN 
complex and also features the criteria of a DDR mediator/adaptor 
protein, including the presence of FHA and BRCT domains (for 
review see  Stucki and Jackson, 2004 ). First, it was shown that 
MDC1 exists in a complex with MRN in extracts of undamaged 
cells ( Goldberg et al., 2003 ). This complex dissociates upon modi-
! cation of the N-terminal FHA domain of NBS1, suggesting that 
the NBS1 FHA domain may be participating in the interaction be-
tween the two factors ( Lukas et al., 2004 ). Second, MDC1 directly 
and speci! cally interacts with the phosphorylated H2AX C ter-
minus through its tandem BRCT domains ( Stucki et al., 2005 ). 
The x-ray structure of the MDC1 – ! -H2AX complex suggests that 
the MDC1 BRCT domains are uniquely tailored to interact with the 
 ! -H2AX chromatin mark ( Stucki et al., 2005 ). Third, a phospho-
peptide derived from the H2AX C terminus interacted with the 
MRN complex only in the presence of MDC1 ( Lukas et al., 2004 ). 
Fourth, experimental disruption of the interaction between MDC1 
and  ! -H2AX ( Stucki et al., 2005 ) or loss of MDC1 expression by 
genetic manipulation and/or siRNA-mediated depletion leads to a 
complete abrogation of MRN foci formation ( Goldberg et al., 
2003 ;  Stewart et al., 2003 ;  Lukas et al., 2004 ;  Lou et al., 2006 ). 
Finally, mutations in the N-terminal FHA/BRCT region of NBS1 
also interfere with MRN accumulation at sites of DSBs ( Kobayashi 
et al., 2002 ;  Zhao et al., 2002 ;  Cerosaletti and Concannon, 2003 ; 
 Lee et al., 2003 ;  Horejsi et al., 2004 ). 
 MDC1 is composed of several distinct sequence domains. 
Besides an FHA domain at its N terminus and the  ! -H2AX – inter-
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A single amino acid (typically Asp) sits in between the highly 
conserved Ser and Thr residues. Thus, we hereafter refer to this 
motif as the SDT motif. The motif also contains two to three con-
secutive acidic amino acids (usually Glu) that are ! ve residues 
C terminal to the initial Ser. Mammalian MDC1 contains a total 
of six SDT motifs (Fig. S1, available at http://www.jcb.org/cgi/
content/full/jcb.200709008/DC1): ! ve are located within the re-
gion of MDC1, whose deletion abrogates MRN foci ( Fig. 2 A ), 
and one is located  ! 80 amino acids N terminal to this region 
(not depicted). Zebra! sh MDC1 features a total of eight SDT 
motifs, and even honey bee MDC1 (the only clear nonvertebrate 
MDC1 orthologue identi! ed to date) comprises a very similar 
motif (Fig. S1), indicating that the SDT motif is conserved in all 
known MDC1 orthologues. 
 In untreated mammalian cells, MDC1 is a phosphoprotein 
that becomes rapidly hyperphosphorylated in response to DNA 
damage in a PIKK-dependent manner ( Goldberg et al., 2003 ; 
 Stewart et al., 2003 ). A large number of constitutive and DNA 
damage – induced phosphorylation sites have recently been iden-
ti! ed in MDC1 by means of several large-scale mass spectrom-
etry screens of the human and mouse proteome ( Beausoleil 
et al., 2004 ;  Olsen et al., 2006 ;  Matsuoka et al., 2007; Villen et al., 
2007 ). Interestingly, many of the constitutive phosphorylation 
sites of MDC1 are located within the SDT motifs ( Fig. 2 A ). 
In summary, it appears that in human cells, a population of MDC1 
molecules is phosphorylated on any Ser and Thr residue in at 
least four of the six SDT motifs in vivo ( Beausoleil et al., 2004 ; 
 Olsen et al., 2006 ). In addition, mouse MDC1 appears to be 
phosphorylated in at least one SDT motif ( Villen et al., 2007 ). 
the ability of MDC1 to mediate NBS1 foci formation ( Fig. 1 B , 
 " I1). Preliminary sequence analysis of this region revealed a 
signi! cant abundance of acidic amino acids as compared with 
other regions of MDC1 ( Fig. 2 A). 
 Interestingly, deletion of a region between amino acids 
51 and 107 of mouse MDC1 (containing the FHA domain) 
did not have any effect on NBS1 accumulation ( Fig. 1 ,  " I2) 
even though overexpression of the FHA domain was reported 
to trigger a dominant-negative effect on NBS1 foci forma-
tion ( Goldberg et al., 2003 ). In summary, these results sug-
gest that an acidic region near the N terminus of MDC1 
mediates MRN accumulation at sites of DSBs. 
 Phosphorylation-dependent interaction 
between the MDC1 N terminus and the 
MRN complex 
 To understand how the region identi! ed by the systematic dele-
tion analysis mediates MRN foci formation, we carefully ana-
lyzed the sequence between amino acids 295 and 452 of mouse 
MDC1. As mentioned in the previous section, this region of MDC1 
is highly acidic with a calculated isoelectric point of 4.04. 
To detect conserved sequence motifs within this region, we com-
pared the mouse sequence to MDC1 sequences from other ver-
tebrate species (including human, dog, swine, and zebra! sh). 
This analysis revealed several conserved patches of 8 – 10 amino 
acids interspersed with less conserved regions of variable length 
( Fig. 2 A ; patches are highlighted by horizontal bars). The con-
served patches feature a repeated sequence motif: Ser and 
Thr residues are embedded in an acidic sequence environment. 
 Figure 1.  An acidic domain near the N terminus of MDC1 is essential for NBS1 foci formation.  (A) Schematic representation of HA-tagged full-length mouse MDC1 
and various deletion mutants. (B) MDC1  – / –  MEFs were transiently transfected with wild-type (WT) MDC1 and the individual deletion constructs. 48 h later, cells were 
irradiated, fi xed with methanol, and stained with antibodies specifi c for HA and mouse NBS1. Nuclear foci were assessed by confocal microscopy. Bar, 10  µ m. 
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 Figure 2.  Phosphorylation-dependent interaction between the MDC1 N terminus and the MRN complex. (A) Sequence alignment of the region in MDC1 
that is essential for MRN foci. The conserved acidic motifs are highlighted by horizontal bars. Phosphorylated residues identifi ed by in vivo phosphorylation 
site mapping are highlighted by arrowheads ( Beausoleil et al., 2004 ;  Olsen et al., 2006 ;  Villen et al., 2007 ). (B, top) Representation of human MDC1 and 
the overlapping GST fragments. (bottom) Two fragments at the N terminus of MDC1 are phosphorylated by CK2 in vitro. Purifi ed GST-MDC1 fragments 
were incubated with purifi ed recombinant CK2 in the presence of radioactive ATP. Proteins were separated by SDS-PAGE, and dried gels were subjected to 
autoradiography. A Coomassie blue – stained gel of the purifi ed GST fragments is shown on top of the autoradiograph. Note that fragment M-6 (PST repeat 
region) was not expressed in bacteria. (C) Purifi ed GST-MDC1 fragments (M-1 – 5) were preincubated with and without recombinant CK2 in the presence of 
ATP. (D) Purifi ed GST-MDC1 fragment M-3 was preincubated with CK2 either in the presence or absence of the CK2 inhibitor TBB. (C and D) The fragments 
were then used to pull down proteins from HeLa nuclear extract. Bound proteins were separated on SDS-polyacrylamide gels followed by immunoblotting. 
The blots were probed with antibodies against RAD50, NBS1, and MRE11. 
 on April 28, 2008 
www.jcb.org
Downloaded from
 
231 MECHANISM OF MRN ACCUMULATION IN DAMAGED CHROMATIN  • SPYCHER ET AL.
 The acidic nature of the SDT motif suggests that it may be 
targeted by acidophilic kinases such as CK1 and 2. Indeed, ana ly -
sis of the MDC1 SDT domain by Scansite ( Yaffe et al., 2001 ) 
revealed that the sequence encompassing the Ser and Thr 
residues within the SDT motifs conform to consensus CK2 
phosphorylation sites. To test whether CK2 would speci! cally 
phosphorylate MDC1 in the SDT region, we generated eight 
overlapping random fragments of the human MDC1 cDNA and 
expressed them in  Escherichia coli as GST fusion proteins. Seven 
fragments were expressed well and were puri! ed ( Fig. 2 B , top), 
whereas one fragment (M-6) comprising the MDC1 PST repeat 
region was not expressed in bacteria. The puri! ed fragments 
were subjected to an in vitro kinase assay using recombinant CK2. 
CK2 ef! ciently phosphorylated fragment M-2 (amino acids 
109 – 330) and M-3 (amino acids 301 – 560) but none of the other 
! ve fragments. Fragment M-2 contains two SDT motifs, and 
fragment M-3 contains the other four SDT motifs. 
 MDC1 exists in a complex with MRN in extracts derived 
from undamaged cells, indicating that these proteins interact con-
stitutively (Fig. S2, available at http://www.jcb.org/cgi/content/
full/jcb.200709008/DC1). However, the mechanism of this 
 interaction has not yet been elucidated. Signi! cantly, GST pull-
down analysis with our GST-MDC1 fragments revealed that 
fragment M-2 and M-3 only pulled down signi! cant quantities 
of the MRN complex from HeLa nuclear extract when pre-
incubated with recombinant CK2 and ATP ( Fig. 2 C , compare lanes 
 Figure 3.  Direct interaction between the 
phosphorylated MDC1 N terminus and the 
MRN complex is mediated by the NBS1 FHA 
domain. (A) MRN proteins were purifi ed as 
described in Materials and methods. Proteins 
were separated on SDS-polyacrylamide gels 
and stained with silver. MR, MRE11 – RAD50 sub-
complex; N, partially purifi ed NBS1. (B and C) 
Purifi ed GST-MDC1 fragment M-3 comprising 
part of the SDT region was preincubated with 
CK2 and ATP. The fragment was incubated 
with purifi ed MRN complex (B), purifi ed MR 
subcomplex (C, top), and partially purifi ed 
NBS1 (C, bottom) followed by GST pull-down 
analysis. Bound proteins were separated on 
SDS-polyacrylamide gels followed by immuno-
blotting. The blots were probed with antibodies 
against RAD50, NBS1, and MRE11. (D, top) 
Schematic representation of NBS1 with its func-
tional domains. (bottom) Purifi ed GST-MDC1 
fragment M-3 was preincubated with CK2 and 
ATP. The fragment was incubated with purifi ed 
MRN complex where the NBS1 subunit was 
either wild type or contained a point mutation 
in the FHA domain (R28A). Bound proteins were 
separated on SDS-polyacrylamide gels followed 
by immunoblotting. The blots were probed with 
a polyclonal antibody against NBS1. 
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 Figure 4.  A repeated phosphorylated motif in MDC1 mediates the interaction between MDC1 and NBS1.  (A) In vitro mapping of the CK2 phosphorylation 
sites in MDC1. (top) Sequence of the human MDC1 fragment comprising the conserved CK2 consensus sites (highlighted in black). The CK2 consensus sites 
are numbered from 1 to 10. (bottom) All of the putative CK2 phosphoacceptor Ser and Thr residues in the above MDC1 fragment (amino acids 141 – 621) 
were mutated to Ala, and the mutants were expressed as GST fusion proteins in  E. coli . The GST fragments were incubated with purifi ed recombinant 
CK2 in the presence of radioactive ATP. Proteins were separated by SDS-PAGE, and dried gels were subjected to autoradiography. A, autoradiograph; 
C, Coomassie blue – stained gel. (B) The SDT repeats are essential for the interaction between MDC1 and NBS1 in vitro. Several SDT motifs in a frag-
ment derived from mouse MDC1 (amino acids 221 – 456) were mutated to SDA (3T > A: T362A, T387A, and T444A; 4T > A: T315A, T362A, T387A, 
and T444A; 5T > A: T300A, T315A, T362A, T387A, and T444A; 6T > A: T222A, T300A, T315A, T362A, T387A, and T444A) and were expressed as 
GST fusion proteins in  E. coli . The purifi ed fragments were preincubated with recombinant CK2 in the presence of ATP. The fragments were then used to 
pull down proteins from HeLa nuclear extract. Bound proteins were separated on SDS-polyacrylamide gels followed by immunoblotting. The blots were 
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with the phosphorylated M-3 fragment of MDC1 and mediates 
the interaction between MDC1 and the MRN complex. 
 NBS1 features two well-established phosphopeptide rec-
ognition modules at its N terminus: an FHA domain and a tan-
dem BRCT domain ( Fig. 3 D , top). It was previously shown that 
introduction of a point mutation in the FHA domain that changes 
a conserved Arg residue to Ala (R28A) disrupted the interaction 
between MDC1 and the MRN complex in vitro ( Lukas et al., 
2004 ) and abolished MRN accumulation at sites of DSBs in vivo 
( Cerosaletti and Concannon, 2003 ;  Lee et al., 2003 ;  Horejsi 
et al., 2004 ;  Lukas et al., 2004 ). Thus, we isolated the MRN 
complex harboring the same mutation in NBS1 from baculovirus-
infected Sf9 cells and compared its binding activity toward the 
phosphorylated M-3 fragment to the wild-type complex. Signi! -
cantly, although the wild-type NBS1 readily interacted with 
phosphorylated M-3, no interaction was detected with the R28A 
mutant ( Fig. 3 D ). This indicates that an intact NBS1 FHA do-
main is essential for the interaction between the phosphorylated 
N-terminal region of MDC1 and the MRN complex. 
 A repeated phosphorylated motif in MDC1 
mediates the interaction between MDC1 
and NBS1 
 To map the phosphorylation sites within fragments M-2 and M-3 
of MDC1, we isolated a new GST fragment comprising amino 
acids 141 – 621 of human MDC1 (M-SDT). The puri! ed frag-
ment was phosphorylated in vitro by recombinant CK2 followed 
by digestion with trypsin. The tryptic peptides were then ana-
lyzed by mass spectrometry. Thus, several phosphorylation sites 
were mapped ( Table I ), most notably all six of the conserved 
SDT motifs that were targeted by CK2 on both Ser and Thr resi-
dues. Next, all of the putative CK2 target Ser and Thr residues in 
the M-SDT fragment were mutated to Ala and expressed in  E. 
coli ( Fig. 4 A , top; the SDT motifs and other putative CK2 target 
sites are highlighted in black and numbered from 1 – 10). The pu-
ri! ed mutants were subjected to in vitro phosphorylation by re-
3 and 4 with lanes 8 and 9; note that the bands in lanes 5 and 10 
in the top panel result from a cross-reactivity of the RAD50 an-
tibody with a contaminating bacterial protein in the GST – M-4 
fraction). In the absence of CK2, no interaction could be ob-
served under these conditions ( Fig. 2 C , lanes 2 – 6). In the pres-
ence of the speci! c CK2 inhibitor tetrabromo-2-azabenzimidazole 
(TBB), recombinant CK2 did not transform fragment M-3 into 
a form capable of pulling down the MRN complex from HeLa 
nuclear extract, indicating that CK2 activity is required for this 
process ( Fig. 2 D ). Together, these data suggest that the phos-
phorylated N-terminal region in MDC1 mediates the interaction 
with the MRN complex in vitro. 
 Direct interaction between the 
phosphorylated MDC1 N terminus and 
the MRN complex is mediated by the 
NBS1 FHA domain 
 To determine whether the MRN complex interacts directly with 
the phosphorylated MDC1 N terminus, we coexpressed all three 
MRN subunits and a subcomplex consisting of MRE11 and 
RAD50 (MR) in Sf9 cells by means of recombinant baculovirus 
infection followed by puri! cation of the recombinant proteins to 
near homogeneity ( Fig. 3 A , MRN and MR). We also isolated 
partially puri! ed NBS1 alone ( Fig. 3 A , N). Interaction studies 
with puri! ed recombinant MRN, MR, and NBS1 were compli-
cated by the fact that these proteins exhibited a signi! cant un-
speci! c binding activity toward the glutathione – Sepharose beads 
used in this analysis ( Fig. 3 B , beads alone). Nevertheless, we 
consistently observed a signi! cant enrichment of puri! ed MRN 
and partially puri! ed NBS1 when we used CK2-phosphorylated 
fragment M-3 in the pull-down assay ( Fig. 3, B and C ; bottom). 
Untreated M-3 or GST alone did not result in such enrichment. 
Similarly, neither phosphorylated nor unphosphorylated M-3 
was capable of ef! ciently binding to MRE11/RAD50 in the ab-
sence of NBS1 ( Fig. 3 C , top). In summary, these results indicate 
that the NBS1 subunit of the MRN complex directly associates 
probed with antibodies against RAD50, NBS1, and MRE11. (C) Mutation of a subset of the conserved SDT motifs abrogates NBS1 foci formation. (top) 
MDC1  – / –  MEFs were transiently transfected with various forms of HA-tagged full-length mouse MDC1, including wild-type (WT) and SDT-defi cient (3T > A: 
T362A, T387A, and T444A; 4T > A: T315A, T362A, T387A, and T444A; 5T > A: T300A, T315A, T362A, T387A, and T444A) variants. 48 h later, cells 
were irradiated, fi xed with methanol, and stained with antibodies against HA and mouse NBS1. (bottom) HA-positive cells were scored for NBS1 foci in 
wild-type and 5T > A-transfected populations (results were consistent in two independent datasets). (D) The SDT in MDC1 is phosphorylated in vivo. (top) A 
phosphospecifi c antibody raised against a doubly phosphorylated SDT peptide (pSDpT) was tested on CK2-phosphorylated GST-SDT. WT, mouse MDC1 
(amino acids 221 – 456); 6T > A, all six SDT motifs were mutated to SDA. (bottom) Immunoblot analysis of phosphorylated MDC1 isolated from HeLa nuclear 
extract by a H2AX phosphopeptide using the pSDpT phosphospecifi c antibody. (E) A synthetic biotinylated peptide comprised of the SDT sequence motif 
and phosphorylated on the Thr residue was either left untreated or was preincubated with  # $ PPase and CK2, respectively. (top) This leads to the three 
indicated products: unphosphorylated peptide, singly phosphorylated peptide (Thr), and doubly phosphorylated peptide (Ser and Thr). The peptides were 
then used to pull down proteins from HeLa nuclear extract. Proteins were detected as in B. Bar, 10  µ m. 
 
 Table I.  Tryptic MDC1 phosphopeptides 
 MDC1 tryptic peptide  CK2 phosphorylation site 
162-LLLAEDpSEEEVDFLSER-179 pS168
186-TTSSSVIVPESDEEGHSPVLGGLGPPFAFNLN(pSDpT)DVEEGQQPATEEASSAAR-238 +2PO 4 
247-QSEAEVVTEIQLEKDQPLVK-266 NA
292-SQPPGEDpSDpTDVDDDSRPPGRPAEVHLERAQPFGFIDpSDpTDAEEERIPATPVVIPMK-348 pS299, pT301, pS329, pT331
361-PGAPGLAHLQESQAGpSDpTDVEEGKAPQAVPLEKSQASMVINpSDpTDDEEEVSAALTLAHLK-420 pS376, pT378, pS402, pT404
445-SQTTTERDpSDpTDVEEEELPVENR-467 pS453, pT455
NA, not applicable.
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 Figure 5.  CK2 is essential for the interaction between MDC1 and NBS1 and for the accumulation of NBS1 at sites of DSBs in vivo.  (A) Down-regulation of 
CK2 % and CK2 % & by siRNA triggers a prolonged DDR. 72 h after transfection with siRNA duplexes, cells were irradiated and harvested at the indicated 
time points. Extracts were prepared and resolved by SDS-PAGE followed by immunoblotting. The blots were probed with the indicated antibodies. 
(B) Down-regulation of CK2 % and CK2 % & by siRNA abrogates NBS1 accumulation at sites of DSBs. 72 h after transfection with siRNA duplexes, cells were 
irradiated, fi xed with methanol, and stained with antibodies against  ! -H2AX and NBS1. (C) Down-regulation of CK2 % by siRNA disrupts the interaction 
between MDC1 and NBS1 in vivo. 72 h after transfection with siRNA duplexes, cells were lysed, and immunoprecipitation was performed using the 
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combinant CK2, and radioactive phosphate incorporation was 
measured by autoradiography ( Fig. 4 A ). This analysis revealed 
that all of the SDT motifs and other putative CK2 target sites 
were ef! ciently phosphorylated in vitro . 
 To test whether the highly conserved SDT repeats were 
necessary for the interaction with the MRN complex, we changed 
the conserved Thr residues to Ala within several SDT motifs 
and phosphorylated the isolated GST fusion proteins by CK2 in 
vitro. Signi! cantly, GST pull-down analysis with the mutant 
fragments revealed that only the phosphorylated wild type was 
capable of pulling down signi! cant quantities of the MRN com-
plex from HeLa nuclear extract, whereas alteration of the three 
C-terminal SDT motifs ( Fig. 4 A,  4 – 6) already reduced the inter-
action to almost background level ( Fig. 4 B ). 
 To test whether the SDT repeats of MDC1 mediate NBS1 
accumulation at sites of DSBs in vivo, we introduced the same 
SDT mutations as before ( Fig. 4 B ) in the tagged full-length mouse 
MDC1 cDNA followed by transient transfection of MDC1  – / –  MEFs 
with those mutants and assessment of MDC1 and NBS1 foci 
formation by indirect immuno" uorescence. Surprisingly, alter ation 
of the last three C-terminal SDT motifs ( Fig. 4 A , 4 – 6) did not 
trigger any signi! cant reduction in NBS1 foci formation ( Fig. 4 C , 
3T > A) even though the corresponding GST fusion protein only 
weakly interacted with the MRN complex in vitro ( Fig. 4 B , 
3T > A). However, mutation of four SDT motifs ( Fig. 4 A, 3 – 6) led 
to a detectable reduction in NBS1 accumulation even though small 
NBS1 foci were still detectable in a subset of the transfected cells 
( Fig. 4 C, 4T > A). Altering ! ve of the six SDT motifs ( Fig. 4 A, 
2 – 6) completely abrogated NBS1 foci formation in all MDC1-
positive cells ( Fig. 4 C,  5T > A). Signi! cantly, although the 5T > A 
mutant was unable to mediate NBS1 focal accumulation in re-
sponse to IR, it still localizes to foci itself, indicating that an intact 
SDT region is not required for MDC1 – ! -H2AX interaction. 
 Collectively, these results show that the SDT motifs are es-
sential for the interaction between MDC1 and the MRN com-
plex in vitro and for NBS1 accumulation at sites of DSBs in 
vivo, suggesting that the SDT motif may de! ne a novel phospho-
speci! c MRN-interacting element within MDC1. To test this di-
rectly, we ! rst sought to ascertain that the SDT motifs of MDC1 
are constitutively phosphorylated in vivo. To this end, we gener-
ated two phosphospeci! c antibodies against doubly phosphory-
lated SDT peptides (pSDpTs) derived from the human SDT 
repeat region (see Materials and methods for details). These 
antibodies were af! nity puri! ed and tested against the puri! ed 
CK2-phosphorylated GST-SDT fragment and its 6T > A mutated 
derivative. Although one of the two antibodies did not recognize 
the CK2-phosphorylated GST-SDT fragment (not depicted), the 
other antibody speci! cally recognized GST-SDT only when it 
was preincubated with CK2 and ATP ( Fig. 4 D , top). Signi! -
cantly, the 6T > A mutant was not recognized at all by this anti-
body, indicating that it is speci! c for doubly phosphorylated 
SDT repeats. We next used this antibody to detect MDC1 in extracts 
from undamaged and irradiated mammalian cells. Unfortunately, 
the pSDpT antibody unspeci! cally cross-reacted with many pro-
teins in whole cell and nuclear extracts, and, thus, we were un-
able to assess the MDC1 phosphorylation status in crude cell 
extracts ( Fig. 4 D , bottom; ! rst lane). However, MDC1 can be 
isolated along with the MRN complex from HeLa nuclear ex-
tract to near homogeneity by a phosphopeptide pull-down strat-
egy using a phosphopeptide derived from the H2AX C terminus 
(Fig. S2;  Stucki et al., 2005 ). When we probed the isolated 
MDC1 – MRN complex with the pSDpT antibody, we observed 
two bands at the position where MDC1 runs on SDS gels, indi-
cating that it is indeed phosphorylated on at least a subset of the 
SDT motifs in vivo ( Fig. 4 D , bottom; second lane). 
 To clarify whether the MRN complex interacts with a sin-
gle doubly phosphorylated SDT motif, we designed a biotinyl-
ated synthetic phosphopeptide comprising the sequence of one 
of the SDT motifs ( Fig. 4 A , 3), which was phosphorylated on 
the Thr residue. This peptide was either left untreated or was 
treated with  # phosphatase and CK2. Mass spectrometry and in 
vitro CK2 assays revealed that such treatment resulted in singly 
phosphorylated SDpT peptide, unphosphorylated SDT peptide, 
and doubly phosphorylated pSDpT peptide ( Fig. 4 E , top; and 
not depicted). Signi! cantly, only the doubly phosphorylated 
peptide, in which both Ser and Thr residues are being phosphor-
ylated, retrieved the MRN complex from HeLa nuclear extract 
( Fig. 4 E ). Collectively, these results suggest that doubly phos-
phorylated SDT motifs interact with MRN and determine MRN 
accumulation in vivo. 
 CK2 is essential for the interaction 
between MDC1 and NBS1 and for the 
accumulation of NBS1 at sites of DSBs 
in vivo 
 Because the SDT repeats are ef! ciently targeted by CK2 in vitro 
( Fig. 4 ), we next sought to investigate whether CK2 activity 
was required for NBS1 accumulation at sites of DSBs in vivo. 
Several commercial small-molecule CK2 inhibitors are available, 
and two of them were tested on human and mouse cells (TBB 
and DMAT). Surprisingly, neither of the two inhibitors triggered 
a detectable reduction in NBS1 foci formation in cultured hu-
man and mouse cells (unpublished data). Thus, we speculated 
that there may either exist additional acidophilic kinases that are 
capable of ef! ciently phosphorylating the SDT repeats in MDC1 
or that the inhibitors are not potent enough to completely elimi-
nate SDT phosphorylation in our experimental settings. 
 To test the latter possibility, we took an siRNA approach 
to down-regulate the two catalytic subunits of CK2 (CK2 % and 
CK2 % & ) in U2OS cells. 72 h after siRNA transfection, CK2 % 
and CK2 % & expression reached background levels ( Fig. 5 A ). 
At the same time, we observed massive cell death and severe 
mitotic defects, corroborating the essential role of CK2 in 
the cellular metabolism and life cycle. Interestingly, we also 
indicated antibodies. Proteins were separated by SDS-PAGE followed by immunoblotting. The blots were probed with antibodies against MDC1, NBS1, 
and CK2 % . Black lines indicate that intervening lanes have been spliced out. (D) MDC1 is associated with CK2 in vivo. HeLa cell extracts were used to 
immunoprecipitate proteins with the indicated antibodies. The immunocomplexes were separated by SDS-PAGE followed by immunoblotting. The blot was 
probed with antibodies against CK2 % and CK2 % & . Bar, 10  µ m. 
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 Figure 6.  Disruption of the MDC1 – NBS1 interaction triggers a partial 
G2/M checkpoint defect.  (A) NBS-iLB1 fi broblasts and NBS-iLB1 fi broblasts 
stably transduced with wild-type NBS1 and R28A mutant NBS1 were ir-
radiated, fi xed with methanol, and stained with antibodies against MDC1 
and NBS1. (B) Whole cell extracts of NBS-iLB1 fi broblasts and NBS-iLB1 
fi broblasts stably transduced with wild-type (WT) NBS1 and R28A mutant 
NBS1 were resolved by SDS-PAGE followed by immunoblotting. The blot 
was probed with antibodies against NBS1 and tubulin. (C) NBS-iLB1 fi -
broblasts and NBS-iLB1 fi broblasts stably transduced with wild-type NBS1 
and R28A mutant NBS1 were left untreated or irradiated with 1 Gy and 
3 Gy, respectively. Cells were harvested 1 h after irradiation, fi xed with 
methanol, and stained with an antibody against phosphorylated H3 
(P-H3) and propidium iodine. The percentage of phosphorylated H3 –
 positive cells was determined by FACS analysis. Error bars represent SD. 
Bar, 10  µ m. 
 observed a prolonged phosphorylation of ATM substrates in re-
sponse to IR ( Fig. 5 A ), suggesting that down-regulation of CK2 
by siRNA may cause a repair defect. 
 Signi! cantly, down-regulation of either CK2 % or CK2 % & 
led to a marked defect in NBS1 foci formation in response to 
IR ( Fig. 5 B , left). At the same time, MDC1 accumulation at 
sites of DSBs was not signi! cantly reduced ( Fig. 5 B , right) even 
though the foci appeared smaller as compared with the foci in 
control siRNA-treated cells. This indicates that CK2 is essential 
for the accumulation of NBS1 at sites of DSBs, whereas it is 
dispensable for the interaction between MDC1 and  ! -H2AX. 
 Next, we tested whether CK2 was required for the consti-
tutive interaction between MDC1 and NBS1. To this end, MDC1 
antibodies were used to coimmunoprecipitate NBS1 from ex-
tracts derived from siRNA-treated human cells. No NBS1 co-
immunoprecipitated with MDC1 from cells that were transfected 
with CK2 % siRNA, whereas a small but signi! cant amount of 
NBS1 coimmunoprecipitated with MDC1 from cell extracts that 
were prepared from control siRNA-transfected cells ( Fig. 5 C ). 
The membrane was also probed with an antibody against CK2 % 
to monitor the ef! ciency of CK2 % depletion ( Fig. 5 C , bottom; 
note that CK2 % corresponds to the faster migrating band). Inter-
estingly, we noticed that CK2 % also coimmunoprecipitated with 
MDC1 ( Fig. 5 C , bottom; third and ! fth lanes), indicating that 
CK2 may exist in a complex with MDC1 in vivo. Indeed, anti-
bodies raised against MDC1 ef! ciently coimmunoprecipitated 
both CK2 % and CK2 % & from HeLa cell extracts ( Fig. 5 D ). 
Notably, the interaction does not change upon the introduction of 
DNA damage by IR ( Fig. 5 D , compare the last two lanes), indi-
cating that it is constitutive and not induced by DNA damage. 
 Collectively, these data reveal that CK2 is essential for NBS1 
foci formation and for the interaction between MDC1 and NBS1. 
In addition, CK2 exists in a complex with MDC1 and, thus, may 
be the primary kinase to target the SDT repeats in vivo. 
 Disruption of the MDC1 – NBS1 interaction 
triggers a partial G2/M checkpoint defect 
 As shown in Fig. 3 D, the R28A mutation in the NBS1 FHA do-
main triggers a severe defect in the association of NBS1 with 
the CK2-phosphorylated MDC1 SDT region in vitro ( Fig. 3 D ). 
Consistent with previous studies ( Cerosaletti and Concannon, 
2003 ;  Lee et al., 2003 ;  Horejsi et al., 2004 ), we also observed 
that this mutant is unable to accumulate in foci in stably trans-
duced NBS ! broblasts, whereas MDC1 accumulation is not af-
fected ( Fig. 6 A ). It was previously shown that the R28A mutant 
was not capable of rescuing the radiation sensitivity phenotype 
of NBS cells, whereas it did fully rescue the intra – S-phase 
checkpoint defect, at least at higher doses of irradiation ( Lee 
et al., 2003 ). In contrast, primary B cells derived from a human-
ized mouse model in which another key amino acid at the phos-
phopeptide recognition interface of the NBS1 FHA domain had 
been mutated to Ala (H45A) showed partial G2/M and intra – S-
phase checkpoint defects speci! cally at lower doses of irradiation 
( Di! lippantonio et al., 2007 ). To test whether the R28A muta-
tion causes a similar checkpoint defect, we measured alterations 
in the mitotic index in response to low (sublethal) doses of ir-
radiation (1 – 3 Gy) in NBS ! broblasts stably transduced with 
full-length wild-type and R28A NBS1. Consistent with previous 
! ndings ( Falck et al., 2005 ), NBS-iLB1 ! broblasts displayed 
a clear G2/M checkpoint defect in this dose range ( Fig. 6 C ). 
Stable transduction with wild-type NBS1 fully rescued the G2/M 
checkpoint arrest in response to 1 – 3 Gy of IR. However, stable 
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 Figure 7.  Model of the mechanism of the MDC1 – MRN interaction before 
and after DNA damage. See Discussion for details. 
transduction with R28A mutant NBS1 only partially restored the 
G2/M checkpoint, which is similar to the situation in the mouse 
B cells expressing the H45A mutant ( Fig. 6 C ;  Di! lippantonio 
et al., 2007 ). Notably, this checkpoint defect was not caused by 
lower expression levels of the mutant transgene as compared 
with the wild type ( Fig. 6 B ). Collectively, these results suggest 
that the constitutive CK2-dependent association of the MRN 
complex with MDC1 plays an important role in eliciting a full 
cell cycle checkpoint arrest. 
 Discussion 
 Previously, we and others have shown that MDC1 mediates accu-
mulation of the MRN complex at sites of DSBs ( Goldberg et al., 
2003 ;  Stewart et al., 2003 ;  Lukas et al., 2004 ;  Stucki et al., 2005 ). 
We also presented evidence that MDC1 exists in a complex with 
MRN in extracts from undamaged cells and that an intact NBS1 
FHA domain is essential for the stability of this interaction and 
for ef! cient retention of the MRN complex in  ! -H2AX – containing 
damaged chromatin regions ( Goldberg et al., 2003 ;  Lukas et al., 
2004 ;  Stucki et al., 2005 ). However, the precise mechanism by 
which MDC1 regulates the MRN complex remained unknown. 
 In this study, we identify a region in MDC1 that is essential 
for ef! cient accumulation of the MRN complex at sites of DSBs. 
This region of MDC1 features a repeated acidic sequence motif 
(the SDT motif), and our data, in combination with the accom-
panying study by Melander et al. (see p.  213 of this issue) and 
several recently published large-scale phosphorylation site screens 
of the human and mouse proteome ( Beausoleil et al., 2004 ; 
 Olsen et al., 2006 ;  Villen et al., 2007 ), suggest that at least a sub-
set of the SDT motifs in MDC1 are constitutively phosphory-
lated by the acidophilic kinase CK2 on highly conserved Ser and 
Thr residues. Furthermore, we present unexpected evidence that 
the doubly phosphorylated SDT motifs regulate accumulation 
and retention of the MRN complex in the DSB-" anking chroma-
tin compartment via a mechanism that involves direct interaction 
with the NBS1 N-terminal FHA domain. Finally, we show that 
CK2 is essential for NBS1 accumulation in damaged chromatin 
and that depletion of CK2 disrupts the MDC1 – MRN complex in 
vivo. Thus, our data successfully integrate and explain two 
observations whose interrelation has previously not been appre-
ciated: ! rst, we provide a mechanistic explanation as to why 
MDC1 and the MRN complex exist in a complex even before 
DNA damage; and second, our ! ndings also put into perspective 
the previous observation that an intact FHA domain of NBS1 is 
critical for ef! cient accumulation of the MRN complex at sites 
of DSBs ( Kobayashi et al., 2002 ;  Zhao et al., 2002 ;  Cerosaletti 
and Concannon, 2003 ;  Lee et al., 2003 ;  Horejsi et al., 2004 ; 
 Lukas et al., 2004 ) and for an intact DDR in living organisms 
( Di! lippantonio et al., 2005, 2007 ). 
 However, it is essential to appreciate that not all MRN 
functions seem to require MDC1. For instance, DNA end pro-
cessing activities of MRN do not appear to be dependent on 
MDC1 ( Jazayeri et al., 2006 ). Furthermore, there are no indica-
tions that MRN ’ s role in mediating ATM activation would re-
quire MDC1 ( Lee and Paull, 2005 ). Finally, MRN seems to 
occupy two distinct compartments at sites of DSBs: it accumu-
lates on single-stranded DNA regions generated by enzymatic 
resection of DSBs ( Jazayeri et al., 2006 ) as well as in large chro-
matin domains " anking DSBs that often span several thousand 
base pairs ( Bekker-Jensen et al., 2006 ). Although the accumula-
tion of MRN on single-stranded DNA does not require MDC1 
( Bekker-Jensen et al., 2006 ), accumulation and retention of MRN 
in  ! -H2AX – containing chromatin are critically dependent on 
MDC1 ( Goldberg et al., 2003 ;  Stewart et al., 2003 ;  Lukas et al., 
2004 ;  Stucki et al., 2005 ) and on CK2-dependent phosphorylation 
of its SDT repeats ( Melander et al., 2008 ; this study). 
 Based on these novel ! ndings and on previously published 
observations, we propose the following model of the events that 
occur before and after a cell has suffered genotoxic stress that 
generates DSBs ( Fig. 7 ): in the absence of DNA damage, MDC1 
is phosphorylated on multiple sites by CK2 and perhaps other 
constitutively active kinases. The MRN complex associates with 
MDC1 through direct interaction between the N-terminal FHA 
domain of the NBS1 subunit and the CK2-phosphorylated SDT 
repeat region of MDC1. Upon induction of DSBs in the genome, 
a fraction of MRN (that is probably not associated with MDC1) 
is rapidly deployed to the free DNA ends. Once bound to the 
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 ! -H2AX – containing damaged chromatin regions, an important 
step in the hierarchy of events that lead to the formation of nu-
clear foci at sites of DSBs has been resolved. Although we do 
not yet understand the function of MRN in the DSB-" anking 
chromatin compartment, one intriguing possibility is that MDC1-
bound MRN may act as a mediator of downstream phosphory-
lation events of the DDR. In this case, the MDC1 – MRN complex 
may enhance the DSB-induced signal by means of a positive 
feedback loop: MDC1 – MRN accumulates as the  ! -H2AX mark 
spreads into more distal chromatin regions, thus helping to trig-
ger a global DDR even in the presence of very low numbers of 
DSBs. Consistent with such a scenario is the observation that 
cells expressing NBS1 with a mutated FHA domain display 
a partial G2/M checkpoint defect at low doses of irradiation 
( Di! lippantonio et al., 2007; this study), whereas the check-
point seems to be normal at higher doses ( Di! lippantonio et al., 
2007 ). This suggests that the prevalent role of the MDC1 – MRN 
complex in checkpoint activation may not constitute the initia-
tion of the signal but rather its ampli! cation. The discovery of 
the SDT region of MDC1 and its speci! c role in MRN localiza-
tion in response to DNA damage will greatly facilitate the in-
vestigation of functional aspects of MRN in the DSB-" anking 
chromatin compartment. 
 Materials and methods 
 Cell culture and gene transfer 
 MDC1  – / –  and MDC1 +/+ MEFs were gifts from J. Chen (Yale University, 
New Haven, CT). NBS-iLB1 cells stably transduced with wild-type NBS1 
and R28A mutant NBS1 were gifts from S. Jackson (University of Cam-
bridge, Cambridge, UK) and K. Cerosaletti (University of Washington, Se-
attle, WA), respectively. MEFs, HeLa, U2OS, and NBS-iLB1 cells were 
cultured in DME (Invitrogen) supplemented with 10% FCS. Transfection of 
plasmids was performed using either Lipofectamine 2000 (Invitrogen) or 
calcium phosphate. Sf9 cells were cultured in Grace ’ s insect medium (Invit-
rogen) supplemented with 10% FCS. Recombinant MRE11, RAD50, and 
NBS1 baculoviruses were gifts from V. Bohr (National Institute on Aging, 
Baltimore, MD). The Bac-To-Bac Baculovirus Expression System (Invitrogen) 
was used to generate and amplify recombinant baculoviruses. All steps 
were performed according to the manufacturer ’ s protocols. CK2 inhibitors 
TBB and DMAT were purchased from EMD. Irradiation of MEFs was per-
formed in an x-ray cabinet (Faxitron) at 5 – 10 Gy/min. 
 Plasmids 
 The full-length mouse MDC1 cDNA was a gift from A. Nussenzweig 
(National Institutes of Health, Bethesda, MD) and was HA tagged at the 
C terminus by PCR and cloned into pcDNA3.1(+) mammalian expression 
vector (Invitrogen). Human MDC1-GST constructs were generated by PCR 
amplifi cation of the human MDC1 cDNA followed by cloning into pGEX4T3 
bacterial expression vector (GE Healthcare). Myc-NBS1 ( Falck et al., 2005 ) 
was subcloned into pFastBac transfer vector (Invitrogen) to generate recom-
binant NBS1 baculoviruses. Deletion mutants were generated by a stan-
dard PCR-based method, and point mutations were introduced using the 
QuikChange Site-Directed Mutagenesis kit (Stratagene). 
 siRNA and transfections 
 The siRNA duplexes were 21 bp with a two-base deoxynucleotide over-
hang (Dharmacon Research). The sequences of the CK2 % and CK2 % & 
siRNA oligonucleotides used were GAUGACUACCAGCUGGUUCdTdT 
and CAGUCUGAGGAGCCGCGAGdTdT, respectively. The control siRNA 
used was CGUACGCGGAAUACUUCGAdTdT. Cells were transfected 
with siRNA duplexes by using Oligofectamine (Invitrogen) according to 
the manufacturer ’ s instructions. Cells were routinely harvested 72 h after 
siRNA transfection. 
 Cell extraction and protein purifi cation 
 HeLa nuclear extract was purchased from Cilbiotech. Cell extraction for 
immunoblot analysis was described previously ( Stewart et al., 2003 ). 
DNA, MRN participates in a multitude of events that include 
DNA end processing and tethering of DNA molecules that may 
facilitate accurate repair as well as activation of the ATM signal-
ing cascade (for review see  Williams et al., 2007 ). Although the 
precise mechanisms of these processes are still not understood 
in detail, there is no experimental indication that the MRN com-
plex would require MDC1 for these functions. However, in a 
second step, after the ATM signaling cascade has been initiated, 
the MDC1-bound fraction of MRN enters the stage; once acti-
vated, ATM phosphorylates a vast variety of targets. Among 
these targets are H2AX molecules in nucleosomes that are lo-
cated close to the break site. Phosphorylated H2AX is recog-
nized by MDC1 through its C-terminal BRCT domains ( Stucki 
et al., 2005 ). MDC1, along with the MDC1-bound fraction of 
MRN, forms a tight complex with phosphorylated H2AX, thus 
recruiting more MRN to the chromatin compartments " anking 
DSBs ( Stucki et al., 2005; Lou et al., 2006 ). This process is 
manifested by the formation of microscopically discernible nu-
clear foci containing both MDC1 and the MRN complex. 
 Although such a model of MDC1 – MRN interplay is in-
triguing, there are several outstanding issues that need to be dis-
cussed. It is clear that the interaction between MDC1 and the 
MRN complex is constitutive, but it is still dependent on the 
phosphorylation of MDC1 by CK2. A very similar mechanism 
has recently been described in two different aspects of the mam-
malian DDR, namely single-strand DNA break repair and DSB 
repair by nonhomologous end joining ( Koch et al., 2004 ;  Loizou 
et al., 2004 ). CK2 phosphorylates XRCC1, an adaptor protein 
that recruits several repair factors to single-stranded break sites 
( Loizou et al., 2004 ). In this case, the CK2 phosphorylation 
mark creates a binding site for the FHA domain – containing 
proteins polynucleotide kinase (PNK), aparataxin, and Xip1 
( Loizou et al., 2004 ;  Luo et al., 2004 ;  Bekker-Jensen et al., 
2007 ). In addition, PNK recruitment to sites of DSBs by XRCC4 
is also mediated by the CK2-dependent phosphorylation of 
XRCC4 ( Koch et al., 2004 ). Thus, the mechanisms of PNK, 
aparataxin, and Xip1 recruitment by XRCC1 and PNK recruit-
ment by XRCC4 closely resemble MRN chromatin retention by 
MDC1. However, although the recruitment of PNK by XRCC1 
was abolished by the CK2 inhibitor TBB ( Loizou et al., 2004 ), 
we were unable to abolish NBS1 recruitment to damaged chro-
matin by using the same inhibitor and other (even more potent) 
small-molecule CK2 inhibitors. One possible explanation for 
this discrepancy may lie in the existence of one or more CK2-
related acidophilic kinases that are capable of targeting the MDC1 
SDT repeats. However, the fact that down-regulation of CK2 
by siRNA completely abolishes NBS1 recruitment to damaged 
chromatin argues against this possibility but rather suggests 
that the CK2 inhibitors were not potent enough to reduce CK2 
activity suf! ciently to produce an effectual reduction in MDC1 
phosphorylation. Indeed, in vivo phosphorylation analysis of 
MDC1 by  Melander et al. (2008) reveals that treatment of cells 
with CK2 inhibitors maximally reduced SDT phosphorylation 
levels to 50%. This may not be enough for a visually discernible 
defect in NBS1 foci formation. 
 With the discovery of the mechanism by which MDC1 
mediates accumulation and retention of the MRN complex in 
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mass spectrometric phospho – amino acid analysis ( Jowsey et al., 2007 ). 
Mutation of putative CK2 phosphorylation sites in the GST-MDC1 fragment 
was performed using site-directed mutagenesis (Stratagene). 
 Checkpoint analysis 
 G2/M checkpoint analysis was performed as described previously ( Falck 
et al., 2005 ). In brief, cells were irradiated with the indicated doses during 
the exponential growth phase. 1 h later, cells were harvested, fi xed with 
70% ethanol/PBS, and incubated overnight at  $ 20 ° C. Fixed cells were 
washed with PBS and permeabilized with 0.25% Triton X-100/PBS on ice 
for 10 min. Cells were stained with an antiphosphohistone H3 antibody 
(Millipore) and propidium iodide. Data were acquired with a fl ow cytome-
ter (FC500; Becton Dickinson). 
 Phosphorylation site analysis by mass spectrometry 
 MDC1 samples that had been incubated with CK2 with or without ATP 
were subjected to electrophoresis on a 4 – 12% polyacrylamide gel that 
was stained with colloidal Coomassie blue. MDC1 bands were excised 
from the gel, washed with 0.1% NH 4 HCO 3 and 50% acetonitrile/50 mM 
NH 4 HCO 3 , reduced with 10 mM DTT in 0.1 M NH 4 HCO 3 for 45 min at 
65 ° C, and alkylated by the addition of 50 mM iodoacetamide for 30 min 
at room temperature. Gel pieces were then washed in 0.1% NH 4 HCO 3 
and 50% acetonitrile/50 mM NH 4 HCO 3 , dried, and incubated with 25 mM 
triethylammonium bicarbonate with 5  µ g/ml trypsin for 16 h at 30 ° C. 
For identifi cation of phosphorylation sites, the extracted tryptic peptides 
were analyzed by liquid chromatography mass spectrometry on a spec-
trometer (4000 Q-TRAP; Applied Biosystems) with precursor ion scanning 
as described previously ( Williamson et al., 2006 ). The tandem mass spec-
trometry spectra were searched against a local database containing the 
GST-MDC1 sequence using the Mascot search algorithm (www.matrix-
science.com) run on a local server. Sites of phosphorylation were validated 
by manual inspection of the mass spectrometry spectra using Analyst 1.4.1 
software (MDS Sciex). 
 Online supplemental material 
 Fig. S1 shows a sequence alignement of the SDT repeats in human, mouse, 
zebrafi sh, and honey bee MDC1. Fig. S2 shows the purifi ed MDC1 – MRN 
complex isolated from HeLa nuclear extract. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200709008/DC1. 
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MDC1-GST fragments were affi nity purifi ed on glutathione – Sepharose 
beads (GE Healthcare). Sf9 cells expressing recombinant MRN, MR, and 
N were lysed by sonication in buffer A (50 mM sodium phosphate, pH 7.0, 
0.3 M NaCl, 10% glycerol, and 0.5 mM PMSF) containing 20 mM 
imidazol followed by centrifugation. The supernatants were loaded on Hi-
Trap chelating (Ni 2+ ) columns (GE Healthcare) equilibrated with buffer A. 
The columns were washed with 50 ml buffer A/20 mM imidazol and with 
50 ml buffer A/50 mM imidazol. Proteins were eluted with a 50-ml linear 
concentration gradient of 50 – 350 mM imidazole in buffer A. MRN-
 containing fractions were pooled and either used directly for analysis after 
dialysis against buffer B (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% 
glycerol, and 1 mM DTT) or loaded on 1-ml HiTrapQ columns (GE Health-
care) for further purifi cation. The HiTrapQ columns were eluted with a 10-ml 
linear concentration gradient of 50 – 500 mM NaCl. 
 Antibodies and immunological techniques 
 Mouse monoclonal HA antibodies were purchased from Covance Research 
Products. The anti – mouse NBS1 antibody was a gift from A. Nussenzweig. 
The antibodies used against human Nbs1 were obtained from Genetex, 
Novus, and Millipore. Antibodies against phospho-Nbs1 Ser-343 and anti-
phospho-H2AX were obtained from Genetex and Millipore, respectively. 
Anti-SMC1, phospho-SMC1 Ser-966, and H2AX antibodies were pur-
chased from Bethyl, and the antiphospho-53BP1 and anti-53BP1 anti-
bodies were obtained from Cell Signaling Technology. Sheep polyclonal 
antibodies against human MDC1, MRE11, and RAD50 have been de-
scribed previously ( Goldberg et al., 2003 ). Rabbit polyclonal antibodies to 
MDC1 have been described previously ( Stewart et al., 2003 ). The anti-
CK2 % and -CK2 % & antibodies were purchased from Santa Cruz Biotechnol-
ogy, Inc. Phosphospecifi c MDC1 antibodies were raised in rabbits to 
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